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Preface
This text:
• Is aimed primarily at trainees working in intensive care. Hopefully will appeal to
multidisciplinary trainees being exposed to ICU for the ﬁrst time under joint col-
lege guidelines for ICU training. May also be of interest to ICU nurses looking for
information on modern medical (in the strictest sense) approaches to ICU ther-
apy. A basic knowledge of physiology and pharmacology is assumed as well as
either a medical background or advanced nursing experience in intensive care.
• May also be a useful “aide memoire” for ICU examinations especially for the
FRCA and diplomas in intensive care.
• The First Edition arose out of a series of ICU study days organised by the editor
in the North West region since 1992. Many of the authors have been lecturers
on these courses.
• The authors are all either experienced ICU practitioners or invited experts on
specialist issues. Being involved in ICU research was not a prerequisite although
many of the authors have been or are involved in ICU research – a clinical com-
mitment at the bedside was thought to be more important for this text.
• Aims to provide practical information on the management of common and/or
important problems in the critically ill patient as well as sufﬁcient background
information to enable understanding of the principles and rationale behind
their therapy. We hope it will prove useful at the bedside but we would like to
emphasise that this, or any other book, is no substitute for experienced super-
vision, support and training.
• Throughout, the importance of cardiac function is emphasised.
• Does not aim to cover all of ICU practice and is not a substitute to the major ICU
reference textbooks. For example, practical aspects of monitoring techniques
are not covered (best learnt at the bedside) but, however, the philosophy of
monitoring is covered where necessary to illustrate important management
points. Similarly, pathophysiology is included to help understand management
principles.
• The Second Edition contains several new chapters on topical aspects of ICU ther-
apy as well as revisions of older chapters – many have been completely rewritten.
• The format is designed to provide easy access to information presented in a
concise manner. We have tried to eliminate all superﬂuous material. Selected
important or controversial references are presented as well as suggestions for
further reading.
xii Preface
Basic principles
Part I

Cardiac function, monitoring, oxygen transport
I. McConachie
Stroke volume and cardiac output
Cardiac output (CO) is the volume of blood pumped by the ventricle per minute.
It ranges from 4–7 l/min in a normal adult at rest and can increase up to 17 l/min
during exercise. CO is normally indexed to body surface area (BSA) to allow com-
parisons of “normal” CO between patients of different height and weight –
Cardiac index (CI):
CO  Heart rate (HR)  Stroke volume (SV)
Factors governing SV include preload, afterload and the contractility of the
cardiac muscle.
HR and rhythm
• Therefore bradycardia will impair CO. Conversely, increases in HR, although
arithmetically increasing CO, may impair overall cardiac function by increas-
ing myocardial oxygen demand, causing ischaemia and reducing time for dia-
stolic ﬁlling. Some units therefore use the response of SV to therapy as being
more appropriate for overall cardiac function.
• An arrhythmia may also be detrimental to cardiac function, for example, in
atrial ﬁbrillation (AF) the loss of the atrial contribution to ventricular ﬁlling
may be signiﬁcant. SV is the volume of blood ejected by the ventricle per heart-
beat. It is the end-diastolic volume minus the end-systolic volume. Normally
70–80 mls for a 70 kg man at rest.
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Preload
• The force of ventricular contraction is related to the myocardial ﬁbre length
(Frank Starling relationship).
• Myocardial ﬁbre length is related to end-diastolic ventricular volume (EDV).
This is commonly referred to as “preload”. The heart beats efﬁciently with ade-
quate preload and thus ﬂuid therapy may increase cardiac function. 
Note: The active force needed for ejection of blood from the ventricle is greater
for a large ventricle than a small one. This is explained by the Law of Laplace
which states for a sphere P  2T/R. Thus ventricular cardiac muscle must gen-
erate a greater tension when the heart is dilated compared to a normal sized
heart to produce the same intraventricular pressure.
• EDV is difﬁcult to quantify though an assessment can be made by echocardio-
graphy.
• Vascular pressures can be measured more easily and both central venous pres-
sure (CVP) and pulmonary artery occlusion or capillary “wedge” pressure (PAOP
or PCWP) are used clinically to reﬂect the end-diastolic pressure (EDP) and thus
the EDV.
• Graphs can be constructed of CO against ﬁlling pressure. Filling pressure can
then be increased until there are no further increases in CO. Preload can then
be considered to be optimal.
• One problem is that with decreased compliance (increased stiffness) of the ven-
tricle wall, for example, following myocardial infarction (MI) the pressure may
be increased relative to the volume. Therefore, the EDP may overestimate true
preload.
Note: Preload gives information about the ﬁlling pressure of the heart. It does not
give any information about the blood volume.
Afterload
This is the force that opposes ventricular muscle contraction, that is, the ven-
tricular wall tension that must develop in order to eject blood from the ventricle.
Afterload is increased by:
• Anatomical obstruction, for example, aortic stenosis.
• Peripheral resistance in the circulatory system. Clinically this is reﬂected by
systemic vascular resistance (SVR).
SVR 
Mean arterial pressure (MAP)  CVP
CO
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The SVR accounts for approximately 95% of the resistance to ejection and is used
clinically to estimate afterload.
• Decreased distensibility of the vascular system. Blood pressure (BP) although
convenient to measure is a poor reﬂection of afterload and gives no informa-
tion about volume and ﬂow to organs.
• Enlarged ventricle (Laplace).
• Increased blood viscosity, which is largely dependent on haematocrit. The
greater the viscosity, the greater the resistance to ﬂow.
• Decreased intrathoracic pressure, see Chapter 9.
Increased afterload will increase the workload of the heart and oxygen consump-
tion and reduce SV.
Afterload is reduced by:
• Reduced SVR.
• Vasodilator drugs, the peripheral vasodilator drugs, can improve the SV of fail-
ing hearts by reducing afterload and ventricular work; vasodilators also reduce
preload via venous dilatation.
• Anaemia.
• Increased intrathoracic pressure.
Contractility
This is the effective pumping ability of the heart muscle. The force and velocity of
cardiac contraction is one deﬁnition of contractility although this is very difﬁcult
to measure in practice as most clinical measurements, for example, CO, ejection
fraction, etc. are inﬂuenced by preload and afterload.
Contractility is increased by the following:
• increased sympathetic activity,
• positive inotropes,
• increased preload.
Contractility is reduced by the following:
• decreased ﬁlling,
• hypoxia and hypercapnia (although both will cause sympathetic stimulation),
• acidosis and alkalosis,
• electrolyte disturbances,
• negative inotropes.
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The ejection fraction is often used as an indirect index of contractility:
Ejection fraction 
end-diastolic volume  end-systolic volume
end-diastolic volume.
The normal value is greater than 60%.
The CO, SV, left ventricular stroke work and ejection fraction are best thought
of as measures of overall cardiac performance, probably clinically more useful.
Ventricular interdependence
Both ventricles share a common septum. Studies have shown that about 20–40%
of the pulmonary systolic pressure and volume outﬂow result from left ventricu-
lar contraction [1]:
• If right ventricular end-diastolic volume increases this shifts the septum
towards the left ventricle (LV) decreasing left ventricular diastolic compliance.
• Right ventricular volumes can increase with pulmonary hypertension.
Heart/lung interactions
In the past, medicine encouraged a systems approach to disease. Thus diseases
of the heart would be taught in one unit and then diseases of the lungs would be
taught in another. Although not without merit this approach has limitations. It is
increasingly recognised that the organ systems work in series rather than in par-
allel, that is, disease or therapy of one directly inﬂuences one or more other
organs. Nowhere is this more apparent than with the heart and lung which after
all are connected by their vasculature and share the thoracic cavity. Indeed, the
lungs are the only organ which receives the whole CO. Forces acting on the lungs
also act on the heart. Pinsky has done much to investigate these issues and pop-
ularised the fact that the heart is a “pressure chamber within a pressure cham-
ber” (see Further reading). This emphasises that pressure applied to the lungs is
automatically applied to and affects the heart. This has several implications:
• It is intuitively obvious that respiratory function and ventilation must have an
effect on cardiac function. This has especial relevance to intermittent positive
pressure ventilation (IPPV) and is discussed in Chapter 9.
• As airway pressure increases, this pressure is transmitted to the right atrium
and acts as a backpressure opposing venous return, that is, venous return and
CO decreases. During normal quiet respiration this effect is minimal but is
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measurable. The effects are of course magniﬁed with IPPV when high pres-
sures are applied to the lungs (see Chapter 9).
• The other main effect of respiration on cardiac function is by changes in tidal
volume. Again during quiet respiration these effects are minimal but with dis-
ease and IPPV effects can be clinically signiﬁcant.
If one takes the linkage of the heart and lungs to its logical conclusion and con-
siders the overall cardiopulmonary unit, the main function of which is to deliver
oxygen to the cells, then one must also take factors such as haemoglobin (Hb)
and blood viscosity into account when assessing the patient. The increase in CO
and minute volume with anaemia is a perfect example of the linkage of different
organ systems to act as an overall cardiopulmonary unit.
Respiratory failure and the heart
Shallow breathing in respiratory failure can increase pulmonary vascular resist-
ance (PVR), partly by collapsing alveoli causing a fall in diameter of extra alveolar
pulmonary blood vessels, and partly by development of hypoxic pulmonary vaso-
constriction. The worsening PVR exacerbates the development of hypoxia and
acidosis which further worsens PVR! Thus, heart/lung interactions in respiratory
failure can result in a progressive, downward spiral of the patient’s condition.
Increased work of breathing and the heart
Any condition increasing work of breathing requires oxygen and energy. This
requires increased blood ﬂow and, in essence, the heart has to work harder. Thus
it is perhaps not surprising that respiratory failure causes a strain on cardiac
function. The potential for myocardial ischaemia is also present especially when
there is associated tachycardia and hypoxaemia.
Shock and respiratory failure
In severe shock, the reduced blood ﬂow to the diaphragm coupled with the
increased minute volume and respiratory energy expenditure causes respiratory
failure, even in normal lungs. This is convincingly demonstrated in animal stud-
ies for example, much of the lactic acid accumulating in shock comes from the
respiratory muscles [2]. IPPV, by reducing the work of breathing, lessens the
blood lactate levels compared with spontaneous breathing. In cardiogenic shock
the mode of death is often from respiratory arrest secondary to diaphragmatic
fatigue, again due to the increased work of breathing.
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Changes in CO and oxygenation
A pitfall is to wrongly ascribe a measured hypoxaemia to a respiratory illness
when the true cause is cardiovascular in origin.
Falls in CO lead to a compensatory increase in oxygen extraction by the tis-
sues. This results in a decrease in mixed venous Hb saturation (SvO2). This
directly results in a decrease in arterial saturation, especially in the absence of
supplemental inspired oxygen. This, in itself, is one rationale for the administra-
tion of oxygen following MI.
An exception to this effect is in the presence of physiological shunting
through the lungs. Here a decrease in CO causes a decrease in the fraction of out-
put shunting through the lungs and no change in PO2.
Monitoring
Monitoring may be described as the intermittent or continuous observation of a
patient using clinical examination and appropriate equipment to assess progress
of the condition:
• The most useful and reproducible monitor remains the thorough and repeated
clinical examination by the doctor.
• Not all critical care environments are the same, and all models of monitoring
equipment are slightly different. The clinician must take time to become famil-
iar with the equipment in his or her own hospital.
Invasive monitoring
By deﬁnition a urinary catheter or a nasogastric tube is a form of invasive moni-
toring. However, by common convention, invasive monitoring is usually taken to
refer to vascular cannulation. Mainly it is vascular pressures which are measured
using pressure transducers although use of the pulmonary artery catheter per-
mits many other measurements, calculations and sampling of blood. Before
instituting invasive monitoring one must always ask “What are we monitoring
and why?” The answer should be that we monitor something to do with one or
more of the following:
• intervene therapeutically in emergency situations,
• guide and plan future therapy,
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• establish diagnoses,
• establish prognosis.
Monitoring is not a therapy in itself which explains the argument that invasive
monitoring does not in itself improve survival. Of course, survival will not be
improved by any monitoring and measurements. Survival will only be improved
if appropriate therapeutic measures are taken on the basis of the measurements
taken. It should also be self evident that the right measurements must be made
and the information acted upon in the right manner. Much of the current debate
regarding the usefulness of the pulmonary artery or Swan–Ganz catheter revolves
around lack of knowledge on the part of the physician inserting the catheter and
inappropriate therapeutic interventions based on the data obtained (see later).
Invasive monitoring is not without complications although these can be
reduced by careful technique and practice. Therefore, one should always moni-
tor non-invasively if possible. For example:
• The use of pulse oximetry has reduced (but not eliminated) the need for regu-
lar blood gas analysis.
• Automatic non-invasive BP measurement negates the need for direct arterial
pressure measurements in many patients.
• Non-invasive CO measurements are reducing the frequency of insertion of
pulmonary artery ﬂotation catheters (PAFCs).
However, in the critically ill patient non-invasive monitoring may not sufﬁce as
discussed below.
Direct arterial BP measurement
• The insertion of a small (common sizes are 20 or 22 gauge) teﬂon coated
catheter into an artery (usually the radial, ulnar, brachial, dorsalis pedis or
femoral are used) allows direct beat to beat assessment of the systemic BP.
• The presence of an arterial line also provides access for the measurement of
arterial blood gas samples.
• When BP is low the “true” arterial pressure may be underestimated by non-
invasive measurements. A common pitfall is to prefer the non-invasive reading
as more accurate – presumably due to the reassurance of a better reading!
• The decision to use invasive BP monitoring is based on the clinical indication,
together with an assessment of the ease with which it can be safely undertaken
and the ability of the staff in the critical care area to look after the set up.
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• It is probably inappropriate to run infusions of inotropic and vasoactive drugs
without direct BP measurement. It is also strongly advised that any ventilated
patient have arterial access both for BP measurement and blood gas analysis.
• Common complications include local bleeding and infection. Serious compli-
cations include embolisation and thrombosis and development of arterio-
venous (AV) ﬁstulae. Fortunately, serious complications are rare and can be
minimised by choosing Teﬂon, small bore catheters inserted percutaneously.
• Intra arterial pressure measurements are not always accurate, usually due to
failure of calibration or wrong height of transducer. In general, the Mean pres-
sure is less prone to error, variation and excessive damping than the Systolic
and Diastolic.
The pros and cons of this monitoring modality can be assessed by comparison
with the non-invasive cuff pressure alternative.
Invasive Arterial BP Non-Invasive BP
Beat-to-beat control “Stat” mode cycles c. 20–30 s.
Unaffected by rhythm Difﬁculty reading BP in AF
Automatic pulse measurement Not always available
Almost always possible Difﬁcult in obese patients
Accuracy unaffected by patient Inaccurate in obese patients
Movement artefact clearly visible Unable to read if moving
Allows blood sampling Not applicable
Susceptible to over and under damping Not applicable
Requires training and practice Easy to use
Potential ischaemic damage Cuff compression injury rare
Danger of accidental injection Not applicable
Massive blood loss if disconnection Not applicable
Echocardiography
Echocardiography, especially by the transoesophageal route, is a useful, com-
paratively non-invasive, means of assessing cardiac function. Advantages include:
• Dynamic as opposed to static assessment, for example, one can see how the
heart functions globally and see regional wall motion abnormalities.
• Easy assessment of cardiac, valvular and major vessel structures.
• Helps to provide the “missing link” between pressure and volume within the
cardiac chambers.
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Intermittent assessment of cardiac function on intensive care unit (ICU) is
becoming increasingly common technique for ICU specialists.
Indices of tissue perfusion and oxygenation
Measurement of pHi (gastric mucosal pH) may be an indicator of splanchnic
perfusion and may predict outcome [3]. Both pHi and blood lactate may be super-
ior to oxygen transport variables in predicting outcome [4].
CVP monitoring
The central (or great) veins within the neck and mediastinum may be thought of
as a manometer tube with four accessible branches: the right and left internal
jugular veins, and the right and left subclavian veins.
Factors involved in the choice of site of CVP monitoring are discussed in
Chapter 4.
The pressure measured within this “venous manometer” is the ﬁlling pressure
responsible for ventricular ﬁlling during diastole. The CVP may be judged clini-
cally as the jugular venous pressure (JVP). This is very difﬁcult to quantify and trends
or sudden changes in the ﬁlling pressures are easier to assess directly.
Many critical care conditions cause the CVP to rise and fall. The usefulness of
this monitoring system may be assessed from the following list.
Conditions causing increase in CVP:
• Cardiac failure: If the right ventricle is unable to efﬁciently eject a SV there will
be increased back pressure in the systemic venous system.
• Cardiac tamponade: Again if the right ventricle is compressed by ﬂuid in the
pericardial sac back pressure in the great veins will cause the CVP to rise.
• Positive pressure ventilation: Increased intrathoracic pressure produced during
inspiration and the application of positive end expiratory pressure (PEEP) both
result in elevation of the CVP.
• Fluid resuscitation: This is one of the commonest causes for CVP monitoring.
To assess response to ﬂuid resuscitation.
• Superior vena cava (SVC) obstruction: This is caused due to tumour or trauma
to the root of the neck.
Conditions causing decrease in CVP:
• Hypovolaemia. Any condition resulting in reduced venous return to the heart,
for example, exsanguination, sepsis, gastrointestinal (GI) tract losses, sweating.
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• Fall in intrathoracic pressure. At the end of a period of positive pressure venti-
lation and during spontaneous inspiration.
CVP monitoring should be considered in all critically ill patients in whom know-
ledge of the ﬁlling pressures of the right heart will assist in the resuscitation and
maintenance of an adequate circulating volume to ensure optimal oxygen delivery.
CVP lines allow for the infusion of vasoactive drugs that would cause con-
striction of small peripheral veins. They may also be used for the infusion of irri-
tant substances, for example, parenteral nutrition and potassium.
After insertion of CVP lines via the above routes, a chest X-ray (CXR) must be
obtained reasonably promptly both to rule out pneumothorax and also to check
catheter tip position (within the SVC is ideal). If during and after CVP line insertion
there is clinical deterioration of the patient the possibility of a Pneumothorax
must be entertained.
Long catheters can be threaded into the thorax via the basilic and cephalic
veins in the antecubital fossae. The advantages are the little risk of bleeding and
zero risk of pneumothorax. However, the complication rate is higher than that of
other routes of central venous access; that is, high infection rate and a high rate
of thrombosis. The success rate is also low, 60% in some series.
Limitations of CVP monitoring or why we need the Pulmonary artery
catheter
CVP reﬂects right atrial pressure (RAP) which is usually taken to reﬂect RV end
diastolic pressure (RVEDP). CVP provides useful information regarding the sta-
tus of the right side of the heart. This is valuable in cases of RV failure or in assess-
ing the RV response to pulmonary hypertension:
• It does not necessarily reﬂect LV preload and also poorly correlates with blood
volume. CVP is often used as a guide to LV function and, indeed, directional
changes in CVP may reﬂect alterations in LV performance. However, if either
ventricle becomes selectively depressed, or in the presence of severe pul-
monary disease, changes in CVP will not reﬂect changes in LV function.
• CVP is “several steps” away from LV end-diastolic ventricular volume (LVEDV)
or true preload and each approximation is inﬂuenced by pathological condi-
tions, for example, LV compliance, mitral valve disease, intrathoraic pressures,
tricuspid regurgitation.
• There are many studies showing a poor relationship between CVP and PCWP
derived from a Pulmonary Artery Catheter in various disease states.
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Pulmonary artery ﬂotation catheter
In 1970 Swan, Ganz and colleagues described a balloon tipped catheter which
could be inserted through the great veins via the heart to the pulmonary circula-
tion. By means of the balloon the tip of the catheter could be isolated from the
pressure generated by the right ventricle. Various additions and modiﬁcations
including further infusion ports, CVP monitoring port, thermistor connection,
heating coil, continuous venous oximetry cable and pacing facilities.
The information gained from the PAFC is of three types:
(1) Pressures derived from catheter placement.
(2) Measurement of CO.
(3) Mathematically derived data.
Pressures derived from catheter placement
During the insertion of the PAFC the pressures produced from the transduced
catheter tip as it “ﬂoats” (balloon inﬂated during insertion) through the right heart
are as follows:
• CVP;
• right atrial (RA) pressure;
• right ventricular (RV) pressure;
• pulmonary artery pressure;
• PCWP.
The PCWP is the pressure measured by the tip of the catheter when the forward
pressure from the right ventricle is obstructed by the balloon (this pressure should be
measured for no longer than 30 s at a time as the pulmonary blood ﬂow is ceased
down stream of the inﬂated balloon making pulmonary infarction a possibility).
The PCWP is also known as the Pulmonary artery occlusion pressure (PAOP).
Provided the tip of the catheter is contained within a continuous column of
blood between it and the LV, then at the end of diastole with the mitral valve
open, the PCWP measures the LV end-diastolic pressure (LVEDP). From Starling’s
law, the force of contraction of the LV is dependent on the degree of muscle ﬁbre
stretch during diastolic ﬁlling. Thus provided the ventricle wall is of normal com-
pliance the pressure developed within the ventricle at end diastole is directly
proportional to the LVEDV and hence to preload. Under these conditions PCWP
directly reﬂects LVEDV.
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Clearly there are situations in which the above relationship does not hold:
• In patients undergoing positive pressure mechanical ventilation with high air-
way pressures the alveolar pressure may exceed the pulmonary venule pres-
sure. In this state the continuous column of blood is “broken” and the wedged
PAFC is measuring the alveolar pressure.
• Mitral valve disease affects PCWP. Mitral stenosis causes a large-back pressure
(“a” wave) on the PCWP trace as the atrium contracts against the stenotic valve.
Mitral regurgitation causes a large “v” wave as the ventricular outﬂow passes
back up the pulmonary venous system.
• The compliance of the ventricle wall is altered in states of cardiac and systemic
disease. MI, cardiac tamponade, aortic valve disease, the cardiomyopathies and
systemic sepsis all cause the PCWP not to reﬂect LVEDV. This observation may
be used clinically to assess the severity of the causative condition.
Pitfalls in the PCWP
• Upper limit of “normal” is 12 mmHg. The optimal PCWP is the PCWP which
provides the best CO without increases in lung water or pulmonary oedema.
The optimal PCWP is rarely above 18 mmHg.
• It is only a guide to the LA pressure. Pulmonary artery (PA) diastolic pressure
usually approximates to PCWP and may sometimes be used if there is difﬁculty
getting the catheter to “wedge”.
• If compliance is increased, for example after previous MI, it is accepted that
PCWP will usually have to be greater than “normal” for optimal SV.
• It can reﬂect transmitted intrathoracic pressure, especially in the presence of
PEEP. To minimise the effect of intrathoracic pressure on PCWP the catheter tip
should be positioned in the lower third of the lung (if higher, alveolar pressure
may exceed pulmonary artery pressure). All PCWP measurements should be
made at end of expiration (EE):
During spontaneous respiration, EE  highest part of waveform.
During IPPV, EE  lowest part of pressure waveform.
• The PCWP is not a measurement of blood volume although changes in PCWP
correlate with changes in blood volume.
Thermodilution CO
Thermodilution PAFC measures temperature in the pulmonary artery (a useful
source of an accurate core temperature). 10 ml of cold ﬂuid is injected through
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the proximal port of the catheter. Blood ﬂow is calculated from the temperature
drop sensed by the Thermistor at the tip of the catheter in the Pulmonary artery
after mixing has occurred. Modern catheters can measure CO continuously by
the same principle but in reverse, that is, heated ﬁlament to produce small
increases in blood temperature:
• The CO measured in this way is still currently viewed as the “Gold Standard”
method of this measurement in the critically ill patient. A full discussion of
non-invasive methods of measuring CO is beyond the scope of this text (see
Further reading).
• Due to the differences in CO with changes in Intrathoracic Pressure during
IPPV, some recommend timing the measurement at EE. However, this begs the
question: Which is the “correct” CO; the one during inspiration or the one dur-
ing expiration? It seems sensible to make the measurements randomly and
obtain an “average” CO. Continuous methods do the “averaging” for us.
• CO varies with height and weight. To enable one patient to be compared with
another the CO is usually indexed to BSA, that is the CI. In theory every patient
has the same “normal” CI.
Mathematically derived haemodynamic data
From the measured data produced by the PAFC together with knowledge of the
systemic mean BP (from the arterial line) and the central venous pressure (from
the CVP line) a further set of derived data may be produced:
• SVR and PVR
• LV and RV stroke work
• LV and RV stroke volume
• RV ejection fraction and RV end-diastolic ventricular volume (RVEDV) (rapid
response thermistor catheters only).
Although mathematical formulae for each of the above ﬁgures exists (see below),
modern monitoring systems calculate them automatically.
• Stroke work index (SWI): It is the work generated by each ventricle during one
cardiac cycle. It is a function of the pressure generated in systole and the SV
ejected. Increases in SWI may be beneﬁcial but also increases myocardial oxy-
gen demand.
• Vascular Resistance, Systemic or Pulmonary: Resistance is determined by divi-
ding the pressure drop across the system by ﬂow. There is controversy as to
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whether SVR and PVR should be indexed to BSA. The main use of the SVR is to
help sort out the speciﬁc problem in cases of hypotension, especially in septic
shock but one should treat the BP rather than the SVR. SVR may be increased
by vasoconstriction or hypertension. Reductions occur in sepsis, cirrhosis and
AV ﬁstulae. Changes in calculated SVR may be seen with changes in CVP with-
out any change in vascular tone.
Normal values
LVSWI  (MAP  PCWP)  SVI  0.0136 44–56 gm.m/m2
RVSWI  (PAP  CVP)  SVI  0.0136 7–10 gm.m/m2
SVR 
MAP – CVP
 80
900–1200 dynes.s/cm5
CO
PVR 
MPAP – PCWP
 80
100–200 dynes.s/cm5
CO
MPAP  mean pulmonary artery pressure.
Indications for the PAFC
• Monitor preload.
• Optimise preload prior to the use of inotropes.
• Pulmonary oedema not responsive to simple measures or where therapy pro-
duces hypotension.
• Shock.
• Complicated MI.
• To enable manipulation of oxygen transport variables.
• Differentiate cardiogenic and non-cardiogenic pulmonary oedema.
• More rarely, after acute MI, to differentiate between acute ventricular septal
defect (VSD) and mitral regurgitation.
• May be inserted prophylactically for high-risk surgery especially cardiac surgery.
Complications associated with the PAFC
During insertion:
• See Chapter 4.
During passage of the catheter:
• Arrhythmias
• Intracardiac knotting
• Cardiac or PA perforation.
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Catheter in situ:
• Pulmonary embolism (PE) and infarction
• Valve damage
• Thrombocytopenia (not such a problem with modern catheters)
• Endocarditis
• PA rupture, increased risk with pulmonary hypertension.
Inaccurate measurements and false interpretations.
Hints on safe use of PAFC
• Balance risk versus beneﬁt.
• Slowly inﬂate balloon while watching waveform.
• On wedging trace stop further inﬂation of balloon.
• If catheter overwedges, immediately deﬂate balloon and withdraw catheter
1–2 cm.
• Minimise duration of balloon inﬂation.
• If balloon inﬂates with less than 1.5 ml of air, withdraw 1 cm.
• Continuously monitor PA trace for spontaneous migration and wedging.
• Minimise number of wedgings in patients with pulmonary hypertension.
Newer techniques of preload assessment
The aim of preload assessment, in general, is to predict and quantify the
improvement in SV in response to a ﬂuid challenge. Neither the CVP or the PCWP
are thought to reliably predict an improvement in cardiac function following
administration of ﬂuid.
The role of the RV end diastolic volume index (RVEDVI) as measured by a
rapid thermistor PAFC in assessing preload has received much attention. The
results from different studies are conﬂicting:
• The RVEDVI may be a better predictor of preload than the PCWP in trauma
patients during large-volume shock resuscitation. When the RVEDVI is
130 ml/m2 or less, volume administration will likely increase the CI [5].
• The RVEDVI may not be a reliable predictor of the response to ﬂuid. As a pre-
dictor of ﬂuid responsiveness, PCWP was superior to RVEDVI [6].
• RVEDV from the rapid response PAFC may overestimate left ventricular 
preload. If RVEDV is used as an absolute value for determining preload,
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patients may be under-resuscitated. Transesophageal echocardiography 
may assist in determining preload and cardiac performance in critically ill
patients [7].
• CI correlates signiﬁcantly better with RVEDVI than PCWP at all levels of PEEP
up to 50 cmH2O. RVEDVI is a more reliable predictor of volume depletion and
preload especially in patients receiving higher levels of PEEP where PCWP is
difﬁcult to interpret [8].
Another simpler method of preload assessment looks promising:
• Recent studies suggest that the presence of arterial pulse pressure variation
(PPV) during the respiratory cycle indicates a relative hypovolaemia [9] and,
indeed, predicts an increase in CO with ﬂuid. Most monitors can “freeze” the
arterial trace and quantify this PPV or one can simply view the “swing” on the
arterial trace.
• Additionally and importantly, it is suggested that if there is no PPV there will be
no increase in CO no matter how much ﬂuid is given [10]. This technique only
seems to apply in the patient undergoing IPPV.
The PAFC controversy
Detractors of the PAFC, state that their beneﬁt in terms of increased survival is
unproven. Of course, survival will not be improved by any monitoring or meas-
urements. (It would be ludicrous to blame thermometers for the high-death rate
from septic shock.) Survival will only be improved if appropriate therapeutic
measures are taken on the basis of the measurements taken. The use of a PA
catheter is only of value if used as part of an overall management plan.
• An important paper by Connors was published in 1996 and caused consider-
able discussion (including the front page of the New York Times). The paper
claimed to show an increased mortality associated from the use of the PAFC
[11]. Direct complications, for example, arrhythmias, pulmonary infarction
were not thought to be responsible as these are, in general, low in experienced
hands. The increased mortality was thought to arise from inappropriate use of
the information obtained especially inappropriate use of “supranormal goals”
of oxygen transport as discussed below. Although there is disagreement with
the methodology of this study (e.g. it was retrospective) there arose calls for
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formal controlled studies of the use of the PAFC in critically ill patients (which
might previously have been considered unethical).
• In addition, inappropriate use of the information obtained from the PAFC may be
compounded by the ignorance of doctors inadequately trained in their use [12].
• A large-retrospective study from the UK failed to ﬁnd an association between
the use of the PAFC and mortality [13].
• Meta-analysis of 12 randomised trials found a statistically signiﬁcant reduc-
tion in morbidity using PA catheter-guided strategies [14].
• A French study [15] is the ﬁrst to show that patients in whom the PAFC is used
are sicker and, therefore, have a higher mortality than other patients. This
study did not get as much publicity as the Connors study!
• A randomised trial of 200 catheters from the UK has also shown no evidence of
increased mortality in those patients receiving a PAFC [16].
• In the most recent published large study, the use of PAFCs inserted preopera-
tively and used to guide the achievement of high oxygen delivery (see below)
failed to show an improved outcome compared with “conventional” therapy [17].
• The UK PACMAN study is as yet unpublished but early presentations at scien-
tiﬁc meetings suggests that there is no beneﬁt (and no harm either) from the
use of PAFCs in ICU patients. This is the ﬁrst adequately powered trial (approxi-
mately 1000 patients prior to the trail being stopped) to address this issue and
broadly supports the other trials in this area.
However, there is no doubt that the PAFC gives us invaluable information, not
readily obtained elsewhere. For example:
• In one study [18] physicians were only able to correctly predict values for
PCWP, CI and PA pressure about 50% of the time. Treatment was changed in
48.4% of patients after catheterisation. This is not meant to suggest that all criti-
cally ill patients should have a PAFC since the most important role of the experi-
enced physician is in deciding who should be catheterised, and when.
• A French study found correctly predicted haemodynamic proﬁles in only 56%
of patients prior to catheterisation. Changes of treatment were prompted in
63% of patients who were unresponsive to standard therapy. The mortality rate
was signiﬁcantly less when the assessment of haemodynamic data led to a
change in therapy despite identical precatheterisation characteristics [19].
Some ﬁnal points:
• Many physicians continue to use the PAFC despite the conﬂicting evidence
and believe it beneﬁts their patients.
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• Even if the PAFC were to be withdrawn from use there are other methods now
widely available to measure CO.
• The PACMAN trial examines the use of PAFCs as part of their units’ current
practice. Should we not now be looking at what constitutes best practice?
Should we throw away the PAFC or learn to use it better? Are the documented
changes in practice after insertion of the PAFC useless? Surely no information
cannot be better than some information?
Further studies may help deﬁne the best therapies in differing circumstances
and deﬁne the overall value of the PAFC in terms of survival.
Oxygen transport
Oxygen delivery or DO2 is the oxygen content of the arterial blood (CaO2) multi-
plied by the blood ﬂow or CO. Thus
DO2  CO  CaO2
The normal CaO2 of 20 ml is the Hb concentration multiplied by 1.34 (the con-
stant for the amount of O2 each gram of Hb can combine with) and the % oxy-Hb
saturation (SaO2). Dissolved O2 is usually considered to be negligible. This is the
CaO2 per decilitre which must, therefore, be multiplied by 10 to unify the units
because CO is measured in l/min. That is, 
DO2  CO  Hb  SaO2  1.34  10
Normal DO2 therefore
5  15  100%  1.34  10  1000 ml/min
If CI is used the resultant DO2 is also indexed to BSA. That is, 
DO2  600 ml/min m2.
Adequate DO2 is achieved by attention to cardiac function, Hb and oxygenation.
Note that the PaO2 contributes little to oxygen content and DO2. (The PaO2 is not
an important measure of arterial oxygenation. The SaO2 is more signiﬁcant in
assessing oxygenation of arterial blood while the PaO2 is important in evaluating
gas exchange in the lungs.)
Oxygen release from Hb at the tissues is increased by factors shifting the 
oxy-Hb dissociation curve to the right, for example, acidosis, fever, increased 
2,3-diphosphoglyceraldehyde (2,3-DPG) while factors which shift the curve to
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the left, for example, alkalosis, hypothermia, reduced 2,3-DPG (stored blood)
impair oxygen release at the tissues.
In patients who are fully oxygenated and have an adequate Hb the only logical
way to increase DO2 is to increase CI. This has practical implications for therapy.
Normal mixed venous SvO2 is 75% (68–77%) and therefore venous oxygen
content (CvO2) is 15 ml. Thus the oxygen extraction ratio (OER) is 25%. Oxygen
consumption (VO2) of the whole body (indexed) is therefore:
VO2  CI  (CaO2  CvO2)  10
 150 ml/min m2
VO2 reﬂects metabolic rate and as such is increased in thyrotoxicosis, fever, phys-
iological stress response, feeding and by a direct calorigenic effect of inotropes
[20]. Anaesthesia, cyanide and carbon monoxide poisoning, and hypothermia
reduce VO2. Sedation of ventilated patients reduces VO2 partly by direct sedative
effect and partly by reducing the work of breathing.
Supply dependency
• The normal response to a fall in DO2 (low CI, anaemia, hypoxaemia) is to main-
tain VO2 by increases in OER and decreases in SvO2. Thus, normally, VO2 is
“supply independent”.
• VO2 is “supply dependent” when extraction does not change in response to
alterations in delivery; that is, further increases in DO2 result in increases in VO2,
revealing potential tissue hypoxia. Supply dependency was widely identiﬁed 
in early studies where DO2 and VO2 were calculated using the shared variables
of CI and CaO2. This leads to a potential error due to “mathematical coupling”.
This ﬁnding led to many studies of increasing DO2 to “supranormal” levels
which is generally no longer recommended [21]. More recent studies, using
truly independent methods of measuring DO2 and VO2, have mainly failed to
substantiate the claims for widespread existence of supply dependency [22].
• In addition, if dobutamine has a direct calorigenic effect to raise VO2 [20], then
this response need not reﬂect tissue hypoxia.
• There are frequent “spontaneous” changes in DO2 and VO2 in ventilated patients
[23]. This limits the value of studies showing that VO2 is dependent on DO2.
• There are still areas of controversy, for example, if the studies showing supply
dependency were due to mathematical coupling why did studies of some
groups of patients show this (e.g. septic and acute respiratory distress syn-
drome (ARDS) patients) while other groups (e.g. heart failure) did not?
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At the other end of the scale, with decreases of DO2:
• Where DO2 is low and lactic acidosis present, increasing DO2 will lead to
increases in VO2 [24], that is supply dependency. In haemorrhagic or cardio-
genic shock, VO2 is maintained by increases in OER down to a critical level of
DO2 (below which further decreases in DO2 lead to the rapid demise of the
patient) at the expense of low levels of SvO2.
• This mechanism of increased extraction is only a short-term answer and the O2
debt has to be repaid. Studies have shown that the magnitude of O2 debt and its
clearance is linked to ultimate survival [25].
Supranormal goals
• The team led by W.C. Shoemaker identiﬁed values of CI, DO2 and VO2 and
blood volume retrospectively associated with increased survival of trauma and
high-risk surgical patients [26]. The “goals” were:
– CI  4.5 l/min m2
– DO2  600 ml/min m2
– VO2  170 ml/min m2
– Normal BP
– Blood volume 500 ml  normal unless PCWP  20 mmHg
• They then attempted to achieve these goals prospectively in an attempt to
improve survival in a similar group of patients with considerable success [27].
• Others attempted to apply these goals in other groups of patients with lesser
success.
• Indeed, it now seems that this approach may be detrimental in some groups of
patients e.g. the elderly in whom attempts to aggressively raise CI may pro-
mote myocardial ischaemia [28].
• Thus it has been concluded that this approach cannot be universally recom-
mended [21] but there may be beneﬁts in speciﬁc groups of patients especially
trauma patients and high-risk surgical patients when applied preoperatively.
This will be explored later in this text.
• A key issue may be timing: early correction of oxygen debt may be helpful but
late intervention will not be. Shoemaker has suggested that “no amount of
extra oxygen can restore irreversible oxygen debt, failed debt or dead cells”
[29]. His recent meta-analysis [29] suggested that there can be signiﬁcant
reductions in mortality in critical illness when patients are treated early to
achieve optimal goals before the development of organ failure, when there
were control group mortalities of 20% (otherwise the patients are not sick
22 I. McConachie
enough) and when therapy produced differences in oxygen delivery between
the control and protocol groups.
Monitoring of venous oxygenation
Mixed venous oxygen saturation: SvO2
This may be measured from a ﬁbreoptic PAFC or by taking a sample from a PAFC
and running it through a blood gas co-oximeter.
• In general if the peripheral tissues are unable to utilise oxygen (e.g. sepsis,
hypothermia) the SvO2 will rise. If the heart is unable to deliver oxygen the tissues
will extract as much as possible from what is available and the SvO2 will fall.
• If the critically ill patient is to survive DO2 must be restored to such a level that
VO2 can be maintained without critically low levels of SvO2. SvO2 levels 60% are
dangerous and levels of 40% are incompatible with long-term survival.
• SvO2 is therefore obviously related to the balance of DO2 and VO2 or more accur-
ately to the balance between the ability to extract oxygen and DO2.
• SvO2 does not necessarily vary with CO. Not all patients can increase their OER
if DO2 falls, for example, septic patients with loss of vasoregulation and mal-
distribution of ﬂow.
• Thus the value of mixed venous oxygenation measurements is that it reﬂects
the balance between CO and OER. As CO is the most important index of DO2 in
most patients, many physicians monitor oxygen transport by measuring CO
and assessing its adequacy to metabolic needs with measurements of venous
oxygenation [30].
• The main ﬂaw in this approach is that global measurements take little notice of
regional disturbances.
• Most recently the monitoring of venous saturation from the central veins via 
a modiﬁed CVP catheter has been shown to be of value in guiding early goal-
directed therapy in severe sepsis [31]. The use of such measurements is the sub-
ject of much research and seems to offer a relatively less invasive (and quick)
guide to the balance of overall oxygen transport.
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Shock
I. McConachie
Shock is a very imprecise term for a common, life-threatening condition.
A modern, acceptable deﬁnition of shock might be “a clinical syndrome resulting
from tissue dysfunction secondary to inadequate perfusion and oxygenation”
(i.e. inadequate DO2 and VO2). Note that hypotension is not part of this deﬁn-
ition; shock and hypotension are commonly linked but not synonymous. One
can be hypotensive without being shocked and one can be shocked without
being hypotensive. Some authorities would insist that unless lactic acidosis is
present (indicating tissue hypoxia) one cannot be said to be “shocked”.
Signs of shock include:
Clinical Low blood pressure (BP) (e.g. 90 mmHg or 60 mmHg below a
previous basal level)
Oliguria 1⁄2 ml/kg/h
Pale, sweaty skin, cool peripheries
Rapid, thready pulse
Reduced conscious level
O2 transport DO2 and VO2 reduced
SVO2 50%
Lactic acidosis
Studies have shown that VO2 decreases before any changes in BP, urine output, etc.
Four main types of shock have classically been described:
(1) Hypovolaemic: Often haemorrhagic in nature
(2) Cardiogenic
(3) Septic
2
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All will be discussed in the appropriate section of this volume.
Less commonly
(4) Anaphylactic: See below
In addition some recognise:
• Traumatic: Effect of tissue injury in addition to haemorrhage.
• Obstructive: A special form of cardiogenic shock due to failure of left ventricu-
lar (LV) ﬁlling due to cardiac tamponade, pneumothorax or venocaval obstruc-
tion. Massive pulmonary embolus leads to a form of obstructive shock.
• Spinal: Not described in this text but the haemodynamic picture is mainly one
of vasodilatation.
Massive pulmonary embolism
Acute circulatory failure is the commonest cause of death from pulmonary embol-
ism (PE). This is believed to follow acute right ventricular (RV) failure secondary to
the acute increase in RV afterload (acute cor pulmonale). Other factors include the
development of RV ischaemia, decreased LV ﬁlling because of ventricular interde-
pendence, hypoxaemia and vasoactive mediator release. Fluid therapy in acute PE
is controversial. On the one hand, the further increase in right atrial pressure (RAP)
should partially restore venous return and improve cardiac output (CO). However,
further increases in right atrial (RA) and RV volumes may further impede LV ﬁlling.
Inotropes may be useful by increasing ventricular contractility and vasopressors
may improve right coronary perfusion. However, these interventions only serve to
buy time for deﬁnitive intervention (e.g. thrombolysis).
Pathophysiology
Although it is common and in many ways appropriate to think of shock in haemo-
dynamic terms (see below) shock is simultaneously a systemic and a cellular dis-
ease leading ultimately to:
• decreased adenosine triphosphate (ATP) production,
• membrane dysfunction,
• cellular swelling,
• cell death.
Once cellular swelling occurs, restoration of local tissue perfusion may not be pos-
sible leading to continuing secondary ischaemia. Damage to other organs such as
the lungs results from leucocyte sequestration and deposition in the pulmonary
capillaries leading to increased pulmonary shunting and increased capillary per-
meability from release of inﬂammatory mediators. The reticulo endothelial system
function is depressed which decreases clearance of toxic materials (e.g. endotoxin,
foreign proteins, immune complexes and platelet aggregates).
Tissue trauma from trauma and surgery has additional effects:
• complement activation,
• coagulation cascade activation,
• cytokine release,
• granulocyte activation leading to the production of oxygen free radicals and
endothelium dysfunction.
During recovery from shock after successful resuscitation there will be an oxygen
debt to be repaid. Studies have shown that failure to repay this debt is associated
with ongoing tissue hypoxia and organ failure [1].
Therapeutic approach to the shocked patient
Unfortunately, our knowledge of the pathophysiological cellular events in shock
outweigh our ability to modify these events. Therapy is still largely “macroscopic”
(i.e. restoration of tissue perfusion not “microscopic”).
(1) Airway, oxygenation and ventilation. The threshold for intubation and venti-
lation of shocked patients should be low:
– Patients are unlikely to be able to guard their own airway. Frank vomiting 
is uncommon but silent aspiration common.
– IPPV will reduce the work and oxygen consumption associated with breath-
ing and hopefully ensure oxygenation.
– Severe shock will cause hypoxia in the absence of respiratory disease due
to a reduction in pulmonary blood ﬂow and low SVO2.
(2) Circulatory support including attention to:
– heart rate and rhythm,
– preload,
– contractility,
– afterload,
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– coronary perfusion and cerebral perfusion pressures,
– haematocrit.
Simple haemodynamic patterns may help in diagnosis of the cause of
shock and guide cardiovascular management although mixed
pathology may coexist. For example:
hypovolaemic shock: low pulmonary capillary wedge pressure (PCWP),
low cardiac index (CI), high systemic vascular resistance (SVR);
cardiogenic shock: high PCWP, low CI, high SVR;
septic shock: low PCWP, high CI, low SVR.
A ﬂuid challenge is appropriate in virtually all patients unless obviously
suffering from gross congestive cardiac failure.
(3) Speciﬁc therapy according to cause.
Progressive or refractory shock
Even in young patients it has been shown that myocardial failure contributes to
the shocked state if the shock is maintained; that is eventually all shock states
will have a degree of cardiogenic aetiology. This is due to a combination of poor
coronary perfusion, acidosis or possibly a depressant factor released from
ischaemic tissue. This will proceed to the so-called refractory shock where loss of
capillary vasomotor control leads to reduced tissue blood ﬂow, sludging in the
microcirculation and cellular hypoxia, and death. It has also been suggested that
refractory shock may partly have a septic component from bacterial or endo-
toxin translocation across the gut wall.
The golden hour
• The original concept of a “golden hour” or a critical therapeutic “window” of
opportunity was applied to shock following traumatic injury but probably applies
to outcome following shock due to any cause. Although generally accepted as a
principle, it was originally based solely on animal studies backed up later by 
circumstantial patient evidence.
• In general, if the duration of shock exceeds an hour, mortality increases pro-
gressively due to development of refractory shock or from the insidious devel-
opment of organ failure. If shock is prolonged the patient is likely to die at a
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later stage from organ failures, even if the original “shock” is subsequently
reversed.
• Thus, speed is of extreme importance in resuscitating shocked patients.
• Therefore, it is common to initiate treatment empirically while the speciﬁc
cause is being identiﬁed although common sense should tell one that the young
man presenting with a large gastrointestinal (GI) bleed is suffering from haemor-
rhagic shock! The urgency of the situation may warrant the use of vasopressors
to maintain coronary perfusion pressure while other therapies and diagnostic
procedures are being instituted.
Anaphylactic shock
In anaphylactic shock the trigger stimulus causes release of histamine, sero-
tonin, slow release substance, kinins and other vasoactive materials mainly from
mast cells. These substances act primarily on smooth muscle leading to peri-
pheral and airway oedema (stridor may not appear until 80% of the airway is
obstructed), bronchospasm and vasodilatation, and capillary leakage. Some of
the mediators may also act directly on the myocardium.
The two major causes of death are “shock” including cardiac depression and
laryngeal oedema.
Management includes:
• Withdrawing the trigger stimulus, basic life support and cardiopulmonary
resuscitation (CPR).
• Laryngeal oedema may require intubation or cricothyrotomy or may settle
with nebulised adrenaline in less severe reactions.
• IV ﬂuids especially colloids should be administered to restore plasma volume.
A 1 mm layer of subcutaneous ﬂuid over the whole body is equivalent to a
loss of approximately 1.5 l of extracellular ﬂuid.
• The agent of choice in severe reactions is adrenaline by incremental dosage as
required. Infusions may be required after the initial treatment especially fol-
lowing reactions to agents with a long plasma half-life such as artiﬁcial col-
loids. In addition to its beneﬁcial cardiac effects it is a speciﬁc antidote as it
blocks mediator release from mast cells. If the intravenous route is not imme-
diately available, adrenaline may be administered down the tracheal tube.
• Steroids are usually administered but take several hours to have an effect.
• Salbutamol may help for persistent bronchospasm but aminophylline should
probably be avoided as there is an increased risk of serious arrhythmias when
given in the presence of increased adrenaline blood levels.
• Antihistamines such as piriton are of little value in acute anaphylaxis as they
do not reverse the effect of histamine already released and have no effect on
the actions of mediators other than histamine. Logically, many authors con-
tend that if antihistamines are desired to be given, both H1 and H2 receptors
must be blocked for maximum therapeutic effect.
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Oxygen therapy
D. Kelly
Gas ﬂow into the lung varies sinusoidally. The ﬂow rate at its peak can vary enor-
mously and reach values over 100 l/min. However values of around 50–60 l/min
are more common. The ﬂow rate depends on several factors such as:
• patient size,
• muscle power and endurance,
• disease state,
• presence or absence of airﬂow obstruction,
• compliance of lung.
Intratracheal oxygen concentrations will only stay constant if the total gas ﬂow is
high enough to meet the demands of the patient at all points of the inspiratory
cycle. Environmental air will be entrained to make up the shortfall if the delivery
system fails to deliver a high enough ﬂow.
Very few oxygen delivery systems meet these requirements and consequently
intratracheal oxygen concentrations can vary enormously:
• both between patients using the same device,
• within the same patient using the same device but under different circumstances.
As the delivered ﬂow rate is not high enough at some point during inspiration, air
is entrained which dilutes the actual FiO2 as Table 3.1 illustrates.
Delivery devices
Nasal catheters
Can be single or double pronged. The single catheters are more recent and are
better tolerated due to a foam collar around their distal end. Nasal catheters are
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better tolerated by patients and are more likely to be kept on. However, as can be
seen from Table 3.1, the intratracheal FiO2 varies with gas ﬂow rate and patients’
inspiratory ﬂows.
Low-ﬂow masks
Masks such as the Hudson rely on the entrainment of air around the mask and
through holes in the mask to meet the patients demand for gas and as explained
earlier this can vary enormously. The higher the inspiratory ﬂow rate, the more
air is entrained and the lower the inspired FiO2.
Low-ﬂow masks with reservoirs
Adding a reservoir for oxygen to these masks diminishes the amount of air that
needs to be entrained to match the inspired ﬂow rates and consequently the FiO2
is higher. Oxygen has to be supplied at a high enough rate to keep the reservoir
bag inﬂated. If this is achieved then the FiO2 can be as high as 85%.
Table 3.1. O2 concentrations prescribed compared with O2 concentrations 
delivered to trachea
% in trachea
% O2 Quiet Normal
Apparatus delivered breathing breathing Hyperventilation
Face mask with 44 39.5 32.7 26
nebuliser at 10 l/min 60 53.4 50.3 41
100 62.7 52 42
Face mask with 44 41.1 34.2 29.1
nebuliser at 15 l/min 60 52.5 46.1 40.1
100 68.1 54 50.2
Venturi mask 24 23.1 22 21
at 4 l/min 28 24.2 23 21.4
Venturi mask 35 32.3 30 26.2
at 8 l/min 40 36.4 33.1 29.4
Adapted with permission from Gibson RL, Comer PB, Beckham RW, Mcgraw CP. Actual tracheal
oxygen concentrations with commonly used oxygen equipment. Anesthesiology 1976; 44: 73.
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High-ﬂow masks
These masks entrain air using the oxygen supply as a jet stream. The fast moving
gas imparts energy to the static gas, that is air and some of this gas is dragged
along with the faster stream. These masks were traditionally known as venturi
masks although it is not strictly a venturi effect which entrains the air [1]. The oxy-
gen concentration is preset if the oxygen ﬂows to the mask are set correctly. These
masks are more likely to provide a more reliable intratracheal oxygen concentra-
tion. However if the inspiratory ﬂow rates are high even these delivery systems
will not meet the needs of the patient and the intratracheal FiO2 will be lower
than prescribed.
T-pieces
These are connected to endotracheal or tracheostomy tubes and are supplied
with humidiﬁed air and oxygen from a variable entrainment device. At the higher
oxygen concentrations the total gas ﬂow is much less and dilution of the inspired
FiO2 from the open end of the T-piece can be considerable. This can be reduced
by adding a length of tubing to this open end which will then act as a reservoir of
oxygen enriched air.
Constant positive airway pressure
This refers to CPAP. These systems aim to maintain the airway pressure positive
relative to atmospheric pressure at all phases of the respiratory cycle. They do
this by utilising expiratory valves which raise the pressure and either high-ﬂow
rates or a mixture of high-ﬂow rates and a pressurised reservoir to minimise the
ﬂuctuations in pressure during the respiratory cycle. The work of breathing is
minimised by keeping the degree of pressure ﬂuctuation to a minimum. In order
to maintain the system pressure it is important to minimise leakage. Tight ﬁtting
face masks are mandatory and avoiding pressure effects from these can be difﬁ-
cult. Owing to the closed nature of these systems and high gas ﬂows utilised the
FiO2 is a much more reliable predictor of intratracheal oxygen concentrations.
Beneﬁts of CPAP
• A predictable FiO2.
• An increase in FRC.
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• A reduction in the work of breathing because the increase in lung volume moves
the lung to a more favourable part of its pressure volume curve.
• A reduction in pulmonary vascular resistance secondary to the improvement
in lung volume and relief of hypoxaemia.
Disadvantages of CPAP
• It increases mean intrathoracic pressure which reduces venous return to the
heart.
• It requires a certain amount of technical expertise to assemble the circuit correctly.
• The high-gas ﬂows are difﬁcult to humidify.
• The tight ﬁtting face masks are sometimes poorly tolerated and cause pressure
effects.
Hypoxic drive
During an exacerbation of chronic obstructive pulmonary disease (COPD) venti-
latory drive can be four times normal [2]. Administering oxygen will reduce the
drive but it does not return to normal and remains elevated [3]. The reduction in
drive however will lead to a rise in the PaCO2. If this is clinically signiﬁcant then
consideration should be given to some form of ventilatory support. A saturation
of 90% should be aimed for. This will avoid most of the consequences of hypox-
aemia without reducing the respiratory drive unduly. However, some patients
with COPD will develop CO2 narcosis when given oxygen therapy, even at low
concentrations. This may sometimes be managed by reducing the concentration
of inspired oxygen. Otherwise, Doxapram may produce a slight and temporary
improvement in blood gases in some patients. Ventilation, by invasive and non-
invasive means, is the only other reasonable alternative at present.
It should be borne in mind that a hypoxaemic arrest is much more damaging
than a hypercapnic respiratory arrest.
Oxygen toxicity
Oxygen toxicity in critically ill patients is perhaps controversial but there is no
doubt that in certain situations an excess of oxygen is toxic (before discussing oxy-
gen toxicity one must not forget other hazards of high concentrations of oxygen,
e.g. ﬁre hazard).
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In general, clinical evidence for oxygen toxicity revolves around three situations:
(1) Oxygen convulsions (the Paul Bert effect)
Exposure to oxygen at greater than 2 atmospheres of pressure may cause
convulsions. The mechanisms are unclear.
(2) Retrolental ﬁbroplasia (RLF)
The observation that hyperoxia is the major aetiological factor in the above
condition has led to tight control of oxygen therapy in neonates. In rare cases
a similar pathology can occur in adults.
(3) Pulmonary oxygen toxicity of major relevance to intensive care unit (ICU) 
therapy
There are considerable problems in investigating pulmonary oxygen toxicity,
not least in distinguishing between the effects of hyperoxia and of the pul-
monary pathology requiring ventilation. Many of the studies demonstrating
oxygen toxicity were done on animals or human volunteers.
Certainly breathing 100% oxygen produces:
• slight respiratory depression;
• painful tracheitis;
• mild depression of both heart rate and cardiac output;
• constriction of blood vessels;
• with prolonged inhalation, depression of red blood cells (RBC) formation;
• reduced secretion of surfactant;
• capillary endothelium permeability may also be increased leading to intersti-
tial oedema;
• absorption atelectasis due to loss of nitrogen “splinting” small airways blocked
by secretions.
In the 1940s it became accepted that the threshold for safety was an exposure to
an inspired concentration of 60% oxygen. However, there is evidence that pul-
monary toxicity may be related to high PaO2 rather than inspired oxygen. During
manned spaceﬂight, exposure to 100% oxygen at 0.3 atmospheres of pressure
produces no great problems.
Thus it is suggested that, at least in part, the mechanism of pulmonary damage
in patients requiring high inspired concentrations of oxygen may be the associated
ventilatory manoeuvres required for patients with signiﬁcant pulmonary path-
ology, that is the high pressures, shearing forces and high lung volumes generated.
In addition, some of the postulated harmful effects may be due to toxic oxygen
free radicals. It has been suggested that a stepwise increase in FiO2 (as is normally
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seen in the face of deteriorating gas exchange) results in the stimulation of protect-
ive enzymes, for example superoxide dismutase which “mop up” the free radicals,
thus preventing many of the harmful effects [4]. Certainly there must be some
protective mechanism at work or no patient ventilated with 100% oxygen should
recover (and some eventually do).
Another problem is that there are some drugs whose ability to cause alveolitis
is enhanced by a high oxygen environment. Bleomycin is the best known but
there are a number of reports implicating amiodarone in acute pulmonary tox-
icity when the lung is exposed to an increased FiO2 [5]. In these circumstances
the inspired oxygen should be kept as low as possible.
Conclusion
• Hyperoxia may produce harmful pulmonary effects, but it is very difﬁcult to
separate these effects from the effects of the pathology which necessitates the
high FiO2 in the ﬁrst place or the associated mechanical ventilation.
• It is obviously sensible to limit the FiO2 where possible (oxygen should be
treated as any other drug with the correct dose being administered and unneces-
sary overdose avoided) to that producing the minimal acceptable PO2.
• However, there is no excuse for allowing a patient to become hypoxic for fear of
the risk of oxygen toxicity.
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Central venous access
T. Owen
Over 200,000 Central venous catheters (CVC’s) are inserted in the UK each year
[1] and many of these are either inserted in, or cared for in the intensive care set-
ting. Therefore a comprehensive knowledge of any complications and methods
of minimising these complications are essential for the intensive care physician.
Indications
The indications are as follows:
• haemodynamic monitoring,
• intravenous infusion of ﬂuids,
• intravenous infusion of drugs (e.g. inotropes, antibiotics),
• total parenteral nutrition (TPN),
• renal replacement therapy,
• intravenous access in patients with poor peripheral access (e.g. IV drug
abusers).
Sites used for insertion
Sites used for central venous cannulation include:
• internal jugular vein (IJV),
• subclavian vein (SV),
• femoral vein (FV),
• external jugular vein,
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• axillary vein,
• peripherally-inserted central catheter (PICC).
The ﬁrst three of the above are the most commonly used, and this chapter will
concentrate mainly on these. The fact that there is such a choice of sites suggests
that there is not one site that is signiﬁcantly better for CVC insertion than any
other. Indeed each one has its own advantages and disadvantages, and choosing
which site to use is also discussed in this chapter.
Insertion technique: landmark or ultrasound?
The standard technique for CVC placement is using the “landmark” method – the
relationship of the chosen vein to known anatomical landmarks is used to guide
the needle in the right direction. However this is now changing with the increas-
ing use of ultrasound guidance to aid insertion. The recent National Institute for
Clinical Excellence (NICE) guidelines on use of ultrasound guidance for CVC
placement [1] have caused considerable controversy amongst both anaesthetists
and intensivists [2–4].
The NICE recommendations are as follows:
• 2-D imaging ultrasound guidance is the preferred method for CVC insertion in
the IJV in elective situations.
• 2-D imaging ultrasound guidance should be considered in most clinical cir-
cumstances, elective or emergency.
• Those using 2-D imaging ultrasound guidance should be appropriately trained
to achieve competence.
• Audio-guided Doppler ultrasound guidance not recommended.
The potential advantages of the use of ultrasound-guided cannulation include:
• Identiﬁcation of anatomical variations in vein position and vein thrombosis:
studies have shown that the IJV does not follow the traditional landmarks, with
abnormal anatomy or thrombosis seen in up to 10–20% of patients [5–7], even
more commonly in some subgroups [8, 9].
• Fewer failed catheter placements: this can lead to potentially critical delays in
instigation of treatment.
• Fewer attempts to pass catheter: it has been shown that the risk of complica-
tions increases with the number of attempts required to pass the CVC [10].
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• Avoidance of arterial puncture and other immediate complications.
• Less time taken: as fewer failed placements and fewer attempts required.
• Cost-effective: due to less time and avoiding the economic impact of treating
complications.
NICE commissioned a meta-analysis by Hind et al [11] to “assess the evidence for
the clinical effectiveness of US-guided central venous cannulation” which
looked at ﬁve outcomes: failed catheter placement, complications from place-
ment, failed ﬁrst attempt at placement, number of attempts required and time to
successful cannulation.
The results showed that US-guided cannulation was more effective than the
landmark method in all ﬁve outcomes for IJV cannulation. Risk of failed catheter
placement for subclavian and femoral approaches was also shown to be less with
ultrasound guidance but from more limited evidence, so no recommendations
were made for these approaches.
The cost-effectiveness of ultrasound guidance was assessed by use of an eco-
nomic model that look into account initial outlay, maintenance, training and the
cost savings of fewer complications. This suggested a saving of £2 per patient
when ultrasound guidance was used.
Although the Royal College of Anaesthetists (RCA) were consulted at the draft
stage of the report, many anaesthetists and intensivists remained critical of a
number of areas of the guidelines:
• The meta-analysis included some unblinded and some under-powered trials.
• The quoted frequency of carotid puncture was considered not wholly accurate.
• Potential for de-skilling of trainees in the landmark approach.
• The potential medico-legal implications of not using ultrasound if one was
available.
• The initial outlay required, and the validity of the analytical model used to
show cost-effectiveness.
Many of these concerns were covered in an RCA statement [12] and a British
Journal of Anaesthesia editorial [2], but the concerns still remain and ultrasound-
guided cannulation is not yet the standard technique the Department of Health
(DoH) would like it to be.
Further studies have been undertaken since the meta-analysis by Hind et al, with
conﬂicting results. A prospective randomised trial compared IJV cannulation
using anatomical landmarks or prepuncture ultrasound [13]. Pre-puncture ultra-
sound only improved complication and success rate in patients where respiratory
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jugular venodilation could not be identiﬁed. A prospective analysis by Martin 
et al [14] also goes against the use of ultrasound, showing no improvement in
CVC placement by junior residents (whatever their year of training).
Two prospective analyses [15, 16] with 29 and 493 patients, respectively did
however support the use of ultrasound, one claiming a change in management
rate of 14% when ultrasound was used, and the other, using a two person tech-
nique showing a signiﬁcant decrease in complication and failure rate when the
“sonographer” was familiar with the method.
The axillary vein is also becoming more popular, being easier to visualise with
ultrasound and having a lower complication rate than the subclavian approach [17].
It is clear then that the controversies surrounding the use of ultrasound guid-
ance are set to continue. A recent postal survey of Scottish and Merseyside ICU’s
[18], with a 73% and 100% response respectively, showed that 65% of Scottish and
all Merseyside ICU’s used ultrasound only in difﬁcult situations, most thought it
took longer and about half were concerned about de-skilling of staff. Very little
formal training was given in either region. However, the majority were planning
to implement the NICE guidelines despite their reservations.
Complications of CVCs
Insertion of a CVC is not a benign procedure and is associated with complications
that can cause considerable morbidity. Death due to a pneumothorax caused dur-
ing CVC insertion has been reported. The following is one of numerous ways of
classifying the complications associated with insertion and use of CVCs.
(1) Mechanical complications (6–19% of patients):
(a) arterial puncture,
(b) haematoma formation,
(c) pneumothorax,
(d) haemothorax,
(e) nerve injury,
(f) arrhythmias,
(g) cardiac tamponade,
(h) arterio-venous ﬁstula,
(i) air embolism,
(2) Failure of cannulation (1–35%);
(3) Malposition of CVC (5–37%);
(4) Thrombosis (2–40%);
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(5) Infective complications (5–26%):
(a) local infection,
(b) catheter colonisation,
(c) catheter-related blood stream infection (CR-BSI).
Mechanical complications
Table 4.1 summarises the frequency of the main mechanical complications at the
three main insertion sites. As can be seen, the risk of complications is similar
with SV and IJV and higher with the FV approach. The SV has the lowest risk of
arterial puncture but the greatest risk of pneumo/haemothorax, whilst the IJV
has a lower rate of pneumo/haemothorax, but a higher risk of arterial puncture.
The FV has no risk of pneumo/haemothorax but the highest risk of arterial punc-
ture or haematoma.
The consequence of each complication is also different at each site. For example,
arterial puncture can cause uncontrolled, concealed haemorrhage if occurring
via the SV approach as the subclavian artery is relatively incompressible and may
track into the pleural space. The same complication with the IJV approach can
lead to cerebrovascular accidents (CVA) if there is severe carotid artery disease or
even airway obstruction if a large haematoma were to form but it is however
more compressible therefore much easier to control any bleeding.
Failure of cannulation
Failed cannulation, as well as being a blow to personal pride, can lead to consid-
erable time consumption and potentially fatal delays in instigation in treatment
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Table 4.1. Frequency of mechanical complications at different insertion sites
From McGee et al [19]
Frequency
Complication IJV SV FV
Arterial puncture 6.3–9.4 3.1–4.9 9.0–15.0
Haematoma 0.1–2.2 1.2–2.1 3.8–4.4
Haemothorax 0 0.4–0.6 0
Pneumothorax 0.1–0.2 1.5–3.1 0
Total 6.3–11.8 6.2–10.7 12.8–19.4
of the patients underlying problems. More attempts at cannulation also increase
the risks of mechanical complications [10]. There is also an economic cost.
Methods to minimise this risk include appropriate training in insertion tech-
niques, correct choice of insertion site, correct positioning of patient and use of
ultrasound-guided cannulation.
Malposition of CVC
CVC’s are ideally positioned either in the superior vena cava (SV/IJV approaches)
or thoracic inferior vena cava (FV approach). Insertion into the right atrium risks
arrhythmias and erosion through the atrial wall leading to cardiac tamponade,
whereas if it is not far enough in the risk of thrombosis is increased [20]. When
checking the position on a chest X-ray, the tip should be level with the carina,
which has been shown to be a consistent anatomical landmark in relation to the
pericardial sac [21].
Placement of CVC’s in the opposite subclavian or neck vein, axillary or even inter-
nal mammary vein is possible and this may require resiting of the CVC. It may also
mean incorrect central venous pressure (CVP) measurements, delivery of irritant
drugs to the peripheral circulation and subsequent inﬂammation or thrombosis.
According to one meta-analysis, malposition is signiﬁcantly less common
with the IJV approach than the SV approach [22] (5.3% versus 9.3%) though other
studies could detect no difference or found the opposite [10, 22–24]. The FV
approach appears to have the highest malposition rate, one study showing 17%
of CVC’s in the right atrium, and only 63% in the thoracic inferior vena cava [26].
Thrombosis
Thrombosis of CVC’s is a frequent (10–66%) complication, but is asymptomatic
in two-thirds of cases. Although most studies in this area looked at long-term
catheters in cancer patients, thrombosis occurred within the ﬁrst 8 days in around
64–98% of those in whom thrombosis developed [27]. The main sequelae of
catheter thrombosis are:
• Catheter-related sepsis: the risk of catheter-related sepsis is 2.6 times greater in
those catheters with thrombosis than those without [28].
• Pulmonary embolism: seen in 7–31% of patients, of which half are asymptom-
atic. They are not usually fatal [27, 28].
• Postphlebitic syndrome: seen in 15–35%, though the long-term consequence of
this is not known [27].
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Prevention of thrombosis can be achieved in the following ways:
• Choice of insertion site: the SV has the lowest frequency of thrombosis (1.9–10%),
with IJV and SV catheter thrombosis much higher (20–40%) [22, 26–28].
• Position of tip: thrombosis is less common when the CVC tip is placed in the
distal superior vena cava rather than proximal [20, 27].
• Anticoagulation: the use of low molecular weight heparin (LMWH) or low dose
warfarin has been shown to decrease the incidence of catheter-related throm-
bosis [27].
Infective complications
Catheter-related sepsis is a major cause of morbidity and mortality in ICU
patients, and is the most common cause of hospital-acquired bacteraemia. As
stated earlier catheter-related infection is generally divided as follows:
• Local infection: presents as local inﬂammation or pus formation around the
site of insertion.
• Catheter colonisation: can be deﬁned as greater than 15 colony-forming units
(CFU’s) from culture of either the catheter tip or subcutaneous portion of the
catheter.
• CR-BSI: culture of the same organism from the catheter and from blood taken
from a peripheral site.
Pathogenesis of CR-BSI
Infections can develop in one of three ways:
• Migration from insertion site: spread from the insertion site along the catheter
track is responsible for most cases of early (10 days) CR-BSI.
• Contamination of catheter hubs: this generally causes CR-BSI in catheters that
have been inserted for longer periods.
• Seeding of catheter from distant location: a focus of infection elsewhere in the
body can occasionally cause CR-BSI.
The organisms responsible include:
• coagulase-negative staphylococci (32–41%),
• Staphylococcus aureus (18–31%),
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• Gram-negative bacilli (10–18%),
• yeasts (9–11%),
• pseudomonas (4–6%),
• Entero/Streptococci (3–14%).
Prevention of CR-BSI
The most recent guidelines for prevention of catheter-related infections are from
the DoH in 2001 [30] and US equivalent in 2002 [31]. There is however continued
research into new methods of prevention published on a regular basis. A brief
summary of the recommendations from these guidelines, together with more
recent research, is summarised as follows:
• Education: Ensuring that all staff are aware and are trained in procedures to
decrease the risk of catheter-related infection is well proven, as are the use of
infection-control teams [31].
• Site of insertion: Despite a lack of randomised studies, the SV approach is gen-
erally excepted as at lowest risk of developing catheter-related infection, while
the FV is the site most likely [29–31]. Use of peripheral venous catheters or
PICC’s will result in a much lower risk of infection.
• Aseptic technique: Use of maximal barrier precautions during insertion (cap,
mask, sterile gown, sterile gloves and large sterile drape) decreases the risk of
infection [30, 31].
• Skin antisepsis: 2% chlorhexidine gluconate has been shown to be more effect-
ive at preventing catheter colonisation than both povidine-iodine and 70%
alcohol [31].
• Catheter site dressings: No difference has been shown between transparent and
gauze dressings [31]. A logical approach would be to use gauze dressings if
there was any ooze or bleeding after initial insertion and then replace with a
transparent dressing so that the site could be observed for signs of infection
without further disturbance. One study has shown a decrease in CR-BSI with
the use of chlorhexidine-impregnated sponge dressing [32].
• Antimicrobial/antiseptic impregnated catheters: CVC’s coated externally with
chlorhexidine and silver sulfadiazine decrease risk of CR-BSI in short-term
catheters [33], but are ineffective in the longer term as would be expected
according to the pathogenesis described previously. Minocycline/rifampin
impregnated CVC’s are coated both internally and externally, and are effective
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in preventing CR-BSI for up to 30 days and appear cost-effective [33]. An as yet
unproven concern is that of potential antimicrobial resistance.
• Single-lumen versus multi-lumen catheters: The requirement for multi-lumen
catheters on intensive therapy/treatment unit (ITU) far outweigh the few stud-
ies that suggest an increased risk of infection.
• Antibiotic prophylaxis: No convincing evidence for this has been found [31].
• Anticoagulant prophylaxis: As discussed earlier, thrombosis has been shown to
increase risk of infection. Most ITU patients have indications for LMWH and
there is enough evidence to suggest it may well decrease the risk of catheter-
related infection [33].
• Routine replacement of CVC: There is no evidence that routine replacement of
CVC’s either at a new site or by guide-wire exchange reduces the risk of
catheter-related infection [30, 31].
• Silver iontophoretic device: May be effective but not proven [33].
• Iodinated alcohol-containing catheter hub: Evidence not convincing, though a
povidine-iodine impregnated sponge over the hub may be effective [33].
• Antimicrobial locks: Vancomycin has been used in long-term catheters with
some success, but routine use on ITU inadvisable due to risk of developing
Vancomycin resistant Enterococci [33].
• Silver impregnated subcutaneous cuff: May prevent CR-BSI for ﬁrst 10 days [33].
Management of suspected CR-BSI
Diagnosis
Infection in an ITU patient can be from many sources, of which a CVC must
always be considered, however well the above recommendations have been
adhered to. There is unfortunately no quick and easy way to identify whether a
CVC is the source of infection or not. An ideal approach would let the diagnosis
or exclusion of a CR-BSI be achieved without the need for removal of the catheter
thereby reducing risks of new catheter placement.
At present, the most common method of diagnosing a CR-BSI is by culture of
the catheter tip (or subcutaneous portion of the CVC) along with a blood culture
from a peripheral site; CR-BSI being assumed if the same organism is grown from
both. This results however in many catheters being removed unnecessarily.
The simplest approach that would avoid CVC removal involves simultaneous
blood cultures from the CVC and a peripheral site. If the time difference to a 
positive culture between the two is 2 h this would suggest the CVC as the
source of infection and has speciﬁcity and sensitivity 90% [34].
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Treatment
If a CVC is thought to be infected and diagnosis is uncertain (a not uncommon
problem), various different methods of treatment have been suggested:
• Removal / resiting of CVC: This is the treatment of choice if there is obvious
exit site infection, if it is no longer required or if there is severe sepsis with no
obvious cause. If there are only mild signs of sepsis however, this method is not
the only option.
• Rewiring of CVC: The DoH guidelines recommend this if there are no signs of local
infection or proven CR-BSI. The CVC should be removed if subsequent micro-
biology proves positive for CR-BSI. A systematic review did show a (non-
signiﬁcant) trend towards increased risk of catheter-related infection with this
technique [35].
• Antibiotics without CVC removal: one study has suggested that CR-BSI caused
by coagulase-negative staphylococcus can be treated without removal of CVC
[36], though other organisms will persist if the CVC is not removed.
The antibiotic of choice depends partly on local policy and partly on the clinical
status of the patient. First-line treatment is generally ﬂucloxacillin or a ﬁrst-
generation cephalosporin unless they are high-risk for methicillin resistant
Staphylococcus aureus (MRSA) or are penicillin allergic in which case a glycopep-
tide would be appropriate.
Which insertion site to use?
As stated previously the three most common sites used for insertion are the FV, SV,
IJV. When deciding which site to use the following questions need to be considered:
• How good is the access to the site?
Obese patients may well have difﬁcult access to the IJV due to obscuring of
landmarks, whilst their groin regions may often be infected, excluding femoral
catheterisation. Patients may have deformity due to trauma, previous surgery
or congenital disease that will make a particular site less favourable.
• What is the frequency of complications at that site?
As described earlier in the chapter, there is an important variation in frequency
of different complications at different sites.
• Which complications do you most want to avoid?
Even if a complication is less common at one site, the potential for harm if it
does occur could be much greater than at other sites. Therefore patient factors
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that may make a particular complication much more serious should have
taken into consideration. Examples include pneumothorax in a patient with
severe respiratory failure, subclavian artery puncture in the coagulopathic
patient, carotid artery puncture in a patient with severe carotid atherosclerosis
and infection in a neutropenic patient.
• Why is a CVC required?
If central venous access is required solely for TPN, a PICC may be more appro-
priate to minimise the risk of infection. If required for haemodialysis the SV
can sometimes be problematic as kinking under the clavicle may prevent 
adequate ﬂow rates.
• How experienced are you in insertion at different sites?
If not trained or experienced in a particular approach, then this approach
should be avoided, although Lefrant et al did not identify operator’s training as
predictive of immediate complications or failure [9].
It is clear from these points that choice of site must be made on a case-by-case
basis, taking into account both technical and patient factors.
A good general approach for the “typical” ICU patient, in whom central venous
access is likely to be required for a considerable time, could be as follows:
• If appropriately experienced, and there are no patient contra-indications
(coagulopathy, respiratory compromise etc.), then the subclavian approach
should be the ﬁrst choice as this has the lowest risk of infection. Use of the lat-
eral approach may well help in visualisation of the vein with ultrasound [17].
• If the SV approach fails or is thought inappropriate then the IJV would be
preferable, but the FV could be used if risks of the IJV were considered unaccep-
table (unable to lie ﬂat, severe carotid disease, respiratory compromise etc.).
• Consider alternative sites such as axillary, external jugular and PICC’s.
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I. McConachie
Fluid therapy in ICU
Maintenance of normal hydration and electrolyte composition is essential in
intensive care unit (ICU) patients.
“Volume loading” is an important principle of cardiovascular management
and is the cornerstone of management of surgical and trauma patients.
Conversely, overhydration may be a factor in poor outcome from ICU care.
Body ﬂuid compartments
Water comprises approximately 60% of body weight. Approximately two-thirds
of this is intracellular ﬂuid and the remainder extracellular ﬂuid. Extracellular
ﬂuid is mainly interstitial ﬂuid with only 15–20% consisting of blood and 
plasma. In critically ill patients there are often considerable increases in extracel-
lular ﬂuid.
In order to understand the principles of ﬂuid therapy one must be aware 
of which body ﬂuid compartment one is wishing to maintain or resuscitate, 
for example:
• Intracellular space – deﬁcits mainly H2O.
• Interstitial space – deﬁcits H2O and electrolytes.
• Intravascular space – deﬁcits of plasma volume and/or red blood cell (RBC).
• Surgical and trauma patients may suffer losses of so-called “third space” ﬂuids
(called because it represents a third extracellular space) due to tissue ﬂuid
sequestration of interstitial ﬂuid (i.e. H2O and electrolytes).
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Fluid therapy involves the use of the following:
Crystalloids
• H2O with electrolytes approximating the composition and osmolality of plasma.
• Crystalloids redistribute through the extracellular ﬂuids and, therefore, only
about 20% of the volume administered will remain in the intravascular space.
• Hartmann’s solution (compound Ringer’s lactate) is closest in electrolyte compos-
ition to that of plasma and interstitial ﬂuid. It has a pH of 6.7. Osmolality slightly
reduced compared to plasma. The administration of lactate containing ﬂuids in
shock was once considered controversial but does not seem to worsen acidosis.
• 0.9% Saline (“normal” saline) contains 150 mmol/l of both Na and Cl: that is,
slightly increased Na but greatly increased Cl cf. plasma and interstitial ﬂuid.
Excess use can be associated with hyperchloraemic acidosis (see below) and
hypernatraemia. It has a pH of 5.7.
• Dextrose 5%. No electrolytes, just dextrose and H2O. Usually considered with
the crystalloids but technically is not one because it contains no Na. It has a pH
of 4.5. Its osmolality is lower than the other common crystalloids. May be use-
ful in the Na overloaded patient to replace H2O but otherwise plays little role in
ICU therapy. Dextrose 5% is not a resuscitation ﬂuid.
• Dextrose 4%/0.18% saline is commonly used as 2–3 l/day will approximate the
body’s requirement for H2O and Na. This is superﬁcially attractive as a mainten-
ance ﬂuid for the young and ﬁt but probably not in critically ill patients. In
addition, excessive use may place the elderly at risk of hyponatraemia due to
its slightly reduced osmolality compared to plasma.
Saline-induced metabolic acidosis and choice of crystalloid
As little as 2 l saline per hour will produce acidosis in healthy young patients
undergoing surgery [1]. The exact signiﬁcance of this with regard to outcome is
debatable.
• Compared with 0.9% saline, volume resuscitation with Hextend (starch with
balanced electrolyte solution) was associated with less metabolic acidosis and
longer survival in an experimental animal model of septic shock [2].
• In elderly surgical patients, the use of crystalloids and colloids containing bal-
anced electrolyte solutions prevented the development of hyperchloremic
metabolic acidosis and improved indices of gastric mucosal perfusion com-
pared with saline-based crystalloid and colloid ﬂuids [3].
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Thus many would consider “balanced” Hartmann’s solution to be superior to
“unbalanced” saline for use as a routine ﬂuid. However:
• The infusion of large volumes of Ringer’s lactate solution during major surgery
leads to postoperative mild hyponatraemia and respiratory acidosis [4].
• Large volumes of lactated Ringer’s solution administered to volunteers 
produced small transient reductions in serum osmolality. Large volumes of
sodium chloride did not change osmolality but resulted in lower pH [5].
In conclusion, excessive volumes of any one ﬂuid may be associated with 
problems.
For a full account of the effects of electrolytes on acid–base balance (see
Further reading).
Colloids
• H2O, electrolytes and other particles (synthetic or natural) large enough to
remain in the intravascular space for several hours.
• Albumin solutions are natural colloids and are discussed in detail below.
• Synthetic colloids are mainly starches or gelatin compounds.
Starches
• Molecular weight varies but most starches have a clinical effect within the
intravascular space of about 6 h. Anaphylaxis is rare.
• The starch particles are taken up by the reticuloendothelial system but long-
term effects of their retention in the body are not known. Itching is a problem
with the long lasting starches [6].
• Opinions differ regarding effects on coagulation – main effect is probably to
promote a dilutional coagulopathy if large volumes are administered. With
large volumes there may also be a reduction in Factor VIII levels and a similar
effect on platelet function to Von Willebrand’s disease.
• Pentastarch 10% is a ﬂuid with a lower molecular weight than Hydroxyethyl
starch – more readily broken down by the kidney and excreted. There was 
some initial enthusiasm that smaller starches such as Pentastarch may “plug”
the leaks in the capillaries in sepsis and other conditions with increases in
endothelial permeability. However, convincing evidence is lacking.
Gelatins
• Relatively cheap and widely used. The clinical effect within the intravascular
space lasts 3–4 h.
• Overuse should be limited by fear of excessive haemodilution which can
reduce DO2 after an initial rise [7].
• Coagulation effects are from haemodilution only. Haemaccel contains calcium
and therefore citrated blood should not be mixed in the same IV giving set.
• Allergic reactions are rare and usually mild.
• Gelatin ﬂuids are derived from bovine collagen but are considered free 
from risk of transmission of prions associated with Bovine Spongiform
Encephalitis (BSE).
Dextrans
• Dextrans contain polysaccharides. Higher-molecular-weight dextrans (dextran
70–70,000 Daltons weight) are effective plasma volume expanders.
• Some practitioners make use of their antithromboembolic and antisludging
properties in situations where peripheral perfusion is compromised.
• In general, they are not routinely used in ICU because they interfere with
crossmatching and large volumes may cause a coagulopathy.
Small volume resuscitation
An initial bolus of 20 ml/kg is often recommended as the initial ﬂuid volume in
resuscitation. Small volume resuscitation aims to achieve the same initial haemo-
dynamic response with 4 ml/kg of ﬂuid with, of course, advantages in terms of
time requirements for infusion and storage space required.
• Commonest ﬂuid studied has been 7.5% saline – signiﬁcantly hypertonic.
• Acts by many mechanisms including redistribution of interstitial ﬂuid to the
intravascular space and decreased cellular swelling, and tissue oedema.
• Increased blood pressure (BP), cardiac index (CI), renal blood ﬂow.
• Short-lived effect unless combined with colloid. Ultimately the interstitial ﬂuid
will have to be replaced.
• Main role has been in ﬁeld resuscitation to “buy time” [8].
• Excessive use will lead to hypernatraemia.
• Due to the reduced tissue oedema, may be useful in head injuries [9].
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Crystalloid versus colloid debate
There has been controversy over the best type of ﬂuid for resuscitation (i.e. crys-
talloids or colloids). Part of the problem is the lack of studies showing a sufﬁ-
ciently clear superiority of one ﬂuid type over another, sufﬁcient to convert its
opponents and without reasonable criticisms of study methodology. There are
several problems with most of the available studies for example, different
species, ﬂuids, injuries, illnesses, complications studied [10].
It is not widely appreciated that many of the original US studies of crystalloids
versus colloids in trauma patients were ﬂawed. This was because most patients
in both groups were given blood transfusions. In the US, patients are commonly
given whole blood (as opposed to packed red cells in the UK) that is, both groups
received colloid from the whole blood (i.e. there was no such thing as a pure crys-
talloid group).
In most studies there is probably a skewed distribution of severity of sickness
with a large group of patients who will do all right whichever ﬂuid is given and 
a smaller group of patients who will die regardless of which ﬂuid is given. These
patients may mask (statistically speaking) a group of patients in whom choice 
of ﬂuid may be critical. This possibility has been seized upon by the colloid
enthusiasts!
There are certain statements regarding the colloid/crystalloid controversy
which can be made which are reasonably accepted by both groups:
• Crystalloids replace interstitial losses. Colloids are superior at replacing
plasma volume deﬁcits – more quickly and lasting longer – giving greater
increases in CI and DO2. Crystalloid administration may also produce such
increases but approximately three times as much will be needed with conse-
quent delays in achieving goals of resuscitation.
• Crystalloids are cheap. Colloids are more expensive. Many centres in the US
use crystalloids almost exclusively. However it has been pointed out that 
whole blood may be a signiﬁcant source of colloid in studies purporting to use
no colloid.
• In most situations: for example, routine surgery both potentially give excellent
results if appropriate amounts are used.
• Many studies show similar effects on respiratory function. Overdose of either
may produce respiratory failure.
• Colloids do have speciﬁc if uncommon side effects such as allergic reactions
and impaired coagulation.
• Overdose of crystalloids certainly cause dramatic peripheral oedema. The
importance of this with regard to outcome is disputed but some concerns are
discussed below.
• In recent years concerns have been raised that the overuse of colloid ﬂuids may
be associated with a worsening of renal function. This has been termed “hyper-
oncotic acute renal failure”. The original reports concerned the use of Dextrans
(and at that time it was thought that there was either direct toxicity or accumu-
lation in the renal tubules) but may be seen with excess use of all colloids espe-
cially if the patient has other renal risk factors or is dehydrated. The problem
may be worse with use of colloids in large volumes or high molecular weights.
The theory proposed is that the resultant high plasma colloid osmotic pressure
counteracts opposing hydrostatic ﬁltration pressure in the glomerulus.
• Many believe in the “Golden Hour” for resuscitation and that, therefore, speed
of resuscitation is crucial. Therefore, when restoration of blood volume, car-
diac output (CO) and tissue perfusion is urgent colloids may be preferable to
crystalloid.
Most reasonable people do not take extreme positions in the debate. In most situ-
ations close monitoring especially with regard to ﬂuid overload is more import-
ant than absolute choice of ﬂuid.
However, recent systematic reviews have failed to uncover any survival beneﬁt
from the use of colloids [11, 12]. Indeed, there seems to be a slight survival beneﬁt
associated with the use of crystalloids compared with colloids in trauma patients.
In the ﬁrst edition of this text colloids, on balance, were favoured over crystal-
loids for many situations – especially in resuscitation. The author acknowledges
that the pendulum seems to be swinging in favour of more routine use of crystal-
loids. However, the most important points to remember are that:
• Anaemia is better tolerated than hypovolaemia.
• There is no doubt that the best replacement for major blood loss is blood.
Fluid maintenance strategies
• Fluid intake comes from total parenteral nutrition (TPN), enteral nutrition,
colloids, crystalloids and medications especially antibiotics. Thermodilution
CO measurements at 10 ml of ﬂuid per measurement must not be forgotten.
• Losses come from urine, faeces especially diarrhoea, skin and lung evaporation
(increases in fever), haemorrhage, third space losses, N/G drainage and ﬁstulae.
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Vascular ﬂuid may be lost to the circulation in ICU patients due to increased capil-
lary endothelium permeability (“leaky capillaries”). Humidiﬁed gases reduce the
insensible lung H2O losses in ventilated patients. Abnormal surgical losses for
example, from ﬁstulae, diarrhoea should be replaced with crystalloids.
• Hormonal changes promote Na and H2O retention following surgery.
• Less well appreciated is that some drugs promote ﬂuid retention – notably
steroids.
Volume-loading strategies
• Hypovolaemia must be treated promptly to restore organ perfusion.
• The consequences of hypovolaemia may be more difﬁcult to treat and carry a
higher mortality than the consequences of overhydration.
• In haemorrhage or hypovolaemia, 20 ml/kg ﬂuid bolus should be administered
rapidly.
• A volume challenge for example 5 ml/kg of colloid is probably indicated in all
cases of acute haemodynamic compromise.
• Inotropes can have disastrous consequences in the presence of hypovolaemia.
(see chapter on Inotropes and vasopressors)
• Fluid administration with for example, colloid is best guided by a response of
increasing stroke volume (SV) as a result of increasing pulmonary capillary
wedge pressure (PCWP); that is, stop administering colloid when there is no
further increase in SV with more ﬂuid.
• In the absence of a pulmonary artery ﬂotation catheters (PAFC), central venous
pressure (CVP) trends can be useful (the absolute CVP is not always that helpful
in ventilated patients) for example:
– No increase in CVP and BP with ﬂuid → Give more ﬂuid
– Increase in CVP and BP, and then decrease → Give more ﬂuid
– Increase in CVP but no increase in BP then → Give no more ﬂuid
– Increase in CVP but decrease in BP then → Give no more ﬂuid
• Overloaded, oedematous patients may still need colloid boluses to maintain
CO and ﬁlling pressures (i.e. the intravascular volume may still be low). The use
of vasopressors to maintain ﬁlling pressures in such patients is controversial as
splanchnic vasoconstriction may occur.
• Although difﬁcult to prove, many specialists believe that colloids are better
than crystalloids in oedematous patients with “leaky capillaries” – if only
because less volume will probably need to be given and, therefore, be available
to “leak out”.
• Short, large bore cannula give best ﬂows for rapid volume loading.
• Generous ﬂuid loading in many patients may be appropriate. For example,
Mythen and Webb showed in high-risk surgical patients that ﬂuid loading after
induction of anaesthesia to a maximum SV led to a reduction of the incidence
of low pHi from 50% to 10% [13].
• Using Doppler ultrasonography to measure CO, Singer showed that intraoper-
ative volume loading increased SV and CO, resulted in a more rapid post-
operative recovery and a reduced hospital stay in a study group of fractured
neck of femur patients [14].
• This approach must be tempered with caution in the elderly or patients with
known heart failure due to the potential risk of ﬂuid overload precipitating pul-
monary oedema. In these patients perioperative invasive monitoring may be
indicated.
The vexed question of albumin
Albumin is a natural colloid derived from pooled human plasma which has been
heat treated to prevent human immunodeﬁciency virus (HIV) and other viral
transmission. There remain concerns about the possible transmission of the BSE
prion by albumin administration.
The use of albumin solutions in ICU is controversial, relates to both ﬂuid ther-
apy and nutritional support, and merits discussion in some detail.
Until relatively recently albumin solutions were the only readily available col-
loid solution available in the USA.
Albumin solutions are still relatively expensive and scarce in many areas. One
American study had difﬁculty with patient inclusion due to an actual shortage of
albumin.
In ICU patients, albumin synthesis is reasonably well maintained but the vas-
cular permeability to albumin increases and the effective volume of distribution
is dramatically increased. In addition, albumin metabolism is also increased.
Thus, albumin blood levels fall rapidly in critical illness and reﬂect the severity of
illness, and mortality rather than nutritional status [15]. Trends in albumin levels
predict the difﬁculty of weaning from mechanical ventilation [16].
Albumin levels are relatively insensitive to nutritional support.
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Albumin blood levels improve as the underlying condition resolves, often
accompanied by a spontaneous diuresis.
Proponents of the use of albumin justify its use by citing:
• Increases in colloid oncotic pressure (COP).
• Free radical scavenging, binding of drugs and toxic substances [17].
• Increased incidence of diarrhoea in hypoalbuminaemia.
• Albumin is a “natural colloid”.
• If it is appropriate to replace low levels of for example, haemoglobin (Hb), elec-
trolytes etc., why not albumin?
However, the plasma/tissue COP gradient remains relatively well maintained and,
thus, numerous studies have failed to ﬁnd a relationship between low albumin
levels and pulmonary oedema. Most studies, for example, by Rubin [18], have failed
to ﬁnd beneﬁts from albumin supplementation in terms of length of stay, outcome
etc. despite signiﬁcant increases in albumin levels. The only signiﬁcant increase in
the albumin group in all studies has been in costs!
A controversial systematic review of the use of albumin concluded that “there is
no evidence that albumin administration reduces mortality in critically ill patients
with hypovolaemia, burns, or hypoalbuminaemia and a strong suggestion that it
may increase mortality. These data suggest that use of human albumin in critically
ill patients should be urgently reviewed and that it should not be used outside the
context of rigorously conducted, randomised controlled trials” [19]. Many believed
the conclusions to be unjustiﬁed and there are signiﬁcant concerns that the analy-
sis was based on studies of the use of albumin in ICU in two distinct circumstances:
• Use in nutritional support/to maintain serum albumin levels.
• Use as a resuscitation ﬂuid.
A landmark study from Australia [20] challenges the conclusions of the above
review. Almost 7000 patients were studied comparing 4% albumin with saline for
intravascular resuscitation. There were no differences in outcome at 28 days. Thus
the most recent (and arguably strongest) evidence suggests that albumin is, at the
very least, safe to give for ﬂuid resuscitation (at least as safe as saline).
Nevertheless, in many ICUs the use of albumin has declined to virtually zero.
Problems of ﬂuid overload
During critical illness many patients’ weight increases, probably reﬂecting
increased endothelial permeability as well as excessive administration of ﬂuids.
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This is associated with a poor outcome [21]. Whether removing or preventing 
this extra ﬂuid which has accumulated as oedema ﬂuid can improve this reduced
outcome back to “normal” is less certain. Certainly, the balance of opinion for
ventilated patients with acute respiratory distress syndrome (ARDS) is shifting
towards “keeping the patient dry” (as long as organ perfusion is well maintained)
[22]. In addition, a pilot study has suggested that at least 1 day of negative ﬂuid
balance by the 3rd day of ICU admission predicts improved chances of survival in
patients with septic shock [23]. A controlled trial of “normal” ﬂuid administration
versus ﬂuid administration aiming to avoid increases in patient weight in colorec-
tal surgery patients showed a dramatic increase in survival and less complications
in patients treated with less intravenous ﬂuids so as not to gain weight [24].
Harmful effects of the extra ﬂuid may include:
• Increased lung H2O, reduced pulmonary compliance and impaired gas exchange.
• Ileus may be promoted due to oedema of the gut. In one study of patients
undergoing major bowel surgery, a positive balance sufﬁcient to cause a 3 kg
weight gain after surgery delayed return of gastrointestinal function and pro-
longed hospital stay [25].
• Tissue oxygenation [26] and, by association, wound healing may be impaired
by the tissue oedema associated with excessive crystalloid administration.
Thus it is important to watch intake closely and match to output where possible.
Useful points are:
• Weighing the patient daily is important.
• Minimise ﬂuids required to administer medications.
• Once patient is established on nutritional support may not require “routine”
maintenance crystalloids.
• Dramatic weight gain should be resisted if necessary by the judicious use of
low-dose diuretics if haemodynamically tolerated.
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Anaemia and blood transfusion
I. McConachie
Anaemia is extremely common amongst critically ill patients, whether as a direct
result of their admission diagnosis, as a complication of their stay in intensive
care or, indeed, from iatrogenic causes:
• In the multicentre European ABC study (Anaemia and Blood transfusion in
Critical care), 29% of patients were anaemic at some point in their stay
(deﬁned as an Hb (haemoglobin) concentration 10 g/dl [1]).
• In non-bleeding ICU patients the average fall in Hb concentration has been
shown in one study [2] to be 0.52 g/dl/day. The decline was larger for the 1st 
3 days than later days and was greater in septic patients.
Aetiology of anaemia on adult intensive care unit
Many factors are involved in the aetiology of anaemia in the critically ill:
• Surgical and traumatic blood loss.
• There is a blunted erythropoietin (EPO) response in critical illness [3]. EPO
production will be further reduced if renal failure develops.
• Gastrointestinal blood loss; either as the admission diagnosis or occurring as a
complication of critical illness. Even without overt melaena and despite the use
of pharmacological prophylaxis a slow but continuous G-I mucosal blood loss
may well be a major contributing factor to the anaemia seen on Intensive Care
Unit (ICU). For example, an endoscopic study [4] performed at the time of ICU
admission found that the frequency of acute gastric erosions was 21.7%. By the
third day of admission the frequency had increased to 37.5% in patients receiv-
ing prophylaxis with Sucralfate and 88.9% in patients with no prophylaxis.
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• With renal replacement therapy one can expect an increase in blood transfu-
sion rate compared to patients not receiving renal support. This is correlated to
the ﬁlter life span i.e. when the ﬁlter membranes become clotted red blood cells
(RBCs) are lost [5]. The anticoagulation necessary for renal replacement ther-
apy may also increase the risk of anaemia.
• Diagnostic blood sampling results in approximately 40 ml of blood loss per day
[2]. This is reduced compared to previous studies suggesting that the now com-
monly used bedside micro-analyser systems may have an impact on the total
blood loss during ICU stay.
• Spillage during vascular cannulation.
• Coagulopathy and haemolysis.
• Other factors (e.g. iron, B12 and folate availability).
Effects of anaemia
Chapter 1 has shown the role of Hb in overall oxygen delivery (DO2). It can easily
be seen that a fall in Hb may have a profound effect on global DO2 unless com-
pensatory mechanisms occur. It is on this premise that RBC are often transfused,
that is, to augment DO2. One must be careful to distinguish between the effects
of anaemia and those of hypovolaemia – especially with acute blood loss. There
is no doubt that hypovolaemia is much poor tolerated than anaemia. Thus,
where hypovolaemia is present, restoration of blood volume and cardiac output
is the ﬁrst priority.
In the normovolaemic patient a rapid fall in Hb brings about certain compen-
satory changes:
• The decrease in plasma viscosity improves peripheral blood ﬂow and thus
enhances venous return to the right atrium. The reduced viscosity also reduces
afterload, which may be an important mechanism in maintaining or increas-
ing cardiac output.
• A rightward shift in the oxyhaemoglobin dissociation curve (ODC) is seen, which
increases the O2 unloading by Hb for a given blood PO2. The primary reason 
for this is the increased red cell 2,3-diphosphoglycerate synthesis seen during
anaemia.
Whether or not these compensatory mechanisms are as successful in maintain-
ing oxygen consumption (VO2) during critical illness as they are during other
anaemic states is unknown.
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There will be additional physiological responses if the anaemia results from
acute haemorrhage leading to a fall in blood volume.
Role of anaemia in morbidity and mortality
Both critical illness and anaemia put stress on the myocardium to increase cardiac
output and hence global DO2. To do so myocardial DO2 must increase to meet its
own increased O2 demand (MVO2). As normal myocardial O2 extraction runs at
between 75% and 80% any increase in MVO2 must be met primarily by an increase
in coronary ﬂow. In the presence of coronary artery disease ﬁxed coronary stenoses
may prevent any increase in myocardial ﬂow, thus limiting myocardial DO2. Thus,
during anaemia the demands of an increased cardiac output may result in cardiac
ischaemia with, at least the potential for increased morbidity and mortality:
• A retrospective analysis by Carson [6] involving Jehovah’s Witnesses undergo-
ing surgery demonstrated a signiﬁcantly higher morbidity and mortality in
patients with a preoperative Hb of 6 g/dl. This effect was substantially more
signiﬁcant in patients with pre-existing cardiac disease and in those who had a
larger blood loss.
• A similar, more recent study [7] found that the risk of death was low in patients
with postoperative Hb levels of 7.1–8.0 g/dl. As postoperative anaemia worsened,
the risk of mortality rises and becomes extremely high below 5–6 g/dl.
• Elderly anaemic patients with myocardial infarction have a higher mortality
rate [8] even when other factors have been taken into account.
Recent studies on the signiﬁcance of anaemia in critically ill patients are difﬁcult
to separate from studies on the beneﬁts or otherwise of transfusion and will be
discussed below.
Management of anaemia in the critically ill
Prevention
A detailed account of perioperative methods of reducing surgical blood loss lies
outside the scope of this text but these include:
• Hypotensive anaesthetic techniques.
• Improved surgical techniques including minimally invasive surgery.
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• Appropriate attention to patient positioning and venous drainage.
• Use of tourniquets and inﬁltration of vasoconstrictors.
• Use of antibrinolytic and other drugs to reduce bleeding.
• Surgery under spinal or epidural anaesthesia as opposed to general 
anaesthesia.
• In addition, the loss of RBCs may be reduced by the use of haemodilution tech-
niques and the use of cell-saver strategies.
In the critically ill patient, interest in prevention of anaemia has centred 
around:
• Improved membrane biocompatibility of extracorporeal technology such as
for renal replacement therapy or cardiac bypass.
• Use of microanalyser systems for blood tests and other “point of care” labora-
tory systems.
• The routine use of pulse oximetry has reduced the need for arterial blood gas
sampling.
• The potential for indwelling vascular oxygenation and pH sensors to reduce
blood gas sampling.
• Preservation of gut mucosal integrity.
• EPO therapy. A study from Holland has shown that critically ill patients with
low levels of endogenous EPO can respond to exogenous EPO by increasing
reticulocytes [9]. Indeed, two randomised-controlled trials (RCTs) have shown
that the prophylactic administration of EPO is potentially of value. The largest,
over 1300 patients [10] showed that patients receiving weekly subcutaneous
injections of 40,000 units of EPO were less likely to undergo transfusion, received
less total number of units of blood over the 28-day study period and had an
increased Hb from baseline to study end. EPO therapy is expensive and the
beneﬁts are, so far, controversial. However, if it reduces red cell transfusion
requirements and avoids the harmful effects of transfusion it may well be a
highly cost-effective therapy for the critically ill patient.
Transfusion in critically ill patients
Prevalence of transfusion in ICU
Transfusion of RBC is extremely common in ICU patients. In the ABC study men-
tioned earlier [1], 37% of ICU patients received one or more units during their
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ICU stay. Older patients and those with a longer ICU stay received more 
transfusions.
Trauma patients, perhaps not surprisingly receive more units of blood [11].
Effect of transfusion on oxygen transport
It has been assumed that an increase in global DO2 (e.g. by red cell transfusion)
would result in an increase in VO2 in critical illness:
• However, Dietrich [12] studied the increase of DO2 by red cell transfusion in
non-surgical intensive care patients. After volume resuscitation, patients were
transfused if their Hb was 10 g/dl. He showed neither an increase in VO2 nor
a decrease in blood lactate levels in any patient and concluded that the shock
state of this patient group was not improved by red cell transfusion.
• In postcardiac surgery patients, the oxygen transport responses to transfusion
vary. Even in anaemic patients there is no consistent VO2 response to
transfusion [13].
Several studies have addressed this issue in patients with sepsis and septic shock:
• Conrad [14] studied augmentation of DO2 by blood transfusion in septic
patients. Transfusion resulted in a signiﬁcant increase in Hb and DO2.
However, despite the increase in DO2, there was no increase in VO2 or decrease
in lactate. Subset analysis showed that a pretransfusion oxygen extraction ratio
(OER) under 24% was associated with an increase in VO2, but the pretransfu-
sion level of cardiac index, pulmonary capillary wedge pressure, lactate, or VO2
was not. It was concluded that an isolated increase in arterial oxygen content
as a means of increasing DO2 does not improve VO2 in septic shock following
adequate ﬂuid resuscitation. However, patients with a low OER represent a
subset of patients which may improve consumption with transfusion, and may
represent a different microcirculatory disturbance.
• Steffes [15] further studied the role of lactic acidosis (implying tissue hypoxia)
as a predictor of response to augmenting DO2 with transfusion. In patients
with normal lactic acid both DO2 and VO2 increased. However, in patients with
lactic acidosis VO2 did not signiﬁcantly change after transfusion despite
increased DO2. He concluded that lactic acidosis may predict patients who will
not respond to transfusion. It was suggested that patients with lactic acidosis
may have a peripheral oxygen utilisation defect that prevents improvement in
VO2 with increasing DO2.
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Thus, increasing DO2 by red cell transfusion may not be of beneﬁt and exposes
the patient to the possible harmful effects of blood transfusion.
Harmful effects of blood transfusion
Problems such as hyperkalaemia, hypocalcaemia, metabolic acidosis, hypother-
mia, dilutional coagulopathy and citrate toxicity, although important, are related
to massive blood transfusion only and will not be discussed further in this text.
Wrong blood
Sadly “wrong blood to patient” errors still occur – and are potentially lethal.
Analysis of incident reports has revealed multiple errors of identiﬁcation, often
beginning when blood was collected from the blood bank [16]. The use of hos-
pital protocols including systems for validation of patient identiﬁcation by more
than one person is vital.
Old blood
There may be several problems arising from the transfusion of old blood in crit-
ically ill patients though their exact clinical signiﬁcance is still debated:
• Stored blood has reduced levels of 2,3-DPG levels causing a leftward shift in the
ODC and a reduced unloading of O2 from Hb.
• The reduced membrane deformability of red cells, brought about through
their storage, is thought to impede their passage through the narrow conﬁnes
of a capillary bed with potential implications for ischaemic organs and tissues.
The high haematocrit of packed red cells will increase blood viscosity and fur-
ther threaten perfusion of such areas.
• A small retrospective study of patients with severe sepsis found that the age of
the stored transfused RBC was directly associated with mortality [17].
• Another retrospective study, this time of post coronary artery bypass grafting
(CABG) patients, showed that the age of the stored blood was associated with
the chance of developing pneumonia [18]. However, another study from the
same group has found no evidence of increased morbidity in cardiac surgery
patients when old blood is transfused [19].
• From a trauma unit database, multivariate analysis has identiﬁed that the mean
age of blood transfused, number of units older than 14 days, and number of
units older than 21 days are independent risk factors for the development of
organ failures [20]. They suggest that fresh blood may be more appropriate for
the initial resuscitation of trauma patients requiring transfusion.
Haemolytic reactions
An estimated 1 in 250,000 transfusions result in an overt haemolytic reaction,
most commonly secondary to minor RBC antigens. This is almost certainly an
underestimate due to under reporting and failure to recognise such a reaction
during either surgery or the course of a critical illness at a time when the 
signs (hypotension, tachycardia, disseminated intravascular coagulation (DIC),
pyrexia) can be attributed to a more common pathology.
Transfusion related acute lung injury
Acute lung injury following blood transfusion is thought to result from the acti-
vation of recipient neutrophils by donor antibodies and donor RBC derived
membrane lipids. Such neutrophil activation increases endothelial permeability
with extravasation of inﬂammatory mediators and ﬂuid. The resultant clinical
picture is indistinguishable from acute respiratory distress syndrome (ARDS):
• In the perioperative or critically ill patient there are often other factors that
could explain why a patient should develop ARDS and so the incidence of
transfusion related acute lung injury (TRALI) is probably underestimated.
• It is possible that the use of leucodepleted blood may reduce the incidence of
TRALI.
Increase in cytokines?
• Laboratory studies have shown that RBC transfusion activates neutrophils
causing a release of inﬂammatory cytokines [21].
• Intraoperative transfusion in cardiac surgery patients increases the inﬂamma-
tory response [22]. During storage the leucocytes lose their membrane
integrity and release substances such as bactericidal permeability increasing
protein (BPI) into the plasma. BPI was found in all units of packed red cells
tested at concentrations up to 15 times preoperative plasma levels in patients.
• However, the issues are complex. For example, one study [23] has found a
greater increase in cytokine concentration after autologous blood transfusion
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than after allogeneic blood transfusion. The lower response in the latter may
result from transfusion-induced suppression of cellular immunity.
Transmission of infection by blood transfusion
• Direct transmission of infection via contaminated blood is small but still
possible.
• Human immunodeﬁciency virus (HIV). This risk is associated with the dona-
tion of blood during the immunologically silent “window period” of infection
prior to the host antibody response. The current risk is estimated to be
extremely low.
• Hepatitis B. The risk of transfusion-associated hepatitis B has fallen dramat-
ically since routine surface antigen testing (1975) and is expected to fall further
as the use of the hepatitis B vaccine becomes increasingly widespread. The
current risk is between 1 in 30,000 and 1 in 250,000 unit transfusions and
accounts for about 10% of all posttransfusion hepatitis [24].
• Transfusion is becoming an increasingly rare cause of hepatitis C infection,
possibly as a result of HIV high-risk donation exclusion but with a high associ-
ated morbidity.
• Transmission of other viruses such as Parvovirus and West Nile Fever have
been reported in the literature but are rare.
• Bacteria contamination of stored blood is related to the length of storage but is
associated with a high mortality. Transmission rates of other quoted transfusion-
associated non-viral infections such as Plasmodium and Trypanosoma cruzi
are vanishingly small.
• The potential for transmission by blood products of protein containing prion
particles such as those responsible for human variant Creutzfeldt Jacob
Disease (vCJD) represents an unknown risk. There has been 1 case of blood
donation from someone carrying the vCJD prion resulting in the later death
from vCJD of both the donor and the recipient. The UK Government has
recently banned the donation of blood by anyone who has received a blood
transfusion since 1980 (to limit donation to those who received transfusion
prior to the assumed introduction of the Bovine Spongiform Encephalopathy
prion into the UK food chain). A screening test for vCJD prion in blood donors
is also being developed. Additional attempts to minimise transmission of 
vCJD by blood products include the purchasing of plasma products from the
USA and the universal leucodepletion of blood components (at a cost of 
£85 million/year).
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Immunosuppressive effects of blood transfusion
The immunosuppressive effects of allogenic blood transfusion are well estab-
lished [25]. The clinical relevance primarily revolves around two areas of concern:
Postoperative infection
The effects of blood-transfusion-induced immunosuppression have been
thought to increase the risk of postoperative infection including wound infec-
tions. Many studies have suggested such an increased infection rate in patients
undergoing colorectal, orthopaedic, gynaecological, trauma and CABG surgery.
Much of the evidence is retrospective and some reports have shown no effect of
transfusion on postoperative infection rates:
• A retrospective study of post CABG patients, showing that the age of the stored
blood was associated with the chance of developing pneumonia [18], has
already been highlighted.
• A further study from Spain [26] examined risk factors from nosocomial pneu-
monia in cardiac surgery patients and concluded that there was a signiﬁcant
association between the transfusion of four or more units of blood products
and the chance of developing nosocomial pneumonia.
Cancer recurrence
Much data exists to support the concept of increased tumour recurrence in patients
who have received perioperative transfusion whilst undergoing potentially curative
surgery for colorectal, breast, lung, sarcoma, hepatic and head and neck cancers.
Vamvakas [27] disputes much of the evidence for infection and tumour recur-
rence, stating that most is retrospective and that analysis of prospective, ran-
domised, controlled trials show very little difference between those transfused
and those not transfused. He suggests that differences are due to retrospective
trial design and that immunosuppression may occur secondary to the variables
that lead to the transfusion and not as a result of the transfusion itself.
Leucodepleted blood transfusion
The evidence from RCTs of infection and recurrence rates comparing allogenic
with either leucodepleted or autologous blood are, as yet, inconclusive:
• Leucodepletion reduces the levels of BPI and other substances in stored 
blood [28].
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• The use of leukoreduced blood was associated with a decrease in the post-
operative length of stay in a study of cardiac surgery patients [29].
• Canada has recently introduced a universal leucoreduction programme. A 
retrospective “before and after” study of hip fracture patients, cardiac surgery
patients and surgical and trauma admissions to ICU (in other words not all types
of ICU patients) has shown reduced in-hospital mortality rates but no decrease
in serious nosocomial infections [30]. The frequency of posttransfusion fever
and antibiotic use also decreased signiﬁcantly following leukoreduction.
• However, the most recent meta-analysis found a weak association between
leucodepletion and a reduction in infection risk but no effect on overall
mortality [31].
Since 1999 all blood for transfusion in the UK has been leucodepleted thus ren-
dering much of the above debate academic.
Transfusion and outcome in ICU
Current recommendations re-transfusion practice apply to the broadest spec-
trum of pathology and pathology severity. Often no mention is made of the critic-
ally ill in whom metabolic demands and cardiorespiratory physiology are altered
in the extreme.
However, a few studies have looked at the impact of transfusion strategy on
outcome in ICU patients:
• In a combined retrospective and prospective cohort study of 4470 general ICU
patients, Hebert [32] found that non-survivors had lower Hb and had received
more transfused red cell units than survivors. From their data the authors con-
cluded that anaemia increases the risk of death in critically patients with cardiac
disease and that blood transfusion of up to 6 units will reduce this risk by 40%.
• The most signiﬁcant study on this issue, from the same group, has been the
Transfusion Requirements in Critical Care (TRICC) study [33]. This Canadian
multicentre, prospective, randomised study compared a restrictive with a liberal
transfusion strategy in 838 general ICU patients. Those in the restrictive strat-
egy group were transfused at an Hb 7 g/dl with packed red cells to maintain
their Hb at 7–9 g/dl. Those in the liberal strategy group were transfused with
packed red cells at an Hb 10 g/dl to maintain their Hb at 10–12 g/dl. In those
patients with an acute physiology and chronic health evaluation (APACHE)
score 20 and in patients aged 55 years the 30-day survival and overall
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hospital mortality was signiﬁcantly better in those randomised to the restric-
tive transfusion strategy. Amongst patients with cardiac disease the 30-day
mortality was reduced, but not signiﬁcantly so, if allocated to the restrictive
strategy. This groundbreaking trial – the ﬁrst large, prospective study of blood
transfusion strategy on outcome in ICU – also showed a signiﬁcant decrease in
organ dysfunction and cardiac complications in the restrictive strategy group.
• Later subgroup analysis of critically ill patients with cardiac disease conﬁrmed
that a restrictive RBC transfusion strategy generally appears safe with the possible
exception of patients with acute myocardial infarcts and unstable angina [34].
• A similar negative effect of transfusion on outcome was demonstrated in
patients having coronary artery bypass surgery [35]. They also demonstrated a
signiﬁcantly increased risk of left ventricular dysfunction and mortality in the
high and medium Hct groups compared to the low Hct group. The authors pro-
posed that increased blood viscosity may require increased myocardial work
while reducing coronary ﬂow.
• A contrary view comes from a retrospective study of data on 78,974 Medicare
beneﬁciaries 65 years old or older who were hospitalised with acute myo-
cardial infarction. Blood transfusion is associated with a lower short-term
mortality rate among elderly patients with acute myocardial infarction if the
hematocrit on admission is 30% or lower [8].
• In a study from a major US Trauma Centre, blood transfusion seems to be an
independent predictor of mortality, need for ICU admission and ICU and hos-
pital length of stay (even after controlling for severity of shock and injury) [36].
Transfusion and mechanical ventilation
Anecdotal reports exist of successful weaning after transfusion to an Hb higher
than that which would now normally be desired in critically ill patients:
• Schonhofer et al [37] demonstrated a decreased work of breathing and
decreased minute ventilation in anaemic patients with chronic obstructive
pulmonary disease (COPD) when transfused from an Hb of 8–9 g/dl to an 
Hb of 12 g/dl. This seemed to be primarily through a decrease in tidal
volumes with a resultant slight rise in PCO2 levels. A similar effect was not seen
in anaemic patients without COPD who were transfused with an identical
strategy.
• This work complements case reports by the same authors concerning six patients
successfully weaned after transfusion to Hb12 g/dl. All patients had failed 
several attempts to wean over several weeks at much lower Hb [38]. Anecdotal
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though this is, it supports a strategy used by many intensivists in which anaemic
patients, who are proving difﬁcult to wean, are transfused to a “normal” Hb.
• A further subgroup analysis of the TRICC study, however failed to demonstrate
any beneﬁt in terms of shortened duration of IPVV in patients in the liberal
transfusion strategy group [39]. However, this was not a study of speciﬁc wean-
ing problem patients.
• Complementing the work on increase in infections associated with transfusion
of allogenic blood comes a large study strongly suggesting that transfusion 
is associated with an increase in the risk of developing ventilator associated
pneumonia [40].
It may be that getting the balance right is important with transfusion being
potentially of beneﬁt to patients who are a problem to wean (and possibly
patients with cardiac disease) while being detrimental to other patients!
Reducing the need for blood transfusion
General
A major trend in recent years has been a greater reluctance to expose patients to
the problems associated with allogenic blood transfusion. This in part reﬂects
greater understanding of these problems but also a realisation that beneﬁcial
effects of transfusion are less apparent in many groups of patients. Requirement
for allogenic blood transfusion can be reduced by:
• Accepting the appropriateness of a restrictive transfusion strategy for most
patients.
• Other methods of combating the development of anaemia in ICU patients
mentioned previously especially, perhaps for the future, the role of EPO.
• Increased use perioperatively of predonation and other forms of autologous
blood transfusion.
Blood substitutes
Interest continues in the use of blood substitutes to reduce the need for allogenic
blood transfusion. In general, there may be toxicity relating to the cell debris con-
tained within preparations of Hb – chieﬂy renal toxicity. Another source of concern
in early studies of free Hb in solution was a marked vasopressor effect probably
76 I. McConachie
related to scavenging of the endogenous vasodilator, nitric oxide. This in itself may
be harmful for trauma patients in the ﬁeld if it encourages further bleeding.
There are several main areas of research:
• Diasprin cross linked haemoglobin (DCLB). Recent multicentre trials show
some effect in limiting the transfusion of allogenic blood. However, two large
multicentre trials have now been terminated early owing to safety concerns.
Interest in this product thus seems to have waned.
• Polymerised human Hb. Seems to be free of signiﬁcant side effects and early
reports regarding efﬁcacy are encouraging.
• Bovine Hb. Has been used successfully in surgery associated with major blood
loss but there are concerns related to increase blood pressure and production
of antibodies. Nevertheless, a commercial product has been approved for use
in South Africa.
• Human recombinant Hb. Likely to be expensive but may prove useful in the
future.
• Perﬂuorocarbons carry increased oxygen in solution but have a requirement
for a high FiO2. Early trials suggest a reduction in the requirement for transfu-
sion of allogenic blood.
Practical approach
Recommendations by the ASA Task Force on Blood Component Therapy [41]
state that transfusion is:
• “rarely required above an Hb of 10 g/dl”,
• “almost always indicated when Hb is 6 g/dl”.
Current evidence supports a restrictive strategy for transfusion in ICU with some
evidence to support a more liberal strategy in patients with cardiac disease and
possibly patients who are proving difﬁcult to wean from intermittent positive
pressure ventilation (IPPV).
FURTHER READING
An entire recent supplement issue of Critical Care Medicine has been devoted to the subject
of anaemia and transfusion practices in critically ill patients. Critical Care Medicine 2003;
31(Suppl 12).
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Nutrition
Appropriate nutrition is vital in the critically ill patient. In its absence there will be:
• Muscle atrophy and weakness.
• Decrease in immune function.
• Decrease in wound healing.
• Impaired weaning off intermittent positive pressure ventilation (IPPV).
• Gut mucosal atrophy.
In the critically ill patient who is markedly catabolic the above may occur in a few
days. Nutritional support improves nutritional status but there is little concrete
evidence for a beneﬁcial effect on survival. However, promoting ongoing mal-
nourishment must be detrimental to the patient. Certainly more than 10,000 kcal
negative caloric balance is associated with a poor outcome in intensive care unit
(ICU) patients [1]. There is little evidence that nutritional support can reverse the
negative nitrogen balance or catabolism which occurs in the critically ill patient.
In which case the purpose of support is to minimise the negative nitrogen
balance.
In simple starvation (i.e. non-physiologically stressed), the energy require-
ments in the ﬁrst week are chieﬂy met by protein breakdown to amino acids and
subsequent glucose formation via gluconeogenesis. The body adapts to a protein
sparing metabolism in starvation, but these changes are absent or opposed in
the ICU patient.
In addition:
• Sepsis results in a preferential metabolism of fat rather than glucose partly due
to inhibition of the enzyme complex pyruvate dehydrogenase.
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• Despite increased protein synthesis for 
(i) inﬂammatory response, 
(ii) wound healing and 
(iii) acute phase proteins; protein breakdown is accelerated leading to a net
negative nitrogen balance – the acute catabolic state.
• Catecholamines, stress response hormones and cytokines (especially tumour
necrosis factor (TNF)) are responsible for the changes compared to starvation.
• Reversal of these obligatory catabolic changes is not possible during severe
physiological stress [2] – only reversed when the cause of the hormonal release
is removed (i.e. resolution of the underlying condition).
• Gluconeogenesis cannot be inhibited completely by provision of adequate
substrate in severe catabolism [3].
• Growth hormone administration to stimulate a positive nitrogen balance
seemed promising in early studies but later studies were stopped due to an
excess mortality in study group.
• Muscle wasting from catabolic changes is compounded by prolonged 
immobilisation.
• “Overfeeding” [4] will not promote a positive nitrogen balance until the under-
lying condition resolves and the patient is mobilising. Body weight may
increase but this is mainly fat and total body protein still falls.
• When the patient is recovering and mobilising, energy and protein intake
should be increased to allow weight gain.
Reasons for feeding the critically ill patient
• To minimise the net negative balance and breakdown of the body’s tissues.
• To provide precursors for the immune response, wound repair and hepatic
protein synthesis.
• Provision of nutritional support may increase the protein synthesis rate even if
it does not decrease the catabolic rate.
• Glucose administration is partly protein sparing [5], but this effect is blunted
by sepsis.
• Even low rates of enteral feeding limit gut mucosal atrophy.
Nutritional status
Nutritional status prior to critical illness is important because:
• Protein reserves are called upon in critical illness. Reserves are low in the mal-
nourished patient.
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• Low body mass index (BMI) (not high BMI) is an independent risk factor for
increased mortality in ICU [6].
• ICU patients lose 1% of lean body mass per day – mainly muscle.
• Sarcopenia (literally means “lack of muscle”) describes both atrophy and red-
uction in the number of muscle ﬁbres. Incidence increases with age – as high
as 50% in the over 80s [7].
• Muscle mass represents a major store of protein and therefore sarcopenia
weakens the metabolic defence to illness. High incidence of sarcopenia in the
elderly is thought to be a major factor in the poor outcome of this group.
• BMI can predict the degree of sarcopenia [8].
Assessment of nutritional status
Malnutrition is very common in hospital patients:
• Common sense clinical examination will be helpful, for example, history of
weight loss and food intake, measured versus usual weight, speciﬁc features
(e.g. of vitamin deﬁciencies and signs of muscle weakness and atrophy).
Measured height and weight should be compared to standard tables.
• Anthropometric measurements, for example Triceps skin-fold thickness and
mid-arm muscle circumference are crude, occasionally useful but are operator
dependent to some degree and may not be reproducible.
• Albumin as an index of visceral protein mass is useful in pure malnutrition.
However, in ICU, inﬂuences of decreased synthesis due to liver disturbances
and loss due to capillary leak confuse the picture (see Chapter 5 on ﬂuid 
therapy).
• Serum transferrin has been suggested as a better index of body proteins as it
has a longer circulating half-life and is not an acute phase protein.
• Lymphocyte count and skin tests for common allergens (an index of immune
competence which is depressed in malnutrition) are useful in pure malnutri-
tion but, again, are less useful in ICU.
• Of experimental interest at present are accurate measurements from bioelec-
trical impedance, which quantitatively measures lean body mass.
In summary, there are no simple tests appropriate for assessing acute mal-
nutrition in critically ill patients. Clinical impression and serial estimations of
weight compared to premorbid weight are probably as useful as more complex
tests [9].
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Timing of initiation of feeding
• Although many patients may seem to tolerate a short period of low or no caloric
intake, the greater the degree of catabolism, the less the period of hypocaloric
intake should be.
• Enteral nutrition (EN) should be attempted within 24–48 h if there are no con-
traindications, due to the rapid onset of gut mucosal atrophy.
• If EN is not possible, total parenteral nutrition (TPN) should be commenced as
soon as the patient is haemodynamically stable.
• Occasionally TPN will be started at the same time as EN in an attempt to 
maximise caloric intake. A systematic review has concluded that, in critically 
ill patients who are not malnourished and have an intact gastrointestinal 
(GI) tract, starting TPN at the same time as EN provides no beneﬁt over EN 
alone [10].
TPN
• Only indicated if unable to feed the patient via the enteral route.
• Gut mucosal atrophy still occurs.
• More expensive.
• More metabolic problems.
• Requires dedicated central venous access (with all its complications).
• Incidence of infectious complications related to the care of the site rather than
the type of site (e.g. tunnelled versus non-tunnelled).
• Usually administered as a 2.5 or 3 l “big bag” feed with all the nutritional com-
ponents mixed in pharmacy in a laminar ﬂow cabinet under strict aseptic 
conditions.
Enteral nutrition
• Eating is normal. The gut is not designed to be rested.
• Mucosal atrophy is rapid.
• Requires a functioning GI tract. Bowel sounds not essential for absorption.
• NG used most commonly, but gastric atony can be a problem. Placement of
the tube distal to the stomach (duodenum or jejunum) is advantageous.
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• Prokinetic drugs (metoclopramide and erythromycin) are useful in improving
gut motility and absorption [11]. Although withdrawn in the UK, cisapride is
also used [12].
• Supports normal gut ﬂora.
• Possibly reduces GI bleeding from stress ulcers.
• Decreases infective complications in surgical patients [13].
• May preserve the gut barrier and prevent bacterial or endotoxin translocation.
• Reduced incidence of acalculous cholecystitis.
• Many commercial preparations. All approximately 1 kcal/ml.
• Cheaper than TPN and with less metabolic and infectious complications.
• Elemental, that is predigested feeds only necessary in short bowel syndrome
following small bowel resection.
• No need for “starter” diluted feeds. If problems occur, start at lower rate rather
than diluting the feed.
• A 4-h rest period during the night is often recommended. Stomach acidity dur-
ing this period may limit bacterial growth in the stomach.
• Continuous pump feeding better than intermittent bolus feeding – less risk of
aspiration.
• Fine bore tubes are difﬁcult to aspirate from, block easily and have few advan-
tages in the critically ill patient.
There is uncertainty from animal studies as to whether enteral feeding promotes
a better outcome or whether TPN promotes a worse outcome due to higher rates
of complications.
Complications of enteral nutrition
• Aspiration – watch for large residual volumes. Large residual volumes are prob-
ably a factor in the development of nosocomial pneumonia.
• Infection/contamination – feeds are excellent bacteria growth media.
• Blockage of tubes – ﬂush all medications with H2O.
• Malposition of tubes – check with chest X-ray.
• Constipation – often due to inadequate H2O intake or possibly lack of ﬁbre.
• Diarrhoea – very common. Check for antibiotics and other medications as
causes of diarrhoea. Clostridium difﬁcile infection must always be excluded. In
the absence of these causes treat symptomatically rather than automatically
stopping the feed. Fibre may be important.
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Nutritional composition
In the last 15 years there have been three major trends in ICU nutrition:
• A shift from parenteral to EN (see above).
• A decrease in the total quantity of calories administered.
• An improvement in the quality of nutrients administered (i.e. novel substrates).
Energy and protein requirements
Formulae (e.g. Harris Benedict) estimate the basal energy expenditure (BEE) based
on patient age, weight and sex. Studies have shown that the mean metabolic rate,
and therefore caloric requirement, approximates to BEE  30%. Adjustments are
often made as percentage increases based on the degree of “stress” and activity
[14]. For clinical purposes 25–30 kcal/kg/day is sufﬁcient. It has been suggested,
however, that caloric requirements may be much higher (50–60 kcal/kg/day) in
the second week after an episode of severe sepsis or trauma [15]. Fear of hyper- 
or hypo-nutritional states have lead to the use of indirect calorimetry. Indirect
calorimetry measures energy expenditure based on measurements of oxygen con-
sumption and CO2 production. The aim is to tailor nutritional needs on a daily
basis, thus avoiding hyper- or hypo-nutritional states. This may be useful but:
• Errors, for example, from leaks are a problem especially when the patient is on
a high inspired O2 concentration.
• Once daily “spot check” measurements may be inappropriately extrapolated to
the whole 24 h day.
• Marked differences have been reported from different studies of similar groups
of patients.
• One review [16] concluded “At present indirect calorimetry may be better
viewed as an investigative tool than a necessary part of routine patient care”.
• With reﬁnement of techniques, this may be a routine measurement in the future.
Protein losses can be measured but in practice 1–1.5 g/kg/day are required.
Alternatively, protein intake can be assessed on the basis of a ratio of 150:1 of
non-protein calories to nitrogen (approximately 6 g protein  1 g nitrogen).
When calculating requirements, an admission “dry weight” should be used as
most ICU patients gain weight as metabolically inactive oedema ﬂuid during their
illness.
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Composition of non-protein calories
There is still controversy over the ratio of fat to carbohydrate (CHO) intake in the
critically ill patient.
Pro fat: Lipid preferentially metabolised in sepsis especially medium chain
fatty acids (MCFA).
Lipid is non-irritant to veins and theoretically can be given via a peripheral vein.
Fat gives more calories per gram compared to glucose (nine compared to four).
Requirement for essential fatty acids.
Con fat: Lipid particles may be taken up by the reticulo endothelial system.
Long chain fatty acid (LCFA) metabolism impaired in sepsis (due to a deﬁcit
of intracellular carnititne).
Fat possesses little or no protein sparing effect.
Hyperlipidaemia may impair oxygenation but changes are small and prob-
ably of little clinical signiﬁcance.
Pro CHO: Some protein sparing effect especially if lipid is also given.
Some glucose intake probably essential.
Con CHO: Hyperglycaemia (see below).
Limit to utilisation – maximum uptake 4–6 mg/kg/min.
Excess CHO leads to hepatic steatosis.
Caution in respiratory failure (see below).
Most authorities recommend approximately 50% of non-protein calories be
administered as fat.
Note: If propofol is infused for sedation one must remember that this is dissolved
in a fat emulsion equivalent to 10% intralipid.
Other nutritional requirements
• H2O and standard electrolytes need to be supplied. Magnesium and phos-
phate supplements may be required.
• Vitamins, both fat and H2O soluble should be supplied in the form of a com-
mercial multivitamin preparation. Requirements are mainly not known with
certainty in the critically ill patient and are often extrapolated from normal
requirements. Water-soluble vitamins should be administered every day. Fat-
soluble vitamins are required at least twice a week. In the long term: vitamins
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B12, K and folate supplements may be required. Currently there is great inter-
est in the role of vitamins C and E as antioxidants.
• Speciﬁc elemental requirements (e.g. zinc and manganese may also be sup-
plied commercially). Trace elements with lesser or unknown requirements can
be assumed to be supplied as contaminants of other ﬂuids and in blood trans-
fusions [17].
• Commercially produced EN preparations are generally balanced nutritional
sources.
Hyperglycaemia
• Common in the critically ill patient due to hormonal changes and insulin
resistance. May be related more to increased production from gluconeogene-
sis rather than decreased utilisation (unless septic).
• Assess whether intake is too high prior to prescribing insulin.
• High levels should not be viewed as innocuous. Associated with osmotic diure-
sis and increased infections.
• Evidence suggests that a very tight control of blood sugar improves outcome in
critical illness [18].
Nutrition in respiratory failure
Malnutrition impairs respiratory muscle strength. On the other hand, glucose
and amino acid infusions increase VO2. Glucose oxidation produces more CO2
per gram than fat and, therefore, excess supply of glucose may increase CO2 pro-
duction, work of breathing and impair ability to be weaned from mechanical
ventilation. Enteral feeds with an increased proportion of fat to CHO may reduce
CO2 production and allow easier weaning [19], although this is still controversial.
It is possible that avoiding excess calories may be as important in this matter as
the source of the calories.
Novel nutritional substrates
The exact mechanism of action of novel substrates is controversial as many have
multiple physiological actions. It has been suggested that some directly “boost”
the immune system – immunonutrition (see below).
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It should be emphasised that in many instances the administration of these
novel substrates is supported by, at best, circumstantial evidence. Few are sup-
ported by adequate controlled studies.
Note: Remember to ensure that sufﬁcient amounts of “conventional” nutri-
ents are supplied before becoming overconcerned with novel substrates [20].
MCFA versus LCFA
(Refers to the position of the ﬁrst double bond in the carbon chain – LCFA usually
 6, MCFA usually  3 – “ﬁsh oils”.)
LCFA may affect the immune system as can enter arachidonic acid pathways,
for example forming prostaglandins, platelet activating factor and leukotrienes.
MCFA are utilised solely for energy and not metabolised to active products. MCFA
in some studies may have beneﬁcial effects on protein balance and may have no
adverse effect on lung function.
Branched chain amino acids
Branched chain amino acids (BCAA) (leucine, isoleucine and valine) are
metabolised in skeletal muscle and, in theory, should decrease muscle protein
breakdown if preferentially administered. In the body their main role may be to
generate glutamine and alanine. Routine use at present is unsubstantiated.
Glutamine
• Not an essential amino acid, that is the body should be able to synthesise suf-
ﬁcient glutamine from other essential amino acids.
• Despite this, it has been suggested that the synthesis of glutamine is inad-
equate in critical illness (i.e. a conditional essential AA).
• The role of BCAA to provide glutamine has led to interest in administering
glutamine itself.
• An essential fuel for bowel mucosal cells (may protect bowel mucosa) and for
ﬁbroblasts, lymphocytes and macrophages.
• Forms approximately 50% of the body’s amino acid pool.
• Plasma and muscle glutamine levels fall after burns, trauma and major 
surgery [21].
• Not included in standard formulations of TPN as is relatively unstable in solution.
• Can be supplied via enteral supplements.
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Arguably, of all the novel supplements, the strongest evidence supports glutam-
ine. Supplementation has been shown to lessen the negative nitrogen balance
after injury and major surgery [22]. A study in a heterogenous group of ICU pat-
ients found a signiﬁcant improvement in outcome in those patients who received
glutamine supplements [23].
Arginine
• Technically another non-essential amino acid.
• Important for wound healing, collagen deposition and immune function.
• Stimulates growth hormone, glucagon and insulin secretion.
• Stimulates T-cell function.
• Precursor of nitric oxide. May have a role in preventing ischaemia/reperfusion
injury [24].
Nucleotides
• May stimulate the immune system.
• Absent in standard TPNs.
Immunonutrition
The concept of certain nutrients (e.g.  3 MCFA, nucleotides and arginine)
directly stimulating the immune system in critically ill patients and therefore reduc-
ing infectious complications and improving outcome is potentially useful.
• One study compared a standard enteral feed with a preparation (Impact®,
Sandoz nutrition) containing the so-called immunonutrients found a reduced
length of stay on average and a decrease in infectious complications in the
immunonutrient group [25].
• The same immune stimulating feed has been shown to improve various indices
of immune status in ICU patients [26].
• A more recent study of major GI surgery found a reduced incidence of late
complications in the study group with the same preparation [27]. Analysis
showed substantial savings in the Impact group because of the reduced com-
plications despite the greater comparative cost of this preparation.
• Immunonutrition strategies have been shown to decrease multiple organ factor
(MOF) scores, length of stay (LOS) and duration of IPPV if started early [28, 29].
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• However, an interim analysis of a multicentre randomised trial comparing an
immune enhancing enteral feed (not Impact®) with TPN in patients with
severe sepsis resulted in the trial being stopped. Mortality in those patients
given the enteral feed was higher than in those given TPN [30]. It has been pos-
tulated that Arginine, being a precursor of nitric oxide, may increase the mor-
tality in septic patients.
• This study has raised many issues not least being a lone modern voice recom-
mending TPN over EN!
Fibre
• Many believe that ﬁbre should be added routinely as part of an enteral feed
regime. Short chain fatty acids produced by its breakdown by gut bacteria are
essential nutrients for the colon. It may support normal gut ﬂora, bind bile
salts, absorb water, reduce gram negative bacteria overgrowth and improve
glucose intolerance.
• Reduces enteral feeding associated diarrhoea in non-critically ill patients but
there are no studies showing deﬁnite beneﬁt in ICU patients [31].
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Non-invasive mechanical ventilation
D. Kelly
As critical care consumes increasing amounts of health care budgets globally
there is an increasing demand for interventions that are clinically effective in the
sense that they reduce patient length of stay, reduce complications and are less
demanding of medical and nursing resources:
• However, the evidence base for critical care interventions is very narrow and it
is often very difﬁcult to ﬁnd any intervention that meets the above criteria.
• Non-invasive ventilation (NIV) comes close if applied to patients with the appro-
priate indications [1].
• Like all interventions, if used indiscriminately these beneﬁts are lost and it is the
purpose of this chapter to give the reader some insight into how best to apply
this technology to achieve the best outcomes.
Deﬁnition
NIV is the application of bi-level airway pressure support using a nasal or full face
mask as the patient interface:
• The lower level of support will be referred to as expiratory positive airway pres-
sure (EPAP) and the upper level as inspiratory positive airway pressure (IPAP).
• If the IPAP is set on zero then the patient will be receiving what is convention-
ally known as constant positive airway pressure or CPAP as it is better known.
• NIV and CPAP as terms are often used interchangeably but they should be
regarded as two quite separate forms of airway support.
It should be remembered that the gas ﬂow that generates the EPAP has another
function. It helps to clear the CO2 and reduce rebreathing.
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History
NIV was initially used to support individuals with neuromuscular disease to avoid
hypoventilation during sleep. It has become the ventilatory support of choice for
all patients at risk of hypercapnia due to neuromuscular disease, chest wall defor-
mity or impaired respiratory drive. Its use in the acute care setting began with 
trials on patients admitted in acute hypercapnic respiratory failure with chronic
obstructive pulmonary disease (COPD) [2].
Machines
When the priorities and market lay in the community the development of NIV ven-
tilators focused on ease of use and minimal reliance on gas supplies. Once it became
adopted by the critical care community for the treatment of acute respiratory failure
in the hospital setting the speciﬁcations changed and became more sophisticated.
There is a huge variety of ventilators to choose from. The range includes:
• Relatively simple ﬂow generators which can be used at home to support hypoven-
tilation in compliant patients who are sleeping.
• Sophisticated intensive therapy unit (ITU) ventilators that have a numbers of
ventilator modes to choose from and can be used in a critical care setting to
support a hypoxic, hypercapnic patient.
It is essential when reading the literature that one is very clear exactly which type
is being used and in what mode, as success or failure with the technique may
depend on using the correct type in the right mode for the appropriate patient.
Deﬁnitions
One must be familiar with the following deﬁnitions to interpret the published
information.
CPAP
This refers to the technique of respiratory support that provides a CPAP through-
out the whole of the respiratory cycle. It will allow higher FiO2 than conventional
face mask oxygen, recruits collapsed lung and will reduce the work of breathing.
Many NIV ventilators will function in this mode but it is not NIV although the two
techniques are often referred to interchangeably.
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Controlled mechanical ventilation
No patient effort is required. Either the inﬂation pressure or the tidal volume is
set. There are numerous ways to reﬁne these settings further but it is rarely used
as a NIV mode.
Assist/control ventilation
Like controlled mandatory ventilation (CMV), the pressure or volume is set by
the operator, as are the number of breaths per minute. Patient triggering can also
cycle the ventilator although the breath delivered is identical to a mandatory breath.
If patient triggering subsequently delays a mandatory breath then the mode is
said to be synchronised and is called synchronised intermittent mandatory 
ventilation (SIMV).
SIMV is a term familiar to critical care staff but is not generally used in NIV
machines where it is more likely to be referred to as spontaneous/timed (S/T) or
IE mode.
Assisted spontaneous breathing
In this mode the pressure is set and the volume delivered depends on:
• the resistance and compliance of the patient: ventilator system,
• the respiratory rate of the patient,
• their compliance with this mode of ventilation,
• the presence or absence of any leaks and their magnitude.
This mode is better known to critical care staff as pressure support. In addition
because it depends on patient triggering there is often the option to set a backup
mandatory ventilator rate in case of apnoea.
In some machines it is known as the S/T mode and the pressure set is the IPAP
pressure.
Bi-level pressure support
This refers to the technique that combines CPAP with pressure support. The
CPAP pressure is set when the EPAP level is adjusted and the pressure support
when the IPAP level is adjusted.
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Patient ventilator interface
These depend on the circumstances. There are mouth pieces, nasal masks and
face masks:
• The biggest problem is with leaks. As you tighten the mask to reduce the leak
you increase the pressure effects on the face and it is usually the nose that bears
the brunt of this leading in some cases to full thickness erosion of the skin on
the bridge of the nose.
• In many of the early trials of NIV in critical care, conventional intensive care
ventilators were used. As these were relatively intolerant of leaks good mask ﬁt
was essential and pressure effects were more of a problem.
• Nasal masks are preferred when possible as they allow the patient to commu-
nicate, eat and drink as required and are less claustrophobic. Gas leaks through
the mouth can be a problem and chin straps can be helpful.
• Face masks are more useful in the hypoxaemic patient as they tend to be mouth
breathers in the acute phase of their illness. In some circumstances the dead
space of the mask can become signiﬁcant and can be the reason why the CO2
fails to fall in a hypercapnic patient despite apparently adequate ventilation.
Compliance with the technique is sometimes helped if the patient is allowed to
settle on a mouthpiece ﬁrst before switching to a face mask [3].
Humidiﬁcation
This is generally not regarded as a major problem as the upper airways are not
bypassed. The addition of humidiﬁcation to a circuit may increase the work of
breathing so must not be done without a thorough consideration of the risks
involved. In some machines expiratory valves are used to ensure CO2 elimination.
Any additional moisture in the circuit can impair the function of these valves
leading to an increase in circuit dead space.
Indications
There are many case reports anecdotally recounting the successful use of NIV in
circumstances where intubation and ventilation would previously have been the
only option. Its growing popularity reﬂects the advantages that it confers as well
as the disadvantages of conventional ventilation that it avoids.
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The advantages include:
• speech is retained,
• eating and drinking are possible,
• it can be delivered intermittently,
• normal humidiﬁcation mechanisms are retained,
• patients do not require sedation,
• respiratory defences against infection are not breached,
• the patients retain mobility,
• monitoring is usually less invasive as a consequence further promoting mobility,
• once stable the patients are less nurse dependent.
It avoids:
• intubation of larynx and trachea, and inevitable trauma,
• immobility,
• haemodynamic compromise of sedation and ventilation.
These reasons alone probably explain the three key beneﬁts seen if NIV is used:
• shorter intensive care unit (ICU) stay,
• shorter hospital stay,
• reduced morbidity particularly from infectious complications of conventional
ventilation such as ventilator acquired pneumonia, sinusitis and line sepsis [4].
It was certainly true in one study of NIV that the NIV group of patients had fewer
lines and catheters [5].
Contraindications
There are very few absolute contraindications especially if NIV is commenced in
an environment where immediate intubation and ventilation is available. If this
is not the case and NIV is commenced in a ward-based setting then the contraindi-
cations acquire more strength. The safe choice then depends on the experience
of the practitioners involved in the initiation of the therapy and the subsequent
degree of supervision.
Most people would agree that the following probably constitute the absolute
contraindications:
• facial burns or trauma,
• obstruction of the upper airway,
• coma,
• haemodynamic instability.
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Relative contraindications exist but it may acceptable to use NIV despite these if
NIV is used as a trial and is to be the ceiling on treatment. Some of them exist because
they herald failure and would be more safely managed by immediate intubation.
These include:
• inability to protect the airway,
• agitation or confusion,
• copious respiratory secretions,
• reduced conscious level,
• life threatening hypoxaemia.
Some however exist because NIV under these circumstances would lead to patient
compromise:
• recent upper gastrointestinal surgery,
• obstructed bowel,
• vomiting.
The list of conditions or clinical circumstances when NIV may be used is growing
everyday but level I evidence of beneﬁt is harder to ﬁnd. There are however a num-
ber of conditions where there is sufﬁcient evidence now to make judgements about
the effectiveness or otherwise of NIV.
COPD
Severe exacerbations of COPD are the commonest respiratory cause for emer-
gency admission in the UK. Overall mortality rates can be as high as 14%. The risk
of death is increased if intubation and ventilation are required [6]. NIV has been
studied extensively as an alternative means of support and it has been demon-
strated that it confers the following advantages if applied to the subgroup who
present with PaCO2 greater than 6 kPa:
• lower mortality,
• reduction in need for intubation,
• shortened hospital stay.
As this can be achieved in ward-based settings and admission to intensive care
averted this technique is a very cost effective intervention that reduces total costs
whilst reducing mortality at the same time.
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Cardiogenic pulmonary oedema
Whilst the use of CPAP is established as a successful support mode in cardiogenic
pulmonary oedema the use of NIV is less certain. One study had an increase in
myocardial infarction in the NIV groups [7]. NIV should only be considered if
CPAP fails despite full medical therapy.
Neuromuscular disorders and chest wall deformities
NIV was well established in the community to support individuals who required
mechanical support to avoid hypercapnia because of chest wall deformity or
neuromuscular disease before it was used in the acute sector. Consequently there
have been no randomised controlled trials in these settings. It remains the sup-
port of choice when these individuals develop decompensation due to acute on
chronic respiratory failure usually as a result of acquired infection. These individ-
uals praise their ability to communicate very highly and fear intubation and
tracheostomy as much as their attendants who are only too aware of the weaning
difﬁculties they will face even with an early tracheostomy.
Haematological disorders and immunosuppression
Any patient with a haematological disorder who presents with acute hypoxaemic
respiratory failure that requires intubation and ventilation has a greater than
70% mortality [8]. Pneumocystis pneumonia in acquired immune deﬁciency
syndrome (AIDS) leading to intubation and ventilation carries a mortality of
approximately 60%. By avoiding ventilator acquired pneumonia and sepsis sec-
ondary to invasive monitoring NIV should improve these ﬁgures and recent
studies conﬁrm that NIV should be considered as an alternative to intubation
and ventilation [8].
These considerations have prompted its use in any patient whose immune
system is so compromised that nosocomial infection constitutes a serious risk and
these include:
• following lung transplantation,
• following any transplantation surgery of any kind,
• reversible insults such as retinoic acid syndrome.
Non-invasive mechanical ventilation 99
Acute hypoxaemic respiratory failure
Although it is tempting to avoid intubation in conditions such as pneumonia and
acute respiratory distress syndrome (ARDS) from any cause there are some haz-
ards that must be considered:
• the failure rate is high;
• secretions can be hard to clear especially if a full face mask is required;
• delaying intubation may mean that the subsequent intubation is much more
hazardous because of life threatening hypoxaemia.
There is now a consensus developing that any condition that is slow to develop and
slow to resolve like pneumonia is less likely to beneﬁt from NIV. Although the
improvement in oxygenation can be life saving it is not the sole reason for resolution
of the presenting complaint and these other factors soon determine whether or not
the condition resolves. For example in one recent study of NIV in acute renal failure
(ARF) due to pneumonia all but one of the failures had developed bacteraemia [9].
Thoracic trauma
Although CPAP is safe and a well-recognised treatment in conjunction with
effective epidural analgesia the role of NIV is less clear. If epidural analgesia is not
possible or there are injuries that are not covered then NIV will allow high-dose
opioid analgesia without the inevitable hypercapnia due to respiratory depression.
However, there is an increased risk of pneumothorax that must be managed.
Postoperative weaning
It is not always easy to predict a successful wean and NIV allows trials of extuba-
tion and reduces the incidence of reintubation. This applies to cardiothoracic
surgery as well as abdominal surgery. This is particularly true in those patients
who have preoperative morbidities such as COPD or obesity.
Diagnostic bronchoscopy
Just as the development of cheap ultrasound devices have revolutionised the place-
ment of central venous catheter (CVC) lines and redeﬁned the gold standard 
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of safe practice the newer generation of NIV machines have allowed diagnostic
bronchoscopy in patients who would otherwise have deemed to be too hypoxic.
It is now possible to support patients through the procedure by NIV application
before, during and after the procedure. This is particularly important if bron-
choalveolar lavage is required as this inevitably leads to a short-term decrease in
an already low PaO2 [10].
There are machines which are designed to tolerate large leaks and these are
ideal for the procedure allowing ventilation even when the bronchoscope is in
situ in the trachea.
Monitoring
Appropriate monitoring will depend on the environment.
In order to choose appropriate monitoring it is essential to be aware of the signs
of impending failure of the technique so that these can be picked up in a timely
fashion. Clinically the patient should have:
• improved chest wall movement,
• good coordination with the ventilator,
• a reduction in accessory muscle use,
• a reduction in heart rate,
• reduced respiratory rate,
• be more comfortable,
• be more awake.
Physiological improvement must include:
• reduction in CO2,
• improvement in PaO2,
• resolution of acidosis,
• these changes are usually seen within 1 h and must certainly be evident at 4 h
otherwise failure is to be expected.
Routine assessment 1 h after commencement should include blood gas analysis.
Thereafter continuous oximetry with 6 hourly gas analysis should sufﬁce. The
intensity of monitoring will be determined by the progress of the patient and the
environment in which the therapy is instituted.
Non-invasive mechanical ventilation 101
The reasons for failure can be as much to do with ﬂaws in the application of the
technique as it can be to do with the patient and the following should be considered:
• Is medical treatment suboptimal.
• Have complications developed (e.g. pneumonia).
• Too much oxygen leading to hypercapnia.
• Too much leak.
• Circuit problems leading to rebreathing or leaks.
• Can one improve patient acceptability.
• Is support adequate.
Weaning from NIV
The patient should be ventilated for as long as they will tolerate initially. Signs of
improvement include:
• heart rate below 110 beats/min,
• respiratory rate less than 24/min,
• SpO2 above 90% on FiO2 less than 4 l/min,
• compensated pH greater than 7.35.
Sometimes the patient will be aware of when they are ready to begin weaning.
Weaning should begin ﬁrst during awake periods. Weaning periods when asleep
should then follow.
NIV facilities
There is a consensus developing about the appropriate setting for the provision
of NIV. The British Thoracic Society Guidelines on NIV (see Further reading) sug-
gest the following:
• Ward-based NIV is appropriate if there is a designated location in the hospital,
appropriately trained staff to manage it and a system in place that ensures that
the right patients get referred in a timely manner.
• Ward-based services should have a designated lead clinician with overall
responsibility for the service.
• Sicker patients who would be intubated if NIV fails, should be managed in a
critical care area.
102 D. Kelly
• Patients with conditions such as pneumonia or ARDS should be managed in a
critical care area unless NIV is the limit to the treatment on offer. This applies to
any condition where the role of NIV has not clearly been established.
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Principles of IPPV
I. McConachie
Mechanical ventilation, especially intermittent positive pressure ventilation
(IPPV) is the mainstay of modern intensive care practice and of fundamental
importance to intensive care unit (ICU) therapy.
Care of the ventilated patient
General issues
• Airway. Access via cuffed tracheal tube or tracheostomy. Secure the tube. Do
not overinﬂate the tracheal cuff. Cuff pressure should be regularly measured,
even in tubes with a high-volume/low-pressure cuff.
• Provide adequate humidiﬁcation and clearance of secretions. The absence of
humidiﬁcation will encourage heat loss and dehydration of the upper respira-
tory tract. This can cause upper airway epithelial damage, and difﬁculties with
clearance of dry secretions. Conversely, excess heat and/or humidiﬁcation can
cause problems.
• Routine nursing care including care of the unconscious patient.
• Monitor appropriately. In view of the unpredictable and complex effects of
IPPV on the circulation be prepared to monitor the central vascular pressures
and cardiac output (CO). An arterial line is mandatory to facilitate blood gas
sampling for all but the shortest periods of ventilation.
• Nasogastric (N/G) tube to relieve gastric distension and permit administration
of medications and nutrition.
• Ensure patient comfort as far as possible. See Chapter 14, Sedation, Analgesia
and Neuromuscular Blockade.
• Ensure adequate nutrition and hydration.
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Speciﬁc issues
Deep vein thrombosis prevention
Deep vein thrombosis (DVT) is common among patients requiring prolonged
mechanical ventilation in the ICU setting despite the use of prophylaxis meas-
ures. Pharmacological prophylaxis is commonly used but mechanical devices may
also be effective and preferred where the risk of bleeding is high. Alternatively, low
molecular weight heparins are associated with less bleeding (and less heparin
induced thrombocytopenia) than standard heparin.
Coagulopathy negates the need for DVT prophylaxis and many hold the admin-
istration of heparin if the International Normalisation Ratio (INR) 1.5:
• In an early study there was a 12% incidence of DVT as documented by duplex
ultrasonography [1]. Ninety-two per cent of patients had received DVT 
prophylaxis. Twelve patients (12%) were documented to have DVT by venous
duplex scans. The incidence of DVT in those patients without signs or symp-
toms of DVT was only 3.6%. However, there was a poor correlation between leg
swelling and DVT.
• In a more recent study of patients ventilated for 7 days, 23.6% were shown to
have a DVT by the use of duplex ultrasonography [2]. All patients had received
prophylaxis. However, there were no statistically signiﬁcant differences in hos-
pital mortality or lengths of stay in the hospital and ICU for patients with and
without DVT.
• Perfusion problems have led to the questioning of the appropriateness of the
subcutaneous route in critically ill patients. A recent study in ICU patients has
shown signiﬁcantly lower anti-Xa levels in response to a single daily dose of
subcutaneous enoxaparin compared with medical non-ICU patients [3].
Pressure area care
In a recent study [4] the risk of developing pressure ulcers in ICU was associated
with the following:
• noradrenaline infusion,
• high acute physiology and chronic health evaluation II (APACHE II) score,
• faecal incontinence,
• anaemia,
• long length of stay.
The usefulness of the commonly used waterlow pressure sore risk (PSR) scale 
in the ICU has been established [5]. In that study, when a patient had a PSR
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score 25 on admission, the risk of developing a pressure sore was signiﬁcantly
increased.
The prevalence of pressure ulcers in Dutch ICUs has been shown to be 28%
[6]. Specialised support systems were only in use in 60% of patients at high risk of
ulcers. Worse, only 37% of patients for whom regular turning was appropriate
were actually being turned. There is no reason to presume these problems are
speciﬁc to Dutch ICUs.
Eye care
Eye problems especially microbial keratitis can have devastating effects on vision
in survivors from ICU. The incidence and prevalence is unknown. Pseudomonas
is commonly the reported infecting organism.
In a small study [7], 60% of ventilated patients receiving sedation for more
than 48 h had developed corneal erosion when assessed using the ocular slit
lamp especially in those patients who were unable to close their eyes. Protective
eyelid taping was effective in preventing and treating the corneal erosion.
The use of an algorithm has been proposed [8] to reduce the incidence of
these problems revolving around:
• Lids closed: no speciﬁc treatment.
• Conjunctive exposed: use of 4 hourly lubricants.
• Cornea exposed: use of tape over eyes  4 hourly lubricants.
• Prone position: use of tape over eyes  4 hourly lubricants.
One must not forget to administer chronic eye medications to ventilated patients,
especially medication for glaucoma. It is important to be aware that other medi-
cations may affect intraocular pressures. For example, the use of dopamine is
associated with increased intraocular pressures in critically ill patients [9]. This
may not be a problem in normal patients but may represent a signiﬁcant risk in
patients with glaucoma.
Daily assessment and management planning (courtesy Dr DR Kelly)
The ventilated patient should receive a full clinical examination each day with
special focus on the cardiopulmonary system. In addition a suggested structured
programme for assessment and management planning is as follows:
(1) Is the diagnosis secure?
(2) If not, what investigations are necessary?
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(3) Are the treatments correct?
Right dose?
Right duration?
Secure from allergy or toxicity?
Effect of renal or liver dysfunction?
(4) Consider the supportive therapy:
Are they on appropriate dose of inotrope?
Are they too vasoconstricted?
Stress ulcer prophylaxis?
DVT prophylaxis?
(5) Consider the haemodynamics:
Adequate organ perfusion?
Adequate ﬁlling?
Appropriate haematocrit?
Adequate monitoring?
Signs of myocardial or other ischaemia?
Antifailure medication optimal?
(6) Consider the ventilation:
Is the tidal volume (TV) appropriate? Low enough?
Adequate positive end expiratory pressure (PEEP) to keep lung open?
Are recruitment manoeuvres necessary?
Appropriate mode?
(7) Consider the lungs:
Are they draining? Are secretions changing?
Does the airway resistance or lung compliance indicate bronchodilators or
steroids?
Pneumothorax?
Plugging/inspissation?
Appropriate humidiﬁcation?
Are they head up?
(8) Can they wean? If not, why not?
(9) Can they be mobilised to a chair? If not, why not?
(10) Is sedation appropriate? What is depth? Is it stopped daily?
(11) Check parameters of liver and renal function. Is renal support required?
(12) Is the gut working? Gut protection prescribed? Prokinetics? Enteral nutri-
tion? Diarrhoea or constipation?
(13) Adequate calorie intake? Adequate non-protein calories? Novel substrates?
(14) What bacteriological evidence is there for antibiotics?
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(15) What specimens have been sent? When? Need repeating?
(16) Any evidence for line sepsis? How old are lines?
(17) Is the white cell count (WCC) rising/falling? Temperature?
(18) Have you checked for focal neurological signs?
(19) Have specialist referrals been done?
(20) Do relatives need counselling?
Airway management
The choice is between oral tracheal tubes, nasal tracheal tubes and tracheostomy
tubes. Each have their advantages, disadvantages and complications.
General disadvantages include:
• bypassing upper airway defences against infection;
• loss of humidiﬁcation of inspired gases;
• less effective cough;
• long term damage to airway;
• increased work of breathing due to increased airway resistance.
Oral tubes
Advantages Usually smooth atraumatic insertion
Easy suction of secretions
Familiarity
Disadvantages Patient discomfort
Obstruction by bite
Problems with oral hygiene and mouth care
Laryngeal damage if cuff overinﬂated (reduced by low-
pressure cuffs)
Occasionally difﬁcult to secure (e.g. patients with beards)
Dental trauma on insertion
Moulding at body temperature and movement within the
oropharynx
Nasal tubes
Advantages Better comfort (i.e. less sedation requirements)
Easy ﬁxation
Less oropharyngeal movement
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Disadvantages Sinusitis as occult source of sepsis
False passages created during insertion
Bacteraemia on insertion
Nasal erosions
Epistaxis on insertion
Difﬁcult for suction
Laryngeal damage, as for above
Longer than oral tubes, slightly increased work of breathing
Overall, most would agree that oral tracheal tubes are preferred to nasal tracheal
tubes for most situations in the adult ICU.
The role of chest X-rays
All new admissions to ICU will need a chest X-ray (CXR), even if only as a 
baseline. In the past it was considered important to perform CXR daily on venti-
lated patients. European legislation mandates us to reduce, where possible,
patients’ exposure to ionising radiation leading to a re-examination of this 
practice:
• Studies show us that clinical examination can effectively predict the need for
radiography [10].
• The most recent study of the value of routine daily CXR found that this prac-
tice was not associated with a reduction in ICU or hospital length of stay or
mortality [11].
• Radiological changes may lag behind clinical changes.
Thus CXRs should be performed largely on the basis of clinical change in the
patient’s condition. In particular, regular CXRs performed on patients who are
rapidly improving seem pointless.
Exceptions to the above are CXRs following central venous pressure (CVP)
placement or following intubation; that is, those circumstances where clinical
assessment of placement position may be unreliable. In addition, many would
still argue for occasional “screening” CXRs to be performed in long stay venti-
lated patients, that is, to assess resolution of ﬁbrosis or early detection of new
inﬁltrates.
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Principles of ventilatory support
• IPPV should only be used where there is a reasonable chance of survival.
• It should not be used as the last therapeutic act in a dying patient purely
because it is available if it will only prolong the act of dying and the relatives’
distress. Patients who are clearly dying should be allowed to do so without a
period of inappropriate therapy on a ventilator. This is explored in Chapter 16,
Withholding and Withdrawing Therapy in ICU.
The prime indication for IPPV outside of the operating theatre is respiratory fail-
ure but modern ICU practice recognises the value of early ventilation as part of
organ support in other critically ill patients, especially in the presence of shock 
or cardiac failure.
Indications
Indications in the ICU include:
• Postoperative management: for example, patients with morbid obesity, post-
operative hypothermia, preexisting lung disease, cardiac surgery and gross
abdominal distension.
• Respiratory disease: for example, pneumonia, lung contusion, asthma and
other chronic obstructive respiratory diseases and acute respiratory distress
syndrome (ARDS).
• Chest wall disease: for example, patient with “ﬂail chest” following trauma.
• Neuromuscular disease: for example, Guillain–Barre syndrome, myasthenia, etc.
• Central nervous system (CNS) impairment: for example, drug overdose,
trauma, status epilepticus, cerebral haemorrhage, tetanus.
• Cardiovascular disease: for example, cardiac arrest, severe shock of any aeti-
ology, pulmonary oedema.
• To provide organ support prior to organ donation in patients fulﬁlling appro-
priate criteria.
Protecting the airway against aspiration strictly only requires tracheal intubation
or tracheostomy, not IPPV, but the clinical circumstances nearly always require
IPPV as well as intubation.
The difﬁcult decision is often not whether to ventilate a patient but more
often when to ventilate a patient (apart from acute emergencies, e.g. cardiac
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arrest). This is difﬁcult to be precise about and experience is often the deciding
factor:
• Certainly gross hypoxia: for example, PO2 8 kPa on 60% concentration of
inspired oxygen is a strong indication if there are no contraindications.
• Similarly, worsening hypercarbia and respiratory and or metabolic acidosis are
highly signiﬁcant.
• Often trends of physical and physiological variables are more useful than
absolute values.
• In accepting this one must not forget that hypercarbia usually develops rela-
tively slowly whereas acute hypoxia can be lethal within minutes. It is better to
intubate early rather than too late!
• General condition of the patient, for example, presence of exhaustion, sweat-
ing, increasing restlessness or an inability to clear sputum is important in indi-
cating need for ventilatory support.
Contraindications to IPPV
The decision to withhold IPPV in patients with chronic respiratory failure is difﬁ-
cult and requires the judgment of experienced practitioners. Ideally, the family
and other professionals involved in caring for the patient should be involved in
this decision. The patient’s wishes should be paramount but unfortunately when
the situation arises the patient is often unable to become rationally involved due
to their illness.
In general, it may be appropriate to avoid IPPV (and possibly try non-invasive
ventilation) in patients with one or more of the following:
• Severe chronic respiratory disease with severe dyspnoea. Such patients are
often receiving domiciliary oxygen.
• No identiﬁable reversible features. In addition, certain precipitating conditions,
for example, heart failure or pneumonia in chronic obstructive pulmonary disease
(COPD) patients also predict a poor outcome and reduced life expectancy [12].
• Poor quality of life (e.g. housebound, wheelchair bound). Take care, as this is
highly subjective! Functional measures; for example, ability to walk unaided are
more objective and also may have prognostic signiﬁcance [13] (in e.g. COPD).
• Previous objective respiratory measurements may be helpful (e.g. documented
functional expiratory volume 1 (FEV1) 0.75) [13].
• If the patient has established or chronic multiple organ failure it may not be
appropriate to offer IPPV if respiratory failure supervenes.
112 I. McConachie
The situation is further complicated by the more widespread use of non-invasive
forms of respiratory support which, indeed, are now the respiratory support
mechanism of choice in exacerbations of COPD. Two points are worth noting:
• A failed trial of non-invasive support does not necessarily mean that IPPV is
inappropriate.
• However, just because a patient is considered suitable for a trial of non-
invasive support does not automatically mandate invasive ventilation if it fails,
especially if IPPV had been originally requested by the referring team and
declined.
Physiological effects of IPPV
Cardiovascular effects
The two main effects of IPPV are:
(1) Lung volumes are increased, often signiﬁcantly compared to spontaneous
ventilation:
– Large TVs causes a rise in pulmonary vascular resistance (PVR) which may
lead to pulmonary hypertension and right ventricular (RV) compromise.
This is due to the over inﬂated alveoli causing compression of the alveolar
blood vessels. (Conversely shallow breathing, e.g. during weaning can also
increase PVR, partly by collapsing alveoli causing a fall in diameter of extra
alveolar pulmonary blood vessels and partly by development of hypoxic
pulmonary vasoconstriction.)
– In addition, large TV leading to hyperinﬂation releases factors into the cir-
culation depressing the blood pressure. Animal studies suggest these to be
prostaglandins.
– Hyperinﬂation can occasionally “squeeze” the heart in the cardiac fossa
causing falls in CO analogous with cardiac tamponade. This is occasionally
seen in severe asthma or emphysemas.
(2) Intrathoracic pressure (ITP) is increased at all points in the respiratory 
cycle, compared to the “negative” pressures generated during spontaneous
ventilation:
– The heart operates as a “pressure chamber within a pressure chamber” (as
described by Pinsky, see Further reading) and it is therefore not surprising
that changes in ITP affect cardiac function.
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– Thus changes in ITP are transmitted to the cardiac chambers during 
ventilation.
– Inspiration during IPPV increases ITP and therefore increases right atrial
(RA) pressure relative to atmospheric pressure leading to a decreased gra-
dient for venous return, reduced RV ﬁlling and reduced RV stroke volume.
In addition the increased ITP decreases the gradient across the left ven-
tricle (LV) that the LV has to work against, this is one aspect of afterload. 
In other words decreased transmural pressure decreases LV afterload. Both
of these effects tend to reduce intrathoracic blood volume.
– Conversely, with decreased ITP, as occurs with spontaneous breathing
during inspiration, the opposite is achieved; for example, decreased RA
pressure, increased gradient for venous return, increased RV stroke vol-
ume, increased LV transmural pressure and increased LV afterload. The
combined effect is to increase intrathoracic blood volume.
– The decreased venous return and therefore decreased CO with IPPV is the
major haemodynamic effect of ventilation in most patients. As it is related
to ITP it is worse if the ventilator is set to provide either a high TV (high-
peak ITP) or a prolonged inspiratory time (high-mean ITP). PEEP also
exacerbates the fall in venous return.
– Venous return and CO can be restored by either ﬂuid infusion or sympa-
thetic drugs both of which restore the gradient for venous return despite
further increases in RA pressure.
Thus increased ITP reduces venous return (preload) but also reduces afterload
on the heart due to effects on transmural pressure. Which effect predominates
depends on several factors; for example, presence of hypovolaemia and, most
importantly, the state of the heart. Any beneﬁcial effect on afterload in the nor-
mal heart is limited by the fall in venous return. In the failing heart the CO is rela-
tively insensitive to changes in preload (ﬂat part of the Starling curve) but
exquisitely sensitive to small reductions in afterload. Thus in heart failure there
may be beneﬁcial effects on CO from increases in ITP with ventilation. In add-
ition it will be crucial in the failing heart to avoid large falls in ITP as may occur
during laboured spontaneous breathing as this can dramatically increase both
preload and afterload producing pulmonary oedema.
With high ITP, RV afterload usually increases due to increasing PVR and devel-
opment of pulmonary hypertension. Thus, high thoracic pressures can reduce LV
ﬁlling due to RV distension pushing the septum to the left to reduce LV chamber
size (known as interventricular independence). This effect of excessive high thor-
acic pressure can counteract the beneﬁcial effects on LV afterload.
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Thus the cardiovascular consequences of IPPV are complex and vary in differ-
ing disease states.
Respiratory effects
• IPPV causes a potential increase in ventilation and perfusion (V/Q) mismatch
due to preferential ventilation of the non-dependant, poorly perfused lung
regions. PEEP in general will improve oxygenation by recruitment of poorly
ventilated lung regions [14].
• In the supine position functional residual capacity (FRC) will be reduced due
in part to upward displacement of the abdominal contents. This contribute to
an increase in micro atelectasis.
• Decreased pulmonary perfusion if CO falls with IPPV causes an increase in
alveolar dead space.
• Surfactant secretion is also reduced by prolonged IPPV.
Other effects
• Humoral effects include an increase in antidiuretic hormone (ADH), renin–
angiotensin and atrial natriuretic peptide leading to an overall retention of
sodium and water.
• The oedema, particularly in the upper body, seen with prolonged IPPV is also
promoted by inhibition of lymph and venous drainage from the upper body.
• The inhibition of venous drainage from the head may also result in a rise in
intracranial pressure (ICP).
Beneﬁcial effects
There is a considerable reduction in work of breathing and proportion of CO and
VO2 going to the lungs and diaphragm with a resultant increase in available CO
and VO2 elsewhere.
There are some who think this may be the only deﬁnite beneﬁcial effect of
IPPV
Other beneﬁcial effects include:
• Improvement in alveolar expansion particularly where there is lobar collapse
often secondary to progressive hypoventilation and exhaustion.
• Recruitment of collapsed lung units.
Principles of IPPV 115
• Oxygenation usually does increase but not necessarily in severe pulmonary
disorders (e.g. ARDS).
• Secretions are easily removed by suction or bronchoscopy.
• It is often only with IPPV support that adequate analgesia can be given to some
patients (e.g. with multiple injuries).
Limitations of IPPV
• In general IPPV does not reverse any intrinsic lung problem and is rarely curative.
• The ventilator should be viewed as adjunctive rather than primary support.
From the moment a patient is connected to the ventilator the goal should be to
remove him from it as soon as it is safe to do so:
• The results of ventilation are best when it is given as pure temporary support of
a patient with a relatively healthy lung (e.g. drug overdose, hypothermia, post-
operative patient).
• Results are not so good for patients with intrinsic lung disease especially if this 
is longstanding as there may not be any improvement possible in the long term.
The aim is such patients therefore is to support respiration while allowing time for
other measures to be effective (e.g. antibiotics in infection, steroids in asthma).
• The results are worst when IPPV is instituted in conditions for which there is 
no speciﬁc therapy for the underlying problem (e.g. ARDS).
Goals of ventilatory support
• Maintain oxygenation. The two main determinants of arterial oxygenation are
the inspired oxygen concentration (obviously) and the mean airway pressure.
This was ﬁrst observed in neonates undergoing IPPV but was later observed in
adult patients with ARDS [15]. Arguably, all other manipulations known to
increase oxygenation, for example, increased TV, PEEP, inverse ratio ventilation
exert their beneﬁcial effect secondary to an increase in mean airway pressure.
However, not all methods of increasing airway pressure may be of equal bene-
ﬁt to the patient (e.g. a minimum level of PEEP may be crucial).
• Recruit alveoli, that is, open lung units and then keep them open. A low level of
PEEP and a low TV avoids overdistension while preventing derecruitment of
alveoli.
• Control PCO2.
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• Reduce work of breathing.
• Achieve patient/ventilator synchrony by use of more ﬂexible modes and/or by
use of sedation.
• Minimise complications of IPPV.
Initial ventilator settings
• Set inspired oxygen concentration. Hundred per cent initially is sensible if there
is doubt regarding the adequacy of oxygenation. This may avoid the patient suf-
fering a period of ongoing hypoxia while waiting for arterial blood gas (ABG)
analysis.
• Adjust inspired oxygen according to ABGs. Accept PaO2 10 for most patients
or oxyhaemoglobin saturations 92%. Patients with severe lung injury may
tolerate a lower PaO2 (“permissive hypoxaemia”) so as to limit the dangers
from excessive TVs or airway pressures [16].
• Set TV at 6–10 ml/kg. Current research supports TVs at the lower end of this
scale (see below).
• Set rate at 10–14 breaths/min. Lower rates may be appropriate in severe
asthma or ARDS (“permissive hypercapnia”).
• Set PEEP. Almost without exception patients beneﬁt from at least 5 cm PEEP if only
to limit the required inspired oxygen concentration and prevent “low level baro-
trauma”, see below. The full recruitment effect may not be seen for several hours.
• Usual inspiratory:expiratory (I:E) ratio 1:2. Patients with ARDS are discussed
elsewhere but they may need a longer inspiratory time setting. Care should be
taken if the patient is at risk of air trapping.
• Usual inspiratory ﬂow rate of approximately 50–100 l/min.
• Continuous ventilation usually initially with pressure support if not deeply
sedated. It is considered desirable to set the ventilator as soon as possible so as to
allow the patient to maintain spontaneous respiratory efforts in order to limit
respiratory muscle wasting and shorten the duration of ventilatory support [17].
• Set volume and pressure alarms.
• Set reasonable trigger sensitivity so as to be able to initiate spontaneous breaths
if appropriate but so as to avoid too sensitive a trigger which may trigger
related to oscillations in the cardiac cycle.
All must be adjusted according to clinical response and frequent assessment.
Lung protective strategies (e.g. permissive hypercapnia are more fully discussed
in the next chapter).
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Complications of IPPV
• Cardiac and ﬂuid retention problems as mentioned above.
• Ventilator induced lung injury (VILI).
• Nosocomial pneumonia (see Chapter 13, Infection and Infection Control).
• Stress ulceration (see Chapter 25, The Patient with Gastrointestinal Problems).
• Complications of airway management.
• Complications associated with ventilator malfunction or human error.
VILI
• Barotrauma strictly refers to any complication of ventilation related to thoracic
pressures and could therefore include the cardiac effects but most limit baro-
trauma to pneumothorax, pneumomediastinum, subcutaneous emphysema
and the rare occurrence of systemic air embolus.
The mechanism is probably related to alveolar and bronchiolar distension
leading to eventual airway disruption and interstitial gas formation. It is gener-
ally accepted that high levels of PEEP, endobronchial intubation and unilateral
lung disease increase the incidence of barotrauma. Many now recommend that
plateau airway pressures be maintained, where possible, below 35 cmH2O [18].
It has become accepted in recent years that “low level barotrauma” can
occur. Here, in the absence of PEEP, repetitive opening and closure of alveoli
cause damage from shearing forces [19].
• It is now believed that in many acute lung disorders, especially ARDS, the dis-
ease process is non-homogenous; that is, there are small, relatively normal
areas of lung in conjunction with areas of diseased lung (known as the “baby
lung” concept). Put another way, in any one patient there will probably be
areas of lung which cannot be recruited for gas exchange, areas which can be
recruited with large TV and pressure and areas of normal lung already recruited
for gas exchange. If sufﬁciently high TV are used to recruit the diseased areas
which can be recruited then the normal areas will be overdistended and dam-
aged. Thus conventional IPPV may contribute to further parenchymal lung
damage.
• The term “volutrauma” itself was coined to emphasise the role of excessive inﬂa-
tion volumes in secondary lung damage. Confusion arose because most early
animal studies of barotrauma raised the airway pressure by increasing TV. A
very elegant study examined pressure and volume truly independently for the
ﬁrst time (using a veterinary “iron lung” to generate volume without increasing
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pressure and thoracoabdominal binding to increase thoracic pressures with-
out altering TV). The authors clearly showed that histological lung damage
only occurred in the high-volume group [20]. Hyperinﬂation may also place
the inspiratory muscles at a disadvantage by ﬂattening the diaphragm.
• High TVs in critically ill patients cause the release of inﬂammatory mediators
into the circulation. A recent study [21] of patients with acute lung injury
demonstrated that low PEEP/high TV mechanical ventilation was associated
with cytokine release into the circulation within 1 h. This could be avoided by
application of a lung protective strategy of high PEEP/low TV. It is uncertain
why ventilating patients with normal lungs in a similar manner does not result
in a similar release of inﬂammatory mediators. For example, during elective
major thoracic or abdominal surgery, IPPV with low TV/PEEP or high TV/no
PEEP did not result in different levels of inﬂammatory mediators [22].
IPPV and the kidney
The retention of sodium and water mentioned above tend to promote a reduc-
tion in urine volumes. In addition, IPPV often leads to reductions in glomerular
ﬁltration rate at the kidney. There are several mechanisms for this:
• decrease CO;
• redistribution of intrarenal blood ﬂow;
• stimulation of sympathetic and hormonal pathways;
• release of inﬂammatory mediators (discussed above). It is of note that the ARDS
net study discussed in the Chapter 24, Acute Lung Injury and ARDS found that
high TVs were associated with an increased rate of renal failure.
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Modes of ventilation and ventilatory strategies
P. Nightingale
This chapter will review:
• lung protective ventilator strategy,
• ventilatory techniques,
• ventilator modes and adjuncts.
Lung protective ventilator strategy
Mechanical ventilation may produce lung damage due to:
• high end-inspiratory lung volume,
• repeated collapse and reopening of distal airways.
In adult respiratory distress syndrome (ARDS) some lung units remain relatively
normal (typically 30%) while others are collapsed, consolidated or ﬂuid ﬁlled.
The lung is actually small and not merely stiff. With volume-controlled ventila-
tion (VCV) using large tidal volumes the relatively normal areas may be over dis-
tended leading to barotrauma.
Modern ventilatory management follows that of the ARDS Network study [1]
and adopts a lung protective ventilatory strategy:
• low tidal volume;
• increasing levels of positive end expiratory pressure (PEEP) to maintain oxy-
genation (see Table 10.1).
This is based on the concepts of keeping the lung open with PEEP, but avoiding
over distension by limiting tidal volume and so end-inspiratory pressure.
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This strategy can use either pressure-controlled ventilation (PCV) or VCV. Modern
ventilators may now have modes that combine elements of both techniques.
However, monitoring the static pressure–volume curve to determine the upper
and lower inﬂection points is not routine in most intensive care units (ICUs),
although some newer ventilators are able to produce a quasi-static curve automat-
ically, for example, the Hamilton Galileo. The role of the dynamic pressure–volume
curve remains unclear.
There have been criticisms of the ARDS Network study:
• the inappropriately high tidal volume in the control group (12 ml/kg);
• the safety of very low tidal volumes.
A number of centres have not adopted the protocol fully [3]. The ARDS Network
have also shown that the level of PEEP is not critical in ARDS when ventilating
patients with 6 ml/kg tidal volume and a plateau-pressure limit of 30 cmH2O [4].
With a lung protective ventilatory strategy, even if respiratory rate is increased,
effective alveolar minute volume is likely to fall and hypercapnia will develop.
This so-called permissive hypercapnia is also seen in severe acute asthma where
low ventilatory rates (6 breaths/min) may be needed to allow sufﬁcient time for
expiration to occur:
• Although there are some potential cardiac and cerebral problems with permis-
sive hypercapnia, at moderate levels (8–10 kPa) it appears well tolerated [5].
Table 10.1. Aspects of a lung protective ventilator strategy
Maintain spontaneous ventilation wherever possible
Initial alveolar recruitment manoeuvres:
• Positional changes (including the prone position)
• Periodical sustained lung inﬂation (e.g. 35 cmH2O for 30 s) [2]
Adequate levels of PEEP to prevent alveolar collapse
Keep above lower inﬂection point on the static pressure–volume curve:
• Measure PEEPi
• Avoid 100% oxygen; may prevent reabsorption atelectasis
Avoid alveolar over distension
Keep below upper inﬂection point on the static pressure–volume curve:
• Limit tidal volume (6–8 ml/kg)
• Limit inspiratory pressure (end-inspiratory plateau 30 cmH2O)
Permissive hypercapnia:
• Allow PaCO2 to rise if there are no contraindications
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• The acute respiratory acidosis does not require bicarbonate therapy.
• Interestingly, there is some evidence that hypercapnia may be beneﬁcial in
acute lung injury [6].
Ventilatory techniques
VCV
VCV with external PEEP has been the traditional mode of ventilation, and is still
used in many ICUs. Tidal volume and ventilator rate are preset and expiration is
time cycled. Inspiratory ﬂow rate is usually preset (60 l/min) and constant,
although it may be possible to set a decelerating waveform. Tidal volume is guar-
anteed in the absence of leaks in the respiratory system, even if there are changes
in airway resistance or total thoracic compliance, although high airway pressures
may be produced. The realization that high airway pressures were associated
with barotrauma led to a degree of pressure regulation by setting an upper pres-
sure alarm limit above which the inspiration was terminated.
PEEP
When airway pressure in the ventilator system has not returned to atmospherical
at the onset of inspiration then, by deﬁnition, there is PEEP present. This may 
be set externally (usually in the range 5–15 cmH2O), but intrinsic PEEP (PEEPi)
may also be present. PEEPi occurs when there is expiratory ﬂow obstruction, 
for example, asthma, chronic obstructive pulmonary disease (COPD), or when 
expiratory time is too short, for example, a rapid respiratory rate, prolonged
inspiratory time. Newer ventilators usually have a means of checking the PEEPi
level. It is important to note that the value on the pressure dial of a ventilator 
during expiration does not reﬂect the level of PEEPi.
When beneﬁcial, PEEP increases functional residual capacity by alveolar recruit-
ment. This reduces pulmonary venous admixture and increases PaO2 at any given
FiO2. However, PEEP may produce unpredictable effects, especially if lung compli-
ance is dyshomogenous, for example, consolidation in one lung. In VCV, PEEP will
increase peak airway pressure and may cause over distension of lung units. Hence:
• Barotrauma is a risk.
• Compression of vessels around distended alveoli may divert blood to under
ventilated regions; hence:
– physiological dead space may be increased,
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– shunt fraction may worsen,
– pulmonary vascular resistance may be increased.
The preset tidal volume must, therefore, be reduced appropriately.
Pressure control ventilation (PCV)
With this technique combinations of rate, inspiratory time or inspiratory:expiratory
(I:E) ratio and pressure level can be set, according to the type of ventilator. Initially,
the pressure is set 25 cmH2O and I:E ratio 1:2 or 1:1 in the patient with acute lung
injury. Adjustments are then made according to achieved tidal volume. Small air
leaks are compensated for and excessive airway pressure is avoided, but tidal volume
will vary with changes in respiratory mechanics. Improvements in compliance can
lead to increases in tidal volume. This can be missed since not all ventilators have a
high tidal volume alarm. In PCV, PEEP will lead to a fall in tidal volume. Hence, preset
pressure or inspiratory time must be increased to compensate for this.
There are some theoretical advantages to PCV when compared with VCV.
These include:
• regional over distension/high regional PEEPi is avoided,
• peak airway pressure is lower for the same mean airway pressure,
• decelerating ﬂow rate may be less injurious,
• alveolar ventilation may be improved.
Inverse ratio ventilation
In this mode the usual set I:E ratio of 1:2 or 1:3 is adjusted by prolonging inspir-
ation so that the ratio becomes 1:1, or greater. This theoretically allows for more
even distribution of inspired gas to lung units with longer time constants. As
expiration is usually not complete before the next inspiration commences, air
trapping occurs and PEEPi develops:
• Inverse ratio ventilation (IRV) can be produced in VCV by an end-inspiratory
pause or use of a slow or decelerating inspiratory ﬂow rate, but there is still a
danger of an excessively high airway pressure developing.
• IRV is often used with PCV by prolonging the inspiratory time. This may be
safer than using VCV since high pressures cannot be developed.
Independent lung ventilation
By using a double-lumen tube it is possible to ventilate each lung separately, 
using different modes and ventilator settings as appropriate. This may be useful
in unilateral lung disease, for example, the presence of one-sided aspiration,
infection or broncho-pleural ﬁstula. The ventilators do not have to be synchronized.
Modes of ventilation
Although a large number of different modes of ventilation are available, it is dif-
ﬁcult to show that any one is superior to the rest. Any mode that allows the
patient to breathe spontaneously, and which minimize further lung damage,
should produce the best outcome.
Triggering
Ventilator manufacturers are continually striving to improve the patient – machine
interface in order to reduce any imposed work of breathing. Patient – ventilator
asynchrony has typically centred on sensitivity of triggering and timeliness of gas
delivery; this may, or may not, be obvious clinically. Flow triggering is preferred
because of the slightly faster response, especially where there is a continuous
background ﬂow of gas through the breathing system. With pressure triggering,
there is a delay before the expiratory valve closes whilst a negative pressure is cre-
ated in the breathing system. When there is PEEPi, an inspiratory effort by the
patient may fail to pressure trigger the ventilator; the PEEPi has to be overcome ﬁrst
before a pressure drop occurs at the ventilator. A new method of triggering which
utilizes changes in the shape of the expiratory ﬂow curve could be useful in these
circumstances. So far, this method (AutoTrak™ sensitivity) has only been used in a
non-invasive ventilator made by Respironics.
Often less well recognized is cycle asynchrony. During controlled ventilation,
the inspiratory time is ﬁxed and there may be failure of the ventilator to end inspir-
ation at the appropriate time in relation to patient effort. The patient may still be
breathing in when the ventilator switches to expiration, or be starting to breath
out whilst the ventilator is continuing to inﬂate their lungs. Although under
appreciated, this occurs frequently and can also lead to patient discomfort and
fatigue. By using an “active exhalation valve” it is now possible for ventilators to let
the patient breathe spontaneously even during prolonged inspiratory periods.
This appears to improve patient discomfort and allows a reduction in sedation
and avoidance of neuromuscular blocking drugs.
Even during pressure support ventilation (PSV), when cycling to expiration is not
time related but rather when inspiratory ﬂow falls to a certain level, asynchrony
126 P. Nightingale
Modes of ventilation and ventilatory strategies 127
occurs frequently. The slope or rise time of the ventilator pressure must be fast
enough to support the inspiratory effort the patient makes, but not so fast that over-
shoot occurs; it is possible to set the rise time manually on some ventilators.
Unfortunately, patient demand is variable, as are lung mechanics due to secretions,
position changes, etc. However, some ventilators can now automatically set the ﬂow.
Volume preset modes
Controlled mandatory ventilation
In this mode, all breaths are mandatory machine breaths and the set minute vol-
ume is delivered totally by the ventilator. The disadvantage of this technique is
that if the patient tries to take a spontaneous breath or cough then not only is it
very uncomfortable, but also surges in peak inspiratory pressure are produced.
Assist control
This term is used when the patient can trigger a mandatory machine breath.
Intermittent mandatory ventilation
This mode was introduced to allow the patient to breathe spontaneously between
mandatory machine breaths. As the frequency of mandatory breaths were reduced
it was thought that the patient could add extra spontaneous breaths to maintain
minute volume. However, the rate and timing of mandatory breaths were ﬁxed,
and once commenced continued until the preset tidal volume had been delivered,
with the potential for hyperinﬂation.
Synchronized intermittent mandatory ventilation
The technique IMV was further reﬁned to allow mandatory mechanical breaths
to be initiated by, and synchronized with, patient effort. This added considerably
to patient comfort with less need for sedation and paralysis. A problem remained,
however, since patients with poorly compliant lungs tend to breathe rapidly. The
increase in physiological dead space commonly seen in these patients meant
that dead space ventilation tended to increase even though minute volume was
maintained. Work of breathing could actually be increased if the ventilator was
not able to respond fast enough to the patient’s effort, see section Triggering in
this chapter.
Mandatory minute volume ventilation
If, during spontaneous breathing, the set minute volume was not going to be
reached, machine breaths were given. Unfortunately, when ﬁrst introduced, the
ventilator was not able to recognize the presence of rapid shallow breathing, and
ventilation remained inefﬁcient despite the set minute volume being reached.
Pressure preset modes
PSV
When the patient takes a spontaneous breath a variable ﬂow inspiratory pressure
is applied to the respiratory system by the ventilator. The level of pressure sup-
port should be set (20 cmH2O initially) so as to give an appropriate tidal vol-
ume. Usually, airway pressure is maintained at the preset level until inspiratory
ﬂow starts to fall, at which point the expiratory phase commences. On some ven-
tilators the level at which this occurs can be adjusted:
• This mode is now frequently used with synchronized IMV (SIMV) as the mode
of ﬁrst choice for initiating mechanical ventilation.
• As with all triggered modes, it is vital that the response time of the ventilator is
rapid or the patient’s work of breathing can be increased dramatically.
• Newer ventilators have more rapid response times, often using ﬂow-triggering,
and the ability to control the rate of increase of airway pressure (“rise time”),
thus reducing the patient’s work of breathing.
PCV
A preset pressure that is maintained within the respiratory system throughout
inspiration; expiration is time cycled. Flow rate is determined by algorithms in
the ventilator, and is initially high in order to pressurize the respiratory system
and then decelerates:
• In clinical practice, for those patients with the most severe forms of respiratory
failure, PCV is frequently used to produce PEEPi by prolonging the inspiratory
time.
• Extrinsic PEEP is still required (8 cmH2O), to stabilize the remaining rela-
tively normal lung units.
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• Unless the patient is on a ventilator that allows spontaneous breaths, this
mode of ventilation is uncomfortable and this should be taken into account
when prescribing sedation and muscle relaxants.
Airway pressure release ventilation
This mode of assisted ventilation utilizes a high level of constant positive airway
pressure (CPAP) with the ventilator falling to a lower level (“release”) at a set time.
The patient can breathe spontaneously at both CPAP levels, but the release of
CPAP from a supra-ambient level to a lower level augments alveolar ventilation
and hence CO2 clearance:
• Typical initial values would be low pressure 8 cmH2O, high pressure 
20 cm H2O and I:E ratio of 1:2.
• Tidal volume is adjusted by varying the pressure range.
Biphasic positive airway pressure
This mode is very similar to airway pressure release ventilation (APRV). Switching
between high and low pressures can be synchronized with patient effort, and
inspiratory efforts pressure supported. Essentially, this mode is PCV but allowing
unimpeded spontaneous breathing at all times [7]. (Biphasic positive airway pres-
sure (BiPAP) is a trademark under license to Dräger and should not be confused
with the Respironics BiPAP non-invasive pressure support ventilator.)
Mixed modes
Electronic control of the ventilators has become extremely sophisticated and this
has allowed a number of other modes to be developed. They all have the same
underlying philosophy, which is to minimize airway pressure while ensuring an
adequate tidal volume. It is now possible for ventilators to calculate the optimum
ventilator settings and then allow breath-by-breath alterations in ventilatory sup-
port, during both controlled and spontaneous breathing.
These modes include:
• Adaptive support ventilation (ASV) and adaptive pressure ventilation (APV)
(Hamilton Galileo ventilator).
• Pressure augment maximum (PAM) (Bear 1000 ventilator).
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• Pressure regulated volume control (PRVC), volume support (VS) and
Automode® (Siemens SV 300 series).
• SIMVAutoFlow® (Dräger Evita series).
• Variable pressure support/variable pressure control (VPS/VPC) (Kontron Venturi
ventilator).
• Volume assured pressure support (VAPS) (Inter7 ventilator).
As rapid advances in developing ventilator technology, the reader is advised to
become familiar with each ventilator in use on their ICU by reading the manu-
facturer’s literature and undergoing appropriate training.
Other modes
Proportional assist ventilation
In this mode neither ﬂow, pressure, nor volume are set by the clinician! A positive
gain control is adjusted to determine what proportion of the patient’s inspiratory
effort (inspiratory ﬂow and volume) is supported by the ventilator. However, to
do this it is necessary to measure respiratory elastance and resistance. This is
technologically very demanding and there is a risk of “run away” ventilation; this
mode has yet to achieve any sort of popularity. The term proportional pressure
support (PPS) is used by Dräger in the Evita series.
High-frequency techniques
These are arbitrarily subdivided into high frequency positive pressure ventila-
tion, high frequency jet ventilation (HFJV) and high-frequency oscillation. The
rate varies from 60 to as high as 3000 ventilatory cycles/min. Since gas distribution
may relate to airways resistance rather than compliance, it is possible to ventilate
areas with both low and high compliance that are adjacent, for example, a patient
with ARDS and a broncho-pleural ﬁstula [8]. Newer machines are capable of pro-
viding better humidiﬁcation, and are powerful enough to maintain lung volume
in patients with ARDS.
Non-invasive techniques
The use of non-invasive ventilation is increasing in hospital practice, particularly
in areas such as the Emergency Department, Coronary Care Unit and in Chest
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Medicine as well as on the high dependency unit (HDU) and ICU. Developments
in non-invasive ventilators mean that these now rival traditional ventilators in
their versatility. This is further discussed in Chapter 8.
Mask ventilation
There have been signiﬁcant improvements in mask design. As well as nasal and
traditional face masks there are now full-face masks and hoods, which are much
more comfortable that previously and allow non-invasive ventilation to be used
in a wider range of patients. However, patient selection is vital, especially the abil-
ity to maintain upper airway protective reﬂexes. Typical uses include acute left
ventricular failure, acute exacerbations of COPD, postoperative atelectasis and
acute lung injury. The evidence for a trial of non-invasive ventilation in an acute
exacerbation of COPD is now compelling. On the ICU non-invasive ventilation is
frequently used as a weaning aid although a large multicentre study has shown
no beneﬁt [9].
External negative pressure ventilation
External negative pressure ventilation (historically provided by an iron lung) may be
performed by applying a cuirass device to the chest wall. The Hayek oscillator main-
tains a negative baseline pressure to increase lung volume and oscillates around
this [10]. There is a built in physiotherapy mode to aid removal of secretions.
Adjuncts
Tracheal gas insufﬂation
Oxygen is delivered to just above the carina (4 l/min) by catheter either continu-
ously or intermittently during expiration. The effect is to reduce anatomical dead
space and increase CO2 clearance [11]. The effect is more marked when there is
permissive hypercapnia but there is obviously the possibility of excessive pres-
sure developing in the lungs.
Automatic tube compensation
It is possible to estimate tracheal pressure based on the length and diameter of
the tracheal tube and gas ﬂow. By increasing ventilator pressure during inspiration
the resistance of the tracheal tube can be overcome and ﬂow improved; this will
reduce the imposed work of breathing. Similarly, if ventilator pressure is
decreased during expiration expiratory ﬂow will be enhanced and PEEPi
reduced. Clinical trials suggest that automatic tube compensation (ATC) has sig-
niﬁcant advantages [12] over simply increasing PSV, particularly by minimizing
PEEPi during spontaneous breathing. ATC is available on a number of ventilators
including the Drager Evita 4 and Puritan Bennett 840.
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Weaning and tracheostomy
J. Cupitt
The key points of this chapter are as follows:
• Mechanical ventilation (MV) is a life-saving procedure but it can also be harm-
ful. Some of the side effects are related to the presence of an endotracheal tube.
• Separating the critically ill patient from the ventilator is referred to as “weaning”.
• It is crucial to discontinue ventilatory support and extubate at the earliest
opportunity that a patient can sustain spontaneous ventilation safely.
• Over 40% of the time that a patient receives MV is spent in weaning.
• The most important indicator of readiness for weaning is resolution of the
acute event which necessitated ventilation.
For the majority of patients, especially those requiring short-term respiratory
support, MV can be removed safely and easily. However, in those recovering from
serious illness or respiratory failure, discontinuation may be associated with
considerable difﬁculty. Few guidelines exist for the optimal approach to this
problem.
Before attempting the weaning process, it is important to satisfy various pre-
conditions related to the patient’s general state:
• absence of major organ or system failure, in particular, a stable cardiovascular
system;
• no severe abdominal distension;
• absence of ﬂuid, acid-base or electrolyte imbalance;
• adequate nutrition;
• correction of pain and anaemia;
• cooperative patient with minimal sedation.
11
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Prediction of successful weaning
Various criteria have been suggested that predict the readiness, and likelihood of
success, of weaning:
• vital capacity 10–15 ml/kg,
• tidal volume 5 ml/kg,
• spontaneous MV 12 l/min,
• respiratory rate 35 breaths/min,
• peak negative inspiratory pressure 20 cmH2O,
• PaO2 8 kPa on fraction of inspired oxygen (FiO2) 0.4,
• pH 7.3.
A recent evidence-based medicine review of weaning parameters concluded that
these predictors had only limited utility in predicting weaning outcome [1]. It has
been shown that a subjective process of patient assessment, independent of wean-
ing indices, yields a satisfactory outcome in the majority of patients [2]. Some
have even questioned whether strict adherence to weaning parameters may even
prolong ventilatory support.
An important study [3] examined various physiological predictors of the like-
lihood of successful weaning. Various indices related to oxygenation or the abil-
ity to generate pressures or volume were not useful. They found that the best
predictor was the ratio of respiratory rate to tidal volume ( f/VT) index. Normally
this ratio is 30. The study found that 80 predicted success whereas 100 pre-
dicted failure in 95% of patients. Unfortunately the ﬁndings have not been con-
ﬁrmed by other investigators [4, 5].
Spontaneous breathing trials
One important strategy used to reduce the duration of both MV and weaning 
is to identify, as soon as possible, which patients are capable of breathing spon-
taneously. This is by means of spontaneous breathing trials. There is little risk in
performing a closely observed trial to assess the patient’s ability to sustain spon-
taneous breathing. This is a simple and reliable method to identify which
patients can be safely extubated without a formal trial of weaning.
Spontaneous breathing trials can be performed via a T-piece, constant positive
airway pressure (CPAP) circuit or pressure support ventilation (PSV, levels up to
10 cmH2O) [6]. The duration of a trial has been set at 2 h but the optimal duration
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is unknown. Recent studies suggest it can be reduced without an increased risk
of reintubation [7, 8].
Weaning techniques
Around 20% of patients receiving MV pose difﬁculties in weaning. Factors inﬂu-
encing the length and difﬁculty in weaning include advanced age, prolonged
ventilatory support and chronic obstructive pulmonary disease (COPD).
There are three main methods available for discontinuing MV:
• T-piece: The oldest method. Represents the only method with no additionally
imposed work of breathing (WOB) in that neither ventilator valves nor circuits
are involved. The only factor which can increase the resistive WOB is the endo-
tracheal tube. This method allows periods of rest when the patient is recon-
nected to the ventilator between periods of spontaneous breathing. Progressive
ventilatory withdrawal is designed to restore muscle function by brief periods
of fatiguing stress followed by longer periods of rest [9]. Particularly useful fol-
lowing brief periods of intermittent positive pressure ventilation (IPPV).
• Synchronised intermittent mandatory ventilation (SIMV): This method is sup-
posed to prevent a patient from “ﬁghting” the ventilator and reduce respiratory
muscle fatigue. The patient is allowed to breathe between machine breaths
and the frequency of machine breaths is reduced as weaning progresses.
Unfortunately intermittent mandatory ventilation may contribute to respira-
tory muscle fatigue.
• PSV: This ventilatory mode allows patients to retain nearly complete control
over respiratory rate and timing, inspiratory ﬂow rate and tidal volume. An
increase in the level of pressure support leads to a reduction in the WOB and 
a decrease in oxygen consumption of the respiratory muscles. The amount of
pressure support is reduced until the patient is doing virtually all the work. 
A low level of PSV will counteract the extra WOB via the ventilator circuit and
endotracheal tube [10].
Two important studies have compared the various weaning techniques [11, 12]. The
study by Brochard et al found that PSV was the best method to separate patients
from the ventilator whilst Esteban et al found the T-piece to be superior. Both stud-
ies concluded that SIMV was the least efﬁcient method of weaning and may prolong
the time to extubation. The most important message is probably that a weaning
method which encourages spontaneous breathing is likely to be appropriate.
Weaning and tracheostomy 137
Automatic tube compensation
Various modern ventilators have the option to automatically compensate for the
presence of the tube be it a oral tube or a tracheostomy tube. Preliminary work
suggests that such a facility may improve the ability to successfully extubate
patients following spontaneous breathing trials [13].
Weaning protocols
Using protocols to wean patients instead of the traditional practice based 
on physician preference and experience can reduce the duration of MV and
weaning.
Nurses using protocol guidance wean patients more quickly than a medical
team following the common practice of physician-directed weaning [14]. It is
likely that when a weaning protocol does not exist, physicians adopt a conserva-
tive approach by reducing support gradually.
Weaning difﬁculties
There are many factors that may be involved in failure to wean:
• Increased WOB due to poor compliance (e.g. obesity, stiff lungs, bronchospasm).
• Unrecognised sepsis, especially nosocomial pneumonia.
• Decreased ventilatory reserve (e.g. muscle wasting and fatigue, negative nitro-
gen balance, electrolyte imbalance).
• Disuse atrophy and fatigue of the respiratory muscles, especially of the
diaphragm.
• Neurological causes of muscle weakness in intensive care unit (ICU) patients
may be a factor in the requirement for prolonged ventilatory support.
• Increased ventilatory requirements, for example, increased dead space, increased
carbon dioxide (CO2) load due to burns, fever or over feeding with carbohydrate
and increased VO2 (e.g. shivering).
• Psychological dependence.
• Abnormal cardiac function (see below).
• Airway factors. Small diameter tracheal tubes increase WOB as do dried secre-
tions in the tube lumen. Adequate humidiﬁcation is essential during weaning.
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• Ventilators. WOB is increased by demand and expiratory valves, tubing, etc.,
especially with SIMV. Also inability of the ventilator to provide peak inspiratory
ﬂow rates on demand. Older ventilators may have an inadequate response
time for cycling when the spontaneous rate 30/min.
Correction of the above problems where possible may help the weaning process
but failure to wean from IPPV is a difﬁcult problem with no simple solution. The
weaning process may be helped by using non-invasive positive pressure ventila-
tion (NPPV) or tracheostomy.
Cardiac problems during weaning
The beneﬁcial effects of IPPV on cardiac function have been alluded to.
Spontaneous ventilation is exercise and it can place an excessive burden on the
heart, induce myocardial ischaemia and promote cardiogenic shock. Much of
the evidence for this is indirect, that is, adverse effects of discontinuing IPPV on
cardiac function:
• Patients with left ventricular failure (LVF) and COPD may develop pulmonary
oedema when IPPV is weaned with increases in pulmonary capillary “wedge”
pressure (PCWP) from 8  5 to 25  13 mmHg [15].
• Cardiac ischaemia, manifested by electrocardiographical (ECG) changes or
thallium scanning defects, can occur during weaning [16].
• A study of patients with COPD but no identiﬁable heart disease demonstrated
reductions in left ventricle (LV) fraction in all patients during spontaneous
ventilation which was not apparent in those patients on PSV [17].
The mechanisms proposed for these observations include:
• Increases in LV afterload with the decreases in intrathoracic pressure. It is recog-
nised that positive pressure unloads the heart and may result in improved 
LV systolic function compared to the negative pressure inspiratory cycles of
extubated breathing.
• Increases in intrathoracic blood volume as venous return increases with the
falls in intrathoracic pressure. The act of spontaneous inspiratory efforts can
precipitate LV dilation.
• Release of catecholamines during spontaneous breathing.
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• Increases in the WOB, myocardial work and myocardial oxygen requirements.
The increased oxygen demand during weaning is met by increasing cardiac
output and/or oxygen extraction. The presence of an increased arterio-venous
O2 difference implies occult cardiovascular insufﬁciency and suggests that wean-
ing trials may fail [18].
• Increases in pulmonary vascular resistance (PVR) with rapid, shallow 
breathing.
Thus diuretics, nitrate infusions and/or angiotensin converting enzyme (ACE)
inhibitors may all be temporarily required during weaning. Inotropic support for
the heart may be beneﬁcial. In many patients the cardiac status is the main limit-
ing factor for successful weaning.
Non-invasive ventilation
NPPV (Non-invasive ventilation) has been shown to be more successful for
weaning than a conventional approach in certain patient groups [19]. Mehta et al
demonstrated a reduced WOB using NPPV [20].
The use of NPPV for weaning might allow extubation much earlier than usu-
ally assumed and it might help to reduce weaning failure rates and episodes of
reintubation.
Patient selection is important, as are the potential side effects, for example,
risk of aspiration.
Iatrogenic ventilator dependency
A tracheal tube increases WOB. Generating pressure to “trigger” the ventilator
during spontaneous breathing requires “work”. It has been suggested that a too
cautious approach to weaning may result in “nosocomial respiratory failure”
[21], that is, tachypnoea during weaning may represent imposed work rather
than patient WOB, and is thus not always a sign of respiratory fatigue. If inad-
equately managed, the patient’s ventilatory support will be increased rather than
the correct response which is to extubate the patient.
A high index of suspicion will help to avoid this situation and performing a
spontaneous breathing trial will assist in the decision of whether to extubate.
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Failed extubation
Failed extubation is distinct from failed weaning. The former is an inability to
tolerate removal of the tracheal tube whereas the latter is an inability to tolerate
spontaneous breathing without ventilatory support.
Pathophysiology of extubation failure is distinct from weaning failure and
includes upper airway obstruction, inadequate cough, excess respiratory secre-
tions, encephalopathy, etc. These become apparent only after removal of the trach-
eal tube.
Extubation failure is highest amongst medical, paediatric and multidiscipli-
nary patients [22].
Risk factors for extubation failure (and thus need for reintubation) include:
• neurological impairment,
• older age,
• prolonged duration of ventilation prior to extubation,
• anaemia,
• severity of illness at time of extubation.
Extubation failure prolongs the duration of MV, increases length of hospital and
ICU stay, increases need for tracheostomy and is associated with higher hospital
mortality.
Tests designed to assess upper airway obstruction, secretion volume and
effectiveness of cough may help predict extubation outcome. Certainly, after
patients recovering from respiratory failure have successfully completed a trial of
spontaneous breathing, cough strength and amount of endotracheal secretions
are important predictors of extubation outcome [23].
Tracheostomy
A tracheostomy offers a number of practical advantages compared to conven-
tional endotracheal intubation:
• Decrease of airway resistance and dead space (and therefore reduced WOB).
• Easy airway suctioning.
• Improved patient comfort and tolerance.
• Avoidance of laryngeal and vocal cord injury.
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• Allows reduction in sedation and awake patients are able to communicate
easier using lip reading.
• Fewer accidental extubations compared with oral tubes.
Potential disadvantages include:
• The surgical technique requires transfer to theatre.
• Early (insertion) complications, for example, bleeding, misplacement creating
false passage, posterior tracheal wall damage (especially percutaneous tech-
nique), pneumothorax/pneumomediastinum.
• Late complications, for example, mucosal ulceration, erosion into innominate
artery or oesophagus, tracheal stenosis.
• Accidental removal may be life threatening until track is well established (48 h).
Indications for tracheostomy are controversial and include:
• To assist in difﬁcult weaning problems.
• Timing in relation to prolonged oral intubation and MV (see below).
• Laryngeal incompetence (e.g. after cerebrovascular accidents (CVA)).
• Reduced level of consciousness (e.g. after head injury).
• Problems with sputum retention.
• Airway obstruction (e.g. after trauma, may be an indication for an emergency
tracheostomy).
Percutaneous tracheostomy
Percutaneous tracheostomy is a technique that can be safely and easily per-
formed at the bedside. It avoids the delays and costs of theatre time. The tech-
nique involves insertion of a needle and guidewire into the trachea followed by
progressive or one-step dilatation of the resultant tract.
Many centre routinely perform this procedure with the aid of bronchoscopic
guidance [24]. This is safe, helps identify needle insertion in the midline of the
trachea, helps avoid damage to the posterior tracheal wall and conﬁrms ﬁnal
tube placement.
Four different types of percutaneous tracheostomy technique based on com-
mercially available kits are commonly used (though others are available):
• Ciaglia set (Cook) – increasing sizes of dilators.
• Portex set (Portex) – specially designed forceps for dilatation.
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• Ciaglia Blue Rhino set (Cook) – single conical (horn) shaped dilator.
• Fantoni translaryngeal set (Mallinkrodt) – specially designed cannula consist-
ing of a ﬂexible plastic cone with a pointed metal tip at its end to enter and
dilate the trachea from its inner lumen outwards.
Many comparative studies have now been performed both between open and per-
cutaneous tracheostomy, and between different techniques of percutaneous tra-
cheostomy. Evidence shows a low incidence of late complications and improved
cosmetic results of percutaneous compared with surgical tracheostomy [25, 26].
A recent meta-analysis of these studies suggests potential advantages of percu-
taneous compared with open techniques including ease of performance and lower
incidence of early bleeding and postoperative infection [27].
Although it appears that the percutaneous technique is becoming the ﬁrst
line method in intensive care patients, one should be aware that a lower risk does
not imply a less serious consideration of indications. Percutaneous techniques
are certainly more cost effective [28].
Timing of tracheostomy
The optimal timing of tracheostomy remains controversial. A tracheostomy need
not be performed at 2 weeks if the patient will be extubated successfully in the
subsequent few days. Conversely, an early tracheostomy should be performed in
a patient requiring long-term ventilation, for example, Guillain–Barré syndrome.
Early tracheostomy avoids the complications arising from prolonged endotra-
cheal intubation and might also reduce ventilator days [29], rates of reintubation
and ICU, and hospital stay.
A recent randomised study [30] of medical ICU patients compared tra-
cheostomy performed at 48 h with tracheostomy performed at days 14–16. The
early group showed signiﬁcantly less mortality, pneumonia and accidental extu-
bations compared with the prolonged intubation group. Time on the ventilator
and in ICU was also reduced.
A major multicentre UK study (Tracman) may help resolve this issue.
Decannulation
When the patient’s condition improves, and as part of the over all weaning process,
the initial cuffed tracheostomy tube can be exchanged for a uncuffed tube with
or without fenestrations. The latter allow for improved translaryngeal airﬂow and
reduce the WOB and allow the patient to speak. Laryngeal competence should be
tested before removing a cuffed tracheostomy tube as even brief periods of endo-
tracheal intubation have been shown to disrupt the upper airway reﬂexes. The
stoma should be covered by a dry, occlusive dressing and allowed to heal spon-
taneously. Note that decannulation results in an increase in dead space which
can increase the WOB by more than 30% [31].
Minitracheostomy
A small diameter uncuffed tube inserted percutaneously via the cricothyroid
membrane. Allows for tracheobronchial suction in patients with poor cough and
sputum retention. Routinely used in some centres to aid sputum clearance fol-
lowing thoracic surgery [32]. Can also be used to administer oxygen, particularly
in the emergency situation.
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Vasoactive drugs
V. Godbole
Inotropes and vasopressors
Support of the cardiovascular system forms a cornerstone in the management of
the critically ill patient:
• Therapy is directed towards optimising cardiac output, organ blood ﬂow and
organ perfusion pressure. This in turn leads to improved oxygen delivery.
• The drugs used to achieve these goals work primarily on receptors found through-
out the cardiovascular system. Other agents act by inhibiting catecholamine
metabolism.
Receptor physiology
• Adrenoceptors form an integral part of the sympathetic nervous system. They
are acted upon by noradrenaline released from nerve terminals, and by circu-
lating adrenaline. The receptors are divided into  and  subgroups:
– 1 receptors are found primarily in blood vessels. Stimulation of these recep-
tors leads to contraction of vascular smooth muscle with subsequent vaso-
constriction.
– 2 receptors are located at pre-synaptic nerve terminals. They have a role in
negative feedback, stimulation inhibiting further noradrenaline release.
– 1 receptors are located in the heart and intestinal smooth muscle. Noradrena-
line and adrenaline are equipotent at these sites. Stimulation results in posi-
tive inotropy and chronotropy. Intestinal smooth muscle is relaxed.
– 2 receptors are found in bronchial, uterine and vascular smooth muscle,
and stimulation results in muscle relaxation. This leads to bronchodilation
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and vasodilation. 2 receptors are more sensitive to adrenaline, suggesting
they act primarily as hormonal receptors.
• The normal heart contains both 1 and 2 receptors in a ratio of 3:1. This may
change to 3:2 in severe heart failure due to downregulation of 1 receptors.
• The effects at adrenoceptors are mediated via second messenger systems
involving G-proteins, coupled to either adenylate cyclase ( receptors) or phos-
pholipase C (1 receptors). Phosphorylation of intracellular proteins then effects
the response to stimulation.
• The natural ligands at adrenoceptors are initially derived from the amino acid
phenylalanine. Hydroxylation of dopamine forms noradrenaline, which is the
immediate precursor of adrenaline.
• Generally speaking, stimulation of 1 receptors leads to an increase in cardiac
output whilst activity at 1 receptors will increase blood pressure.
Dopaminergic receptors
• There are two main sub-types of dopaminergic receptors – D1 and D2. Both are
present in the central nervous system (CNS), where dopamine is an important
neurotransmitter, and at peripheral sites:
– D1 receptors are found in vascular and mesenteric smooth muscle – stimulation
leads to relaxation and subsequent vasodilation.
– D2 receptors are believed to have a role in pre-synaptic inhibition.
• Stimulation of dopaminergic receptors found in the renal and splanchnic beds
results in increased renal and splanchnic blood ﬂow.
Vasoactive drugs may act upon the various receptors to differing degrees, 
resulting in a mixture of effects. This has led to the terms inodilator and 
inoconstrictor.
• An inodilator is a drug with positive inotropic and vasodilator effects (e.g.
enoximone).
• An inoconstrictor has positive inotropic and vasoconstrictor effects (e.g.
adrenaline).
The armamentarium of agents has changed little over the past few years although
our understanding of the effects of these drugs on the various organ systems has
improved.
Note: Catecholamines appear to modulate cytokine response and may improve
outcome in patients receiving supranormal oxygen delivery for sepsis [1].
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Individual drugs
Adrenaline (epinephrine)
Adrenaline is the body’s natural sympathomimetic agent. It is active at all adreno-
ceptors and an infusion will lead to an increase in cardiac output and blood 
pressure with an accompanying tachycardia.
The use of adrenaline as a single agent is attractive but there are serious side
effects associated with its use:
• It has potent dysrhythmogenic effects. The increase in cardiac workload may
result in myocardial ischaemia.
• In severe sepsis the use of adrenaline can reduce splanchnic blood ﬂow [2]. A
recent study compared the effects of adrenaline, noradrenaline and dopamine
on the splanchnic circulation in septic shock [3]. Whilst there was no difference
in blood ﬂow between the agents in patients with moderate shock, in severe
shock splanchnic blood ﬂow was lower during infusion of adrenaline than with
noradrenaline.
• Administration of adrenaline may lead to lactic acidosis in patients with severe
infections [4]. It can be postulated that this is a reﬂection of reduced hepatic
blood ﬂow.
• Metabolic disturbances such as hyperglycaemia and hypokalaemia can occur.
Adrenaline remains the agent of choice in the cardiac arrest situation and in the
treatment of anaphylaxis.
Noradrenaline (Norepinephrine)
This compound is predominantly used for its effects at 1 receptors where stim-
ulation results in vasoconstriction with a resultant increase in blood pressure. It
also has activity at 1 receptors.
Noradrenaline is usually the ﬁrst-line vasopressor and is often used to coun-
teract the vasodilatory effects of sedation.
The agent is widely used in the treatment of sepsis where vasodilation is a
major component of the disease process. However, there have been concerns
regarding its potentially detrimental effects on various regional circulations.
However:
• In the normal mammalian circulation noradrenaline infusion has been shown
to improve renal and coronary blood ﬂow [5].
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• In severe sepsis the use of noradrenaline improves splanchnic blood ﬂow
(despite its vasoconstrictor properties), oxygen delivery and oxygen uptake [6].
• A commonly expressed fear is that use of noradrenaline may cause falls in 
cardiac output due to increases in afterload. In fact, adding noradrenaline 
to patients resistant to dobutamine commonly causes increases in cardiac 
output [7].
Why should noradrenaline, a vasoconstrictor seemingly have a more beneﬁcial
effect on splanchnic blood ﬂow than adrenaline, another vasoconstrictor? One
theory is that it relates to the different ways they may be used. Noradrenaline is
often used in combination with dobutamine and its effects are titrated to reverse
the abnormal degree of vasodilation while, hopefully avoiding actual vasocon-
striction. If adrenaline, however, is used as a sole agent one cannot modify in the
same way its potential to cause actual vasoconstriction.
Dobutamine
Dobutamine is a synthetic drug acting mainly at  receptors although it does pos-
sess some  activity. It is a potent inotrope and is the agent of choice in cardiogenic
shock.
• The increase in cardiac output secondary to increased stroke volume may be
due to improved ventricular compliance [8].
• Tachycardia may be troublesome.
• Dobutamine may improve renal function [9] probably as a result of improved
cardiac output.
• When compared to dopamine, dobutamine improves gastric mucosal perfu-
sion in septic patients [10]. This may be beneﬁcial during the establishment of
enteral feeding.
Dopamine
Dopamine acts at ,  and dopaminergic receptors. At low doses (5g/kg/min)
the dopaminergic effects predominate leading to improved renal blood ﬂow. The
 and  effects, seen at concentrations of 5–10g/kg/min and 10g/kg/min,
respectively, allow the drug to be used as an inotrope and a vasopressor.
However, individual variation does not allow for such easy prediction of effects
at a given dose.
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Renal dose dopamine
• It would seem logical to use dopamine at low doses for the prevention and
treatment of acute renal failure.
• Both diuresis and natriuresis can be demonstrated following dopamine adminis-
tration. The increase in urinary ﬂow most likely results from improved renal blood
ﬂow secondary to an increased cardiac output, although activity at dopaminergic
receptors may also play a part.
• Dopamine has direct effects on renal tubular cells. It inhibits Na/K ATPase, which
results in decreased sodium reabsorption [11]. This in turn leads to a natriuresis.
• Despite these effects the evidence against dopamine as a renal-protective agent
is substantial.
• A recent multi-centre trial randomised 328 patients with at least two criteria for
systemic inﬂammatory response syndrome (SIRS) and evidence of early renal
dysfunction, to receive either dopamine or placebo [12]. The primary endpoint
was peak serum creatinine concentration during the infusion. There was no
difference in endpoint between the two groups.
• Two recent meta-analyses have shown that dopamine has no renal-protective
effect [13, 14].
Whilst dopamine increases renal blood ﬂow it may have deleterious effects on
splanchnic blood ﬂow. In an animal model of haemorrhagic shock splanchnic
ischaemia worsened during an infusion of dopamine at 2g/kg/min [15].
Dopamine may also reduce gastric mucosal perfusion in septic patients [10].
Clearance of dopamine is reduced in the critically ill [16]. This makes predict-
ing the correct dose for a given effect even more difﬁcult and increases the risk of
adverse events.
Other suggested problems are the following:
• The commonest side effects of dopamine are tachycardia and arrhythmias.
• There is evidence to suggest harmful effects of dopamine on neuro-endocrine
function, with infusions inhibiting prolactin, growth hormone and thyroid-
stimulating hormone (TSH) release [17].
• Dopamine disrupts immune function, one result being the inhibition of T-cell
proliferation [18].
A recent review by Holmes and Walley concluded “there is no longer a justiﬁca-
tion for using low-dose dopamine in treating critically ill patients” [19].
Despite these adverse effects and the lack of any renal protection the use of
dopamine remains widespread with many considering it to be a “safe” drug.
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Dopexamine
This is a relatively new drug with mainly 2 activity. It is a synthetic analogue of
dopamine and also demonstrates agonism at dopaminergic receptors:
• Dopexamine increases renal and splanchnic blood ﬂow. Concerns over the
effects of dopamine have led to the use of dopexamine as an alternative.
• Many studies have looked at the use of dopexamine to optimise oxygen delivery in
high-risk surgical patients. Wilson demonstrated reduced morbidity when dopex-
amine was administered preoperatively [20]. However in a multi-centre study
involving 412 patients Takala et al were unable to show an improved outcome [21].
More recently Stone and colleagues failed to demonstrate any beneﬁt in giving
dopexamine intraoperatively [22].
• Dopexamine does not prevent the development of multi-organ failure in the
critically ill when commenced after initial resuscitation [23].
• At doses of 1g/kg/min dopexamine exhibits an inhibitory effect on pro-
lactin release, similar to that seen with dopamine [24].
Tachycardia may be pronounced during dopexamine administration.
Whilst the use of dopexamine may seem attractive its beneﬁts are still being
evaluated. The use of dopexamine as part of a perioperative optimisation strat-
egy is fully explored in Chapter 17.
Enoximone
Enoximone is a phosphodiesterase III inhibitor and acts to reduce the break-
down of cyclic AMP. This leads to vasodilation and increased cardiac output (i.e.
it is an inodilator).
The drug also exhibits lusitropy – enhancing ventricular relaxation allows
increased coronary blood ﬂow.
Its use is limited due to the signiﬁcant hypotension that can occur.
Enoximone may have some beneﬁcial effects on hepato-splanchnic function
when compared to dobutamine [25].
Milrinone
This phosphodiesterase inhibitor has similar properties to enoximone.
Hypotension may be worse with milrinone and its use is restricted to the
treatment of severe cardiac failure.
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Phenylephrine
This agent is a potent 1 agonist. It is used primarily in vasodilation unresponsive
to noradrenaline.
Vasopressin
Vasopressin is a naturally occurring compound, which is synthesised in the
hypothalamus and released from the posterior pituitary gland. It has both vaso-
pressor and anti-diuretic activity, mediated via vasopressin receptors (V1 and V2).
V2 receptors are located in the renal-collecting tubules and stimulation promotes
water reabsorption. V1 receptors are expressed in vascular smooth muscle and
are responsible for vasoconstriction:
• Studies have demonstrated that in early septic shock the level of circulating
vasopressin rises.
• However during prolonged shock the level falls. This relative deﬁciency is seen
in a third of patients and may contribute to refractory hypotension [26].
• A low-dose vasopressin infusion may have some beneﬁt in these patients and
allow withdrawal or reduction of catecholamines [27, 28]. Infusion is recom-
mended at 0.02–0.04 units/min with adverse cardiac events seen at higher
doses. This is not a titratable drug.
• Outcome studies in septic shock are still awaited.
The role of Vasopressin in cardiac arrest is discussed in Chapter 30.
General points for inotropes and vasopressors
• Positive inotropes increase cardiac output. Mean arterial pressure (MAP) will
usually increase as a secondary effect.
• Vasoconstrictors will increase blood pressure.
• Fluid resuscitation should precede the start of cardiovascular support in the
presence of hypovolaemia. Starting therapy in a “dry” patient may have disas-
trous consequences.
• Severe metabolic derangements (e.g. hypophosphataemia), can impair car-
diac function. They should be sought for and corrected.
• Catecholamines may affect blood glucose control and frequent measurements
should be taken.
• Vasoactive drugs are rapidly acting with a short half-life. They are given by
intravenous infusion that allows easy titratability to desired end points.
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• Drugs with  effects should be given into a central vein as extravasation can
lead to tissue necrosis.
• Ideally, appropriate monitoring should be in place prior to the commence-
ment of any infusions.
• It is advisable to titrate speciﬁc drugs to speciﬁc effects; for example, dobuta-
mine to improve cardiac output; noradrenaline to increase blood pressure in
the presence of a normal cardiac output.
• It is becoming increasingly clear that one drug does not ﬁt all.
• Some patients are exquisitely sensitive to any interruption of the infusion. In
order to minimise these effects it is advisable to “piggy-back” syringes – starting
the new infusion shortly before the near-empty syringe runs out.
• Whilst the data sheet advises infusion rates in g/kg/min; in practice working in
ml/hr to a desired clinical effect is often more manageable. Many patients will
require infusion rates greater than the manufacturer’s recommended maximum.
• Prolonged exposure (72 h) to positive inotropes leads to a downregulation of
1 receptors. This may result in the need to increase the rate of infusion, and
does not herald a deterioration in the patient’s condition.
• When using cardiac monitoring it should be remembered that systemic vascu-
lar resistance (SVR) is a derived variable. In the presence of an adequate cardiac
output and MAP a low SVR should not be treated to “make the numbers better”.
Hypotensive agents
• Occasionally it is necessary to lower a patient’s blood pressure (e.g. the obstet-
ric patient with pre-eclampsia).
• Acute uncontrolled hypertension requires rapidly acting agents to minimise
end-organ damage.
The commonest drugs in use are brieﬂy outlined below.
Directly acting vasodilators
• Glyceryl trinitrate (GTN): Predominantly causes venodilation resulting in
reduced pre-load. Useful in patients with myocardial ischaemia and ventricu-
lar failure. Given by intravenous (IV) infusion.
• Hydralazine: Direct arteriodilator. Can be given orally or administered IV 
as a bolus or infusion. Mainly used in the treatment of pregnancy-induced
hypertension.
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• Sodium nitroprusside: Arterio- and veno-dilator. Acts by stabilising smooth
muscle membrane. Infusion leads to compensatory tachycardia. May cause
cyanide toxicity.
Adrenergic receptor antagonists
• Labetalol: Acts at 1 and  receptors, the latter predominating especially on
intravenous administration. Useful in obstetric hypertensive emergencies.
• Esmolol: Rapidly acting, selective 1 blocker. It has a short life (9 mins) making
it eminently suitable for IV infusion.
• Phentolamine: Competitive  blocker used in the treatment of hypertension
associated with phaeochromocytoma.
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Infection and infection control
N. Randall
Infection is a common cause of admission to intensive care units (ICUs). In add-
ition, around 30% of patients in ICUs will acquire infection (nosocomial infec-
tion) during their admission. The resulting increase in mortality is between 20
and 80% depending on site of infection and organism. The impact on length of
stay and costs is substantial [1]. Increasing severity of illness is inevitably associ-
ated with more frequent infections.
Certain causes for admission are more commonly associated with infection:
• trauma,
• burns, 
• following emergency surgery (particularly intra-abdominal).
Common intensive care interventions also increase nosocomial infections:
• tracheal intubation and ventilation,
• intravascular catheters,
• urinary catheters,
• drugs (sedatives, muscle relaxants, corticosteroids, antibiotics),
• blood transfusion.
Some patients are predisposed to infection:
• elderly,
• malnourished,
• high alcohol intake,
• heavy smoking,
• diabetes,
• neutropenia.
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The EPIC study
Although 10-year old, the Early Pseudomonas Infection Control (EPIC) study [2]
still gives a useful overview of infection in ICUs.
Causative organisms isolated in the EPIC study
• Enterobacter 34%.
• Staphylococcus aureus 30%, (60% MRSA) – probably now higher, with a greater
proportion of MRSA.
• Pseudomonas 29%.
• Staphylococcus epidemidis 19%.
• Candida 17%.
The source of infection is evenly divided between the patients’ bacterial ﬂora and
exogenous causes.
Site of infection in EPIC study
• All lower respiratory tract 65%.
• Urinary tract 17%.
• Blood 12%.
Pyrexia and leucocytosis are unreliable indicators of infection. C reactive protein
trends are not speciﬁc. Although not well established, Procalcitonin shows prom-
ise as a more speciﬁc and sensitive indicator of developing infection [3]. However,
any deterioration in the condition of a patient should stimulate a search for infec-
tion in each body system. Blood culture should always be part of the process.
Chest and central vein catheter (CVC) infections are discussed below. In addition
consider other sites:
• urine,
• abdomen including gall-bladder,
• surgical wounds,
• heart valves,
• nasal sinuses,
• central nervous system,
• prostheses (heart valves, vascular grafts, mesh implants, orthopaedic implants).
Appropriate and adequate cultures should usually be taken before antibiotics 
are started. If antibiotics are started empirically, microbiological results must be
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reviewed to check that the drug is appropriate. For patients on antibiotics who
appear to be developing a secondary infection, it is preferable to stop antibiotics
and take cultures after a 24–48 h antibiotic-free period.
After 48–72 h of treatment, the response should be assessed. If treatment seems
to be unsuccessful, then further cultures should be taken.
The advice of a microbiologist is valuable.
Nosocomial respiratory infections [4, 5]
In the ﬁrst 3 days of hospital admission, infections are usually community acquired.
After 5 days, infections are usually hospital acquired. Between 3 and 5 days, both
should be considered.
Hospital-acquired pneumonia (HAP) increases with:
• length of hospital stay,
• severity of underlying illness,
• presence of co-morbidities,
• immobility,
• abdominal distension,
• decreased cough reﬂex (debility, drugs, head injury).
Additionally, the following factors increase the risk of pneumonia while venti-
lated (ventilator-acquired pneumonia, VAP):
• endotracheal intubation,
• reintubation (following planned or unplanned extubation),
• sedation,
• supine position.
Keeping patients semi-recumbent (more than 30°) is the only measure shown to
reduce VAP.
Choice of antacid treatment, oro- or naso-gastric tubes, enteral feeding,
humidiﬁcation, and suction management have not been shown to consistently
affect VAP [6, 7]. Selective decontamination of the digestive tract (SDD) is dis-
cussed below.
The diagnosis of VAP depends on:
• Clinical features
– white cell count (high or low),
– pyrexia,
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– increased and/or more purulent secretions,
– deterioration in oxygenation.
• Chest X-ray
– new inﬁltrates (but these have to be distinguished from worsening acute
respiratory distress syndrome (ARDS) or heart failure).
• Bacteriology
– tracheal aspirates (poor sensitivity and speciﬁcity, both improved if cultures
are quantitative rather than just qualitative),
– invasive specimens (i.e. bronchoscopic, either by lavage or protected speci-
men brush (PSB) yielding 80% sensitivity and speciﬁcity),
– non-bronchoscopic invasive techniques (blind PSB and mini-BAL, show some
reduction in sensitivity and speciﬁcity compared with guided techniques).
Combining these factors into a score (clinical pulmonary infection score) has not
been widely validated or adopted.
Other sites should be considered, as respiratory deterioration may be triggered
by non-respiratory infection.
The treatment of VAP should be guided by bacteriological results. Empirical
treatment will need to cover likely organisms:
• aerobic Gram-negative bacilli (including Pseudomonas aeruginosa and
Acinetobacter),
• methicillin-resistant S. aureus (MRSA),
• Candida remains an under-diagnosed cause [6].
Local patterns of antibiotic resistance will guide the choice of drug.
Absence of clinical improvement by 72 h indicates the need for further inves-
tigation. At this point, ongoing antibiotic treatment seems to have less effect on
bacteriological results, particularly on BAL specimens [4].
The mortality of VAP is 20–50%. How much of this is directly attributable to
the VAP (rather than VAP identifying a group with worse survival) is debated.
CVC infections [8, 5, 9]
Routine cultures of CVCs removed from critical care patients will be positive in
15–40%. The incidence of bacteraemia from catheters is less common, at around
0.5% per 100 catheter days, occurring in between 3% and 7% of patients with CVCs.
The attributable mortality is around 12%.
The morbidity results in an extra week in intensive care and an extra 2 weeks
in hospital.
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Colonization of the catheter occurs within a bioﬁlm on the catheter. This is
more commonly extra-luminal.
Bacteria may be carried into the subcutaneous tissue at the time of insertion,
or may migrate along the CVC at a later time. Some infections are intraluminal,
arising from CVC hub contamination. Infusates are exceptionally rare causes 
of infection. Administration sets are more likely to become infected if used for
parenteral nutrition, blood, or several lots of ﬂuid.
CVC infection should be a constant consideration in the management of 
critical care patients. The diagnosis of CVC infection is by culture of more than 
15 colony forming units from a removed line.
CVC induced bacteraemia is conﬁrmed by ﬁnding the same organism in
peripheral blood and from no other site. The CVC remains the likely culprit even
if the organism is found elsewhere, or if the patient’s condition improves after
catheter removal.
CVC infection can be reduced by the following:
• Experienced operator.
• Aseptic technique:
– surgical scrub handwash,
– hat, mask, gown, gloves,
– 2% chlorhexidine antiseptic skin preparation,
– wide sterile ﬁeld.
• CVC care protocol:
– non-occlusive dressing,
– blood administration sets removed immediately after use,
– other administration sets changed at 72 h,
– aseptic technique when opening hubs, then new cap,
– staff education programme.
• Subclavian route rather than jugular or femoral.
• Tunnelled lines (if femoral or jugular).
• Line replacement when clinically indicated. Guide wire exchange only in excep-
tional circumstances.
• Antiseptic impregnated catheters (and are probably cost-effective).
• Antibiotic impregnated catheters; effective but carry reservations over induc-
tion of bacterial resistance and drug allergy.
Antibiotic and antiseptic ointments at the puncture site have not consistently been
shown to reduce CVC infection. Studies of antibiotic and anticoagulant luminal
ﬂush locks have also generated conﬂicting results (and studies are often in haema-
tology patients).
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The commonest organisms causing CVC infection are S. epidermidis and
S. aureus. Less commonly, Candida and Gram-negative organisms are found.
Treatment is removal of the line. Removal should be for clinical reasons; sched-
uled removal after a ﬁxed period does not reduce infection rates. It then follows
that guide-wire exchange should only be used in exceptional circumstances.
This topic is also discussed in Chapter 4.
Speciﬁc nosocomial organisms
The risk factors (disease process, treatments, co-morbidities) for nosocomial
infections have been listed above. The use of (broad spectrum) antibiotics results
in certain organisms becoming more of a problem as an ICU admission lengthens.
MRSA [10]
MRSA is now endemic in many countries. An exception is the Netherlands, where
strict antibiotic policies have controlled the incidence. ICUs often have the high-
est incidence in a hospital. High cephalosporin and quinolone usage correlates
with increased MRSA colonization and infection.
MRSA carries signiﬁcant attributable mortality, probably greater than that of
methicillin-sensitive S. aureus (MSSA).
Treatment is by:
• vancomycin
• teicoplanin
• linezolid.
Vancomycin has to be administered slowly to avoid anaphylactoid reaction.
Drug level monitoring is needed, particularly in renal impairment. Teicoplanin 
is less nephrotoxic but drug levels still need monitoring to ensure therapeutic
levels as well as to avoid toxicity. Linezolid (see below) may be more effective than
vancomycin [11] in treating MRSA pneumonia. Topical treatment of line sites,
wounds, and nose and pharynx is usual.
Control of MRSA is difﬁcult. In addition to general infection control measures
(see below), routine screening and isolation of patients has not been widely
adopted, although there is some evidence to support it [12].
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Candidiasis
In the EPIC study [2], 17% of patients had a deep Candida infection, with signiﬁ-
cant morbidity and mortality. However, the spectrum of disease is wide:
• Superﬁcial: Oropharyngeal, oesophageal, vaginal. Limited signiﬁcance. Topical
treatment.
• Urinary: In isolation, of limited signiﬁcance. Change catheter, amphotericin
bladder irrigation, with or without ﬂuconazole. Recurrence may represent haema-
togenous spread from another more clinically signiﬁcant site.
• Deep infection: Candidaemia, often from CVC infection. Pneumonia, difﬁcult to
diagnose. Tracheal aspirates may represent colonization rather than infection.
Signiﬁcant pneumonia may not release Candida in to bronchial secretions result-
ing in under-diagnosis [6]. Peritoneal Candida may also be missed; a cause of 
late recurrence of abdominal infection after a perforated viscus. Fundoscopy will
identify retinal abscesses in 10% of disseminated Candida infection.
Treatment of deep infection [13]. Candida albicans remains widely sensitive to ﬂu-
conazole; deep infections will need 6 mg/day and up to 10 mg/kg/day. In the
unstable patient, amphotericin use should be considered (particularly in the
absence of species identiﬁcation or known sensitivity to ﬂuconazole). Failure to
respond to ﬂuconazole should also lead to the consideration of amphotericin. In the
critical care setting, one of the lipid-based formulations of amphotericin is usually
more appropriate than the standard preparation. The possibility of non-albicans
Candida would lead to an amphotericin formulation as ﬁrst-line treatment. Sources
of infection should be removed (CVCs, drainage of abdominal collection).
Prophylaxis (using ﬂuconazole) for Candida has been suggested for critical
care patients who have had a perforated viscus [14].
Two new anti-fungal agents are available. Caspofungin [15] is an echinocan-
din, fungicidal for Candida and Aspergillus. Voriconazole is a triazole related to
ﬂuconazole. Both have far fewer side-effects compared with amphotericin, but
there is no evidence for improved efﬁcacy [16].
Clostridium difﬁcile (Cd)
This Gram-positive spore forming bacillus is widely present in the environment
and is part of the bowel ﬂora in 15–30% of patients. Prior exposure to antibiotics is
usually required to precipitate a clinical problem. Third generation cephalosporins
and clindamycin produce most Cd infections.
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Clinical consequences are variable:
• colonization,
• diarrhoea (morbidity rather than mortality),
• pseudomembranous colitis (life threatening).
Diagnosis is by detection of the A and B toxin; this is more signiﬁcant than cul-
ture of Cd.
Treatment is with metronidazole or oral vancomycin, for 10 days.
Vancomycin-resistant enterococci (VRE)
Two species of Enterococcus, faecium and faecalis, have a high level of resistance
to vancomycin (Van A and Van B types).
Again, the consequences are variable:
• colonization,
• a range of infections, of gut, urine, blood, soft tissues, and CVCs,
• some excess morbidity and mortality.
There remains continuing concern about transmission of vancomycin resistance
to S. aureus.
Extended spectrum beta-lactamase (ESBL) organisms
A range of Gram-negative organisms (Pseudomonas, Acinetobacter, Serratia and
others) may acquire resistance to a wide range of antibiotics by the development
or acquisition of beta-lactamases. These organisms may then be responsible for
epidemics of infections in ICUs.
Control of infection [1, 17]
There are two broad strategies:
• prevention of spread of infection between patients,
• management of patients to reduce the incidence of infection.
Prevention of spread of infection
Spread is by contact or airborne. It can be reduced by the following:
• Unit design; size of bed space, “corridor” through unit, provision of cubicles,
air-conditioning, provision of sinks, soap and alcoholic rub dispensers.
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• Operational policies; staff and visitor access, clean/dirty utility rooms, clean-
ing and waste disposal.
• Clinical policies; nurse–patient stafﬁng levels, staff clothing, hand-washing,
use of gloves and aprons, tracheal suction.
• Microbiological policies; screening of admitted patients, epidemiology of unit
infections.
Hand-washing (easier with alcohol rub preparations) and other basic clinical
practices are at the core of infection control.
Patient management strategies
Those strategies related to respiratory infections and CVCs have been discussed
above. In addition, two areas are of note; antibiotic management and SDD.
Antibiotic management
• Policies for choice of empirical antibiotics and drug change in response to
microbiology results have been shown to improve outcome.
• Duration of antibiotic courses remains arbitrary [18] at between 5–10 days.
• Scheduled rotation of use of groups of antibiotics (antibiotic cycling) may reduce
the emergence of resistant organisms.
SDD
SDD is a regimen of non-absorbable topically applied antibiotics (usually
polymixin B, tobramycin, and amphotericin B) combined with a systemic broad-
spectrum antibiotic (often cefotaxime). The objective is to decontaminate the
upper gastro-intestinal tract and prevent nosocomial (mainly respiratory) infec-
tions. Anaerobic bacteria are preserved.
Meta-analyses [19] support the use of SDD, particularly in surgical and trauma
patients. The beneﬁts are reduction in episodes of infection and improved sur-
vival. Some studies [20] have shown additional beneﬁts of reduced antibiotic use
and less antibiotic resistance.
However, concerns remain regarding the lack of consistency in studies included
in the meta-analyses as well as conﬂicting results. Areas at issue are the import-
ance of the systemic component of the SDD, more antibiotic-resistant organisms
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(particularly Gram-positive ones), and whether there really is a beneﬁcial effect on
survival [21].
The context in which SDD is used is important; case-mix of patients, antibi-
otic usage, and prevalence of resistant organisms such as MRSA and VRE will
change the risk/beneﬁt of SDD [22].
SDD is also discussed in Chapter 25.
Antibiotic guidelines
The aim of such guidelines is to facilitate:
• effective treatment,
• reduce antibiotic side-effects,
• reduce antibiotic resistance.
This requires the following:
• Assessing the probability of infection, its source and likely organisms.
• Obtaining adequate specimens.
• Starting the most appropriate antibiotic(s) at the correct dose (considering body
weight, renal function, and severity of infection).
• Reviewing treatment as results become available, trying to reduce the anti-
biotic spectrum of activity to a minimum.
• Critically assessing the response to treatment and changing therapy if it is failing.
• Limiting treatment courses to between 5 and 7 days (some exceptions).
The following table shows some antibiotic guidelines:
Infection Treatment Comment
Community-acquired Ceftriaxone  erythromycin Clarithromycin and 
pneumonia (or clarithromycin) or rifampicin for Legionella,
levoﬂoxacin for 3 weeks
Hospital-acquired Piperacillin–tazobactam or Gram-negative bacteria 
pneumonia ciproﬂoxacin more common; consider
anti-MRSA cover
ICU-acquired pneumonia Ciproﬂoxacin or piperacillin– ESBL cover needed; 
tazobactam or ceftazidime consider anti-MRSA cover
Abdominal sepsis Cefuroxime  metronidazole Initial treatment; poor
response, consider 
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Infection Treatment Comment
undrained infection, ESBL,
MRSA or Candida
Pancreatitis Antibiotics only if infection
Biliary tract infection Cefuroxime or ciproﬂoxacin
Renal tract Cefuroxime or gentamicin
Meningitis (adult) Ceftriaxone or cefotaxime Add in ampicillin in elderly
(Listeria cover); acyclovir if
encephalitis not excluded
Febrile neutropenic Piperacillin–tazobactam Cover may have to be 
patients extended for S. epidermidis
and Candida
Practical points
• Aminoglycosides: efﬁcacy dependent on high-peak concentrations. Higher peaks
depress bacterial growth for longer (post-antibiotic effect). Nephrotoxicity related
to high trough levels. Once-daily dosing is a useful strategy in ICU patients whose
renal function and volume of distribution may be ﬂuctuating. Trough drug levels
may then be checked before each dose.
• Cephalosporins: renal excretion, but drugs vary; for example, ceftriaxone needs
no reduction unless severe impairment; ceftazidime needs reduction at mod-
erate renal impairment. Ceftazidime usually effective against Pseudomonas.
• Quinolones: ciproﬂoxacin usually effective against hospital-acquired Gram-
negative organisms, including Pseudomonas. Levoﬂoxacin has poorer Gram-
negative cover, but better Gram positive, so useful for community-acquired
pneumonia. All quinolones reduce seizure threshold and may precipitate ﬁts.
Ciproﬂoxacin increases theophylline levels.
• Carbapenems: Broad-spectrum cover, including ESBL organisms. Imipenem
formulated with cilastatin to inhibit renal clearance. Convulsant metabolites
may accumulate in renal failure. Meropenem does not have this problem.
• Fluconazole: useful anti-fungal, but dose at 5–10 mg/kg/day in serious infec-
tions. Decrease dose in renal impairment but double dose if haemoﬁltered.
• Amphotericin: 1 mg over 30 mins as test dose, then 0.5–0.7 mg/kg/day. Signiﬁcant
volume load. Hypokalaemia, hypomagnesaemia, renal and liver impairment are
all common to varying extents. Colloidal and lipid-based preparations have fewer
side-effects. Caspofungin is reported to have less renal toxicity than liposomal
amphotericin [23].
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• Linezolid [24]: from a new class of antibiotics, the oxazolidinones. Works by
inhibiting the initiation of protein synthesis in the 50S sub-unit of bacterial 
ribosomes. Effective for Gram-positive organisms, including MRSA, VRE, Listeria
and C. difﬁcile. Particularly useful for pneumonia and soft tissue infections. An 
alternative for beta-lactam sensitive patients with pneumococcal pneumonia.
Intravenous and oral (well absorbed) preparations. Enough liver metabolism
(oxidation) for dosage adjustment not to be needed. Removed by haemodialysis.
Few side-effects: reversible thrombocytopenia after long (2 weeks) courses, weak
monoamine oxidase inhibitor, not reported to be clinically signiﬁcant.
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Sedation, analgesia and neuromuscular blockade
N. Sharma and R. Morgan
Introduction
The two terms, sedation and analgesia, as used in the intensive care unit (ICU)
setting, may be deﬁned as follows:
• Sedation: for hypnosis and anxiolysis.
• Analgesia: for pain relief and suppression of respiratory drive.
In the 1980s ventilated patients were often deeply sedated and routinely para-
lysed with muscle relaxants.
In recent years many critically ill patients have come to be managed at much
lighter levels of sedation, often without the coincident use of muscle relaxants [1]
as a result of the following developments:
• Novel modes of mechanical ventilation which more readily complement and
synchronise with the patient’s own intrinsic respiratory pattern.
• A steady trend towards early percutaneous tracheostomy.
• Wider appreciation of the hazards and negative effects of excessive sedation
and analgesia and the routine use of muscle relaxants.
Sleep, factual memory and amnesia
Patients in the ICU rarely have a normal sleep cycle [2]. They experience reduced
rapid eye movement and slow wave sleep, both of which are important for the
integration of factual memories [2, 3].
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Complete amnesia results in fragmentation and distortion of patient’s mem-
ory of their ICU stay in turn leading to delusional dreams with impairment of the
experience and recognition of external reality [4]. This sequence of events has
been postulated as a cause of anxiety, depression and later chronic stress dis-
orders in some ICU patients [5].
Thus, complete amnesia with the total abolition of factual memories may not
be appropriate for ICU patients, other than during periods of pharmacological
muscle relaxation and for the facilitation of full intermittent positive pressure
ventilation (IPPV) [6].
There is also evidence that hallucinations and delusions, coupled with sleep
deprivation, may generate a state of paranoid delusions, hallucinations, panic
and terror in ICU patients [7]. This transient psychosis may precipitate a with-
drawn state, often mistakenly diagnosed as depression and treated with anti-
depressants rather than with anxiolytics.
However, whilst much can be achieved by explanation and reassurance, intu-
bated patients undergoing mechanical IPPV generally beneﬁt from a period of
pharmacological sedation and analgesia, if only to facilitate “acclimatisation”.
Indications for sedation
In addition to pain, patients in the critical care environment commonly experi-
ence fear and anxiety as a result of their “surfacing” in an alien and apparently
hostile critical care environment. Many patients also experience profound appre-
hension upon coming to a realisation of the severity of their critical illness and of
their consequent vulnerability.
Most patients appear to ﬁnd the experience of tracheal intubation and posi-
tive pressure mechanical ventilation to be, at the very least, unpleasant.
Whilst alleviating overt distress, anxiety and pain, appropriately managed
sedation and analgesia may also lead to a decrease in the work of breathing,
myocardial and respiratory oxygen demand and a reduction in the level of meta-
bolic and hormonal response to critical illness.
Sedation may also be indicated for the:
• control of agitation,
• control of intra-cranial pressure and seizures,
• patient’s and health care professional’s safety,
• facilitation of safe patient transport.
Therapeutic sedative agents
For patients undergoing Intermittent positive pressure ventilation (IPPV) there
are several choices:
• Midazolam: Midazolam is administered by bolus (1–2 mg) or, more commonly,
by infusion (1–5 mg/h). Concern has been expressed that this drug has the
potential to accumulate in the critically ill patient with impaired hepatic and or
renal function [8]. Midazolam is also extensively protein bound leading to a
potential increase in depth of sedation and prolongation of action in hypo-
albuminaemic critically ill patients.
• Diazepam: Diazepam is considered to have an unacceptably long, context sensi-
tive half-life for intravenous use in ICU. It also generates pharmacologically active
metabolites. Oral diazepam nevertheless does have a useful short-term role in the
non-ventilated critical care patient suffering from severe acute anxiety.
• Propofol: Propofol may be administered by infusion at between 5 and 20 ml/h
depending upon response. It results in much less hangover than other intra-
venous hypnotic drugs and signiﬁcantly shortens weaning time to ventilator
independence [9] when compared with alternatives. Although propofol is
expensive, it has been shown to be cost effective in terms of shorter weaning
times after 5 day administration thus minimising undesirable delay between
discontinuation of the drug and the regaining of consciousness [10].
Despite its apparent ideal qualities the routine use of propofol may not be
appropriate for every ventilated patient. It is principally indicated where short-
term ventilatory support is expected (e.g. 24–48 h). Propofol may also be sub-
stituted for longer acting sedatives, after a prolonged period of IPPV, in order to
allow those longer acting drugs to be cleared from the system whilst maintain-
ing sedation control.
In similar vein, propofol is a useful background sedative in cases of over-
dose with depressant drugs in order to maintain sedation control whilst the
offending depressant drugs are metabolised and eliminated.
• Haloperidol: Some practitioners use major tranquilisers such as haloperidol
[11] to control agitation in ventilated patients.
• Clonidine: Clonidine, a centrally acting 2 agonist, in a dose of 50–250g IV,
may be used to control agitation, delirium, anxiety and the coincident sym-
pathetic hyperstimulation often associated with alcohol or opiate withdrawal
[12, 13]. Clonidine also decreases the quantity of opioids required to achieve a
given level analgesia with a corresponding reduction in hypotensive and respira-
tory depressant side effects.
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• Dexmedetomidine: Dexmedetomidine, another 2 agonist, when compared to
propofol, provides an equivalent depth of sedation without increasing time to
extubation. It also exhibits analgesic effects together with the capacity to attenu-
ate the cardiovascular stress responses [14].
• Temazepam: Temazepam may be employed as an effective hypnotic in an
effort to restore a “normal” sleep cycle.
• Isoﬂurane: Although an effective sedative at appropriate inhaled concentra-
tion, isoﬂurane is unsuitable for long-term ICU sedation on the grounds of
cost and the requirement for efﬁcient scavenging and vaporiser compatible
ventilators.
• Narcotic analgesics: Intravenous opiates in general do also contribute to sed-
ation, with the possible exception of alfentanil, which behaves almost as a pure
analgesic respiratory depressant. Analgesia still remains the principle indica-
tion for the use of opiates along, with the facilitation of ventilator compliance
through their respiratory suppressant effects.
Analgesia
Many patients in the ICU experience pain during their period of critical care 
[15, 16]:
• Postoperative surgical patients have painful wounds.
• Vascular cannulation, wound dressing, endotracheal and endobronchial suc-
tioning, physiotherapy, etc. may also cause pain and discomfort.
• Uncontrolled pain frequently leads to agitation and anxiety in the ICU setting.
As previously noted, whilst the drive to breathe against IPPV may be reduced by
appropriate selection of ventilator mode, constant “ﬁghting” and failure to syn-
chronise with mechanical IPPV may require pharmacological (opiate) therapy to
suppress respiratory drive.
Therapeutic analgesic agents
• Regional blockade: The use of regional blockade, including epidural and inter-
pleural local anaesthesia by continuous infusion, may be useful in speciﬁc cir-
cumstances (e.g. after thoracic injury or following major surgery). Epidural
analgesia is discussed further in the chapter on the surgical patient.
Inﬁltration of local anaesthesia prior to vascular cannulation should always
be considered even in the sedated patient.
• Morphine: Morphine by infusion (1–5 mg/h) is commonly used for analgesia in
critical care causing few cardiovascular problems when given. Morphine and
its pharmacologically active metabolites may, however, accumulate in patients
suffering from renal failure [17].
• Fentanyl: Fentanyl at 1–5g/kg/h by infusion, is an alternative to morphine
though more costly. Like morphine, fentanyl may accumulate with prolonga-
tion of action following long-term administration.
• Alfentanil: Alfentanil administered by 5 mg bolus followed by an infusion of
2–5 mg/h is a further alternative to morphine. Although costly, it is predictably
short acting after brief administration. Long-term infusions of alfentanil may,
however, also lead to prolongation of effect as a result of its context sensitive
half-life and renal elimination.
• Remifentanil: Remifentanil at an infusion rate of 1–10g/kg/h is, by contrast,
an ideal choice of analgesic for patients with renal failure [18]. This drug has a
rapid onset of action (less than 60 s), a predictable metabolic proﬁle and a rela-
tively constant, context independent half-life of 2–3 min. It can therefore be
used for long periods without the risk of accumulation.
Tolerance to opiate infusions is common in ICU. Discontinuing continuous infu-
sions may prove challenging with some patients suffering from classical narcotic
“withdrawal” (see later).
Whilst they are predictably effective analgesics, opiates alone cannot be relied
upon to provide adequate sedation. The co-administration of an additional
sedative such as midazolam is usually required although the absolute sedative
dose requirement is often less in conjunction with opiates than when midazolam
is administered alone.
Management of sedation and analgesia
It has been suggested that the goals of sedation and analgesia should be to
achieve:
• a pain-free patient, who is clear, calm and cooperative during the day and has
sufﬁcient restful sleep at night;
• a patient who can be rapidly weaned from ventilatory support once sedation is
switched off.
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These goals may be difﬁcult to achieve because of the following:
• the “ideal” drug does not exist;
• tolerance to pharmacological sedatives and analgesics is common;
• drug accumulation is common in the critically ill;
• whilst drug infusion rates are often increased during invasive procedures they
may not be reduced again at procedural completion. This phenomenon may
result in a “ratchet effect” leading to stepwise increases in drug plasma levels;
• critical care nursing and medical staff are sometimes inclined to accept an
unresponsive patient who, though “ﬂat”, is also relatively “low maintenance”.
Thus over sedation may be more common than under sedation and, on casual
examination, less obviously a problem. Over sedation, however, should not be
considered an acceptable substitute for inadequate levels of critical care staff.
Sedation should be for the beneﬁt of the patient and not for the convenience of
medical and nursing staff.
The adverse consequences of over sedation include:
• cardiovascular and respiratory depression,
• decreased immune function,
• decreased cough reﬂex activity and strength,
• prolonged weaning with consequent increased risk of opportunist infection,
• suppression of neurological responses thus making assessment difﬁcult and
resulting in unnecessary diagnostic imaging,
• gastro-intestinal stasis, especially with opiates,
• increased risk of pressure sore development,
• increased risk of venous thrombo-embolism,
• development of physical and psychological drug dependence leading to with-
drawal complications,
• increased risk of undesirable drug interactions,
• increased direct cost and secondary cost from increased length of stay in ICU.
There does, however, remain a group of patients who do need deep sedation
whilst receiving muscle relaxants to permit optimal mechanical ventilation for
the indications mentioned earlier.
The process of initiation and maintenance of sedation and analgesia in criti-
cal ill patients is as important as is the choice of individual sedative or analgesic
drug. Agents should be individually titrated against deﬁnable end points appro-
priate to the given patient.
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The monitoring of sedation through the use of target criteria can be effective
in ensuring that individual goals are met.
The following approaches may help optimise sedation and analgesia in given
patients:
• sedation scoring systems,
• guidelines for use in speciﬁc patient groups, for example renal and/or hepatic
failure,
• nurse directed sedation protocols [19],
• daily interruption of sedation.
Numerous scoring systems have been developed suggesting that there is, as yet,
no “ideal” system [20].
Sedation scoring system
Subjective scoring systems include the following:
• The Ramsay system scores comfort, sedation and agitation and, along with the
Cook system, has been shown to have good reliability when scored at a single
point in time [21]. System responsiveness and reliability when scored over a
period of time, however, is either poor or has not been subject to analysis.
• The UK Intensive Care Society (ICS) has recommended the routine use of regu-
lar sedation scoring using the society’s subjective criteria and numerical desig-
nations for different levels of sedation [22]. These ICS guidelines on sedation
also include an operative ﬂow chart for use with the scoring criteria.
Objective scoring systems are attractive in principle but difﬁcult to apply in prac-
tice because of the following:
• Plasma drug concentration does not necessarily correspond with effector
organ concentration.
• Frontalis muscle electro-myography and lower oesophageal sphincter contrac-
tions have low sensitivity and vary between individuals [23].
• Continuous electro-encephalography also varies between individuals and
according to chosen sedative [23].
• The cerebral function and cerebral function analysing monitors are complex
and difﬁcult to interpret [24].
• Bi spectral index (BIS) varies between patients [25] and is affected by the use of
opioids [26] becoming unreliable at deeper levels of sedation [27].
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• Auditory evoked potentials (AEP) are not reliable at light levels of sedation and
remain under evaluation [23].
Daily interruption of sedation
Daily interruption of sedation implies switching off sedative infusions comple-
tely every day in order to assess conscious level and minimise the risk of unde-
tected drug accumulation.
Interrupted infusions are recommenced when necessary. Where there is no
signiﬁcant drug accumulation this may be almost immediately. Where accumu-
lation has occurred the interrupted infusion(s) may not need recommencing for
several hours allowing clearance of excess sedative agent and potentially short-
ening time to wean from ventilatory support [28].
Whilst daily awakening does not demonstrably contribute to the develop-
ment of depression or post-traumatic stress disorder after ICU discharge [29],
daily sedation holds may be counterproductive in some groups of patients, for
example those with signiﬁcant ischaemic heart disease.
Delirium in the intensive care patient
• Delirium is a manifestation of acute cerebral insufﬁciency accompanied by
neurotransmitter abnormalities.
• It affects cognition, wakefulness and psychomotor behaviour.
• It may be manifest as extreme agitation or as quiet withdrawal.
• The onset of delirium may be sudden or occur more slowly over days. It typ-
ically ﬂuctuates periodically with symptoms and signs often being more ﬂorid
at night.
• The true overall incidence of delirium in critically ill patients is unknown
(32–67%) being commonly misdiagnosed or unrecognised [30].
• Its incidence in surgical ICU patients is 40%, increasing to 60% in elderly.
• Whilst sometimes a consequence of haemodynamic and metabolic decom-
pensation, delirium can also be caused by pain, anxiety and disruption of 
normal circadian rhythms.
• Delirium is also a common side effect of sedative and analgesic drugs themselves.
Agitation may make patients uncooperative, difﬁcult to monitor and treat. Deli-
rium and agitation can thus pose risks to both patients and carers.
The management of delirium and agitation includes:
• Sympathetic communication with the patient to calm him or her down.
• Identiﬁcation and treatment of underlying remediable patho-physiological or
pharmacological causes.
• The administration of pharmacological sedatives when no other remediable
causative factors can be identiﬁed and treated [31].
Suitable sedatives include:
• Butyrophenones: Haloperidol works by preventing dopamine surges and is
best used intravenously beginning with a low dose at which it may not cause
signiﬁcant sedation.
• Benzodiazepines: Longer acting agents such as lorazepam and diazepam may
be given by intravenous bolus and shorter acting agents such as midazolam, by
continuous infusion.
• Propofol: Propofol is best reserved for circumstances where agitation and
sedation represent life-threatening emergencies.
• Opiates: Drugs such as morphine or fentanyl have calming effects in some
patients.
• 2 agonists: Clonidine has sedative, axiolytic analgesic effects in addition to
attenuating the stress response.
•  blockers: Agents such as esmolol suppress noradrenergic hyperfunction.
Drug dependence and withdrawal
Tolerance to sedatives and analgesic drugs may develop in patients on long-term
infusions leading to an increase in the amount of drug required [32, 33]. Sudden
cessation or too rapid weaning of these drugs may precipitate withdrawal symp-
toms with a potential incidence in excess of 30% [34].
The diagnosis of drug dependence and withdrawal in critically ill patients is
challenging because many of the signs of acute withdrawal are:
• non-speciﬁc (tachycardia, hypertension, fever, tachypnoea, mydriasis, agita-
tion, delirium and seizures) [35];
• difﬁcult to elicit in ventilated patients (opioid craving, cramps, aches and
dysaethesia) [35].
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Gradual reduction in sedative and opioid infusion rates and/or supplementation
with drugs such as methadone may help decrease the incidence of withdrawal
phenomena.
The establishment of balanced sedation and analgesia, and its subsequent
smooth withdrawal, may be further complicated as a result of patients’ existing
habituation to alcohol and nicotine at the point of their admission to inten-
sive care.
In addition, increasing numbers of patients are regular users of pharmaco-
logical substances for recreational purposes and, indeed, may be admitted to inten-
sive care as a consequence.
Consideration of alcohol, nicotine and narcotic analgesic replacement ther-
apy for habituated patients whilst in intensive care has been recommended by
some authorities [36] though the related ethical questions remain a subject of
debate.
Pharmacological muscle paralysis
• The use of muscle relaxants is usually necessary for safe intubation.
Suxamethonium (1–1.5 mg/kg) is the muscle relaxant of choice provided the
serum potassium level is in the normal range.
• Whilst most ventilated patients do not need continued neuromuscular block-
ade to facilitate ventilation, in certain circumstances neuromuscular blockade
is indicated.
The following are examples of such circumstances:
• Minimisation of peak inﬂation pressures in ventilated patients with severe acute
asthma.
• Control of surges in intra-cranial pressure associated with coughing in patients
with severe head injury.
• Possible improvement of effective mechanical ventilation in patients with crit-
ical oxygenation and poor lung compliance undergoing inverse ratio or prone
ventilation or high frequency oscillation.
• Assurance of safe transport of the critically ill ventilated patient.
• Assurance of full ventilatory control during airway procedures such as tracheo-
stomy and bronchoscopy.
• Control of muscles spasms in tetanus and rabies.
Therapeutic agents
• Atracurium: In general the properties of atracurium (0.5–1 mg/kg/h) make it
an ideal muscle relaxant for use by infusion. Signiﬁcant haemodynamic insta-
bility is rare and the production of active metabolites does not pose a problem.
Dose requirements are reduced in hypothermic patients and increased in
pyrexial and hyperdynamic septic patients.
• Cis-atracurium: Whilst cis-atracurium is a costly alternative it does not gener-
ate the histamine release often observed with the mixed isomer.
• Vecuronium and rocuronium: Medium duration muscle relaxants such as
vecuronium and rocuronium may also be used for continuous infusion in ICU
though their duration of action may be unpredictable and prolonged against a
background of hepatic or renal dysfunction.
Problems with neuromuscular blockade
Neuromuscular blockade can lead to the following problems for ICU patients:
• Awareness which cannot be communicated to critical care staff.
• A variant of critical care myo-neuropathy especially if concurrent use of steroids.
• Prolonged weaning as a result of loss of muscle bulk secondary to pharmaco-
logical-induced disuse atrophy.
• Inability to clear secretions through prevention of effective coughing.
Patients on infusions of muscle relaxants should have their level of neuromuscu-
lar blockade regularly checked with a peripheral nerve stimulator to avoid over
dosage. One or two “twitches” in response to a supra-maximum stimulus of four
twitches at 2 Hz is satisfactory in practice.
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Continuous renal replacement therapy
R. Brits
Renal replacement therapy (RRT) forms a very important part of the combined
management of multiorgan failure along with mechanical ventilation and car-
diovascular support:
• Severe acute renal failure (ARF) is a common complication in patients with
multiorgan failure (10–20% of all critically ill patients) and 70% of these
patients will require RRT [1, 2].
• In previous studies mortality rates have been reported to be as high as 33–93%
[1, 2].
• In contrast, single organ ARF has a much lower-mortality rate – less than 10%.
RRTs
RRTs can be classiﬁed as continuous or intermittent. Units differ nationally as
well as internationally regarding their preference of therapy. In Europe and
Australia continuous renal replacement therapy (CRRT) predominates while in
the USA intermittent replacement therapy (IRT) is preferred.
Haemoﬁltration (CRRT)
There are several methods of CRRT:
• Continuous veno-venous haemoﬁltration (CVVH) uses a double lumen
venous cannula and a peristaltic pump which allows higher blood ﬂows and
increased membrane surface area, thus higher ultraﬁltration rates and better
uraemic control. CVVH produces an ultraﬁltrate by maintaining a pressure 
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difference over a highly permeable membrane (convection). Water is pushed
across the membrane and carries dissolved solutes (known as solvent drag). A
physiological substitution ﬂuid is infused into the patient to maintain hydra-
tion status and chemical balance.
CVVH is the most commonly used CRRT in intensive care unit (ICU). Less
common or historical methods of CRRT are as follows:
• Continuous arterio-venous haemoﬁltration (CAVH) uses the arterio-venous
pressure difference across a membrane to continuously produce an ultraﬁl-
trate. Disadvantages include cannulation of both artery and vein which is
associated with a much higher morbidity and also limited solute clearance.
• Slow continuous ultraﬁltration (SCUF): Fluid removal by ultraﬁltration.
• Continuous veno-venous haemodialysis (CVVHD): Fluid and toxins are
removed through a process of diffusion with the use of a dialysate.
• Continuous veno-venous haemodiaﬁltration (CVVHDF): Widely used in
Australia but less so in other countries. Fluid and toxins are removed through a
combination of diffusion, convection and ultraﬁltration.
Haemodialysis IRT
• Haemodialysis produces dialysate by counter circulation of the patient’s blood
and dialysis solution while being separated by a semi-permeable membrane.
Solutes move down a concentration gradient across the membrane – the
process is known as diffusion.
• Treatments are intermittently 3–4 times per week, each treatment lasting
approximately 4 h. However, if IRT is to be used in ICU there is evidence that
daily dialysis decreases mortality in medical ICU patients [3].
• IRT is mainly used in the management of end stage renal failure or single organ
ARF. IRT is still the preferred method of RRT in the USA. However, even in the
USA, CRRT is gaining increasing acceptance in many units.
Advantages of CRRT
• CRRT is slow and “gentle” on the cardiovascular system of these unstable
patients. However, despite this, large volumes of ﬂuid can still be removed if
required. The continuous removal of ﬂuid creates room for the administration
of nutrition and other ﬂuids.
• Adequate uraemic control is achieved even in very severely catabolic patients.
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• CRRT may have other advantages like removal of cytokines and proinﬂamma-
tory materials (the “middle molecules”) from the circulation of the critically ill
(see below). This is, because of the bigger pore size of the ﬁlter membrane.
• Techniques of CRRT are easy to learn.
• IRT is associated with hypotension, which is more severe in those patients with
cardiovascular instability.
Advantages and comparisons are further explored below when discussing 
controversies.
Indications for starting RRT
Most common indications are:
• anuria or oliguria (urine volumes less than 200 ml/12 h),
• hyperkalaemia (serum potassium persistently more than 6.5 mmol/l),
• severe acidaemia (pH 7.1),
• azotaemia (urea 30 mmol/l or creatinine 300 mmol/l),
• pulmonary oedema.
Other indications may include:
• diuretic resistant cardiac failure,
• anasarca,
• uraemic complications (encepholopathy, pericarditis, neuropathy or myopathy),
• dysnatraemia (sodium 160 mmol/l or 115 mmol/l),
• temperature control (hyper or hypothermia),
• drug overdose (salicylates, methanol, barbiturates, lithium, amino glycosides,
cephalosporins),
• sepsis.
Timing of CRRT
Most clinicians would prefer to prevent complications arising from the develop-
ment of uraemia and institute CRRT early. In addition, recent studies examining the
role of early versus late intervention of renal support are of interest. For example:
• Early initiation of CVVH in a small study of patients with septic shock has been
shown to improve haemodynamic and metabolic responses and improve 
survival [4].
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• Early haemoﬁltration is associated with better than predicted survival in ARF
after cardiac surgery [5].
• Despite similarities in injury severity and risk of developing renal failure, sur-
vival was increased in the early ﬁltration group in a retrospective review of 
100 trauma patients [6].
Thus, many ICUs institute support at an early stage before biochemical decom-
pensation occurs.
Efﬁcacy of CRRT
Size of molecules cleared by CRRTs
Type of Mode of 
molecule Size Example removal
Small 500 Da Urea, creatinine, Convection, 
amino acids diffusion
Middle 500–5000 Da Vit B12, inulin, Convection 
vancomycin diffusion
Low-molecular 5000–50,000 Da B2 microglobulin, Convection or 
weight proteins cytokines absorption 
Large proteins 50,000 Da Albumin Only minimal 
removal by CRRT
As regards creatinine and urea clearances; high-volume CVVH may approach
clearances associated with intermittent haemodialysis (IHD). Creatinine clear-
ances of 30 ml/min are not unrealistic [7]. Clearance increases with increasing
ultraﬁltrate volumes and decreases with decreased ﬁlter life.
Practicalities
Initial settings
• An adequate pump speed is required, for example, approximately 200 ml/h
blood ﬂow through the machine.
• A ﬂuid exchange/ultraﬁltrate rate of 35 ml/kg/24 h is recommended (see below).
• Fluid deﬁcits can be set as required (automatically on many modern machines).
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Filters (membranes)
As blood comes into contact with the ﬁlter (membrane) surface, complement
and leucocytes can be activated, therefore triggering the inﬂammatory and coagu-
lation cascade. The degree of activation is variable, depending on the degree of
the biocompatibility of the membrane. Greater triggering occurs with bioincom-
patible membranes and it has been suggested that biocompatible membranes
are associated with better outcomes.
Membranes used during RRT can be divided into two groups:
(1) Cellulose based membranes:
• cuprophan, hemophan, cellulose acetate,
• generally considered low-ﬂux membranes and are very thin,
• strongly hydrophilic,
• bioincompatible.
(2) Synthetic membranes:
• polysulfone, plyamide, polyacrylonitrile,
• high ﬂux-membranes,
• hydrophobic,
• biocompatible,
• better than cellulose membranes in removing “middle molecules” which
include proinﬂammatory mediators.
Four randomised controlled trials have been published comparing the use of
biocompatible versus bioincompatible membranes in the critical ill patient [8–11].
Two trials found a signiﬁcant difference in survival and recovery of renal function
in favour of biocompatible membranes. A third study did not show any difference,
but it must be pointed out that the trial was sponsored by a bioincompatible mem-
brane manufacturer and one of the most potent inducers of complement was used
as the biocompatible membrane. The fourth study did not show any difference
either, but compared a semi-synthetic membrane with a synthetic membrane.
Replacement ﬂuid
During RRT a sterile replacement ﬂuid is infused to replace the ultraﬁltrate
removed with haemoﬁltration or haemodiaﬁltration. There are two ways of
infusing the replacement ﬂuid:
(1) Pre-dilution:
• Fluid is infused before the ﬁlter.
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• Lowers haematocrit of blood passing through the ﬁlter and, therefore,
reducing anticoagulant requirements.
• There are 10% less solute clearance compared to the post dilution method.
(2) Post-dilution:
• Fluid is infused into blood leaving the ﬁlter.
The concentration of sodium, potassium and glucose can be varied according
to the patient’s requirements, but the ﬂuid does not contain phosphate and this
may need to be supplemented.
Buffers
The main buffers in replacement ﬂuid are lactate or bicarbonate. A study by
Barenbrock et al [12] found bicarbonate buffer solutions to be superior in nor-
malising acidosis and reduced the incidence of cardiovascular instability in
patients with renal failure.
Acetate buffered solutions are also available, but studies have shown both lac-
tate and bicarbonate buffer solutions to be superior.
Note: Lactate-free haemoﬁltration replacement ﬂuid contains no buffer, so
bicarbonate must be infused separately at an appropriate rate to supply this.
Vascular access
Extracorporeal treatments require vascular access and there are mainly two
approaches:
(1) Veno-venous mode:
• Most commonly used method in critical ill patients.
• Requires cannulation of a large central vein with a double lumen 
catheter.
• A peristaltic pump, pumps blood through the ﬁlter, drawing blood through
an “arterial” or outﬂow limb and returns via a “venous” or inﬂow limb.
• Blood ﬂow is usually between 150 and 200 ml/min.
(2) Arterio-venous mode:
• Rarely used.
• Requires cannulation of artery and vein, hence higher-complication 
rates.
• The arterio-venous pressure gradient drives blood through the circuit.
• Blood ﬂow is usually 50–150 ml/min.
Anticoagulation
All forms of RRT expose blood to contact with a non-biologic surface and there-
fore, activation of the clotting cascade. Despite coagulation abnormalities often
seen in critical care patients, they still require anticoagulation to prevent ﬁlter
and circuit clot formation during CRRT. No correlation has been found between
routine coagulation variables and duration of ﬁlter survival.
Anticoagulation options include:
• anticoagulant free,
• continuous pre-ﬁlter unfractionated heparin infusion,
• low-molecular weight heparin,
• sodium citrate,
• regional heparisation,
• prostacyclin,
• recombinant hirudin.
Anticoagulant free
• Critical ill patients often have deranged clotting, thrombocytopenia or a com-
bination of both. Anticoagulation-free CRRT is made easier with good venous
access, good blood ﬂow rates and pre-dilution.
• Tan et al have reported the safe use of CRRT with pre-dilution and no pharma-
cological anticoagulation in patients with coagulation abnormalities [13].
Continuous pre-ﬁlter unfractionated heparin infusion
• Infusion of doses (5–10 IU/kg/h) that does not alter activated partial thrombo-
plastin time.
• It may have some unpredictable and undesirable effects on systemic clotting
mechanisms.
• Infusion doses are adjusted, aiming for an activated clotting time (ACT) of
180–200 s.
Low-molecular weight heparin
• Reeves et al showed identical ﬁlter life, comparable safety but increased cost
when they compared ﬁxed dose low-molecular weight heparin (dalteparin)
with unfractionated heparin [14].
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Regional anticoagulation
• Heparin or sodium citrate.
Heparin is infused pre-ﬁlter while protamine is infused post-ﬁlter as the 
neutraliser.
• Sodium citrate may be used as an alternative to heparin in order to avoid
heparin induced thrombocytopenia.
• A technique that involves the pre-ﬁlter infusion of sodium citrate and post-
ﬁlter infusion of calcium as a neutraliser.
• Although earlier techniques were associated with metabolic complications,
two recent studies with simpliﬁed protocols have shown the safe use of citrate
anticoagulation [14, 15].
Prostacyclin
• Prostacyclin inhibits the interaction between platelets and artiﬁcial mem-
branes and, therefore, prevents extra corporeal thrombus formation. Heparin
is relative ineffective towards platelets.
• It inhibits ﬁbrin, leucocyte and platelet base micro-aggregates which might
prevent renal, pulmonary and neurological dysfunction.
• A study by Kozek-Langenecker et al showed that prostaglandin’s were most
effective in prolonging ﬁlter life, when co-administered with heparin. Bleeding
complications were also less in the group receiving both prostacyclin and
heparin, than in the group receiving heparin alone [16].
Drug removal
Many of the drugs we administer to patients may be removed during CRRT
including drugs which normally accumulate in renal failure. Some drugs may
suffer increased removal. Thus, dosages may have to be increased or decreased
or dosage intervals changed to achieve an adequate therapeutic effect.
A detailed description of the proportional removal of different drugs is beyond
the cope of this text. Readers are advised to check the large reference texts avail-
able, consult the drug data sheet or take advice from their hospital pharmacy.
The controversy – CRRT or IRT?
No conclusive evidence exists to determine the best form of RRT for critically ill
patients. There is, therefore, controversy over which type of RRT should be used
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in ICU, with practitioners in Europe and Australia increasingly adopting CRRT,
while the American nephrologists choose to remain with IRT:
• After adjusting for poor quality and severity of illness, a meta-analysis of 
13 studies by Kellum et al showed that mortality was lower in patients treated
with CRRT [17]. The fact that trials have excluded patients with cardiovascular
instability from intermittent renal replacement therapy (IRRT) probably sup-
ports the use of CRRT in critically ill patients [18].
• The French HEMODIAFE study is as yet unpublished but early presentations at
scientiﬁc meetings suggest mortality of approximately 70% in patients in ICU
given either CVVHDF or IHD. It is of interest that the IHD groups showed
improved survival through the length of the study, that is intermittent dialysis
got “better” in critically ill patients with more training, longer duration of treat-
ment and increase in the dialysis “dose”. Deﬁnitive studies comparing CVVH
and IHD remain to be performed.
In addition to potential beneﬁts in terms of survival, there may be other beneﬁts
associated with the use of CRRT compared to IRT:
• The rapid ﬂuid shifts and haemodynamic upset associated with dialysis are
associated with further ischaemic insults to the kidney in animals.
• Creatinine clearance falls after dialysis! (but does not after CVVH) – presum-
ably because of these shifts [19].
• Computed tomographic (CT) studies of the brain demonstrate changes after
dialysis consistent with increased brain water which are not present after
CVVH [20].
• A randomised clinical trial (RCT) has shown that intrinsic renal function
among survivors of ARF recovers to a predetermined level in over 90% of
patients treated with CVVH but in only 59% of patients treated with dialysis
(i.e. more patients will require chronic renal support when ARF is managed
with intermittent dialysis) [21].
High-volume haemoﬁltration?
• The volume of ultraﬁltrate may be important. Large volumes of ultraﬁltrate
(high volume or “aggressive” CVVH) increase creatinine clearance and may
remove greater quantities of inﬂammatory mediators. The only large RCT of
over 400 patients demonstrated improved survival with high volumes of ultra-
ﬁltrate compared to lower volumes [22]. The authors recommend ultraﬁltrate
volumes of at least 35 ml/kg/h.
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• In addition a study of over 300 patients from Holland managed with high vol-
ume CVVH had a mortality of 33% compared with a predicted mortality of 67%
given by the Madrid ARF score [23]. A subsequent smaller, randomised study
from the same group has, however, failed to conﬁrm these ﬁndings.
Fluid and electrolyte control
Another controversial area where CRRT may prove to be beneﬁcial is the control
of ﬂuid and electrolyte balance:
• Patients with acute respiratory distress syndrome (ARDS) have increased extra
vascular lung water and in an attempt to improve oxygenation a negative ﬂuid
balance can be introduced. Loop diuretics usually results in the loss of water
but not in a salt diuresis, therefore hypernatremia develops and extra vascular
lung water remains high. In such circumstances CRRT will normalise sodium
levels and remove extra vascular water. This often leads to a substantial improve-
ment in gas exchanges and lung compliance.
• Some patients in cardiogenic shock post-cardiac surgery might require extra
corporeal membrane oxygenation and will usually also require large amounts
of clotting factors. CRRT can be used to maintain an even ﬂuid balance by
removing ﬂuid while clotting factors are transfused. The development of ARDS
and pulmonary oedema can be prevented, while factors are infused.
• One study comparing CVVHDF with IRT showed that normalisation of sodium,
potassium and bicarbonate levels was more frequently achieved with CRRT [24].
• It has been suggested that transfusion requirements may be associated with
ﬁlter life – frequent clotted ﬁlters resulting in greater requirement for blood
transfusion.
Septic shock, multiorgan failure, ARF and RRT
• Many patients with ARF have severe sepsis, multiorgan failure and a major sys-
temic inﬂammatory response. The activation and ampliﬁcation depends on the
release of proinﬂammatory mediators into the circulation. Targeting the systemic
effects of these mediators seems to be a logical goal in the treatment of patients
with severe sepsis. Speciﬁc single mediators has been targeted, but with disap-
pointing results. Therapies targeting the removal of several circulating inﬂamma-
tory mediators may prove to be more effective. CRRT is one of these therapies.
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• Standard CRRT (exchange rate 1–2 l/h) has shown clinical improvement with
severe septic shock, independent of ﬂuid balance, but has failed to reduce
inﬂammatory mediator plasma concentrations. Recent animal and human 
studies have suggested that if haemoﬁltration is to have an additional role in the
management of severe sepsis, the plasma exchange rate has to be increased
[25–27].
• Blood puriﬁcation using high-volume haemoﬁltration (6 l/min) or coupled
plasma ﬁltration with adsorption has been shown to decrease the need for
vasopressor therapy in septic shock.
• In experimental studies results were more striking when the therapy used was
high volume and convective. Cole et al found high volume haemoﬁltration to
be associated with signiﬁcant decrease in vasopressor requirements [25]. The
decrease was greater than during standard CVVH. Secondly they also showed a
signiﬁcant decrease in plasma levels of C3a, C5a and IL-10. Changes were more
striking during the early part of therapy, thus suggesting that the early decline
in plasma concentration is due to membrane adsorption as the major removal
modality. High volume haemoﬁltration (HVHF) increase adsorption because of
an increase in transmembrane pressure and larger ﬁltering membrane area.
Convective clearance will mainly take place after membrane saturation has
taken place through adsorption.
• Other possible explanations for improved haemodynamic parameters are the
possibility that other unmeasured vasodilatory solutes are removed during
CVVH causing vasoconstriction and decreased vasopressor requirements.
Hypothermia induced by CVVH might also reduce requirements. It is also pos-
sible that sedative removal is greater during HVHF, therefore also reducing
vasopressor requirements. Cole et al found during their study that more than
half of the patients required more sedation [25].
• Protective molecules, such as vitamins and aminoacids, might also be removed
during HVHF having a negative effect on an already critically ill patient. No
studies have yet been done to look at this effect.
FURTHER READING
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Withholding and withdrawing therapy in the ICU
I. McConachie
“To cure sometimes, to relieve often, to comfort always”
15th Century French quote
Many patients die in intensive care unit (ICU) either as a result of failed therapy
or, increasingly, as a result of withheld or withdrawn therapy. It wasn’t always so;
in the early days patients were only seen as appropriate for ICU admission if they
were clearly recoverable. Now ICU is sometimes seen as a place where patients
go to die.
Indeed, it is estimated that:
• 20% of all Americans over the age of 65 die in or having recently been in ICU
(half of all the deaths in hospital),
• 10–12% of all health care expenditure in America is spent in the last 6 months
of patients’ lives.
Almost certainly these percentages will be less in Europe and the UK (so far) but,
even in the UK, dying is almost an everyday occurrence in ICU.
Thus it is increasingly important to address:
• end-of-life (EOL) care in the ICU,
• withholding and withdrawing of therapy,
• optimal care of the dying patient.
This chapter will discuss these three aspects of ICU therapy, although unlike
other chapters, there may be as many questions raised as answered. Much is, and
will probably remain, controversial.
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EOL care in the ICU
Who makes decisions?
Ideally the patients would make these decisions in conjunction with their 
families and after discussions with their nursing and medical carers. Autonomy
and other ethical matters will be discussed below. Decisions should be made
early (before ICU admission) so that decisions do not need to be made during 
a time of crisis, or grief and so as to avoid families feeling under any form of
duress.
ICU is just a place in the hospital in this context. There is sometimes a reluctance
to engage in discussion of EOL issues on general wards but this is often the best
place for such discussions.
In most instances the discussions are initiated by the team of carers with a
small proportion of discussions initiated by the family or patient. Often there is
little consultation – decisions are exclusively made by the carers with the results
just communicated to the patient or family. Often discussions may be implicit,
that is, prognosis or futility alone are talked about with the family with the 
result of withdrawing therapy glossed over. Direct, explicit agreements are to 
be preferred where it is made clear that withholding or withdrawal will lead 
to death.
Nurses should have a major role in inﬂuencing the decisions made by both
physicians and families due to the unique and central nature of their relationship
with all involved parties.
Sjokvist [1] asked lay people, nurses and doctors in Sweden who should make
these decisions on EOL care. He outlined two scenarios for discussion – a men-
tally competent patient in ICU and an incompetent, comatose patient in ICU.
• For the competent patient: 48% of the public, 31% of nurses, and 8% of physi-
cians thought that decisions about continuing ventilator treatment should be
made by the patient and family; 87% of doctors would wish to make the deci-
sion themselves with the aid of the family and patient.
• For the incompetent patient: 73% of the public, and 70% of the nurses thought
that a joint decision should be made by the doctors and the family; 61% of the
physicians would wish to decide this on their own – a view supported by only
5% of the public and only 20% of the nurses.
Thus, in Sweden, the public favour more patient and family involvement than
the doctors would wish.
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In practice, there are geographical and cultural differences re-decision-making
for EOL care.
• Family should decide – US Guidelines.
• Physician should decide – European Guidelines.
There are arguments in favour of both approaches, and indeed, some combin-
ation of the two would seem ideal. The American legal system places more
emphasis on transfer of responsibility to the family – a substituted decision
maker. In Europe, the families have less legal status and, in general, are not legally
able to make consent type decisions on behalf of the patient. European argu-
ments for physician based decision-making include the undoubted emotion and
distress caused to families by being involved in these decisions (and in rare cases,
genuine concern re personal or ﬁnancial motivation).
When making these decisions one must never forget that one must take note
of the views expressed by a competent adult. In the ICU, it is often too late – few
of our patients can be considered competent and even fewer have some form of
advance directive. Advance decisions or directives are increasingly accepted in
the UK. Surrogates have recently been deﬁned by law in Scotland.
Which patients?
Which ICU patients should be considered for discussions re-EOL care issues?
Should we include:
• 77-year-old postoperative laparotomy admitted for overnight ventilation?
• 22-year-old hypotensive trauma patient?
• 55-year-old patient admitted with metastatic disease?
• Patients with predicted length of stay of more than 5 days?
• Predicted mortality of more than 25%?
• Certain groups, for example multiple organ failure?
• Certain chronic premorbid conditions, for example congestive cardiac failure
(CCF) or chronic obstructive pulmonary disease (COPD)?
Individual ICUs may wish to develop their own policies.
Training in EOL care and communication
EOL care should be part of the core competencies of ICU doctors but formal
training and assessment of this rarely occurs. Doctors in training, when asked
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often express dissatisfaction with their skills and training in this area. In one 
survey [2]:
• 96% of ICU residents thought EOL care was important,
• 42% felt their training in this area had been “fair to poor”(compared to only 7%
giving a similar poor rating for their training on sepsis),
• Alarmingly 88% thought they had been asked to prolong the dying process
inappropriately.
Communication and communication skills are the key. There is evidence of wide-
spread dissatisfaction with communication in the ICU [3]. However, studies show
that doctors can be taught:
• improved communication skills,
• to reduce emotional distress during discussions.
Language is important and it must be clear and unambiguous.
“Easy” words calculated not to upset the relatives often serve only to confuse
and underplay the realities of the situation. Certain words, phrases and technical
expressions, in particular, which are clear to us may not be clear to lay people.
For example:
“Wrong” words? “Better” words?
Arrest Heart stopped
Stable Drugs are still required to…
Ventilator Breathing machine
Filter Kidney machine
Asleep Sedated
Paralysed Drugs to relax the muscles
Critical Might die
Passed on Died
Gone to a better place Died
Certain metaphors and cliches are also best avoided, for example:
Had a good innings (successful at cricket?)
At peace (previously at war?)
Expired (past sell by date?)
Doctors sometimes avoid difﬁcult decisions and difﬁcult discussions with
patients and/or their relatives. Although perhaps understandable, this must be
resisted. Families will have these EOL discussions once, twice or at most three
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times in their life whereas they are a regular part of life for ICU doctors! However,
one implication of this is that the family will remember what you say to them and
how you say it. Therefore, doctors have a duty and professional responsibility to
prepare for these discussions and be prepared to have unpleasant discussions
and potential disagreements with families.
Mixed messages and differing opinions within the team are unhelpful and
cause considerable distress and confusion amongst the family. Any differences
between members of the team should be sorted out in private so a “team mes-
sage” can be presented to the family.
All communications should be witnessed, preferably by the nurse involved,
and recorded in the form of a written summary including all the key points raised
and the family’s reaction.
Withholding and withdrawing therapy in ICU
Historical background
The evolution of the history of withholding and withdrawing ICU therapy is well
documented in the USA. In the early ICUs in the 1960s therapy could not, in gen-
eral, be withdrawn. (Prior to that ICUs did not exist as we know them so the ethical
and legal dilemmas associated with life-support technology did not occur.)
The following is a summary of some of the landmark events and cases which
illustrate the changes since the 1960s.
1968 Harvard The original description of brainstem death was published
partly because it was not believed that Intermittent positive pres-
sure ventilation (IPPV) could be stopped unless the patient
had already been declared dead.
1975 Quinlan A case of persistent vegetative state. After 9 months coma, family
petitioned the courts for the right to take patient off the ventila-
tor (against the will of the attending doctors). Court ruled that
family can speak for patient as surrogate decision-maker.
1983 Herbert Patient was removed from the ventilator and feeding was stop-
ped. After death, the District Attorney charged two Doctors
with Homicide!
They were acquitted but, understandably, this caused much 
disquiet amongst ICU doctors and led to a marked reluctance
to withdraw ICU therapy.
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1990 Cruzan Another patient with persistent vegetative state. The Supreme
Court allowed the physicians as, surrogate decision makers, to
make the decision and remove the patient from the ventilator.
1990 Wanglie In this case the husband insisted on full treatment against the
judgement of the doctors. The hospital went to court to ask for
permission to remove the husband as decision-maker so as to
enable them to withdraw therapy.
In essence, the position had come full circle from a time when therapy could not
be withdrawn (prior to Harvard) even though the family wished to do so (Quinlan)
to a position where the hospital were prepared to withdraw care against the
wishes of the family (Wanglie). In other words doctors in America have changed
their attitudes and now are prepared to ﬁght for the right to let patients die
(Wanglie) even against family wishes whereas previously they were prepared to
ﬁght to keep the patient alive against family wishes (Quinlan).
There have been several recent landmark cases in the UK:
• A doctor was found guilty of attempted murder in 1992 after administering KCl
to a terminally ill patient in severe pain in an attempt to relieve her suffering.
(The charge was attempted murder rather than murder because it could not be
proved conclusively that the injection killed her.) Thus, euthanasia or doctor
assisted suicide is illegal in the UK.
• In 1993, the courts permitted the removal of nutritional support in the case of
Anthony Bland who had been in a persistent vegetative state for over 3 years.
• In 1999, a general practitioner (GP) was acquitted of murder after admitting
giving a large, lethal dose of diamorphine to a terminally ill patient with cancer.
He claimed that it was his intent to relieve pain rather than to kill. This case rul-
ing provides some legal backing and protection to the so-called “double effect”
principle, that is, it is permissible to give potent analgesics to relieve suffering
even though it is recognised that it could hasten the death of the patient. It is
still illegal for the primary intent of the doctor to be to kill.
• In 2002, Diane Pretty died a natural death after she lost, in both the UK and
European courts, her ﬁght to allow her husband to assist her to commit 
suicide.
• Also in 2002, Miss B, who was quadriplegic, asked to be removed from her ven-
tilator. The court granted her petitioned to be moved to another hospital where
the doctors would permit her request (her doctors at the original hospital had
refused). She subsequently was removed from the ventilator and died. This case
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arguably is based more on the principle of the right of a competent adult to
refuse treatment rather than a “right to die”.
Deﬁnitions
Withholding is not offering or providing therapy. Not admitting a patient to ICU
for organ support is the easiest example but not increasing vasopressors or not
providing CPR are examples of withholding therapy while in the ICU.
Withdrawing is stopping or removing therapy with an intent to substitute other
(palliative) therapies. Examples on ICU include:
• stopping vasoactive drugs,
• stopping ventilatory support,
• reducing inspired oxygen concentrations,
• removing the haemoﬁlter,
• extubating the patient.
Both withholding and withdrawing are likely to lead to the patient’s death from
their disease and, as such, are ethically equivalent (no ethical difference between
positive and negative acts).
Withdrawal may be seen as easier (for the doctor!) in some circumstances:
• Easier: Multiple organ failure on ventilator.
• More difﬁcult: Poor neurological state, low oxygen requirements but ventilator
dependent.
• Most difﬁcult: Awake, ventilator dependent patient. This type of patient may be
mentally competent to be involved in the decision.
Euthanasia (from the Greek words for “good death”) is the administration of
therapy, at the speciﬁc request of the patient with the sole aim of causing death
(see below re-palliative care, the “double effect” principle and the ethics of
intent). As such neither withholding nor withdrawal can be considered to be the
same as euthanasia.
Withdrawal, for example of IPPV, at the request of the patient could be con-
sidered equivalent to passive euthanasia but, as we have seen, the competent
patient has the right to refuse any or all treatments.
Palliative care is the care of terminally ill patients where the focus is on holistic
support of the patient and relief of symptoms rather than seeking to cure the
patient. Management is active, intends neither to hasten nor to postpone death
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and is not guided by hopelessness or fatalism. Good palliative care should reduce
any requirement or need for euthanasia.
Differences between killing and letting die
Crippen [4] makes the point that if extraordinary support is withdrawn, and the
patient dies, it is the disease that has killed them not the withdrawal of support, as
these supports (e.g. IPPV, inotropes, etc.) are not required for life under normal
circumstances.
Thus, withdrawal of IPPV does not cause death. IPPV, up to the point of with-
drawal, has merely temporarily prevented the occurrence of death.
If one cannot accept this [5]:
• One would have to accept that withdrawal of any therapy may lead to death
rather than the disease process.
• One would conclude that doctors cause the vast majority of deaths in termin-
ally ill patients.
• All cases where cardiopulmonary resuscitation (CPR) is stopped would be 
doctors causing death as the CPR is supporting the circulation and maintain-
ing life and could have been continued for longer!
• The law would have to examine thousands of medical cases as potentially
manslaughter or murder. If withdrawing therapy is considered to cause death
then the legal situation would only be manageable if the law was changed to
permit causing death!
• Interestingly, in a trauma case, withdrawal of therapy has led to a plea that the
assault did not cause the death. Fortunately, this has been rejected by the courts.
Reasons to withhold or withdraw therapy [5]
(1) Ineffective or futile treatment. Doctors do not have a duty to provide futile
treatment and patients and families cannot expect such treatment. Futility is
discussed further below. However, it is not acceptable to provide no treatment
when some would be beneﬁcial, for example analgesia or sedation.
(2) Treatment would impose excessive burdens in the opinion of the patient
(assuming the patient is not motivated by suicidal intent). Excessive burdens
may include:
• pain (there are limits to everyone’s courage),
• emotional and psychological burdens,
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• restrictions on liberty (e.g. balance between an extra year of life gained ver-
sus that year being spent in hospital),
• ﬁnancial burdens (hopefully not in UK),
• in the ICU, burdens of tubes, ventilators, monitoring, etc.
(3) Treatments not considered to further the patient’s medical good, for example
nasogastric feeding in advanced cancer which may prolong survival only for
the patients to die of other complications of the cancer.
(4) Treatments not considered to further the patient’s total good, for example
antibiotics to treat pneumonia in comatose patients who have had a massive
stroke.
The ﬁrst two reasons are most common especially in ICU and related areas. The
latter two are most difﬁcult and arouse considerable emotion amongst carers.
Factors in the decisions for withholding or withdrawing therapy
Firstly, the wishes of the competent or autonomous patient should be taken into
account followed by an acknowledgment of the wishes of the family. Other mem-
bers of the multidisciplinary team have a right to be included in the discussions
and decision-making.
“Quality of life” is very subjective and what is an unacceptable quality to the
carers may be acceptable to the patient and vice versa. Actual studies of quality
of life following ICU admission show variable results:
• Konopad [6] found ICU survivors to have a decreased level of activity 1 year
after ICU discharge.
• Niskanen [7] found that quality of life of ICU survivors was good but that
recovery of physical function was slower than mental and social recovery.
• Danis [8] found that 70% of patients and families would want ICU care again 
if it granted them one extra year of life. There was no relationship between this
and quality of life. However, 88% of patients and 41% of families would refuse
ICU if no chance of recovery.
Factors in the decision to withhold or withdraw therapy throughout the world
that have been identiﬁed in studies include:
• previous quality of life (but many pitfalls);
• previous health;
• futility of proposed therapy;
• age; again, many pitfalls but many studies show no survivors from prolonged
IPPV in patients over the age of 85 [9];
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• cost (unacceptable to many on an individual basis but condoned by society
e.g. unavailability of chronic dialysis facilities).
The decision should be direct and explicit including discussions on withholding
and withdrawal. If doubt arises (as is often the case) one solution is to admit the
patient according to the following classiﬁcation:
• Patient reasonable chance of recovery – admit – full treatment.
• Patient no chance of recovery – do not admit – withholding.
• Patient low probability – admit – full treatment 24/48 h – reevaluate with the
possibility of withdrawing.
Although sometimes seen as problematic there no ethical differences or difﬁcul-
ties with admitting for a trial of ICU therapy which is withdrawn if it is ineffective.
This is sometimes called the ICU test – “we will admit for IPPV for a few days to
give the antibiotics time to work”. This approach is valid if actively managed. If the
few days are up, and there is clearly no improvement, then “we will see tomorrow”
is inappropriate.
Incidence of withholding or withdrawing therapy
In the USA, where most studies have been done, the proportion and number of
patients having withdrawal (withholding commoner in Europe) of therapy is ris-
ing with time as is the “do not resuscitate (DNR)” rate. There are major variations:
• Some hospitals issue no DNR orders in dying ICU patients and no withdrawal
of therapy.
• In some hospitals, up to 90% of dying patients in ICU involve withdrawal of
therapy [10].
• The rate of withdrawal of therapy in one study in the USA was highest when the
patients were cared for by ICU specialists compared to when the decisions were
made by their private physicians [11].
There is an expectation that patients in whom ICU therapy is withheld or with-
drawn will die:
• withholding – associated with an 89% mortality,
• withdrawing – associated with a 99% mortality.
Both statistics are from Ethicus (the European study on ethics in ICU) as yet
unpublished.
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It is interesting to speculate on these results:
• Would admitting the refused patients produce more survivors without impos-
ing an excessive burden on the majority?
• Would the 11% who were not admitted have still survived if exposed to the haz-
ards, side effects and complications associated with ICU care?
Futility
Futility is increasingly debated and the concept “used” frequently in the USA.
A good deﬁnition is that a treatment is futile if it has no reasonable chance of
producing beneﬁt capable of being perceived by the patient not just some measur-
able improvement in some parameter or merely prolonging a period of support.
A treatment may be futile but care is never futile (so do not use the term “futile
care”). Palliation is never futile (but may not include admission to ICU).
The deﬁnition of what therapy is futile in a certain circumstance is a matter of
clinical judgement on an individual basis (as long as the decision is consistent
with general medical opinion in that ﬁeld).
There are grey areas and disagreement but to take one example: studies have
shown no survivors amongst 400 patients who develop multiple organ failure
after receiving a bone marrow transplant and require IPPV [12]. Is it not futile to
offer IPPV to such patients on the grounds of reasonable certainty? If not, how
many patients must be cruelly exposed to the burdens of this treatment in the
hope of achieving one survivor? Is this moral?
The issue is whether the treatment can deliver its intended beneﬁts not
whether the patient is “worth” treating (otherwise we could stop all care and end
what has been judged as a worthless life).
Sometimes treatment is suggested because it gives the patient or family hope –
this provides false hope, is without counterbalancing beneﬁt and, therefore, causes
harm. Our duty is to do no harm.
Outcome prediction and futility
There are many scoring systems to assess severity of the patient’s critical illness.
Although these systems may enable a calculation to be done which predicts the
probability of death during that admission (based on the databases from which
the scoring system has been devised) these are not designed to be used to deter-
mine the outcome of an individual patient. Their main use is in prediction in popu-
lations and for audit. They may predict probability of death but care is necessary
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with this concept as the general public, and many doctors do not really under-
stand probability.
In terms of predicting an individual patient’s outcome, studies suggest that an
experienced clinician is probably as accurate as the scoring systems [13]. Our
judgement is able to take into account local experiences as well as large statis-
tical databases. Referring physicians are less accurate at predicting patient
survival [14].
Outcome prediction models:
• Are most accurate in very low risk and very high risk situations.
• Cannot predict side effects of treatments.
• Are probably more accurate as time passes (trends) in the ICU, that is, take into
account the response to treatment.
• Do not fully allow for the detrimental effect on prognosis of delays in diagnosis
and treatment or the problem of no clear underlying diagnosis (except for the
effect these delays may have on physiological parameter scoring).
• Do not fully allow for the detrimental effect on prognosis of extreme age as few
patients of extreme age in the databases!
The more recent development of early warning scores do not help guide our
decisions re-prognosis, outcome and futility as they tell us who is sick enough to
go to ICU but they do not tell us who is too sick to go to ICU.
Thus, severity scoring and formal models for outcome prediction only pro-
vide some general guidance in decisions regarding futility and withholding and
withdrawing therapy.
What do ethical principles tell us about decision-making?
The four main principles of medical ethics are:
• Beneﬁcence: The desire and aim to do good.
• Non-maleﬁcence: The desire and aim not to do harm.
• Autonomy: Self awareness and the right to self determination. Linked to men-
tal competence.
• Justice: Equal access for all.
Most ICU patients have lost their autonomy. Autonomy should always be res-
pected but should not be the overriding principle. The goal of health care must be
the promotion of health not the promotion of autonomy. If not, what would be the
goals of treatment for non-autonomous patients?
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Relatives may reﬂect patient wishes:
• Uhlmann [15] found that in given scenarios, families are better than doctors at
predicting patient preferences.
• However, Emanuel [16] found that family were unreliable at following the
patient’s wishes.
Thus, doing what relatives want may not always be to the patients’ overall good.
Doctors, nurses and other carers should always act as the patient’s advocate
rather than doing what the relatives want. This may take some courage as doing
what the family want may well be the easiest option!
The above is true also for autonomous patients. We should respect their
wishes but should also do no harm. Indeed, it is our professional duty to act in
the patient’s best interests and to do no harm.
Problems with autonomy as overriding principle:
• Does a patient have the right to ask for bizarre, harmful treatment, for example
beta blockers for asthma?
• If autonomy is the overriding principle, as some would suggest, then doing
what the patient wants would be seen as “good” and anything else would be
“bad”. What would be the goals of treatment for non-autonomous patients?
• Harm and beneﬁt would then be seen as totally subjective and doctors and nurses
would be avoiding their professional responsibilities and accountabilities.
• There must, surely, be some objective assessment and understanding of the
concepts of harm and beneﬁt.
• If autonomy were the overriding principle, then we would have to legalise
euthanasia and assisted suicide. Most would consider this undesirable.
• Autonomy would, in theory, override justice and lead to demands for treat-
ment even if the result were unjust deprivation of others, for example, patients
and their families cannot demand to stay in ICU if there is no clinical need thus
denying critically ill patients the chance of life-saving treatment. The problems
of scarce resources are also relevant to the principle of justice though preferably
society should make these judgements. Health professionals arguably have an
ethical duty to use resources appropriately.
• If autonomy were the overriding principle, then the next step is to see non-
autonomous patients as having less worth and expendable in the interests of the
autonomous.
Few ICU patients are autonomous. In one study [17], 62% of those that were
competent still wanted a surrogate to act as decision maker in EOL decisions –
mainly the family.
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However, arguments based on the principle of justice favour the doctor as
decision-maker – can’t ask family to choose between their patient and another.
The principle of non-maleﬁcence extends to not desiring to impose the burden
of decision-making to the family.
In America, Advance Directives such as:
• Living wills
• Durable power of Attorney orders
act to transfer autonomy and serve to free the family from the burdens of deci-
sion making.
The above promotion of the doctor as primary decision maker (in consult-
ation with other carers and the family), reﬂecting the principles of beneﬁcence
and non-maleﬁcence, is seen by some as paternalistic.
Paternalism (medical autonomy?) is an emotive term and seems somehow 
to be outdated and “bad” whereas autonomy is “good”. However, both points of
view are relative rather than absolute.
Doctors do not always know what is best but we do have a professional duty of
care and it is unprofessional to pass the burden in its entirety to the family at a
time when they are most vulnerable. Jacob interviewed 17 relatives involved in
EOL decision making. The common theme reported was one of emotional bur-
den [18]. Indeed, many relatives of ICU patients show symptoms of anxiety and
depression [19].
We should also, where possible, protect them from the guilt of a “wrong deci-
sion”. Such guilt may even interfere with the subsequent grieving process.
As has been stated before the ultimate decision and responsibility rests with the
doctor after discussion with the other carers and the family. Ideally it is a shared
decision and the answer to the conﬂict between autonomy and paternalism is that
the correct approach lies somewhere along a spectrum as shown below:
Autonomy Paternalism
Different families may be at different points along the spectrum.
Disagreements with family
If the family and the carers disagree, then a dilemma involving one “winner” and
one “loser” can’t be resolved ethically. The solution, however difﬁcult, is to reach
agreement.
• One solution is to defer to autonomy unless to continue is clearly futile. The
concept of futility itself is not a solution; it merely helps structure, the discus-
sion and may help in reaching agreement.
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• Another solution is to avoid placing the burden on the family. Many families
don’t wish to be involved. It is reasonable to ask the family if they wish to be
involved. If asked, and they want to be involved, they still may disagree!
Neither solution avoids disagreement but, nevertheless the principle is that
agreement solves the problem.
Neither “I win because I am the doctor” or “You win because you are the family”
are appropriate. Neither autonomy nor paternalism solve the problem. The “gold
standard” is that long, difﬁcult discussions must take place and agreement must,
somehow, be reached. “Nobody wins” if the courts have to be involved (though
rarely they may have to be involved).
Note: The longer the talks go on with treatment being continued, in a sense,
the family win! If need to take a ﬁnal decision suggest:
• Second opinion.
• Ethics consultation: Ethics consultations and ethics committees are an advis-
ory and consultative service. They do not have decision-making powers for
individual patients but have a valuable role in arbitration of difﬁcult patients.
Are ethics consultations “helpful” or merely “ethical” or are they only “helpful”
when they agree with us?
• Multidisciplinary case conference.
Withdrawal of speciﬁc therapies
It may be appropriate to withdraw any or all therapies but when consideration is
being given to withdrawal one should consider withdrawal of all therapies:
• Partial withdrawal strategies are confusing and difﬁcult to carry out.
• Tapering of therapy, for example weaning of vasopressor infusions as opposed
to cessation only serves to prolong needlessly the dying process.
• One should not give a timescale for death.
• Death is not to be hastened if withdrawal does not lead to death as quickly as
anticipated.
IPPV is an intervention that is commonly withdrawn.
• Terminal weaning and rapid extubation are both acceptable techniques.
• Terminal weaning, for example no pressure support, “room air” and no positive
end expiratory pressure (PEEP), may be preferable as it limits gasping and dis-
tressing obstruction.
• Extubation, however, has the advantage of being morally transparent [20] and
cannot be confused with a normal weaning process.
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• There were no differences in mental status, ventilatory status, age, or duration
of survival between the patients who had support removed gradually and those
from whom it was abruptly removed [21]. Interestingly, there seems to be no
increase in pCO2 but a decrease in pO2 following removal of ventilatory support.
• If patient is to be abruptly separated from the ventilator some anticipatory
analgesia and sedation may be required.
In those physicians who withdrew IPPV in one survey [22]:
13% preferred extubation,
33% preferred terminal weaning,
54% used both.
The differing groups both felt that family perceptions of care were improved by
their method!
An appropriate procedure is to:
• Decide to withdraw after discussion with colleagues and other carers.
• Discuss with family.
• Plan for performing procedure and dealing with complications.
• Ensure patient is in the right setting.
• Document in records as for any other ICU procedure. Full documentation
reﬂects the conviction that palliative care is as important as restorative care.
• Evaluate outcomes to improve procedure and palliation techniques. EOL care
is a highly appropriate topic for audit.
• Protocols and guidelines may be useful.
Reasons why therapy may not be withdrawn
There are several reasons why individual physicians may not consider with-
drawal of therapy or why therapy may not be withdrawn in selected patients:
• Religious convictions on part of carers or physicians.
• Hope for a miracle (itself a religious concept) on part of family.
• Fear of failure.
• Pride (personal or professional).
• Fear of litigation/media involvement.
• Family aggression.
• Blind optimism.
• Pressure from physicians or surgeons (potential impact of development of
league tables?).
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• Compensating for or covering up of medical errors.
• Reverse ageism, that is, overtreatment of very elderly patients so as not to be
accused of being ageist.
Problems with not withdrawing therapy
If treatment is not withdrawn when it perhaps should be there are potential
problems:
• Danger of promoting false hope.
• Harmful effect on morale of nurses and other carers.
• May be against the ethical principle of justice especially if other patients are
denied support.
• May impose an inappropriate burden on the patients or their families.
• Shamefully, there are instances reported where patients being maintained on a
ventilator have developed rigor mortis of the limbs or putrefaction.
Optimal care of the dying patient
Patient and family experiences and wishes
Perhaps obviously, there are no reports in the scientiﬁc literature of patients
reporting their satisfaction with their own dying process. Thus, there will prob-
ably always be certain unanswerable questions:
• Is it better to extubate?
• When is tachypnoea uncomfortable?
• Should comatose dying patients receive sedation?
• Should we sedate dying patients at all?
Surveys [20] suggest that patients fear a prolonged, painful (and in some coun-
tries), expensive death in an impersonal and technological environment sur-
rounded by machines and prevented by incapacity from communicating with
loved ones.
Does that not sound all too familiar?
Instead a “good death” is:
• free from avoidable pain and suffering,
• in accordance with the wishes of the family,
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• consistent with clinical, legal, ethical, cultural and religious issues,
• at home or in a familiar environment.
Note: In surveys a high proportion of patients would wish spiritual issues to be
addressed during their ﬁnal illness. Physicians rarely consider this important.
Improving care of dying patients in the ICU
The key to optimal EOL care is relief of suffering including excellent palliative
care (although relief of symptoms should be a goal for all ICU patients).
Is it appropriate for ICU to be a provider of palliative care? It may not be
appropriate to admit patients to ICU for palliative care but it is entirely reason-
able to provide palliative care for patients in ICU whose therapy has failed or
been withdrawn, that is to switch to comfort measures and care of the dying
process rather than trying to promote recovery of health. Palliative care includes
such procedures as tracheal suction – which may not be adequately performed
on a general ward.
EOL care in the ICU can include “keeping things going” until all the family 
is present. Dignity is improved by nursing the patient in a quiet, preferably 
side room with full visiting rights by all the family. Monitor alarms should be
switched off.
The Society of Critical Care Medicine in America says that the goals of ICU
care include assuring patients of a good death. They, and other societies strongly
support a multidisciplinary approach with other professionals (including clergy)
and the essential involvement of the family and close friends. Families should 
be encouraged to be involved in care and to touch patients – family are not just
visitors.
The ICU societies also support a shared decision model in accord with the
four ethical principles outlined earlier (without ranking them in priority or
importance). They reject a narrow, medicalised approach to dying.
To improve quality of the dying process in ICU [20] one should:
• avoid inappropriate prolongation of the dying process,
• strengthen relationships with loved ones where possible,
• provide patients and families with a sense of control,
• provide good pain/symptom management,
• provide clear explanations to patients and families,
• provide privacy and comfort to patients and families,
• give opportunities for the family to voice concerns.
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Studies show that patients and families wish the following from their doctors:
• emotional support,
• honesty,
• good communication,
• no contradictions,
• accessibility,
• continuity of care,
• information on diagnosis, treatment, prognosis and the dying process.
Another study [23] found that families were most satisﬁed with:
• nursing skills,
• caring attitudes of staff,
• sympathetic management,
and least satisﬁed with:
• the waiting room environment,
• physician communication.
A recent multicentre Canadian study [24] found that most of the patients’ fam-
ilies perceived that the patients whose therapy was withdrawn died as follows:
• totally comfortably 37.2%
• very comfortably 24.5%
• mostly comfortably 29.6%
This is encouraging but still shows room for improvement.
Care of the dying patient in ICU may be improved by introducing checklists for
aspects such as “do not resuscitate” and the process of Withdrawal of therapy [25].
Sedation, analgesia and paralysis
Pain and the distress from drips, drains, tubes, machines, etc. must be relieved 
by adequate doses of systemic analgesics. Occasionally regional analgesic tech-
niques such as epidurals may play a part in providing sufﬁcient analgesia. There
may be distress from “ﬁghting the ventilator” and a sensation of dyspnoea which
may require analgesia and/or sedation. Opiods are often administered.
Strong opiod analgesics are associated with sedation and, in addition, speciﬁc
sedatives are often administered to ensure lack of distress. Strong opiod analge-
sics also inhibit respiratory drive.
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In one study [26], average dosages of sedative drugs before and after treatment
withdrawal were examined:
Drug 24 h before withdrawal 24 h after withdrawal
Diazepam 2.2 mg/h 9.8 mg/h
Morphine 3.3 mg/h 11.2 mg/h
There were no differences in time from withdrawal to death between those
patients who did and those who did not receive sedation (mainly comatose
patients).
In the Canadian study already mentioned [24], the most frequently used drugs
(though not all drugs were used in each patient) and the cumulative doses in the
4 h prior to death were:
Drug Mean dosage (range)
Morphine 24 mg (2–450 mg)
Midazolam 24 mg (2–380 mg)
Lorazepam 4 mg (1– 80 mg)
There is a theoretical potential for conﬂict between
• a desire for the patient to be awake, surrounded by family to say “last good-
byes” and
• the need to be sedated to relieve distress.
However, hypotension and low cardiac output itself lowers cerebral perfusion and
impair conscious level. In practice, few families wish the patient to be unsedated
during EOL care.
Paralysing agents should not be routinely given:
• not part of comfort care,
• not usually necessary if sufﬁcient sedative and anlgesics are given,
• may mask patient’s ability to show signs of distress.
All interested groups and societies support our professional obligation to relieve
suffering even if the administration of the appropriate drugs may hasten death.
This is the principle of double effect and is the ethical foundation for providing
palliative care to the dying patient. Our intent is to relieve suffering and the “side
effect” of hastening death by respiratory depression in an extubated patient is
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merely foreseen. It is considered better to administer an analgesic drug such as
morphine by titrated infusion rather than by a large bolus.
• Titration to effect shows our intention to relieve suffering.
• There is no maximum dose and, indeed, high doses may be required.
• If a large bolus is given it may be less plausible that the intent is just to relieve pain.
• Since paralysing drugs have no analgesic effects, their use cannot be covered
by the principle of double effect.
Despite the case of the GP in 1999 already mentioned many are uncomfortable
that the double effect principle provides full protection from the courts. There
are concerns that lack of intent may not be sufﬁcient defence from a charge of
manslaughter as, arguably, if the consequences of an action can be foreseen then
that may be interpreted as intent.
Fortunately the judiciary seem unlikely to bring such cases from ICU to the
courts as they recognise that an inability to provide palliative care in any form
(which would be the clear consequence of negating the double effect principle)
is clearly not in the interests of a civilised society.
However, we at all times must be certain of the purity of our intentions if only
to satisfy our own moral and ethical conscience.
General aspects of care of the dying patient
• Good mouth care is essential and may reduce the prospect of distress due to
lack of oral ﬂuids.
• Pressure area care is important but turning patients for pressure area care has
to be balanced against pain caused by the physical act of turning. Keeping the
patient clean and dry is helpful for skin care.
• The beneﬁts from nursing the patient in a side room have already been alluded
to, where possible invasive lines, monitors and other technology should be
removed.
• Chest suction may be appropriate but aggressive physiotherapy may not be.
• Non-palliative medications should be stopped. There are occasions where
continuing anticonvulsants, non-steroidal anti-inﬂammatory drugs (NSAIDs),
antipyretics and steroids may all be worthwhile. Blood products should no
longer be given.
• Antibiotics are not appropriate in the dying patient unless, rarely, they may be
given for painful conditions such as a painful otitis media.
• The patient should not be subjected to further laboratory tests or X-rays.
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• If patients experience dyspnoea; symptomatic relief may occasionally be
achieved by having air from a fan blowing air over the face (air may be as effect-
ive as oxygen at relieving dyspnoea [27]).
Thirst and hunger versus artiﬁcial feeding and hydration
The loss of body water is part of the normal dying process. If “near end of life”
means the last few hours or days prior to death (as happens in ICU) then issues
of hydration versus dehydration become irrelevant, superceded by issues of care,
comfort and support for the patient. However, if “near end of life” is deﬁned as
last few days or weeks (as happens in Hospice care), then issues of hydration ver-
sus dehydration become more relevant – and controversial.
In ICU, some would argue that ﬂuids and nutrition should be given to all
patients, including those who are clearly dying, because:
• It is their “right”.
• It is part of ordinary care.
• There may be distressing symptoms of either hunger or thirst/dehydration in
the dying patient.
Here, it can be argued that discussions of “ordinary” versus “extraordinary” care
only confuse in that one should do what is appropriate for the patient’s needs. It
is important to realise that dehydration at the end of life may not be associated
with distress:
• Dehydration and loss of appetite are part of the dying process.
• Dehydration is associated with reduced conscious level.
• Dehydration may be associated with less gastric secretions.
• The discomfort from a dry mouth can be dealt with by local mouth care.
There may be additional problems and sources of additional distress arising
from the process of hydration or nutrition:
• Discomfort or infection at the site of intravenous (IV) cannulae.
• Restriction of the patient’s limb and restriction of family access and contact.
• Removal/reinsertion of nasogastric tube by the patient.
• Regurgitation of gastric contents following enteral feeding.
Occasionally a patient undergoing hospice care, who is mentally competent,
feels strongly about being hydrated until the end. These wishes should, of course,
be respected.
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Care of the relatives
The family should be dealt with sympathetically. Many ICUs have access to short
term accommodation for the use of the family of patients in the ICU. The family
should have ready access to food, drink and pleasantly furnished areas to rest.
Access to clergy is seen as important by many families. Providing a pager or
mobile phone enables the family to be contactable even if not present on the ICU.
At the end the family should have some private time with their deceased rela-
tive prior to removal of the body from the ICU. Religious and cultural beliefs
should, wherever possible be respected at this time.
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Speciﬁc problems
Part II

The surgical patient in the ICU
I. McConachie
This chapter brings together many aspects of relevance to “high-risk” surgical
patients admitted to the intensive care unit (ICU).
For a full discussion of
• aspects of risk assessment,
• anaesthetic and surgical risk factors,
• cardiac risk, scoring systems and investigations,
• respiratory risk and the role of pulmonary function testing.
the reader is recommended to consult Anaesthesia for the High Risk Patient by
the same author and publisher.
Preoperative assessment
The aim of preoperative assessment is to minimise morbidity and mortality.
Three questions should be asked when assessing surgical patients with the
aim of minimising operative risk:
(1) Is the patient’s medical and physiological status optimum?
(2) If not, can the patient’s status be improved (time permitting)?
(3) If not, should the operation still proceed? In other words, do the risks of not
operating outweigh the risks of operating? For example, medical status is
almost irrelevant if the operation is clearly life saving. Thus, no patient is “not
ﬁt” for surgery – it just depends on the urgency of the situation. However, the
patient should be considered salvageable by surgery. If not, palliative care
may be more appropriate than heroic interventions.
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Preoperative assessment should identify those patients who are at high risk of
per- or postoperative organ failures. Such patients may need additional monitor-
ing and may warrant admission to ICU or a high-dependency unit (HDU) post-
operatively for organ function monitoring or support.
Patients are usually believed to be “high risk” because of the following:
• Respiratory disease predisposing to respiratory failure postoperatively.
• Cardiac disease predisposing to myocardial ischaemia or cardiac failure post-
operatively.
• Less commonly, patients with renal insufﬁciency may develop renal failure
postoperatively – vascular surgery patients are especially at risk.
One should not discount the effect of heroic surgery or increasing age (see below).
Respiratory disease
Presence of signiﬁcant respiratory pathology will lead to an increased morbidity
and, for major surgery, mortality. Anaesthesia may not pose much problem but
respiratory failure may result in the postoperative period. This in part will be due
to the inevitable changes in respiratory mechanics associated with anaesthesia
and the surgery performed:
• Respiratory excursion will be impeded by pain which may result in atelectasis.
• Pain may also inhibit coughing resulting in sputum retention.
• The site of operation is important, for example, thoracic followed by abdom-
inal sites being the worse – partly because these are the sites of incisions asso-
ciated with most pain.
A review of preoperative respiratory function testing is beyond the scope of this
text (readers are referred to standard anaesthetic texts) but certain risk factors
are worth emphasising:
• Presence of hypoxia.
• Presence of hypercarbia.
• Breathlessness at rest.
• Smoking is a major risk factor [1].
• Increasing age is a risk factor due to, for example, increased closing volume
and increased sensitivity to opioids.
• Site of surgery – highest for upper abdominal and thoracic surgery.
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• Length of surgery.
• Obesity – increased closing volume and increased incidence of airway obstruc-
tion and sleep apnoea.
In order to attempt to reduce this risk the patient may be admitted preopera-
tively for
• abstinence from smoking,
• bed rest,
• physiotherapy,
• bronchodilator therapy if bronchospasm present,
• steroids may be beneﬁcial in chronic obstructive pulmonary disease (COPD),
• antibiotics if infection present,
• nutritional assessment and supplementation if necessary,
• diuretics if cor pulmonale present.
Cardiovascular disease
Presence of pre-existing cardiac disease is undoubtedly a predictor of increased
perioperative risk. More speciﬁcally many studies have identiﬁed cardiac risk
factors which include:
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The most important development in cardiac perioperative risk assessment and
guidelines for perioperative investigations in recent years have been the joint guide-
lines from the American College of Cardiology and American Heart Association.
These were ﬁrst published in 1996 [2] and updated in 2002 [3]. These should be
essential reading for all anaesthetists and critical care practitioners.
The overall message is that patients with severe heart disease and old and
“sick” patients are at risk of increased adverse cardiac outcome. Although anaes-
thesia can be problematic, most problems occur in the postoperative period
emphasising the importance of adequate monitoring and treatment of compli-
cations in the ICU in the postoperative ICU or HDU.
• Previous myocardial infarction (MI) • Left ventricular hypertrophy
• Hypertension • Diabetes
• Renal failure • Decompensated heart failure
• Old age • Signiﬁcant arrhythmias
• Emergency operation • Severe valvular disease
• Unstable or severe angina or electro-
cardiographic signs of ischemia
There are currently two main theories as to how cardiac disease might con-
tribute to perioperative mortality in the surgical patient:
(1) Poor cardiopulmonary physiological reserve: The physiological reserve of the
heart and lungs is insufﬁcient to meet the increased demands of surgery. In
physiological terms, oxygen delivery does not fulﬁl oxygen consumption
(VO2) requirements. End-organ ischaemia results in multi-organ dysfunc-
tion syndrome (MODS) and death. This is discussed further below in the sec-
tion on perioperative optimisation.
(2) The development of myocardial ischaemia in patients with coronary artery
disease (CAD).
A thought provoking review highlights the, at times, conﬂicting priorities in
managing surgical patients at risk of myocardial ischaemia and those in whom
the cardiac output and oxygen delivery need to be increased [4]. Both are at risk
of an adverse outcome but the approach is different and identiﬁcation of the
group that patients belong to is important.
Prevention of myocardial ischaemia
• The majority of perioperative ischaemic episodes occur in the postoperative
period.
• However, perioperative cardiac instability (especially tachycardia) is a major
risk factor [5]. Thus, anaesthetic techniques and problems are important.
• Choice of anaesthetic drugs is, however, relatively unimportant providing
myocardial oxygen balance is maintained, for example:
– Factors increasing myocardial oxygen demand:
(a) Tachycardia
(b) Hypertension
(c) Increases in contractility
(d) Increases in wall tension (e.g. increased preload).
– Factors reducing myocardial oxygen supply:
(a) Tachycardia
(b) Hypotension (especially low diastolic pressure)
(c) Anaemia
(d) Coronary artery spasm.
• Continuance of preoperative cardiac medications especially is vital.
• Perioperative Myocardial infarction (MI) (peak incidence on the second or third
postoperative day) is commoner in patients with a recent MI but the incidence
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can be reduced by invasive monitoring and careful control of haemodynamic
parameters [6].
• Landmark studies have indicated that the prophylactic use of -blockers in the
perioperative period in patients with CAD, or risk factors for CAD reduces peri-
operative cardiac risk [7]. This is probably the most important intervention in
order to reduce perioperative cardiac risk in these patients. However, chronic
-blockade does not seem to confer the same advantages as acute -blockade.
• Smaller studies suggest a similar beneﬁcial role from the sympatholytic effect
of 2-agonists such as clonidine [8].
• Animal studies support the role of sympatholysis from thoracic epidural anaes-
thesia and analgesis in reducing cardiac ischaemia. Perhaps this may be valu-
able following coronary artery surgery but in vascular patients the evidence is
conﬂicting – one study showing no difference in ischaemia between the use of
thoracic epidurals and patient-controlled intravenous opioids [9]. A meta-
analysis has claimed that the use of thoracic epidurals reduces the incidence of
postoperative MI [10].
Ongoing ischaemia in the ICU may be a problem. This will be “silent” in the
sedated, ventilated patient and may not be accompanied by overt ST changes on
the electrocardiogram (ECG). A recent study [11] has suggested that mildly 
elevated Troponin I levels (below the threshold for MI) are not uncommon. This
may reﬂect ongoing myocardial injury and may be associated with a worse out-
come. The authors speculate that the administration of -blockers and aspirin 
in the ICU may improve outcome.
Stress response to major surgery
• The intensity of the stress response is related to the degree of tissue trauma, that
is, minor surgery stimulates a minor, transient response whereas major abdom-
inal surgery may stimulate a stress response lasting days to even weeks. Other
factors promoting the stress response after major abdominal surgery include gut
stimuli via the sympathetic nervous system, local tissue factors and cytokines.
Haemorrhage, hypothermia, sepsis and acidosis will all exacerbate the response.
• The response is multifactorial, thus neural blockade will not completely pre-
vent this. Aspects of the cytokine response have been shown to be modiﬁed by
the use of steroids, nonsteroidal anti-inﬂammatory drugs and the use of differ-
ent catecholamines.
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• The role of the stress response is to mobilise substrate and acute proteins for
wound healing and the inﬂammatory response. Possible detrimental effects of
a profound stress response following major surgery include increased demands
on organs which may have reduced reserve, pulmonary complications, throm-
boembolism and pain and fatigue. The appropriateness of an unmodiﬁed
response is, therefore, debatable.
• Intraoperative regional anaesthesia may only delay the development of the
stress response. The optimum duration of blockade is not known.
• If the response is desired to be modiﬁed into the postoperative period a con-
tinuous regional technique is required – continuous epidural analgesia has
been most studied.
• Epidural analgesia has signiﬁcant modifying effects on the hormonal and cat-
echolamine responses to lower abdominal surgery.
• The effects of epidural anaesthesia on the stress response following upper
abdominal and thoracic surgery is less impressive. This could be due to failure
to adequately block all afferent stimulation. For example, continuous spinal
anaesthesia, with its denser block, is more effective at blocking the hormonal
stress response compared with epidural anaesthesia.
• Central neural block may mitigate various aspects of postoperative morbidity
but the evidence is really only convincing for decreased blood loss, reduction
in deep vein thrombosis (DVT) and limiting gastrointestinal (GI) stasis after
abdominal procedures.
• Spinal opioids have less effect on the stress response. Their effect on morbidity
is unclear but is likely to be less due to lesser effects on stress response.
• The ability to inﬂuence changes in immune function after surgery is less well
studied than the effects on metabolic responses. In general, any modiﬁcation
of the immune response to surgery by regional compared to general anaesthe-
sia is probably of minor clinical importance.
The importance of adequate analgesia
In years past severe pain was accepted as an inevitable consequence of trauma
and surgery, and little effort was made to provide adequate pain relief in the
majority of unfortunate patients:
• Whilst adequate pain relief is a laudable objective from the humanitarian 
perspective, modern understanding of the pathophysiological effects of pain
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makes appropriate pain relief a primary objective in avoiding the common
morbidities associated with surgery.
• There is little doubt that pain increases the stress response to surgery, pro-
motes atelectasis and sputum retention and is a factor in myocardial ischaemia.
• The patient who is at “high risk” either because of the trauma of their surgery
or their poor physiological reserve therefore requires effective pain relief to
avoid these potentially lethal complications.
• If this is not achieved, then these are the patients most likely to slide down the
slippery slope to critical illness.
• Early mobilisation can be facilitated by good pain relief and this in turn
reduces the likelihood of deep venous thrombosis and pulmonary embolus
and will reduce the likelihood of hypostatic pneumonia.
Modern approaches to the management of acute pain rely heavily on two anal-
gesic techniques, patient-controlled analgesia (PCA) using an opioid self-admin-
istered in small doses by the patient, and epidural analgesic techniques. The
provision of adequate analgesia may be more important than the method of
analgesia employed.
Nevertheless, the use of PCA opiod techniques has not been shown to improve
outcomes [12] (but provides good analgesia).
The problems of pain and analgesic regimens in high-risk surgical patients
are fully discussed elsewhere by Duncan and Counsell [13].
Epidural anaesthesia and analgesia
A possible effect of epidural anaesthesia and analgesia on perioperative outcome
is of major interest. This includes effects on coagulability and ﬁbrinolysis with
their impact on blood loss and thrombotic complications, which are part of the
effect on the stress response. In addition, the role of regional anaesthesia and
postoperative analgesia on overall morbidity and cardiac and respiratory com-
plications has been increasingly investigated.
• There is no consensus on whether certain types of patient undergoing certain
types of surgery beneﬁt more from a regional, a general or a mixture of the two
types of anaesthesia.
• In truth, there may not be a signiﬁcant difference for all patients. Much will
depend on how a technique is performed rather than which technique is per-
formed, the skill of the practitioner, patient factors such as cardiac or respira-
tory disease and the occurrence of side effects or complications.
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• Evidence obtained from systemic review of relevant randomised-controlled
trials obtained by the Australian Working party group (National Health and
Medical Research Council, NHMRC) demonstrates that postoperative epidural
analgesia can signiﬁcantly reduce the incidence of pulmonary morbidity [14].
• Several studies have examined whether epidural anaesthesia in association
with general anaesthesia or, more, commonly, on its own results in less cardiac
morbidity. This could be possibly related to a reduction in thrombotic ten-
dency, reduction in catecholamine levels and avoidance of cardiac depression.
Trials so far have found no signiﬁcant reduction in cardiac morbidity from the
use of epidural anaesthesia in vascular surgery patients [15].
• However, there are other beneﬁts from the use of epidurals in aortic and
peripheral vascular surgery such as improved graft patency due to reduced
thrombotic tendency and improved graft blood ﬂow [16].
The effect of epidurals on overall mortality
• In particular there is no clear consensus on whether the use of epidurals intra-
operatively provides the same, lesser or even greater beneﬁt than those epi-
durals carried on into the postoperative period. The role of epidurals on the
ordinary ward versus those cared for in an ICU environment is unclear as is the
desirability of continuing epidural infusions in the ventilated patient with
haemodynamic instability.
• The original prospective randomised trial to address this issue reported bene-
ﬁcial effects from epidural anaesthesia in high-risk surgical ICU patients [17].
Unfortunately, this and other studies have shown conﬂicting results with inter-
pretation of these studies hampered by their lack of statistical power and poor
control of other management protocols.
• Subsequent studies of larger numbers of patients found no overall effect on
mortality but one [18] showed important improvements in outcome in aortic
surgery and the other showed a reduction in postoperative respiratory failure [19].
• Various meta-analyses have been performed including one [20] which claimed
that epidurals reduce surgical mortality by one-third compared to general
anaesthesia without an epidural.
• Reasons for the disparity between large trials and meta-analysis when looking
at mortality may include the incorporation of older trials into the meta-analyses.
In particular many of the older trials were performed at a time when DVT 
prophylaxis was not widespread – leading to a reduction in morbidity and
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mortality in the epidural patients from the reduction in thrombotic compli-
cations. It is unlikely that there is as signiﬁcant a beneﬁt today from reduction
in thrombotic complications in an era when DVT prophylaxis is standard 
practice.
Problems associated with the use of epidurals [13]
• The complications of epidural catheter insertion include epidural haematoma
and abscess, intravenous injection of local anaesthetic and inadvertent dural
tap. The risk of neurological complications either of a minor or major nature
has yet to be clearly deﬁned but must be considered when balancing the risks
against the beneﬁts of epidurals.
• Itching, nausea and vomiting are all recognised side effects of epidural opioids.
Though respiratory depression is rare monitoring of sedation level is mandatory.
• Hypotension (systolic blood pressure 80 mmHg) is common. The fall in
blood pressure results in loss of the often claimed beneﬁt from epidurals (i.e.
the potential increase in colonic blood ﬂow).
• Care should be taken with the timing of prophylactic heparin injections in rela-
tion to insertion and removal of epidural catheters to reduce the likelihood of
epidural haematoma.
• Epidural analgesia is associated with the development of pressure sores particu-
larly on the heels. This can happen even in young healthy people and nursing
vigilance is essential. Debilitated patients are at higher risk of developing this
complication. Strong local anaesthetic solutions administered via the epidural
in theatre may be a factor in the development of these sores. A sensible pre-
caution is to switch off epidural infusions if patients’ legs are still paralysed
beyond 2 h after surgery. It can be recommenced when the block has regressed
enough to allow leg movement. This precaution also facilitates early detection
of epidural haematoma.
Aspects of surgical nutrition
• A large study demonstrated an increase in infectious complications in patients
undergoing major surgery who received perioperative total parenteral nutri-
tion (TPN) [21]. Guidelines suggest that preoperative TPN is not appropriate in
patients with only mild to moderate degrees of preoperative malnutrition [22].
The surgical patient in the ICU 233
Postoperative TPN is only required if the patient cannot receive enteral nutri-
tion within 7–10 days. The most important conclusion is that short-term TPN is
probably to be avoided because the beneﬁts do not warrant the complications.
• Early enteral nutrition (EN) feeding is clearly associated with improved outcome
[23] (though a minority view would hold that EN is only better because TPN is
worse, that is, EN avoids the metabolic and infectious complications of TPN).
A recent meta-analysis of 11 studies has concluded that there are no beneﬁts in
keeping surgical patients “nil by mouth” after GI surgery [24]. However, some
caution is required as most of these patients will not have been sick enough to
require critical care support. Nevertheless, those patients receiving early enteral
feeding had reduced septic complications and length of hospital stay. A further
meta-analysis states that EN is to be preferred over TPN in patients with 
pancreatitis [25].
Oxygen transport in the high-risk surgical patient
Shoemaker in his original papers deﬁned what he considered to be high-risk sur-
gical patients [26]. Many studies have used these criteria:
Previous severe cardio respiratory illness (e.g. acute MI or chronic obstructive
airways disease).
Extensive ablative surgery planned for malignancy (e.g. gastrectomy,
oesophagectomy or surgery 6 h).
Multiple trauma (e.g. more than three organ injury, more than two systems or
opening two body cavities).
Massive acute haemorrhage (e.g. more than eight units).
Age above 70 years and limited physiological reserve of one or more organs.
Septicaemia (positive blood cultures or septic focus) white cell count (WCC)13,
pyrexia to 38.3 for 48 h.
Respiratory failure (PaO28 Kpa on an FiO20.4 or mechanical ventila-
tion48 h).
Acute abdominal catastrophe with haemodynamic instability (e.g. pancrea-
titis, perforated viscus, peritonitis, GI bleed).
Acute renal failure (urea 20 mmol/l, creatinine 260 mmol/l).
Late stage vascular disease involving aortic disease.
Shock (e.g. mean arterial pressure (MAP) 60 mmHg, central venous pressure
(CVP) 15 cmH2O, urine output 20 ml/h).
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Why might the surgical high-risk patient require increases in cardiac output and
oxygen delivery? Reasons suggested are:
• Animal studies show that for an equivalent degree of blood loss, traumatic injury
results in greater tissue hypoperfusion and a greater “injury” than simple
haemorrhage.
• The wound is metabolically active with a resultant requirement for increased
VO2 and glucose oxidation – the concept of “the wound as an organ”. In add-
ition to the local reasons for increased metabolic demands, there are systemic
inﬂammatory and catabolic causes of increased metabolic demand requiring
an increased cardiac output compared to normal. This may imply a need for
increased cardiac output and oxygen delivery in trauma and high-risk surgical
patients – in line with Shoemaker’s optimal goals as discussed in Chapter 1.
• There are studies demonstrating that high-risk surgical patients develop an
intraoperative “oxygen debt”, the magnitude and duration of which correlates
with the development of lactic acidosis, organ failure and increased mortality
[27]. This oxygen debt is postulated to potentially arise from anaesthetic car-
diac depression, direct anaesthetic reductions in tissue oxygen uptake, failure
to maintain adequate ﬂuid levels during surgery and perhaps hypothermia.
Studies of high-risk surgical patients: Perioperative optimisation or
perioperative optimism?
• The best evidence for a beneﬁcial therapeutic effect of maximising oxygen
transport is from studies where therapy was initiated very early in the presence
of tissue hypoperfusion, that is, preoperatively in high-risk surgical patients
[28]. Shoemaker’s original prospective, randomised study demonstrating the
virtues of optimising oxygen transport was performed in surgical patients [29].
• The crucial message is that high-risk surgical patients may have reduced car-
diac reserves, especially in the elderly, suffer occult tissue hypoperfusion with
a developing oxygen debt postoperatively, proceed to multiple organ failure if
there is no intervention to reverse the tissue hypoperfusion and have a higher
mortality than patients who do have sufﬁcient reserves to reverse their oxygen
debt and prevent serious tissue hypoxia.
• As stated in Chapter 1, a key issue may be timing – Shoemaker has suggested
that there can be signiﬁcant reductions in mortality in critical illness when
patients are treated early to achieve optimal goals before the development of
organ failure, when there were control group mortalities of 20% (otherwise
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the patients are not sick enough) and when therapy produced differences in
oxygen delivery between the control and protocol groups [30].
• In the most recent large study, the use of pulmonary artery ﬂotation catheters
(PAFCs) inserted preoperatively and used to guide the achievement of high
oxygen delivery (see below) failed to show an improved outcome compared
with “conventional” therapy [31].
The speciﬁc issue of dopexamine in high-risk surgical patients
• Boyd [28] in his study on perioperative optimisation showed improvements in
survival in the high oxygen delivery group. It was later suggested that the
improvement may have been related to the choice of inotrope – dopexamine –
rather than the cardiac output achieved in the patients.
• Splanchnic blood ﬂow may be increased with dopexamine, increased pHi may
be normalised and indices of GI permeability reduced, but evidence comes
mainly from animal studies. The signiﬁcance of these with regard to outcome
is currently unclear.
• The most interesting aspect of dopexamine and the most controversial is the
suggestion that dopexamine may have speciﬁc anti-inﬂammatory properties
[32]. (Catecholamines may have differing effects on inﬂammation, for example,
1-stimulation may be pro-inﬂammatory while 1- and 2-stimulation may
be anti-inﬂammatory.) Most of the evidence for this to date is from animal
studies but a few studies on surgical patients broadly support this hypothesis.
Further evidence is eagerly awaited.
• Wilson’s study [33] included three groups: a control group managed conven-
tionally and two other groups who were admitted preoperatively to intensive
care and given goal-directed therapy with either adrenaline or dopexamine.
Both the treatment groups had signiﬁcantly improved survival rate, however
only the dopexamine group saw a signiﬁcant reduction in morbidity. This is
particularly interesting because the dopexamine treated group did not see an
increase in cardiac index by as much as the adrenaline treated group. The
reduced morbidity was due to a reduction in sepsis and acute respiratory dis-
tress syndrome (ARDS). An economic analysis on this trial data has shown that
this approach to high-risk patients is cost-effective [34].
• However, a follow-up study from the same group found no apparent beneﬁt
from dopexamine in surgical patients [35] (though perhaps there was a beneﬁt
in both groups from volume loading).
236 I. McConachie
• This echoed a multicentre European study which also failed to ﬁnd any bene-
ﬁt from the routine perioperative use of dopexamine in elective surgery [36].
However, the authors suggested, based on subgroup analysis and stratiﬁcation
according to the number of risk factors, that dopexamine should be further
tested in patients at higher risk of complications or undergoing emergency
surgery. This supports Shoemaker’s contention that beneﬁts will only be seen
when the patients are sick enough and/or the control group have a high enough
mortality to enable a beneﬁt to be shown [30].
One conclusion from the above is clear, when the patients are not “high-risk” and
the expected mortality from surgery is low, there will be no beneﬁt from peri-
operative optimisation.
GI surgery: the ultimate in high risk
The general public (and many practitioners) would no doubt consider such 
surgery as open heart surgery as being amongst the most riskiest of surgical
operations in terms of immediate and early mortality. In fact, certain relatively
common GI operations are arguably amongst the highest risk procedures per-
formed. For example, perusal of a recent standard surgical text [37] reveals the
expected operative mortality for the following operations and conditions:
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Operation Operative mortality (%)
Ca colon resection 5–10
Large-bowel obstruction 10
Small-bowel obstruction 30
Ca pancreas 20
Ca oesophagus 10
Predicted mortality may be expected to increase if the surgery is performed as an
emergency.
The lessons to be learnt are:
• GI surgery is high-risk surgery and warrants senior input and appropriate 
facilities.
• With the expected mortality, palliation may be better than attempting a cure in
some patients.
Reasons for being high risk
• Coexisting medical diseases. Many of the patients are elderly with signiﬁcant
medical problems.
• Type of surgery. Often long procedures with signiﬁcant blood loss, ﬂuid shifts,
electrolyte and nutritional problems, and signiﬁcant postoperative pain.
• Abdominal surgery is associated with a profound physiological stress
response.
• Emergency or elective. Many of these patients will present as urgent or emer-
gent cases. This is well recognised to be associated with a worse outcome.
Problems associated with emergency cases include less time to evaluate,
investigate and treat patients.
• High incidence of ﬂuid shifts and perioperative hypovolaemia.
• Abdominal surgery is associated with signiﬁcant respiratory embarrassment –
upper abdominal more than lower.
• Many patients will suffer from pre-, per- or postoperative sepsis. We all have a
lethal dose of endotoxin contained within our gut!
Recovery of bowel function
• Epidural analgesia. Postoperative ileus involves sympathetic and parasympa-
thetic pathways. These can be blocked by epidural analgesia leading to a reduc-
tion in the incidence of ileus following abdominal surgery [38]. The bowel is
relatively contracted – which some surgeons dislike. Postoperative nitrogen bal-
ance after bowel surgery is improved by extradural anaesthesia [39]. Surgeons
are often concerned that the increase in intestinal motility with epidurals may
increase the incidence of anastomotic breakdown. However, a review of 12 trials
has found no evidence of harmful effect [40] (but concluded that larger studies
are needed for a deﬁnitive answer). Indeed, by increasing intestinal blood ﬂow
one might expect epidural anaesthesia to have a favourable effect on a bowel
anastomosis.
• Opioids. Morphine has a major effect on bowel motility, signiﬁcantly prolong-
ing the time to recovery of bowel function after colonic surgery [41].
• Neostigmine increases intraluminal pressure (not prevented by atropine) and
has been implicated in the past (mainly by surgeons) as a cause of anastomotic
breakdown. Animal studies do not support this assumption. A large patient
study found no difference in the rate of anastomotic leakage with or without
neostigmine [42]. Surgical factors are undoubtedly more important than
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anaesthetic factors in determining the fate of the anastomosis. Anaesthetists
can help by maintaining good oxygenation (including into the postoperative
period), prompt treatment of hypovolaemia and hypotension and avoiding
hypocapnia.
Respiratory aspects of abdominal surgery
Respiratory function is signiﬁcantly impaired after abdominal surgery, especially
upper abdominal surgery. A combination of factors are involved:
• Reduced functional residual capacity (FRC).
• Pain leading to decreased cough and atelectasis. Pain is greater following
upper abdominal incisions compared with lower abdominal incisions.
• Diaphragmatic dysfunction.
Several randomised trials have highlighted the role of physiotherapy in reducing
respiratory complications following abdominal surgery. Physiotherapy is beneﬁ-
cial both prophylactically, that is, preoperatively and also postoperatively. One
large study concluded that low-risk patients beneﬁt from breathing exercises and
high-risk patients beneﬁt from incentive spirometry exercises [43].
Important factors
• Most studies have examined the effects of different analgesic regimens. Meta-
analysis conﬁrms that the excellent postoperative analgesia with continuous
epidural analgesia leads to a reduction in respiratory complications [44]. The
impairment in respiratory function following abdominal surgery is lessened –
but respiratory function is still reduced compared to preoperative values.
• Large tidal volumes during anaesthesia are beneﬁcial on respiratory function
[45] but it is less certain if there are residual beneﬁts postoperatively. Positive
end-expiratory pressure (PEEP) has been shown to be beneﬁcial in morbidly
obese patients but not normal patients [46].
• Interestingly, pancuronium is associated with postoperative complications when
given for patients undergoing lengthy operations compared with atracurium
[47] – implying perhaps that repeated doses of pancuronium are associated with
residual neuromuscular blockade.
• Surgical factors have been less well studied but it seems that length of surgery
and blood loss are predictors of postoperative respiratory complications.
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The elderly patient
Age should not be a discriminator to admission to a HDU or ICU. Indeed if it is felt
that major surgery will be of beneﬁt to the patient then it seems perverse to deny
them appropriate postoperative care. A recent debate in the literature was pro-
voked by a case report [48] that documented the pre- and postoperative care of a
113-year old on an ICU. The majority of aged patients will be adequately cared
for on a general surgical ward but a few will require postoperative HDU or ICU
care which, providing that surgery was appropriate, should be made available.
Nevertheless, it would be foolish to deny that surgical risk and ICU mortality
is increased in the elderly patient [49]. Outcome is dramatically worse in the very
old. Reasons for this include:
• Altered pharmacokinetics and pharmacodynamics.
• Altered physiology which can best be summarised as loss of homeostatic abil-
ity. There is a progressive loss of cardiorespiratory reserve (see monitoring
strategies below) and a loss of tissue elasticity. This leads to:
decreased myocardial and respiratory compliance,
decreased maximum stroke volume (SV), heart rate (HR), vital capacity (VC),
decreased lean muscle mass,
increased work of breathing,
increased closing volume (may be greater than FRC).
Many of these changes are minimal at rest, but increased during stress, includ-
ing surgical stress. Thus with surgery or trauma, cardiorespiratory reserve may
not be sufﬁcient and failure occur.
• In the kidney, nephron numbers fall leading, again, to loss of functional reserve
and loss of problems with Na loading and depletion, problems with ability to
concentrate or dilute urine and difﬁculty excreting an acid or alkali load.
• High incidence of comorbidities.
• High incidence of adverse drug interactions due to polypharmacy.
• High incidence of surgery for malignant disease.
• Malnutrition is common in the elderly and inﬂuences prognosis in many ways
including decreases in immune function and decreases in wound healing.
• Sarcopenia [50]. Of these, sarcopenia is an under recognised problem in the
anaesthetic, ICU and surgical literature as a cause of failure to thrive in ICU
and increased perioperative morbidity and mortality. Its nature, implications
and potential for improvement are subjects of much research in the geriatric
literature.
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Sarcopenia and the elderly patient
• Sarcopenia literally means lack of muscle. Skeletal muscle is approximately
40% of a young man’s weight and 50% of his body protein. Total lean body mass
(exclusive of bone) and total skeletal muscle mass both are greater in men than
women and decrease progressively with age. Body composition, therefore,
changes with ageing.
• It seems that there is a fall in muscle ﬁbre number as well as atrophy. Thus, the
sarcopenia seen in the elderly is not just muscle atrophy and differs from the
atrophy seen after immobilisation following fracture – however it is acceler-
ated by physical inactivity. It seems that the patient’s body mass index (BMI)
predicts the degree of sarcopenia [51].
• The muscle mass of the body is a major store of protein. This is a major physio-
logical reserve called upon in critical illness. The “stress response” associated
with surgery and critical illness promotes a catabolic state with mobilisation of
muscle protein and muscle wasting. Thus the reduced muscle mass found in
the elderly shortens and weakens the metabolic defence to illness leading to a
worse impact of major surgery and critical illness. In addition the muscle loss
in the elderly is from a reduced amount to start with!
• The loss of muscle mass obviously affects muscle strength. At the age of 80
years, muscle strength is approximately 50% what it was at the age of 20 years.
One implication of this is that late in life, a large number of elderly people
reach low levels of muscle strength that are associated with increasing physical
disability. Less well recognised is the prognostic importance of the reduced
muscle strength – reduced strength being associated with increased mortality
[52] (probably more important prognostically than the loss of muscle mass). In
addition, the reduced strength will result in the patient being easily fatigued,
poor mobilisation and worsening chest problems associated with being
immobile bed.
• With increasing age and muscle loss, an individual’s maximal strength for a
given everyday activity becomes the same as the minimum required to per-
form that same everyday activity. Thus, at that threshold, it only takes a small
further decline to go from being “just able” to being “just unable” to perform
that activity. Many elderly patients effectively are at that threshold.
• The small further decline may be caused by:
major surgery,
critical illness with catabolic loss of muscle protein, or
disuse atrophy associated with immobilisation/bed rest.
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• Indeed, a complication which slows progress is liable to have a consider-
able impact on outcome by prolonging the period of immobilisation, causing 
further muscle wasting which exacerbates their reduced reserve because of
sarcopenia.
Interestingly, obesity does not seem as important a factor in predicting poor out-
come as malnutrition and sarcopenia [53]. Whereas obesity leads to increased
complications especially respiratory complications and longer length of stay in
ICU, a low BMI is a deﬁnite predictor of increased risk of mortality.
Monitoring strategies in the elderly surgical patient
Invasive monitoring of elderly surgical patients has revealed a high incidence of
“hidden” abnormalities reﬂecting their reduced physiological reserve even in
patients “cleared” for surgery. Invasive monitoring during anaesthesia and in the
postoperative period results in early recognition of problems, “ﬁne tuning” of car-
diovascular parameters and an improved outcome [54].
Postoperative hypothermia
Postoperative hypothermia has become recognised in recent years as a signiﬁ-
cant, and common, problem:
• Delayed awakening due to decreased clearance of anaesthetic agents.
• Most organ function is depressed by hypothermia.
• Haemodynamic instability during rewarming – increased ﬂuids often needed
as the patient vasodilates during rewarming. The hypotension thus produced
can be confused with continued bleeding.
• The VO2 is increased by about 140% by shivering during rewarming [55]. If oxy-
gen delivery to the tissues is not able to match this increase, the oxygen debt is
prolonged.
• Wound infection may be increased by reducing skin blood ﬂow. In addition,
cell mediated immune function may be reduced.
• Hypothermia causes coagulopathy and a decrease in platelet count. Intra- and
postoperative blood loss is increased with hypothermia, for example, the typical
decrease in core temperature during hip replacement increases blood loss by
about 500 ml [56]. Normalisation of clotting problems will require normalisation
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of temperature as well as giving clotting factors. Note: Laboratories perform
coagulation studies at 37°C – regardless of the temperature of the patient at the
time the sample was taken. Thus, these studies may underestimate the degree
of impairment of coagulopathy in the hypothermic patient – what is after all a
dynamic problem in vivo rather than in vitro.
• Adrenergic responses are increased postoperatively in hypothermic patients –
responsible for increased cardiac morbidity. There is a 55% less relative risk of
adverse cardiac events when normothermia is maintained [57].
The degree of hypothermia in many of the studies cited was not that severe – 35°C.
Thus, development of hypothermia after prolonged surgery is signiﬁcant and
warrants management in the ICU. Forced warm air rewarming systems seem
most effective for rewarming such patients. However, prevention is better than
cure!
Possum
This scoring system is of interest in that it was developed speciﬁcally to examine
the overall perioperative risk of surgical patients.
Possum is an acronym for the Physiological and Operative Severity Score for
the Enumeration of Mortality and Morbidity. Copeland et al [58] developed this
scoring system in 1991 for audit purposes. It requires 12 physiological variables,
a number of operative severity score factors and is reliant on outcome for ﬁnal
score and therefore is not suitable for preoperative risk prediction:
• It has mainly been utilised in the UK to date.
• Its main use is to compare hospitals for audit purposes and identify differences
between individual surgeons.
• Possum is better than acute physiology and chronic health evaluation II
(APACHE II) in predicting mortality in HDU patients [59].
• For colorectal surgery, predicted mortality with possum equals actual mortal-
ity but the score may overpredict mortality in low-risk patients and reports sug-
gest it may not predict mortality accurately for ruptured aortic aneurysms or
oesophagectomy patients. Modiﬁed forms have been developed, for example,
for orthopaedic surgery and perhaps it is appropriate for different hospitals to
modify its use for different types of surgery. This is exactly the opposite approach
to, say, APACHE II scoring systems which are completely standardised with large
databases.
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FURTHER READING
Biccard BM. Peri-operative beta-blockade and haemodynamic optimisation in patients
with coronary artery disease and decreasing exercise capacity presenting for major
noncardiac surgery. Anaesthesia 2004; 59: 60–8.
Hanson GC. Critical Care of the Surgical Patient. Chapman and Hall, 1997; London.
McConachie I (Ed.). Anaesthesia for the High Risk Patient. Greenwich Medical Media, 2002;
London.
All major textbooks of Anaesthesia will cover many of the topics included in this
chapter.
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The trauma patient
J. Costello
Trauma related deaths typically demonstrate a tri-modal distribution:
• Initial mortality, within 30 min of the traumatic event, (e.g. great vessel rupture,
gross cerebral disruption) constitutes 50–60% of all trauma-related deaths.
• 30% constitute deaths within 4 h – usually due to considerable volume loss
compounded by ventilatory failure.
• The remainder constitute mortality in the days/weeks following the initial
event and is typically due to a combination of multi-organ failure and sepsis.
The notion of “The Golden Hour” suggests active resuscitation within the ﬁrst
hour of trauma impacts positively on mortality.
Epidemiology of trauma
In the UK:
• Trauma cases occupy 850,000 bed nights (Average hospital stay 10–12 days).
• 0.5–1.0 major trauma cases/1000 population/year.
• 75% major trauma cases admitted between 5 p.m. and 8 a.m. (80% 45 years).
• Males constitute 72% of trauma related deaths and 56% of non-fatal injuries.
• Road trafﬁc accidents (RTA) are a major cause of trauma mortality (in the USA,
mortality from RTA accounts for 40% of total trauma mortality).
• UK has the highest paediatric RTA rate in the world.
Trauma death rates per million of population/per annum:
• UK 88/18,000.
• US 111/165,000.
18
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Trauma is the third commonest cause of death in all age groups (UK and US) and
the commonest cause of death in 45-year-old age group.
One quarter of survivors from trauma have a disability lasting 6 months or
longer and in the USA, there are 80,000 new patients with major permanent dis-
ability per year.
RTA
• Most RTA involve one (or more) of: speed, alcohol, non-restraint.
• Restraints offer 75% efﬁciency rate in prevention of fatality and 50% fatal head
injuries could be avoided by use of such restraints.
• Bicycle crashes and Motorcycle RTA account for 1200 and 5000 fatalities every
year (respectively) in the USA (Head Injury accounts for 85% of these deaths).
• 60% of RTA involve alcohol excess.
Mechanism of injury in the multiple injured patient
Penetration injury
• Common in the USA.
• Usually an isolated injury requiring deﬁnitive surgery.
• Amount of tissue damage is proportional to the object velocity as the kinetic
energy of the object is transferred to the surrounding tissues.
• KE  M  V(squared)/2 (KE: Kinetic Energy; M: Mass; V: Velocity).
• Missile velocity has a greater impact than missile mass.
• Surface area and density of affected tissues are important determinants of
degree of tissue “cavitation” caused.
High velocity objects demonstrate a biphasic mode of tissue damage.
• The initial “positive” shock wave (“temporary pulsating cavity”).
• The secondary “negative” aftershock (negative pressure phase).
The former involves “stretch/shear” the latter involves “disruption/extravasation”.
Blunt injuries
• Common in the UK.
• Usually associated with multiple injuries (surgery frequently not deﬁnitive).
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• Kinetic energy is transferred into shock waves (or “force”).
• F  M  V/T (F: Force; M: Mass; V: Velocity change; T: Time interval).
• Blunt trauma force may be external (fall, RTA, Assault) or internal (compres-
sion, deceleration).
Blast injuries
These involve rapid transformation of small volumes of media (gas, solid, liquid)
into expanding gaseous products. Energy transfer occurs as pressure waves
induce oscillation in the media through which it travels.
• Primary Blast Injuries due to direct effect of pressure waves and are most injuri-
ous to gas containing organs (ears, lung, eyes, bowel).
• Secondary Blast Injuries are due to ﬂying debris (thus usually penetrating).
• Tertiary Blast Injuries result in victim as missile (thus usually blunt).
Pathophysiology of trauma
Neuroendocrine response
Brainstem sympathetic outﬂow results in
• Increased Chronotropy, Inotropy and systemic vascular resistance.
• Increased Glucagon production and Lipolysis.
• Reduced Insulin synthesis.
Respiratory response
Respiration is initially compromised in trauma by a combination of “Direct”
(blunt, penetrating, inhalational injury) and “Indirect” (hypovolemia, sepsis,
over zealous ﬂuid administration) insults.
Renal response
Hypovolemia results in reduced organ perfusion (mediated by Aldosterone 
and ADH).
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Immunomodulation
Cytokine mediated cascade of pro-inﬂammatory mediators result in ion-pump
dysfunction (cellular oedema), cellular dys-motility (leucocyte responsiveness to
stress hormones) and cell death. This ultimately leads to over-whelming sepsis, 
systemic inﬂammatory response syndrome (SIRS) and multi-organ dysfunction
syndrome (MODS) (see Chapter 22) and subsequent acute respiratory distress syn-
drome (ARDS), disseminated intravascular coagulation (DIC), Hepato-renal failure.
Note: Sepsis still accounts for three quarters of late mortality in the multiple
injured patient.
Severity of illness trauma “scoring systems”
Whenever possible, level of risk (and outcome) should be assessed on a continu-
ous basis as this has implications for clinical management decisions, cost and
resource utility.
Trauma scoring systems (see further reading for references)
• Glasgow Coma Scale (GCS) – primarily for neurological status in Head Injuries.
• Trauma Score.
• Trauma Index.
• CRAMS scale (Circulation, Respiratory, Abdominal, Motor, Speech).
• Abbreviated Injury Scale (AIS).
• Injury Severity Score (ISS).
• The trauma and injury severity score (TRISS) Methodology.
• Pediatric Trauma Score.
The Trauma Score combines GCS with cardio-respiratory indices (systolic blood
pressure (BP) and respiratory rate). The Trauma Index is primarily a pre-hospital
tool incorporating injury (type and location) and indices of function (cardio-
respiratory and neurological).
CRAMS constitutes a simpliﬁed “trauma score” for pre-hospital use but car-
ries poor overall sensitivity. The AIS is a crude anatomical-based scoring system
applied to blunt trauma patients but also carries poor sensitivity. The ISS, also, is
based on anatomical systems incorporating AIS but is complex in application.
TRISS Methodology combines the revised trauma score (“RTS”) with the ISS
to provide a standard approach for evaluating outcome of trauma care and is 
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primarily used in quality assessment reviews (applicable to all trauma types).
Mortality from trauma depends on the degree of physio-anatomical derange-
ment, age ﬁt and type of injury. TRISS Methodology combines these to provide a
measure of the survival probability.
These scoring systems have little predictive purpose during the intensive care
unit (ICU) episode and do not aid clinical decision-making. Accrued mortality
estimates are reviewed retrospectively thus they have little practical application.
However some authors suggest such scoring systems complement ongoing man-
agement and concurrent non-trauma score systems.
Trauma scoring systems have been recently reviewed [1].
The concept of traumatic shock
Advanced trauma life support (ATLS) teaching and the RTS [2] emphasise 
the importance of monitoring progressive changes in heart rate and BP in the
injured patient. This does not always happen in the multiple injured patient.
Heart rate
• Heart rate is thought to be of poor value in the assessment of traumatic hypov-
olemia [3].
• Evidence suggests the biphasic response of heart rate [4] (i.e. bradycardia fol-
lowing tachycardia depends on the injury type). Concomitant direct tissue
injury attenuates the magnitude of the bradycardic response to severe “simple”
blood loss (variceal rupture, vessel penetration) thus concealing the true extent
of hypovolemia [5].
BP
• BP is usually maintained until a deﬁcit of approximately 30% blood volume
(Class 3 Shock). Earlier progressive blood loss is suggested by a drop in pulse
pressure (Class 2 Shock)[6].
• In trauma, such alterations are unpredictable and delayed due to injury-
induced endogenous pressor response and reduced sensitivity to baro-receptor
reﬂex involving “nociceptive” stimuli [7].
This attenuation of cardiovascular response may offer some degree of protection
against the effects of hypovolemia. However, animal studies have shown that
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induced blood loss and concomitant electrical nerve stimulation (to simulate
injury) resulted in lower Cardiac Index (CI), systemic oxygen delivery (DO2) and
higher mortality than that of simple blood loss alone.
Assessment of the trauma patient
ATLS teaching is one of many accepted systems enabling a stepwise approach to
management of the trauma patient and is followed here; although other man-
agement tools exist, historically they have received little attention.
“Team Leaders” in trauma should be ATLS trained. Designation of responsibil-
ities to “team members” (prior to arrival of the injured patient) enables coordinated
and prioritised approach. Enlist additional/senior help in the case of multiple
victims.
Immediate priority
Detect and treat immediately life-threatening injuries in the order of:
• Airway (and C-Spine) → Resuscitate.
• Breathing (and Ventilation) → Resuscitate.
• Circulation → Resuscitate.
Concurrent team management of these systems is usual and to be expected.
Airway (and C-Spine)
Airway must be immediately assessed. If not patent, deﬁnitive airway must be
established by intubation (oral, nasal or ﬁbreoptic) or surgical (cricothyroido-
tomy in the emergent setting) means.
Rapid Sequence Induction (RSI) (and Intubation) following preoxygenation is
frequently employed in the emergency setting of trauma but has been associated
with 1–2% failure rate especially if performed by inexperienced practitioners.
Strategies to deal with failed intubation should be tailored towards use in the
Emergency department [8].
Cricoid pressure to reduce the risk of aspiration of stomach contents should
be performed.
Intubation during C-Spine precaution necessitates in-line manual immobil-
isation. Routine use of a gum elastic bougie is recommended as poor laryngeal
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views are frequent. It is difﬁcult to ﬁnd good evidence that this technique, prop-
erly performed, has resulted in additional neurological impairment in any
trauma patient with cervical spine injury. Neurological signs should be docu-
mented before intubation, if possible.
Other options include nasal or ﬁbreoptic intubation but there are pitfalls in
the use of such techniques in the trauma patient.
Fibreoptic awake intubation Nasal intubation
Unfamiliar technique for most Increased failure rate
practitioners Epistaxis
Uncooperative or obtunded Bacteraemia
patient Potentially greater C-Spine movement.
Surgical airway is indicated if the above fail and requires personnel trained in its
application.
C-Spine injuries occur in 2–12% of blunt trauma cases [9], in up to 20% of ser-
ious head injuries [10] and 1 in 300 RTAs [11]. The reported incidence of missed
(or delayed diagnosis) cervical C-Spine injuries is said to be 4.6% [12] – with
potentially up to 30% incidence of secondary neurological deﬁcit in those patients.
There are no controlled trials comparing methods of C-Spine handling with
radiological evaluation thus current standards of care (guidelines) are based on
level two or three evidence.
• High levels of radiographic misinterpretation still exist.
• Always assume C-Spine injury in the trauma victim. Application of hard collar
(or) side support blocks is mandatory until clinical/radiological screening is
complete.
• Always immobilise C-Spine if injury mechanism is suspicious, if history is
inadequate or victim communication is poor. Loss of (or) deﬁcit in conscious-
ness is predictive of unstable C-Spine injury [9].
• Hard collar application may increase intracranial pressure (ICP) in the head
injured patient and is thus not considered an absolute requirement in the 
adequately sedated head injury patient who has normal plain radiography. Hard
collars provide incomplete immobilisation, may utilise excess staff resource
and cause tissue ulceration and necrosis.
• Plain Radiography (at least) is required in patients with GCS 15 [13], sedative
drug or alcohol co-ingestion or distracting pain [14].
• If victim is uncooperative/agitated (head injury, shock, hypoxia) forced restraint
is ill advised. Abandonment of manual immobilisation, victim reassurance
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and reversal of obvious causes (ﬂuid, oxygen) should be initiated. Allow the
collar to remain in-situ to prevent extremes of movement. If this fails, considera-
tion should be given to RSI [14].
• In the vomiting victim, a head-down tilt is ideal (even in the head-injured
patient). Other options would include coordinated log-roll or spinal board-
board tilt [14].
Once deﬁnitive airway is established, C-Spine can only be fully cleared when the
patient regains consciousness.
Current guidelines suggest awaiting successful weaning before formal C-Spine
assessment, particularly if consciousness is anticipated within 48 h.
If intubation is expected for 48 h satisfactory clearance of C-Spine should be
actively sought by:
• Additional plain radiography [13].
• Plain radiography with computerised tomography (CT) of C1–C3 (false nega-
tive rate 0.1%) [14].
• Plain radiography with dynamic ﬂuoroscopy/stress views.
• Magnetic Resonance Imaging [15].
• National guidelines for CT of C-Spine exist [16] but compliance is questionable
and reliability remains to be established [17].
Considerable variation still exists in relation to C-Spine management between
individual ICUs [18].
A recent review in Anaesthesia gives a thoughtful review of cervical spine
immobilisation in the ICU – especially with regard to its limitations and compli-
cations [19]. The reader is also strongly recommended to read the recent British
medical association (BMA) review article by Morris on spinal immobilisation for
unconscious patients with multiple injuries cited in the Further Reading section.
The authors suggest that the risks of prolonged immobilisation beyond 48–72 h
exceed the risks of a serious missed cervical spine injury after normal plain ﬁlm
and CT studies.
Breathing (and ventilation)
Immediate administration of high ﬂow oxygen (with reservoir) to all trauma
patients is essential.
Adequate ventilation is determined by patency of airway and lung/diaphragm/
chest wall function.
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Immediate life-threatening causes of inadequate ventilation include:
• tension pneumothorax,
• ﬂail chest (with pulmonary contusion),
• open pneumothorax,
• massive haemothorax,
– all should be immediately recognised and resuscitated during the primary
survey.
If doubt exists, it is safer to opt for elective intubation and ventilation.
Circulation (and haemorrhage control)
Haemorrhage is the commonest cause of preventable trauma-related mortality
• Assume hypotension is due to blood loss.
• Control obvious external haemorrhage immediately.
Assessment of circulation is by:
• Non-invasive indices (pulse, BP, skin colour, temperature, level of consciousness).
• Invasive indices (Central venous and arterial cannulation, Urine output).
• Normal pulse and BP does not always suggest normovolemia (see earlier) –
especially in the elderly, multi-medicated or young trauma victim.
Immediate resuscitation requires at least two large bore cannulae with large vol-
ume warmed infusion. Due consideration must be given to “concealed” blood
loss (up to 4 units from femoral fractures).
ATLS guidelines suggest blood transfusion is indicated if bolus intravenous
crystalloid (or colloid) is ineffective. Cross-matched, Type speciﬁc and Group O
negative is administered (in order of emergent priority).
The crystalloid/colloid debate continues and is discussed further in Chapter 5.
Two litres (Crystalloid) or one litre (Colloid) is the accepted initial bolus in adult
trauma prior to consideration of blood transfusion. (APLS teaching suggests
blood product administration subsequent to 2  20 ml/kg bolus’ crystalloid/
colloid in paediatric trauma patients).
The use of at least one manufacturer’s rapid infusion device has been shown
[20] to be beneﬁcial compared to standard ﬂuid administration – resulting in less
ﬂuid required and less coagulopathy (both thought to be due to efﬁcient heating
of the ﬂuids and less patient hypothermia).
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The role of hypertonic crystalloid in trauma has gained popularity owing to
• positive mortality outcome,
• improved cardiac efﬁciency and (DO2),
• improved immunologic function.
Its incorporation into practice, however, is not widespread in the UK.
Massive administration of blood product/ﬂuid (dilutional coagulopathy),
hypothermia (disruption of clotting cascade and platelet disruption) and head
injury (neural thromboplastin release) all add to “traumatic coagulopathy”.
Transfusion of platelets, cryoprecipitate or fresh frozen plasma (FFP) should be
guided by baseline coagulation parameters taken initially.
It is currently not advised to empirically administer such blood products
unless a known coagulation disorder (or history of anticoagulant medication)
exists [21].
Note: Blood transfusion requirement is an independent predictor of mortality,
ICU admission and length of stay (ICU and Total Hospital) [22].
Permissive hypovolemia/hypotension
Bickell [23] suggested a survival beneﬁt associated with “delayed” ﬂuid resuscitation
in cases of penetrating trauma (with presentations suggestive of hypovolemia).
Theoretical beneﬁts (as suggested by animal studies) include:
• reduced rupture of microvasculature clot tamponades,
• reduced dilutional coagulopathy,
• increased haemoviscosity,
• reduced “hydraulic acceleration” of haemorrhage.
Clinical parameters suggest limiting ﬂuid resuscitation to achieve a Mean arter-
ial pressure (MAP) of approximately 50 mmHg until deﬁnitive surgical control of
haemorrhage; thereafter, resuscitation is suggested as outlined in ATLS.
This approach is not favoured for many patients owing to:
• The false assumption of prompt surgical resource deployment. The patients
will need prompt deﬁnitive intervention to minimise the oxygen debt. Delays
in surgery for example in rural area may be better with “normal” resuscitation.
• Isolated penetrating torso trauma comprising the minority of all trauma cases.
• Inapplicability in the context of coexistent head injury.
• Equivocal therapeutic utility [24].
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The biggest problem is that this study was performed in penetrating injuries.
Patients with blunt trauma (the majority) are not so likely to have deﬁnitive sur-
gical interventions.
Differences between blunt and penetrating trauma
Penetrating Blunt
Common in the USA Commoner in Europe
Often sole injury Not usually in isolation
Diagnosis often simple Diagnosis often complex
Surgery often deﬁnitive treatment Surgery rarely deﬁnitive
Therefore, this approach is not recommended in patients suffering blunt trauma.
It would be unfortunate if improvements in trauma management related to
an understanding of the importance of rapid resuscitation (the “Golden hour”
concept) with volume infusion as a cornerstone of that resuscitation were lost
because ﬂuid restriction was seen as appropriate in any but a few speciﬁc (and
uncommon) circumstances.
Resuscitation indices
Non-invasive
• BP Trend (includes pulse pressure).
• Heart Rate.
• Temperature.
• Level of consciousness.
• Urine Output.
Invasive
• Central Venous Catheterisation.
• Pulmonary Artery Flotation Catheter.
• Arterial Catheter.
Invasive indices are usually required if there is no resolution with current man-
agement. A lower threshold for instituting invasive monitoring should be adopted
in the case of trauma in the elderly, blunt chest trauma or haemorrhagic shock.
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Scalea [25] showed a 40% mortality reduction in cases of elderly blunt trauma
with early invasive monitoring. Similar trends are reported in the younger popu-
lation [26]. The improvements are thought to arise from early identiﬁcation of
occult low cardiac outputs which, if not promptly reversed, result in the develop-
ment of organ failures.
Adequacy of resuscitation
Non-invasive goals
Normalisation of non-invasive goals is ideal although these may not always
reﬂect the true status (see earlier).
Increase Decrease
BP Heart rate
Urine output
Consciousness
Invasive goals
The therapeutic goal must be to optimise tissue oxygenation.
The magnitude of the oxygen deﬁcit is a key factor in determining outcome in
patients with haemorrhagic or cardiogenic shock – see also Chapter 1.
Indices of systemic oxygen transport (CI, DO2, Oxygen Consumption (VO2))
provide the most direct measurement of resuscitative progress. Maintenance of
adequate oxygen transport is thought to reduce endothelial hypoxia-induced
inﬂammatory cascade activation (“the oxygen debt”).
• Most studies relate to mortality reduction in critically ill surgical or septic
patients, but evidence does also suggest beneﬁt in the multiply injured [27].
• “Goal-directed therapy” has received criticism but it is thought that in some
situations failure of this approach may be due to delay in achieving the goals.
• Mixed Venous Saturation is becoming an important component of goal-
directed therapy [28] and may have a role in the multiple injured patient.
• Blood Lactate increases in proportion to the systemic oxygen deﬁcit and is
indicative of supply dependency of systemic VO2 and of prognostic value in
severe trauma. Similarly, Base Deﬁcit correlates well with injury severity and
outcome [29].
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• The measurement of gastric mucosal pH (pHi) may be of beneﬁt but has
received little attention in the context of trauma [30].
Thoracic trauma
Europe and the USA demonstrate a predominance of blunt and penetrating
chest trauma respectively.
Chest trauma carries an overall 10% mortality (in-hospital mortality is 5% and
rises to approximately 33% in severe multi-system trauma) and surgical inter-
vention is required in 15%.
The severity of the injury predicts clinical course and outcome [31].
Thoracic trauma proﬁle
Six life-threatening injuries must be immediately identiﬁed and treated in the
primary survey.
• Airway Obstruction.
• Tension Pneumothorax.
• Open Haemothorax (Sucking chest wound).
• Massive Haemothorax.
• Cardiac Tamponade.
• Flail Chest.
Immediate management
• Ensure patent airway (deﬁnitive if required) and administer oxygen.
• Immediate needle decompression if suspecting tension pneumothorax.
• Obtain vascular access.
• Intercostal drain placement subsequent to needle decompression or for sus-
pected or conﬁrmed pneumothorax (apical placement) or haemothorax (basal
placement).
• Tube placement may occasionally not initially be required owing to delayed
presentation or small size traumatic pneumothorax.
Beck’s Triad consists of elevated jugular venous pressure (JVP), hypotension,
mufﬂed heart sounds, Kussmaul’s sign and pulsus paradoxus. Patients may have
normal cardiac silhouettes on Chest X-rays (CXR). This may occur with Cardiac
Tamponade, Tension Pneumothorax, Myocardial dysfunction or Systemic Air
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Embolism. Pericardiocentesis of as little of 5 mls in Cardiac Tamponade may
temporarily augment stroke volume by 25–50%.
Six “potentially” life-threatening injuries are usually identiﬁed in the second-
ary survey.
• Aortic Disruption.
• Myocardial Contusion.
• Pulmonary Contusion.
• Traumatic Diaphragmatic Rupture.
• Tracheobronchial Disruption.
• Oesophageal Disruption.
A detailed discussion on recognition and management of the above is out with
the scope of this text.
Indications for emergency thoracotomy
Cardiac arrest
Emergency Thoracotomy may be appropriate for victims with penetrating chest
trauma with witnessed signs of life during transport or in the emergency depart-
ment and at least cardiac electrical activity on arrival [32]. However, there is no gen-
eral consensus on what “signs of life” constitute. They may include any combination
of palpable pulse, BP, reactive pupils, corneal reﬂex, gag reﬂex or respiratory effort.
ATLS Guidelines suggest thoracotomy is indicated for penetrating chest
trauma with PEA (pulseless electrical activity).
Note: Animal studies show that external cardiac massage is ineffective at pro-
viding organ perfusion if preload is reduced that is external cardiopulmonary
resuscitation (CPR) is unlikely to be successful in cases of exsanguinations [33].
For blunt trauma, some authors suggest thoracotomy is only indicated if signs
of life are present at least on patient arrival. However, ATLS guidance recom-
mends that thoracotomy is not indicated in cases of blunt trauma irrespective of
the existence of PEA.
Massive haemothorax
This constitutes less than 5% of all haemothoraces. Thoracotomy is indicated if
initial blood loss (per drain) is 200 mls/hr or 1.5 litres on immediate chest
tube placement.
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Cardiac tamponade
Emergency Thoracotomy is indicated only if haemodynamically unstable with
suspected penetrating myocardial injury.
Contusional injuries
Blunt myocardial injury
This is usually suggested by:
• mechanism of injury (accelerative-decelerative or compressive);
• examination (arrhythmia, isolated tachycardia, cardiac failure, any part of
Beck’s Triad) radiography (increased cardiac silhouette, high rib fractures);
• electrocardiographic (ST anomalies, conduction abnormalities that may mimic
Myocardial Infarction).
Adverse outcome is rare [34]. Conservative management is the norm.
Pulmonary contusion
• Occurs in 20% of blunt trauma cases with ISS of 15 or higher.
• 85% present within 6 h (95% within 1 day).
• Over half present with haemoptysis.
• Overzealous ﬂuid administration may result in lung injury – judicious use is
advised.
• Typically no ventilatory support is required if 10% lung volume involved.
Management should include:
• Humidiﬁed oxygen therapy.
• Chest physiotherapy.
• Incentive spirometry.
• Intercostal nerve block or Epidural analgesia.
The role of ventilatory support
• Ventilatory support is typically required if 30% lung volume is involved.
• 40–60% ultimately require ventilatory support [35].
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• Prognosis is variable and mortality rates vary between 40–60% – largely depend-
ent on the presence of other injuries and the degree of parenchymal injury as
reﬂected by the impairment of oxygenation.
Chest wall injuries
Rib injuries
• 50% not seen on X-ray. 90% are associated with other injuries.
• High rib fractures are associated with poor outcome (usually associated with
head injury or great vessel rupture).
• Low rib fracture is associated with viscus damage – in multi-trauma, CT
abdomen should be considered.
• Elderly patients admitted after rib fractures have increased mortality even after
taking comorbidities into account.
The management goal is:
• to detect signiﬁcant complications such as haemopneumothorax, pulmonary
contusion, vascular injury,
• to provide adequate analgesia.
Analgesic options include:
• Oral analgesia (non-steroidal anti-inﬂammatory drugs (NSAIDs), opiate-based
analgesia).
• Intravenous patient-controlled analgesia.
• Regional anaesthesia (intercostal, intrapleural, epidural). Epidural analgesia is
generally considered to be superior [36].
Flail chest
This is a clinical diagnosis. The pathophysiological insult includes parenchymal
contusion, impaired compliance and intrapulmonary shunting resulting in
reduced vital capacity.
There are three grades of severity:
• Grade 1: Can ventilate and cough/no associated injuries.
• Grade 2: Cannot cough/Has other injuries.
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These are managed by combination of analgesia, physiotherapy and ﬂuid
restriction.
• Grade 3: Hypoxia, exhausted, multiple injuries, elderly.
These require ventilation.
Up to 50% are managed conservatively. The remainder require ventilation.
Many will require an intercostal drain.
Progress is evaluated by:
• Repeated clinical assessment and examination.
• Arterial blood gas analysis.
• Serial vital capacity measurements.
Indications for early ventilation in ﬂail chest
• Shock.
• Three associated injuries.
• Severe Head Injuries.
• Co-Morbid Lung disease.
• Eight Rib fractures.
• 65 years of age.
Ciraulo et al [37] suggests the degree of contusion as the best guide to estimating
requirement for ventilatory support and emphasises that ﬂail chest is a marker of
high kinetic energy absorption.
Surgical ﬁxation of ﬂail segment remains controversial.
Operative intervention
• Many trauma patients will need surgery.
• In general, all the required surgical procedures should be performed acutely
that is during one anaesthetic providing the patient has been appropriately
resuscitated and is haemodynamically stable.
• The rationale is that, once the patient is resuscitated, the patient may be in the
best condition that he will be in for some time that is before the development
of sepsis, tissue oedema, malnutrition and metabolic complications.
• Delayed ﬁxation of long bone fractures may increase the incidence of ARDS
[38]. The mechanisms are uncertain but probably include ongoing bleeding,
increased pain and physiological stress response and possible fat embolus.
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• Conversely if the patient undergoing surgery is unstable, with developing
hypothermia, coagulopathy and acidosis, prolonged surgery has a high mor-
tality. Many surgeons now accept that the best way to manage these patients is
to “bail out” for example pack the abdomen to stop bleeding, bring out bowel
ends on to the abdominal wall etc. and take the patient to ICU for stabilisation
and further resuscitation. Further surgical intervention is deferred to a later
date. This has been described as “damage control surgery” [39].
• Blood clots, packing the abdomen, ileus and tissue oedema all, however, con-
tribute to the development of an abdominal compartment syndrome where
the increase in pressure literally squeezes the kidney. This causes a reduction
in renal blood ﬂow, glomerular ﬁltration rate (GFR), direct compression of the
renal parenchyma and increased release of ADH and Aldosterone from stimu-
lation of abdominal wall stretch receptors. In general intra abdominal pres-
sures of 15–20 mmHg are associated with oliguria while pressures greater than
30 mmHg may be associated with anuria.
• Interestingly, the use of large volumes of ﬂuids in an attempt to achieve supra-
normal resuscitation goals has been shown to be associated with an increased
incidence of abdominal compartment syndrome [40]. This variant of abdomi-
nal compartment syndrome has been called secondary compartment 
syndrome.
Injury associated organ failures and outcome
• Patients admitted to ICU following multiple injuries often have a protracted
length of stay, duration of intermittent positive pressure ventilation (IPPV) and
consume a lot of resources [41].
• Isolated pulmonary contusion in young trauma patients has a good 
prognosis [42].
• One study [43] found ﬂail chest and pulmonary contusion to both be associ-
ated with approximately 16% mortality. The mortality was increased to approxi-
mately 42% if they were combined in the same patient.
• Length of stay and mortality are increased in the elderly trauma patient with a
greater proportion requiring chronic care following discharge from ICU.
• Young trauma patients have a better prognosis and, those who survive, have a
good prospect of rehabilitation and a fairly good ultimate outcome.
• Pelvic fractures in the elderly are of greater signiﬁcance than in younger
patients and are more likely to be associated with death [44].
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• Delayed ﬁxation of fractures has already been noted to be associated with the
development of ARDS [38]. Later work has shown that early ﬁxation of femur
fractures (24 hrs) is associated with better outcomes – even in patients with
other head and chest injuries [45].
• Development of sepsis and multiple organ failure is responsible for much of
the late mortality. Recently, it has been shown that single organ failure is asso-
ciated with a good outcome – mortality being more related to the underlying
injury [46]. It seems that the mortality for multiple organ failure may be less
than what it was 15–20 years ago. However, mortality for patients with four or
more organ failure remains almost 100% [46].
• The development of ARDS in trauma patients is associated with a prolonged
ICU stay but, surprisingly is not a factor in a worse outcome – outcome being
more closely linked to injury severity [47].
• Studies on tight glucose control and avoidance of hyperglycaemia (see 
Chapter 22) have been repeated in trauma patients [48]. Early hyperglycemia is
associated with signiﬁcantly higher infection and mortality rates independent
of the injury.
• In many patients with multiple injury the single most crucial factor in predict-
ing their outcome is the extent of their neurological injury.
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Acute coronary syndromes
R. Beynon and D.H. Roberts
Acute myocardial ischaemic events provide a large portion of the workload of
hospitals in the developed world. Presentations may vary from an acute ST ele-
vation myocardial infarction (STEMI) with chest pain to an asymptomatic peri-
operative event picked up on enzyme rise.
With the advent of new, more sensitive biochemical tests (troponins) many
patients who would have previously been given a diagnosis of unstable angina
have now been shown to have suffered small amounts of myocardial necrosis or
“infarction”. This has resulted in the need for a new deﬁnition for the term “myocar-
dial infarction (MI)”.
The current American College of Cardiology (ACC) and European Cardiac
Society (ECS) consensus guidelines suggest the following deﬁnition [1].
Criteria for acute, evolving or recent MI
Either one of the following criteria satisﬁes the diagnosis for an acute, evolving or
recent MI:
• Typical rise and gradual fall (troponin) or more rapid rise and fall (creatinine
kinase MB, CK-MB) of biochemical markers of myocardial necrosis with at
least one of the following:
– ischemic symptoms;
– development of pathological Q-waves on the electrocardiograph (ECG);
– ECG changes indicative of ischaemia (ST segment elevation or depression);
– coronary artery intervention (e.g. coronary angioplasty).
• Pathological ﬁndings of an acute MI.
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Criteria for established MI
Either of the following criteria satisﬁes the diagnosis for established MI:
• Development of new pathological Q-waves on serial ECGs. The patient may or
may not remember previous symptoms. Biochemical markers of myocardial
necrosis may have normalized, depending on the length of time that has passed
since the infarct developed.
• Pathological ﬁndings of a healed or healing MI.
The inevitable conclusion of this deﬁnition is an enormous expansion in the
numbers of people being classiﬁed as having suffered an MI. As the deﬁnition
encompasses such a heterogeneous population the ACC and ECS have stated the
term MI should not be used without further qualiﬁcations such as size of infarct
and timing [1]. In clinical practice this centres around the development of 
Q-waves, the presence or absence of ST elevation and the development of areas
of poorly functioning myocardium on echocardiography.
Current management groups people into three categories. The ﬁrst two are
termed ACS and are discussed in this chapter:
(1) STEMI.
(2) ACS without ST elevation – encompassing all patients with ECG changes
and/or troponin rises.
(3) Stable angina.
Acute STEMI
The pathogenesis of acute MI with ST elevation involves the rupture of an
unstable atherosclerotic plaque and subsequent thrombus formation via platelet
activation resulting in total coronary occlusion.
The natural history of acute MI treated in the community is poor with an over-
all fatality of between 30% and 50% in the ﬁrst month of which about a half occur
in the ﬁrst 2 h [2]. Those patients that arrive in accident and emergency depart-
ments form a self-selected group. Studies on hospital groups have shown a
reduction in 1-month mortality from 25% to 30% in the 1960s to 7–8% in the
most recent trials [3].
Clinical presentation
• Pain: The most consistent feature of STEMI is pain. It is usually felt centrally or
left sided in location and is described as tight or crushing in character. It often
radiates to the neck and/or arm, and typically does not respond to sublingual
glyceryl trinitrate (GTN). Diabetics can present silently without chest pain.
• Breathlessness: This often accompanies the pain and may be due to the
myocardial ischaemia itself or be a manifestation of acute pulmonary oedema.
• Sympathetic and parasympathetic over activity. This often leads to vomiting,
sweating, dizziness, palpitations and feeling clammy.
• Typically symptoms have no obvious precipitating factor but in a proportion of
patients an MI occurs following anxiety or strenuous activity. There is also a
well-documented circadian variation, with a peak occurring in the early morn-
ing (6–9 a.m.). This is probably related to increases in catecholamines and
platelet aggregability.
• Regrettably one of the commonest presentations of acute MI is sudden death,
where the MI has usually been associated with sudden fatal ventricular dys-
rhythmias. 50% of MIs may present this way.
Diagnosis
The clinical management of patients with ST elevation has progressed following
clinical trials involving thrombolysis and percutaneous coronary intervention
(PCI). The following criteria are required before considering thrombolysis or pri-
mary angioplasty:
• typical cardiac chest pain not responding to GTN spray;
and ECG changes:
• 1 mm ST elevation in two or more adjacent limb leads or
• 2 mm ST elevation in two or more adjacent chest leads or
• new left bundle branch blockage (LBBB).
Clinical conditions which can look similar to acute STEMI include pericarditis
and previous infarcts with an aneurysmal segment. The presence of an evolving
ECG can be invaluable. If there is doubt then an opinion should be sought from
a senior or specialist colleague. Those patients who do not fulﬁl current diagnos-
tic criteria with less ECG changes should currently be managed as ACS without
ST elevation.
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Patients with STEMI classically exhibit a rise in biochemical markers includ-
ing CK, CK-MB and troponin:
• CK: It is released following any kind of muscle damage. It can give information
as to the size of infarct sustained but is relatively non-speciﬁc. CK-MB, which is
almost exclusively found in myocardium is a more sensitive assay. These enzymes
increase within 4–6 h of infarction and can remain elevated for 3–4 days.
• Troponins: Both the I and T isoenzymes are more speciﬁc and sensitive than
CK-MB. They can be detectable within 4 h but for a acceptable sensitivity have
to be sampled at 12 h. They may stay elevated for up to 3 weeks.
Clinical management
Basic immediate management includes cardiac monitoring for dysrhythmias,
inhaled oxygen, analgesia (morphine or diamorphine) and an antiemetic (meto-
clopromide or cyclizine).
Routine bloods should be sent for:
• full blood count (FBC);
• urea and electrolytes (U&Es), glucose and lipids;
• cardiac enzymes should be sampled following admission. Many institutions
measure troponin and CK at 12 h.
The urgent requirement in a patient with acute STEMI is the restoration of cor-
onary ﬂow and tissue perfusion. This is performed with antiplatelet therapy,
thrombolysis or PCI.
Antiplatelet therapy
Aspirin
• Give 300 mg stat.
• 75–150 mg daily lifelong.
The only licensed antiplatelet therapy for acute STEMI is currently aspirin. It
inactivates cyclooxygenase and so inhibits platelet aggregation.
Aspirin alone is beneﬁcial for treatment of evolving acute MI with a 35-day
number needed to treat (NNT) of 50 [4]. This confers almost as much beneﬁt as
modern thrombolytic regimes.
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Other antiplatelet agents: clopidogrel
• Give 300 mg stat.
• 75 mg daily.
Clopidogrel selectively prevents the activation of the glycoprotein (GP) IIb/IIIa
complex, thereby inhibiting platelet aggregation. There is currently no evidence
that clopidogrel has a role in acute STEMI, but its use would appear sensible in
the small group of patients who are aspirin intolerant.
The use of various forms of the GPIIb/IIIa blockers (eptiﬁbatide and abcix-
imab) in the management of acute STEMI continues to be studied but has yet to
be shown to be more beneﬁcial than thrombolysis.
Thrombolysis
More than 150,000 people have been enrolled into studies comparing the use 
of thrombolysis versus control. Approximately 30 deaths are prevented per 1000
patients treated who present within 6 h of symptom onset, with ST segment eleva-
tion or bundle branch block. Twenty deaths are prevented per 1000 patients treated
for those presenting between 7 and 12 h [5]. Beyond 12 h there is no convincing evi-
dence of beneﬁt. As a result thrombolysis should be considered in those patients
presenting within 12 h of onset of symptoms who fulﬁl ECG criteria.
ECG changes
Most beneﬁt is seen in patients with new LBBB or anterior changes. Inferior
infarctions also beneﬁt but the NNT to save one life is four times the number for
anterior changes or LBBB [5].
ECG changes compatible with posterior infarction warrant the use of throm-
bolysis but the diagnosis is more difﬁcult and best left to experienced hands.
Age
Thrombolysis is beneﬁcial whatever the age of the patients but the degree of
beneﬁt for patients over the age of 75 is less. Potential complications should be
explored fully prior to commencement of treatment [5].
Patients with diabetes have been shown to derive more beneﬁt from throm-
bolysis than those people with normal blood sugar.
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Which thrombolytic agent?
Currently there are four agents in routine clinical use:
• Streptokinase, given as an infusion over 30–60 min.
• Accelerated tissue plasminogen activator (tPA), given as a bolus then infusion.
• Reteplase, two boluses 30 min apart.
• Tenecteplase (TNK-tPA), given as a single bolus.
Most institutions offer two options, streptokinase and one other:
• tPA and streptokinase have been compared, and a small additional beneﬁt was
seen with tPA but at the expense of an increase in intracerebral haemorrhage.
Beneﬁt was highest in patients presenting within 4 h of onset of symptoms
with anterior infarcts [6].
• TNK and reteplase are similar to tPA, and are both easier to administer. They
are becoming more widely used.
• tPA, reteplase and TNK all require the use of concomitant intravenous (IV)
heparin for 24–48 h after thrombolysis. Streptokinase does not require the use
of heparin.
Complications
Complications following thrombolysis centre on the risk of serious bleeding. The
chance of intracerebral haemorrhage is on average1% but increases with increas-
ing age, uncontrolled hypertension, low body weight and the use of tPA. With no risk
factors the risk is about 0.3% but with three risk factors can reach 2.5% [7].
Contraindications
Patients who have signiﬁcant contraindications to thrombolysis should be dis-
cussed with a regional referral centre regarding the need for transfer and PCI.
Mechanical reperfusion/PCI
Current practice in the UK involves the use of thrombolysis to achieve vessel
patency after occlusion from a thrombus. However, there is much interest in the
use of coronary angioplasty and stenting as an alternative to thrombolysis. This
is termed primary angioplasty.
Trials have compared:
• thrombolysis versus PCI in patients presenting to a regional referral hospital,
• thrombolysis versus transfer to a regional referral hospital for PCI in patients
attending a district general hospital (DGH) [8].
Current trials are looking into:
• thrombolysis versus thrombolysis then transfer for PCI,
• ambulance thrombolysis and PCI.
Most trials have not shown a signiﬁcant mortality beneﬁt from PCI as opposed to
thrombolysis. There was however a signiﬁcant reduction in non-fatal strokes and
the need for readmissions due to angina.
Failed thrombolysis/reinfarction
A number of patients fail to fully respond to thrombolysis with:
• failure to achieve resolution of ST segments,
• continuing cardiac pain,
• further chest pain and ECG changes after successful thrombolysis.
These groups should be discussed with the regional centre with a view to poten-
tial transfer for urgent angiography and revascularization.
Adjunctive medical therapy
Beta blockade
Since the advent of thrombolysis there has been no signiﬁcant evidence of a
prognostic beneﬁt for immediate beta blockade [9]. However, short-acting beta
blockers (e.g. metoprolol) should be considered where the patient is tachycardic
or still in pain as long as there is no evidence for heart failure.
Placebo-controlled trials have shown that chronic beta blocker therapy
improves prognosis post MI. Most of these studies were in the prethrombolytic
era but it would now be unethical to repeat these studies with thrombolysis [10].
Beta blockers should be increased to aim for a target heart rate of 50–60 beats per
minute. The development of acute heart failure, asthma or heart block should
lead to a reduction in dose or cessation in treatment.
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Intensive insulin therapy
The use of insulin following MI has become standard treatment since the publi-
cation of the Diabetes mellitus, Insulin Glucose infusion in Acute Myocardial
Infarction (DIGAMI) trial that showed prognostic beneﬁt for early intensive
insulin treatment [11]. The DIGAMI regime should be commenced on:
• any known Type 1 or 2 diabetic, or
• any patient with random serum blood glucose 11 mmol/l.
Patients should then be referred to the diabetes specialist team for further man-
agement. These patients require an admission haemoglobin A1c (HbA1c) level
checked.
Secondary prevention
Statins
The use of cholesterol lowering medication post-MI has been extensively studied
[12]. Current UK guidelines (National Service Framework for Coronary Heart
Disease, NSF for CHD) suggest that statins and dietary advice should be given to
aim to lower serum cholesterol concentrations either to:
• 5 mmol/l (low-density lipoprotein cholesterol (LDL-C) to below 3 mmol) or
• by 30% (whichever is greater).
Recent European guidelines have lowered targets to total cholesterol 4.5 and LDL
to 2.5 [13]. Cholesterol levels will drop within 12–24 h after MI so consequently it
is best to measure levels directly on admission.
Angiotensin-converting enzyme inhibitors
The beneﬁts of angiotensin-converting enzyme inhibitor (ACEI) in patients with
cardiovascular disease are well proven. Initial trials looked at patients with left
ventricular (LV) dysfunction; however, recent data has shown that they are of
beneﬁt to all patients with cardiovascular disease and should be started post-MI
in all patients no matter what age or degree of LV function [14]. Blood pressure
and renal function should be monitored.
Free fatty acids
There is recent evidence that dietary supplementation with polyunsaturated fatty
acids can reduce cardiac events following MI [15]. Only one company currently
has a product in the form of Omacor. Its use is now becoming more widespread.
Symptomatic treatment
Nitrates, calcium channel blockers and nicorandil are all used for the symptom-
atic treatment of angina, pre- or post-infarction. There is no conclusive evidence
that they have any prognostic beneﬁt either acutely or long term. It is important
to recognize that if symptomatic treatment is required post-ST elevation MI then
the patient has post-infarct angina and thus an indication for urgent angiogra-
phy to prevent further myocardial loss.
Complications
Right ventricular infarction
Right ventricular (RV) infarction should be suspected in patients with:
• hypotension,
• clear lung ﬁelds,
• raised jugular venous pressure (JVP).
It can be conﬁrmed by echocardiography.
Inferior MIs complicated by RV infarctions have a poor prognosis with a 31%
in-hospital mortality rate. This is compared with a 6% mortality rate in those
without RV involvement [16]. Treatment of RV infarction includes:
• Maintenance of RV preload with IV ﬂuids.
• Avoidance of preload reducing medication such as nitrates and ACEI.
• Inotropic support of the dysfunctional right ventricle.
• Early thrombolysis or PCI.
Heart failure
Heart failure is common after MI. It should be treated with:
• ﬂuid restriction,
• nitrates,
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• IV diuretics,
• ACEI therapy,
• spironalactone/beta blockers.
A close eye should be kept on the patients’ blood pressure looking for signs of
cardiogenic shock. Regular blood samples should be sent for U&Es. The investi-
gation and treatment of heart failure is covered in Chapter 20.
Cardiogenic shock
Cardiogenic shock is a clinical state of hypoperfusion characterized by:
• systolic pressure 90 mmHg;
• central ﬁlling pressure 20 mmHg;
• cardiac index 1.8 l min1 m2.
Patients should be investigated with echocardiography to look for mechanical
complications that are treatable along with the presence of RV infarction that can
improve with ﬂuids. The use of inotropes should be considered.
Treatment with intra-aortic balloon pump (IABP) and angiography followed
by PCI or coronary artery bypass grafting (CABG) has been investigated as a pos-
sible treatment for cardiogenic shock in an attempt to revascularize ischaemic
and hibernating myocardium. Overall this was found to have a non-signiﬁcant
beneﬁt at 30 days but survival was signiﬁcantly improved at 6 months [17].
Free wall rupture
Sudden ventricular free wall rupture is almost invariably fatal. Subacute rupture
may occur resulting in rapid haemodynamic compromise and the presence of
pericardial tamponade on echocardiography. The need for pericardialcentesis is
urgent and if necessary deﬁnitive surgical treatment.
Ventricular septal rupture
A clinical deterioration in the patients’ condition with the development of a sys-
tolic murmur should raise the possibility of a ventricular septal defect (VSD). It
can be conﬁrmed by echocardiography and most patients will require urgent
surgical treatment.
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Mitral regurgitation
Mitral regurgitation commonly develops after MI and may be caused by:
• Ventricular dilatation leading to valve annular dilatation and resulting poor
coaptation of valve leaﬂets.
• Ischaemia driven mitral regurgitation.
• Papillae muscle rupture leading to pulmonary oedema and cardiogenic shock.
Echocardiography is mandatory and if rupture is conﬁrmed the placing of an
IABP followed by urgent surgery is required.
Aneurysm/pseudoaneurysm
Post-infarction a thinning of the LV free wall may result in a ventricular bulge or
true aneurysm. Alternatively a ventricular rupture may be sealed off by overlying,
adherent pericardium resulting in a pseudoaneurysm formation. Consideration
should be given to surgical resection of the aneurysm especially in symptomatic
patients with LV dysfunction.
Pericarditis
Inﬂammation of the pericardium can follow soon after MI. Alternatively 1–3
weeks post-MI patients may develop fever, pleuritis and pericarditis in the form
of Dresslers syndrome. Patients usually complain of sharp pleuritic pain that
may be relieved by sitting forward. A pericardial rub may be present and ECG
changes may be seen with concave or saddle-shaped ST segment elevation. Patients
should have an echocardiogram to look for pericardial ﬂuid, and treatment involves
non-steroidal anti-inﬂammatory drugs (NSAIDs) and rarely steroids.
Heart block
• First degree and Mobitz Type 1 (Wenekebach) requires no treatment post-MI.
Patients should be monitored.
• Patients with anterior infarction and Mobitz Type 2 require temporary cardiac
pacing as it often progresses to complete heart block (CHB). Otherwise Mobitz
Type 2 requires no immediate treatment.
• Patients with CHB should be temporary paced. The risk of asystole is signiﬁ-
cant, and permanent pacing is usually required.
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Temporary pacing
Temporary pacing can occur via:
• internal jugular,
• subclavian,
• femoral venous access.
Balloon ﬂotation devices can be extremely useful in an intensive care unit (ICU)
environment as ﬂuoroscopic control is not required and the patient need not
move from ICU. These devices are best inserted from the internal jugular or sub-
clavian route. Immediately post-thrombolysis venous cannulation of the internal
jugular or subclavian vein can result in bleeding complications so the femoral
route is usually advocated. Insertion of a temporary pacing wire can be a difﬁcult
procedure unless in skilled hands and the use of femoral access is usually the
easiest approach [18].
Dysrhythmias
Dysrhythmias are common post-MI and should be closely monitored.
Electrolytes should be optimized and the introduction of a beta blocker is usually
helpful. The use of IV magnesium has been shown to be beneﬁcial and if the
patient is haemodynamically compromised then they should be electrically car-
dioverted. The introduction of amiodarone can help to cardiovert patients and
suppress paroxysmal dysrhythmias.
Ectopics and runs of bigeminy are common immediately post-MI, but if they
become regular and more prolonged can be a poor prognostic sign. Ventricular
dysrhythmias should be investigated if necessary with angiography and revas-
cularization.
The National Institute for Clinical Evidence (NICE) has stated that the use of
implantable cardioverter deﬁbrillators (ICDs) should be routinely considered for
patients with a history of previous MI and all of the following [19]:
• Non-sustained ventricular tachycardia (VT) on Holter (24-h ECG) monitoring.
• Inducible VT on electrophysiological testing.
• LV dysfunction with an ejection fraction (EF) 35% and no worse than 
Class III of the New York Heart Association functional classiﬁcation of heart
failure.
ACS without ST elevation
The pathogenesis of ACS without ST elevation is similar to that of ST elevation
MI. An atherosclerotic plaque ruptures and causes reduced blood supply to a
coronary artery. Unlike ST elevation MI this occlusion is temporary or the artery
is subtotally occluded resulting in critical ischaemia and brief cell necrosis.
Clinical presentation
Clinical features are usually similar but less severe than ST elevation MI. Cardiac
chest pain and breathlessness are common but silent ischaemia, especially peri-
operatively, may occur. Symptoms may be worse on exertion.
Diagnosis and investigations
In patients presenting with cardiac symptoms the diagnosis is conﬁrmed by:
• Rise in biochemical enzymes above reference ranges.
• ECG changes with ST depression and/or T-wave changes.
Perioperatively symptoms may be lacking and diagnosis rests with enzymes and
ECG changes.
Patients should be thoroughly investigated and treated for secondary causes
of ischaemia including anaemia, fever, thyrotoxicosis, hypoxia, tachyarrhyth-
mias, aortic stenosis or sympathomimetic drugs.
Clinical management
The optimal clinical management of ACS has over the last 10 years seen a pro-
gression from purely symptomatic treatments alone to interventions designed to
alter prognosis.
Basic immediate management includes cardiac monitoring for dysrhythmias
and inhaled high ﬂow oxygen.
Routine bloods should be sent for:
• FBC;
• U&Es, glucose and lipids;
• most institutions measure troponin 12 h following the commencement of symp-
toms to optimize sensitivity.
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Antiplatelet therapy
Aspirin
• 300 mg stat.
• 75–150 mg daily lifelong.
Aspirin is the cornerstone of antiplatelet therapy in ACS. Studies shows clear
beneﬁt [20] with treatment for 3 months resulting in one less death or acute ST
elevation MI for 20 people treated:
Clopidogrel
• 300 mg stat.
• 75 mg daily for 9–12 months.
For those patients who are aspirin intolerant then clopidogrel is an alternative.
The Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE)
study showed clopidogrel to be at least as effective in preventing events as
aspirin with minimal extra side effects [21]. The additional beneﬁt of clopidogrel
on top of aspirin was studied in the Clopidogrel in Unstable angina to prevent
Recurrent Events (CURE) trial [22]. There was a 2.2% reduction in MI, stroke or
cardiovascular death but a 0.6% increase in major bleeding. There is only limited
data regarding its safety with GPIIb/IIIa inhibitors. Current ECS guidelines are
that it should be given acutely, continued for 9–12 months and then disconti-
nued as long-term effects are not known.
GPIIb/IIIa inhibitors
Activated GPIIb/IIIa receptors connect with ﬁbrinogen to form bridges between
activated platelets, leading to formation of platelet thrombin. The use of various
GPIIb/IIIa inhibitors has been investigated with randomized-controlled trails
(RCTs) and studies show a small but consistent beneﬁt [23]. Current NICE guide-
lines indicate that GPIIb/IIIa inhibitors should be used in high-risk patients [24].
Anticoagulation
There is convincing evidence that in aspirin treated patients anticoagulation with
low-molecular-weight heparin (LMWH) reduces rates of death, MI or recurrent
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ischaemia [25]. Choice of LMWH is dependent on hospital protocols and should
be continued for at least 2 days.
Symptomatic management
• Beta blockers: It can be given orally or IV and doses should be titrated to keep
the patients heart rate between 50 and 60 bpm.
• Calcium channel blockers: A useful adjunct in angina and if the patient is intoler-
ant to beta blockers, verapamil or diltiazem can help to control ventricular
rate.
• Nitrates: Given sublingually, orally or IV. Extremely useful in controlling 
symptoms.
• Nicorandil: A potassium channel opener given orally and useful for symptom-
atic relief.
These agents lower blood pressure, slow heart rate or depress LV contractility, and
hence reduce myocardial oxygen demand. Whilst all the drugs help to reduce
symptoms none have shown convincing prognostic beneﬁt.
Insulin treatment
There is currently no evidence that intensive insulin management alters progno-
sis in ACS without ST elevation. However, the DIGAMI study was published prior
to the advent of troponins and many institutions are adopting DIGAMI protocols
for patients with ACS without ST elevation.
Invasive versus conservative management
The beneﬁt of managing patients with ACS without ST elevation with a strategy
of early angiography and revascularization as opposed to symptomatic treat-
ment, and non-invasive risk stratiﬁcation has been fully investigated [26]. There
was a clear prognostic beneﬁt seen in patients in the invasive groups. Current
international guidelines [27] advocate predischarge angiography in patients with
chest pain and any of the following:
• raised troponin,
• ST depression,
• recurrent ischaemic pain.
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Within the UK this policy has yet to be fully adopted. Predischarge exercise toler-
ance tests are sometimes used to further risk stratify patients and identify high-
risk groups.
The recent National Service Framework and increased central funding for 
cardiac services are increasing resources and invasive management may soon be
the norm for all suitable patients.
Secondary prevention
As with ST elevation, MI secondary prevention measures include the introduc-
tion of beta blockers, statins, ACEI and free fatty acids. For full details refer to the
same section covered earlier in this chapter.
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Heart failure
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The prevalence of symptomatic heart failure in Europe is thought to be between
0.4% and 2.0% with the mean age being 74 years. Where the underlying problem
cannot be rectiﬁed the prognosis is poor with 50% of people dead within 4 years.
In patients with severe heart failure 50% will die within 1 year [1].
Acute versus chronic
Heart failure may be acute with a low cardiac output resulting in hypotension
with poor organ perfusion and/or pulmonary oedema. It may also be chronic
with output insufﬁcient to provide the optimal needs of metabolizing tissues
resulting in decreased tissue performance. The patient may complain of lethargy
or reduced exercise tolerance.
Systolic versus diastolic
Severe heart failure is usually due to poor myocardial contractility. However the
myocardium may inadequately relax resulting in reduced stretch of myocardial
ﬁlaments and decreased cardiac output. This is termed diastolic heart failure and
often occurs with systolic failure but may exist with the presence of a normal
ejection fraction.
Aetiology
The commonest cause of heart failure in the Western world is myocardial ischaemia
from coronary artery diseases. However potentially treatable and reversible aeti-
ologies should be considered.
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Cardiac
• Valvular dysfunction
• Arrhythmias
• Hypertension
• Pericardial disease.
Non-cardiac
• High-output states; anaemia, pregnancy and thyrotoxicosis
• Vitamin deﬁciencies
• Alcohol
• Autoimmune diseases
• Infections
• Drug toxicity (e.g. calcium channel blockers, beta blockers).
Acute heart failure
For some patients the presentation of acute heart failure may be an exacerbation
of a long running medical complaint, for others it may be a new ﬁnding.
Signs and symptoms
Patients present with symptoms of breathlessness, decreasing exercise tolerance
and orthopnoea. Signs include:
• Tachycardia
• Hypotension
• Peripheral oedema
• Raised jugular venous pressure (JVP)
• Displaced apex beat
• Third heart sound
• Crackles and cardiac wheeze.
Investigations
Routine blood should be requested in all patients with suspected heart failure
including:
• full blood count (FBC),
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• urea (U) and electrolytes (Es), liver function tests (LFTS),
• thyroid function tests (TFTs) glucose and lipids.
Unless there is a high index of suspicion of ischaemia then troponins should not
be requested as they have been shown to rise in pulmonary oedema. Other
investigations include:
• Electrocardiograph (ECG): Is usually abnormal with Q-waves, bundle branch
block or signs of new ischaemia (e.g. ST segment or T-wave changes).
• Chest X-ray: Cardiomegaly can be seen and in patients with acute pulmonary
oedema dilation of the upper lobe pulmonary veins, kerley B-lines and the
presence of interstitial oedema can be seen.
• Echocardiography: An echo is not usually required to make the diagnosis of
acute heart failure but once the patient is stable it can give an idea of progno-
sis and reveal important valvular pathology. If a mechanical cause (e.g. papil-
lary muscle rupture or new ventricular septal disease (VSD)) is suspected then
an urgent echo is required.
Clinical management
• Patients should be sat up and given high-ﬂow oxygen. If there is a suspicion of
chronic obstructive airways disease (COAD) then arterial blood gases should
be sent otherwise oxygen saturation provides adequate information to guide
treatment.
• 2.5–5 mg of diamorphine should be given. Diamorphine eases patient distress
and promotes venous vasodilatation so ofﬂoading the heart.
• 50–100 mg of intravenous furosemide or an equivalent dose of bumetanide
should be administered. They promote vasodilatation in a matter of minutes
and a later diuretic effect off-loads the heart.
• Venous vasodilators: Intravenous nitroglycerine may be given, starting with
0.25g /kg/min, and increasing every 5 min until a fall in blood pressure by
15 mmHg is observed or the systolic blood pressure falls to 90 mmHg.
• Correct any acute arrhythmia that may promote poor cardiac output.
• Most patients will improve quickly with aggressive diuretic and nitrate therapy
but a few will remain in pulmonary oedema. As treatment increases some may
become hypotensive precluding further drug increases. They should be con-
sidered for inotropes and mechanical ventilation.
• Patients with hypotension and pulmonary oedema have cardiogenic shock.
Inotropes should be considered along with the need for ventilatory support.
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• The use of non-invasive ventilation has been extensively studied in exacerba-
tions of chronic lung disease whereas only a few studies have looked at bene-
ﬁts in patients with cardiogenic pulmonary oedema. Three randomized
controlled trial (RCT) have compared continuous positive airway pressure
(CPAP) with standard medical therapy and found a decrease in need for endo-
tracheal intubation but no signiﬁcant mortality beneﬁt [2]. Bi-level non-
invasive positive pressure ventilation (NPPV) has not been compared with
standard treatment in a RCT. CPAP has been compared with bi-level NPPV in
one RCT [3]. NPPV was found to improve vital signs and ventilation more rap-
idly than CPAP but this was at the expense of a signiﬁcant increase in the num-
ber of myocardial infarctions. On this basis the trial was terminated early.
Currently it would seem sensible to offer CPAP to patients with severe pul-
monary oedema in an attempt to reduce the need for invasive ventilation.
• For some patients there is the need for invasive mechanical ventilation. Given
the poor prognosis for severe heart failure consideration should be given for
the potential for improved function prior to intubation.
• For some patients who are not deemed suitable for mechanical ventilation the
presentation may represent a terminal event. The use of diamorphine, an anti-
emetic and midazolam should be considered to aide distress.
Surgical treatment
A minority of patients present with acute heart failure secondary to a sudden
mechanical complication usually post-myocardial infarction. Papillae muscle
rupture or a new VSD is a potentially curable medical emergency requiring
urgent surgery.
Ventricular assist devices are mechanical pumps that take over the function of
the damaged ventricle. They are used in patients with myocardial infarction,
acute myocarditis or end-stage heart disease who are not expected to recover
adequate cardiac function and who require mechanical support as a bridge to
transplantation.
Chronic heart failure
Chronic heart failure is common and often goes undiagnosed. Its prognosis is
signiﬁcant and the recent NICE guidelines go some way to raise the proﬁle of a
much neglected disease group [4].
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Signs and symptoms
Patients present with a heterogeneous range of symptoms depending on the
severity of disease and current medication use.
Breathlessness, fatigue and decreased exercise tolerance are common whilst
some patients may have variable signs of acute left ventricular (LV) failure or in
some cases minimal clinical signs.
Investigations
Routine blood including FBC, U and Es, LFTS, TFTs glucose and lipids should be
requested in all patients with suspected heart failure.
• Consider a chest X-ray, serial peak ﬂows and pulmonary function tests in
patients with sign or symptoms compatible with asthma or COAD.
• ECG: A 12-lead ECG should be requested in all patients. A normal ECG has a
high negative predictive value for heart failure.
• B-type natriuretic peptide (BNP): Several clinical and epidemiological studies
have related decreasing cardiac, usually LV function with increasing plasma
natriuretic peptide concentrations raising the possibility of a diagnostic “blood
test” for heart failure. BNP is the most sensitive test and has a strong negative
predictive value [5].
• Echocardiography: For patients with a positive BNP or abnormal ECG,
echocardiography is the diagnostic tool of choice to diagnose heart failure. A
normal BNP and ECG should point the physician to an alternative diagnosis.
Clinical management
The therapeutic approach to chronic heart failure centres on improving symptom
status in the short term, and introducing medication to promote cardiac remodel-
ling and hence long-term sustained improvement. There are three approaches:
(1) Non-pharmacological measures.
(2) Pharmacological therapy.
(3) Devices and surgery.
Non-pharmacological management
Patients and their families require counselling and advice. Recent NICE guidelines
suggest this should be in a specialist setting if the disease is severe. If overweight
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the patient should be actively encouraged to loose weight and in patients with
advanced heart failure ﬂuid and salt intake should be restricted. Exercise should
be encouraged and exercise training programmes have been shown to improve
symptoms and quality of life.
Pharmacology
Angiotensin converting enzyme inhibitors
The use of angiotensin converting enzyme (ACE) inhibitors in patients with both
symptomatic and asymptomatic LV dysfunction has been standard practice in
the UK and abroad since the publication of a numbers of RCT showing clear
mortality and morbidity beneﬁt [6]. However, the indications for ACE inhibitor
therapy have widened dramatically over the last few years with the publication of
recent trials, which showed long-term beneﬁts in high-risk patients with normal
LV function [7].
ACE inhibitors should be used with caution in patients with renal vascular
disease, a creatinine greater than 250 and a systolic blood pressure 100 mmHg.
Potassium should be monitored along with U&Es at regular intervals. The most
common side effect is a dry irritating cough. If not tolerated an ACE inhibitor
may be substituted with an angiotensin 2 blocker.
ACE inhibitors should be titrated up to the maximal amount tolerated by the
patient.
Angiotensin 2 blockers
A small group of patients are unable to tolerate ACE inhibitors, usually because
of a dry irritating cough. For these people the addition of an angiotensin 2
blocker in place of an ACE inhibitor has been shown to improve morbidity and
mortality but not to the same extent as ACE inhibitors [8]. Current interest sur-
rounds the addition of an angiotensin 2 blocker to established ACE inhibitor
therapy. Results from RCTs have been mixed to date.
Diuretics
For patients who are ﬂuid overloaded the immediate concern is for the addition
of a diuretic and a ﬂuid restricted diet. Patients are generally treated with a loop
diuretic as they are stronger than thiazides but doses should be kept at a minimum.
294 R. Beynon and D.H. Roberts
Blood pressure and renal function should be regularly monitored. A potassium
sparing diuretic can often be added to aid diuresis and keep electrolytes within
acceptable limits. Diuretics were introduced prior to the use of RCT and as a
result there are no large prospective trials showing beneﬁt.
Beta blockers
There is good evidence from a number of RCTs that the use of beta blockers in
patients with chronic heart failure increases life expectancy and reduces hospi-
talizations [9]. Not all beta blockers are licensed in the UK for heart failure and
current evidence suggest that carvedilol or bisoprolol should be used. A low dose
should be used at the start and the dose doubled not less than at 2 weekly inter-
vals. Aim for highest dose tolerated keeping heart rate 50 bpm.
Aldosterone antagonists
The use of spironalactone in patients with moderate to severe heart failure (NYHA 3
or 4) was found to increase life expectancy and reduce hospitalizations in the RALES
study [10]. Patients should be given 25 mg and potassium and creatinine should be
monitored regularly. The mechanism of action is not thought to be diuretic induced
but involves the inhibition of aldosterone and hence a reduction in vascular ﬁbro-
sis, decreased sympathetic activation and increased parasympathetic tone.
Digoxin
Digoxin has been shown to have positive inotropic effects but this has not been
consistently borne out in large-scale randomized trials [11]. There are no pub-
lished data in patients in sinus rhythm to suggest it improves quality of life,
symptoms or life expectancy. There has been some evidence to show reduced
hospitalizations. Its use should be restricted to patients with severe heart failure
of those in atrial ﬁbrillation.
Anticoagulation
In patients with a dilated poorly functioning LV there is a theoretical risk of
intracardiac thrombus formation and thromboembolism. There is however no
convincing evidence of beneﬁt with the use of oral, intravenous or subcutaneous
anticoagulation unless the patient is in atrial ﬁbrillation.
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Devices and surgery
Revascularization
The major cause of heart failure in the Western world is occlusive coronary artery
disease. For some patients the presence of a critically narrowed stenosis can
result in impaired myocardial function that would improve if the blood supply is
restored to normal. These areas of myocardium are “hibernating”. Dobutamine
stress echocardiography and nuclear perfusion scanning can both be used to
look for areas of hibernation that may improve with revascularization.
Resynchronization therapy
Thirty percent of patients with severe heart failure have evidence of intraventric-
ular conduction disturbances manifest by bundle branch block on a surface 
12-lead ECG with QRS duration being longer than 120 ms. The result can often be
asynchronous contraction of the LV free wall, right ventricle and intraventricular
septum with resulting impaired cardiac output. The use of a biventricular pace-
maker with leads pacing the right atrium, right ventricular and left ventricle via
the coronary sinus has been shown to resynchronize contraction and improve
cardiac output and exercise tolerance.
Heart transplantation
Cardiac transplantation offers hope to patients with severe end-stage heart fail-
ure and has been shown to increase survival, quality of life and exercise capacity.
Five-year survival approaches 70% but morbidity can be signiﬁcant with the
intense immunosuppression needed.
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Arrhythmias
S. Vaughan
Cardiac arrhythmias are common in the critically ill. This chapter will give an
overview of the prevalence, aetiology, therapy and impact of cardiac arrhythmias
in the intensive care unit (ICU).
Amiodarone is a drug increasingly being used to treat arrhythmias within the
ICU, but it is not without hazard. Amiodarone will be discussed but there is no
scope in this chapter for in-depth discussion of the other anti-arrhythmic agents.
Prevalence of arrhythmias in ICU
Some of the early work on the prevalence of arrhythmias in ICU came from South
America [1]. Artucio and co-workers looked at over 2800 patients admitted to
their ICU over a 12-year period between 1971 and 1983. They found:
• An overall prevalence of cardiac arrhythmia of 78%.
• Atrial tachyarrhythmias were the commonest arrhythmia (28%) followed by
ventricular tachyarrhythmias (22%).
• Atrial ﬁbrillation (AF) and atrial ﬂutter accounted for 52% and 27% of the atrial
tachyarrhythmias, respectively.
• Ventricular tachycardia accounted for 43% of the ventricular tachyarrhythmia
which was only exceeded by ventricular premature beats (VPB) (56%).
The surprisingly high prevalence of arrhythmias in this study can be explained
by the patient population and study design. The data was collected from medical
ICU (that included post-cardiac surgery patients); a very high proportion of
patients had been admitted with cardiac (63%) and respiratory (12%) disease. Not
surprisingly subgroup analysis revealed the highest prevalence of arrhythmias in
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these groups. Moreover, arrhythmia diagnosis was all inclusive; in that sinus
bradycardia, sinus arrhythmia, atrial and VPB as well as bundle branch block were
included, and increased the prevalence of recorded arrhythmias.
More recent studies from mixed ICU or surgical high dependency units (SHDU)
are more representative of the patient case mix seen within the UK.
• Bender found that 14% of post-operative surgical patients developed a supra-
ventricular tachyarrhythmia [2].
• Batra and colleagues also found that 13% of patients on a SHDU developed an
arrhythmia of which AF was the commonest [3].
• Reinhelt and co-workers found that nearly 20% of their patients on a mixed
ICU developed an arrhythmia of which the majority were ventricular in origin [4].
They also showed that the majority of arrhythmias occurred in those patients
with cardiac disease or who had undergone cardiac surgery.
In summary, the prevalence of cardiac arrhythmia within the ICU population is
between 0% and 20%.
Aetiology [5, 6]
Arrhythmias can be broadly classiﬁed into:
• Disorders of conduction: heart block.
• Disorders of impulse formation (rate or site): bradycardias and tachycardias.
There are three basic electrophysiological mechanisms for disordered conduction
and abnormal impulse formation which themselves result from the “recognised”
causes of arrhythmias.
The “recognised” causes of arrhythmias are:
Congenital (prolonged Q–T interval)
Jervall–Lange–Neilsen disease (autosomal recessive and associated with deaf-
ness) and Romano–Ward syndrome (autosomal dominant).
Myocardial ischaemia
This is probably the commonest cause of arrhythmia outside of the ICU. However,
patients may be admitted to the ICU with acute coronary syndromes, have
298 S. Vaughan
chronic myocardial ischaemia as a co-morbidity or even suffer a myocardial
infarction whilst on the ICU. Moreover, it has been shown that cardiac troponin I
(cTnI) is elevated in critically ill patients and that higher levels are seen in those
who have ECG evidence of ischaemia, tachycardia, arrhythmia, hypotension and
inotrope therapy. This suggests that critical illness and/or therapy on ICU causes
myocardial damage [7].
Electrolyte imbalance
Changes in K, Mg2 and Ca2 are all linked to arrhythmia generation. Hypo-
kalaemia and hypomagnesaemia frequently co-exist as they are both lost through
the kidney and gut. Calcium deﬁciency rarely causes clinical problems whilst the
main effect of hypokalaemia and hypomagnesaemia is to prolong the Q–T inter-
val (see below). Conversely the effect of hyperkalemia and hypercalcaemia is to
shorten the Q–T interval. Hypermagnesaemia is iatrogenic and aside from ﬁrst
degree heart block, will be asymptomatic.
Hypoxia and hypercarbia
Arrhythmia genesis is from associated myocardial ischaemia and pH-induced
electrolyte disturbance.
Drugs
Drugs which prolong the Q–T interval are pro-arrhythmogenic. Drugs with such
actions include:
• phenothiazine,
• tricyclic antidepressants,
• antihistamine,
• pentamidine,
• cisapride (now withdrawn from use in the UK),
• erythromycin the latter which has been implicated in fatal ventricular ﬁbrilla-
tion if given by rapid intravenous infusion [8].
The other major class of drugs that can initiate cardiac arrhythmias are the anti-
arrhythmic agents themselves [9].
• Class Ia (quinidine, procainamide and disopyramide) and Class III (amiodarone
and sotalol) drugs in the Vaughan–Williams classiﬁcation. Like the drugs listed
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above, these drugs pro-arrhythmic action seems to be due to prolongation of
Q–T interval.
• Flecanide, a Class Ic drug which shortens the action potential, should not be
used in those patients with acute coronary syndromes as they have been shown
to increase mortality from arrhythmia [10].
• Digoxin, which inhibits the Na–K ATPase pump results in a rise in intracellu-
lar calcium as Na is exchanged for Ca2. Raised intracellular Ca2 is the mech-
anism for arrhythmias generation (see below).
It should be noted that all anti-arrhythmic agents have the potential to generate
arrhythmias by local changes in cardiac muscle physiology.
ICU speciﬁc conditions
There are a few conditions that may provoke arrhythmias that are almost exclusive
to the ICU environment.
• Central venous cannulation has been shown to produce arrhythmias in nearly
one-third of all insertions, a rate reduced to 5% when the guidewire was inser-
ted to only 20 cm at the skin [11]. The incidence of arrhythmia during Hickman
line insertion was reported to be 14% [12].
• High-frequency oscillation (HFO) is a technique well established in paediatric
ICU and is now increasingly used in adult ICU. This may be associated with
severe bradycardia, particularly in the recovery phase when the lung compli-
ance improves. This is thought to be due to excessive stimulation of the pul-
monary stretch receptors and responds well to conversion to conventional
ventilation [13].
• Therapy with inotropes (1 agonists) and phosphodiesterase inhibitors (increase
intracellular cAMP), acid–base disturbance and raised intracranial pressure can
all lead to arrhythmias.
The electrophysiological aetiology of arrhythmias
To discuss the electrophysiological basis of arrhythmias, one ﬁrst needs to 
re-consider the cardiac muscle action potential.
• Phase 0 is the rapid depolarisation of the myocardial cell membrane caused by
opening of fast Na channels and Na inﬂux into the cell.
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• Phase 1 is the initial repolarisation of the membrane from the closure of the
fast Na channels and the action of the Na–K ATPase pump removing Na
from the cell in exchange for K.
• Phase 2 is the plateau phase caused by the opening of slow Ca2 and slow Na
channels resulting in inﬂux of Na and Ca2 and hence delaying repolarisation.
• Phase 3 is the closure of the slow Ca2 and Na channels and restoration of the
resting membrane potential by the action of the Na–K ATPase pump.
• Phase 4 only occurs in conducting cardiac tissue and is spontaneous depolar-
isation of the myocyte cell membrane from opening of slow Ca2 and Na
channels.
There are three electrophysiological mechanisms for arrhythmia generation:
(1) Re-entry
This is the commonest cause of arrhythmia formation. In essence a wave of
excitability spreads down one pathway whilst being “blocked” in another
then to return to the original pathway via the “blocked” pathway to set up a
circle of activity. It requires three pre-conditions:
– two pathways separated by non-conducting tissue;
– differing conduction speeds in the pathways;
– differing refractory periods in the pathways.
It follows that the fastest pathway must have the longer refractory period to
enable a circle of electrical activity!
Myocardial ischaemia is the main cause of re-entry arrhythmias as it will result
in non-conducting tissue surrounded by conducting tissue of varying quality
although electrolyte disturbances can generate the same pre-conditions. Some
patients may not have all of the pre-conditions but develop an arrhythmia when
a second insult provides the other pre-conditions for re-entry arrhythmias.
(2) Abnormal automaticity
This is when spontaneous phase 4 depolarisation occurs in non-conducting or
pacemaker myocytes. This commonly results from ischaemia but can also result
from metabolic derangement, hypokalaemia, drugs and sympathomimetic
agents.
(3) Triggered activity
This refers to abnormal depolarisations that occur in the plateau phase of the
cardiac action potential. There are two types; early after depolarisations (EAD)
and delayed after depolarisations (DAD).
– EAD result from delayed closure of the slow Ca2 and Na channels and, 
if of sufﬁcient amplitude, may trigger an abnormal impulse. The formation
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of EAD is favoured by conditions, which prolong the Q–T interval such as
bradycardia, drugs, hypokalaemia and congenital conditions (see above).
The presence of EAD is strongly associated with genesis of torsade de
pointes ventricular tachycardia.
– DAD result from raised intracellular Ca2 levels of which the classic 
example is digoxin (see above), but they can also be generated by
ischaemia, catecholamines and tachycardia.
Treatment of arrhythmias [9, 14, 15]
The basic treatment aims of arrhythmia management are:
• To restore sinus rhythm and hence optimise cardiac ﬁlling and cardiac output.
• To control rate improve the balance between myocardial oxygen consumption
and myocardial oxygen delivery.
• To treat complications, namely thrombo-embolic phenomena.
On the ICU, restoration of sinus rhythm and rate control will have a greater sig-
niﬁcance than prevention of complications, but these should not be ignored.
A few simple rules are presented to help as an aide memoir for treating an
arrhythmia developing in an ICU patient. In a perverse way, although the critical
illness and its treatment predispose to cardiac arrhythmias, the ICU actually
provides an ideal environment in which to treat arrhythmias as one will have a
(usually) sedated, ventilated and fully monitored patient!
(1) Treat the patient and not the monitor!
The degree of haemodynamic disturbance will determine the urgency of 
therapy. It is obvious that hypotension, evidence of ischaemia on the ECG or 
cardiac monitor and signs of cardiac failure require urgent intervention and
treatment of the rhythm disturbance.
(2) Rapid identiﬁcation and treatment of as many potential contributing factors
as possible.
– Make sure the K is at least 4.5 mmol/l or higher as a higher K concen-
tration will shorten the action potential and lessen the risk of triggered
arrhythmias.
– Correct magnesium deﬁciency, particularly if there is co-existing hypo-
kalaemia. The plasma level of Mg2 should be at least 1.0 mmol/l and per-
haps be between 1.4 and 2.0 mmol/l as levels within this range have been
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shown to be superior to direct current (DC) cardioversion in the termina-
tion of atrial tachyarrhythmias [16].
– Correct hypoxia, hypercarbia and acidosis as the patient’s clinical condition
allows.
(3) If the patient is pulseless treat according to current ACLS guidelines [15]. See
also Chapter 30.
(4) If the patient has a palpable pulse, then treatment should be based upon the
UK Resuscitation Council peri-arrest algorithms [15].
The reader is strongly advised to acquaint themselves with the algorithms.
The algorithms are extensive and cover the management of bradycardia, broad
and narrow complex tachycardia and AF. However there are some important
points to note from the algorithms:
• Magnesium is only included in the broad complex tachycardia algorithm. There
is evidence that magnesium will convert atrial tachycardia to sinus rhythm [16]
and so the author believes that magnesium should be administered for all
types of arrhythmia. A suitable initial dose would be 8 mmols over 10–15 min.
• Except for the broad complex arrhythmia, Class Ia drugs (quinidine, pro-
cainamide and disopyramide) are not used because they have been shown to
increase the mortality in the treatment of AF [9].
• Class Ib (lidocaine and mexilitine) drugs are only recommended in broad complex
tachycardia. Class Ib agents are only effective for ventricular arrhythmias [9] and
hence are included should the broad complex rhythm be ventricular in origin.
• Class Ic (ﬂecainide) agents should only be used in the absence of coronary
artery disease [10].
• Class II drugs (-blocking agents) should not be used in conjunction with Class
IV agents (calcium antagonists) as this may precipitate complete heart block.
• There is no algorithm or mention made of extrasystoles and whether these
should be treated despite the fact that both atrial premature beats (APB) and
VPB may herald a more sustained arrhythmia. The CAST trial showed that VPB
should not be treated after a myocardial infarction as mortality was increased
[10] and so it is difﬁcult to recommend therapy for VPB beyond correcting elec-
trolyte abnormalities, acidosis and hypoxia. Digoxin may be considered for
APB occurring in a background of ischaemic or valvular heart disease.
• Amiodarone appears in the ACLS and all the peri-arrest algorithms (except
bradycardia). Amiodarone is a drug that is being increasingly used in the crit-
ical care setting and is discussed in more depth below.
Arrhythmias 303
• DC Cardioversion is safe: The ICU patient is the “ideal” patient for cardioversion.
Although the peri-arrest algorithms state that electrical therapy is for the unstable/
symptomatic patient, the author believes that if medical cardioversion of the
arrhythmia is considered then D.C. cardioversion should be considered too.
Amiodarone [17]
Amiodarone is rapidly achieving the status of ﬁrst line anti-arrhythmic agent in
the ICU. Its use, though, is not without signiﬁcant risk to the patient.
Pharmacokinetics
Amiodarone is a lipid-soluble drug and therefore has:
• high degree of plasma protein binding (96%),
• a large volume of distribution (1–65 l/kg),
• a mean half-life of 52 days (16–180 days),
• a single dose intravenous dose has a half-life of 18–36 h.
Amiodarone undergoes hepatic metabolism with production of a weak active
metabolite, desethylamiodarone. Metabolites are excreted via the biliary system
rather than the kidneys and so amiodarone is safe in renal failure. There is very
little accumulation of active metabolite even after days of infusion. Extensive
hepatic metabolism means that the oral bioavailability is low (30–50%).
The usual dosing regimen is:
• a loading dose of 5 mg/kg over 1 h but can be given over 3 min in an emergency,
followed by
– 15 mg/kg in the ﬁrst 24 h reducing to
– 11 mg/kg on day 2 reducing to
– 7.5 mg/kg on day 3 until a total of 15 g is given and then
– a maintenance dose of 200 mg/day.
Pharmacodynamics
• Although appearing as a Class III agent in the Vaughan–Williams classiﬁcation,
amiodarone is unique as it possesses Class I–IV actions. It is therefore useful in
the termination of AF, supraventricular and ventricular tachycardias. However,
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when given intravenously it main effect is  blockade (Class II) with decreased
conduction across the atrio-ventricular (A-V) node and an increased A-V node
refractory period.
• Although negatively inotropic it is the least cardiac depressant of the anti-
arrhythmic agents. A reduction in cardiac afterload compensates for the nega-
tive inotropicity such that cardiac output is unchanged or even increased.
• Heart rate and mean arterial blood pressure are unchanged or minimally
reduced.
• A most important and under recognised effect of amiodarone is direct coron-
ary vasodilatation.
Drug interactions
Amiodarone will:
• Prolong the Q–T interval if given with other drugs that prolong the Q–T interval.
• Result in a bradycardia or heart block if given with Class II or IV drugs.
• Increase plasma levels of digoxin.
• Reduce warfarin metabolism.
Side effects
• Cardiovascular: Amiodarone will prolong the Q–T interval predisposing to
arrhythmias. It may give rise to heart block, bradycardias and hypotension.
• Pulmonary: It is well known that amiodarone causes chronic pulmonary ﬁbro-
sis. More recently a more serious acute pulmonary toxicity has been described
[18, 19]. The incidence is between 5% and 10% of all those treated and it usually
occurs within the ﬁrst few day or weeks of treatment. Signs and symptoms are
fairly non-speciﬁc with a fever, cough, pleuritic chest pain with a pleural rub and
crackles on chest auscultation. There may be a raised white cell count, erythro-
cyte sedimentation rate (ESR) and lactate dehydrogenase (LDH) and a chest
radiograph may reveal diffuse ﬁne reticulo-nodular shadowing. Diagnosis may
well be very difﬁcult on the ICU as most of the signs and ﬁndings can be found
from other commoner causes, such as a ventilator associated pneumonia, so 
a high index of suspicion is needed for the diagnosis. Broncho-alveolar lavage
will reveal foamy macrophages. Another interesting ﬁnding is that acute pul-
monary toxicity may be related to high-inspired oxygen concentrations (50%)
[20]. Treatment is supportive with cessation of amiodarone whilst some have
suggested the use of corticosteroids. Acute pulmonary toxicity may be fatal.
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• Other organ systems: Amiodarone can cause damage in the eyes, liver, thyroid
gland, skin and peripheral nerves.
Impact of arrhythmias in ICU
It is easy to focus on the immediate problems that arrhythmias can cause, such
as hypotension, but to lose sight of the overall impact that the development of a
new arrhythmia will have on an ICU patient. Two studies [2, 21] have shown that
the onset of new atrial arrhythmias in the critically ill is associated with:
• a greatly increased mortality rate,
• an increase ICU length of stay,
• an increased hospital length of stay.
In both these studies the excess mortality was not directly related to the cardiac
rhythm disturbance. The excess mortality seen in those with arrhythmias is also
borne out in subgroup analysis of Artucio’s work [1]. In all the patient groups,
those with an arrhythmia had a higher mortality, for example although septic
patients made up only 7% of the total admissions, those with an arrhythmia had
a mortality rate of 70% compared to 50% without an arrhythmia (relative risk
reduction, RRD 1.5).
Another very important ﬁnding is that the onset of a new arrhythmia can herald
or be co-incident with the onset of new sepsis [2]. Therefore amongst the inves-
tigations of a new arrhythmia, one must consider a new focus of infection, par-
ticularly of central venous catheters or of pulmonary or intra-abdominal sites.
Summary
• Arrhythmias are common (up to 20%) and the commonest type are atrial 
tachyarrhythmias.
• Arrhythmias are caused by myocardial ischaemia, electrolyte imbalance, drugs,
acid–base disturbance, inotropic therapy and hypoxia. Always think of new
sepsis with the onset of an arrhythmia.
• Hypokalaemia and hypomagnesaemia frequently co-exist.
• Correct any identiﬁed contributing factors.
• Magnesium should be given even if levels are “normal” and the K should be 
at least 4.5 mmol/l.
• Electricity is safe; anti-arrhythmics agents cause arrhythmias!
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• Use amiodarone cautiously particularly if the patient is receiving high-oxygen
concentrations (50%) and limit it use to 24–48 h as most arrhythmias will not
be sustained, particularly if contributing factors have been corrected.
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The patient with sepsis
R. Markham
Sepsis is the leading cause of multiple organ failure and the most common cause
of mortality in the intensive care unit (ICU): in the ﬁrst 24 h of intensive care
admission, 21.7% of patients in England, Wales and Northern Ireland fulﬁl the
criteria for severe sepsis [1]. Of these, 35% die on ICU and a further 12% die
before discharge from hospital. In the USA, sepsis is responsible for as many
deaths as acute myocardial infarction [2].
The mortality of septic shock varies from 40% to 80%.
Deﬁnitions
In 1992, the American College of Chest Physicians (ACCP) and the Society of Critical
Care Medicine (SCCM) proposed deﬁnitions of sepsis which were re-validated at
a 2001 consensus conference [3]:
• Sepsis: A clinical syndrome deﬁned by the presence of infection and a systemic
inﬂammatory response.
• Infection: A pathological process caused by the invasion of normally sterile 
tissue, ﬂuid or body cavity by pathogenic microorganisms.
• Systemic Inﬂammatory Response Syndrome (SIRS): Two or more of the following:
– temperature 38°C or 36°C,
– heart rate 90 beats/min,
– respiratory rate 20 breaths/min or PaCO2 4.3 kPa,
– white cell count (WCC) 12,000 or 4000 or 10% immature band forms.
• Severe sepsis: Sepsis associated with organ dysfunction, hypoperfusion or
hypotension (but not requiring inotropes or vasopressors).
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• Septic shock: Acute circulatory failure in the presence of sepsis. This is deﬁned
as sepsis with hypotension despite adequate ﬂuid resuscitation.
SIRS may be triggered by localised or generalised infection, trauma, burns or
sterile inﬂammatory processes (e.g. acute pancreatitis).
SIRS emphasises that the host response to infection and non-infectious stimuli
is the same and that the severity of the response determines the outcome.
However, the SIRS criteria are non-speciﬁc and are widely considered to be over-
sensitive (more than two-thirds of ICU patients meet SIRS criteria) [4]; but until
further immunologic and biochemical markers of sepsis have been identiﬁed, and
more appropriate deﬁnitions introduced, it remains an important concept [5].
PIRO: a staging system for sepsis
A staging system was proposed by the consensus conference to stratify patients by
baseline risk and potential to respond to therapy. It is based on the concept of the
tumour, necrosis and metastasis (TNM) system for classifying malignant tumours:
• P: Predisposition. Premorbid factors such as illness or genetic predisposition
may inﬂuence both incidence and outcome of sepsis.
• I: Insult. Site, type and extent of infection.
• R: Response. Nature and magnitude of the host response.
• O: Organ dysfunction. The number or severity of failing organs.
At present, the PIRO system has not been validated and remains an experimental
concept.
Pathophysiology
Bacterial infection [6, 7]
• Previously, Gram-negative infections (especially Escherichia coli, Klebsiella
species and Pseudomonas aeruginosa) were the most common cause of severe
sepsis, however Gram-positive infections (particularly staphylococci and
streptococci) have increased and now account for about half of all cases. Fungi,
mainly Candida are responsible for about 5% of cases of severe sepsis.
• Invading microorganisms are detected by pattern recognition receptors on the
surface of innate immune cells called toll-like receptors (TLRs), which activate
intracellular signalling pathways to initiate the inﬂammatory response. 
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Gram-negative and Gram-positive infections are mediated via different recep-
tors: endotoxin (lipopolysaccharide) requires TLR4 to activate the immune
response, whilst TLR2 is involved in the recognition of cell wall components 
of Gram-positive bacteria such as peptidoglycan and lipoproteins.
• Clinical manifestations of different bacterial infections vary due to differential
expression and release of inﬂammatory mediators. Hence streptococcal toxic
shock syndrome produces a very different clinical picture to meningococ-
caemia. This suggests speciﬁc host responses for each pathogen.
Inﬂammatory and procoagulant response [8]
• Infection results in monocyte and macrophage activation with consequent
platelet activation and aggregation, and the release of inﬂammatory cytokines;
particularly interleukin (IL)-1, IL-6 and tumour necrosis factor  (TNF-).
• Cytokines are newly synthesised and released in response to inﬂammatory
stimuli, and have synergistic, overlapping and antagonistic effects.
• Inﬂammatory cytokines stimulate the release of tissue factor from the
endothelium, which activates the coagulation cascade resulting in the forma-
tion of thrombin and a ﬁbrin clot.
• Thrombin is itself pro-inﬂammatory via multiple pathways including platelet
activation and mast cell degranulation. It also impairs ﬁbrinolysis by release of
plasminogen-activator inhibitor-1 (PAI-1) from platelets and endothelium. PAI-1
inhibits the endogenous ﬁbrinolytic pathway, tissue plasminogen activator.
• Activated protein C levels are reduced. The conversion of protein C to serine
activated protein C occurs on the endothelium and requires thrombin bound
to thrombomodulin. Endothelial injury results in reduced thrombomodulin
levels. Activated protein C is an endogenous protein that promotes ﬁbrinolysis
by inhibiting PAI-1; it is anti-thrombogenic by inhibiting factors Va and VIIIa
and hence thrombin production; and it is anti-inﬂammatory, possibly by
inhibiting cytokine production.
• The end result is diffuse endothelial injury and microvascular thrombosis
leading to organ ischaemia, multi-organ dysfunction and, eventually, death.
Cell apoptosis may contribute to this effect.
Myocardial depression [9]
• Myocardial depression occurs due to a circulating myocardial depressant fac-
tor, with reduced left and right ventricular contractility.
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• Initially, tachycardia and increased left ventricular (LV) compliance (by ven-
tricular dilatation and increased preload), together with reduced systemic 
vascular resistance, attempt to compensate for this impaired contractility.
However, cardiac output remains low to normal.
• Eventually, aggressive ﬂuid resuscitation may compensate for these changes
and adequate left ventricular preload is re-established, producing a high car-
diac output, low systemic vascular resistance state.
• However, up to a third of patients with septic shock remain with a low cardiac
output shock [10]. Such patients typically have bacterial peritonitis and this
may reﬂect overwhelming myocardial depression especially in patients with
pre-existing cardiac disease.
• A recent important study demonstrated signiﬁcant increase in cardiac Troponin
I levels in patients with septic shock [11] implying signiﬁcant myocardial cell
damage. (This is despite, in general, evidence of well-maintained coronary
blood ﬂow in septic shock.) Serum troponin levels tended to be lower in sur-
vivors than in non-survivors and tended to be higher in patients on large doses
of inotropes and vasopressors. This study raises serious questions, at present
unresolved:
– Is the reduction in cardiac function and cardiac dilatation in septic shock
related to myocardial depression or myocardial injury, or both?
– Is the use of inotropes and vasopressors necessary because of the myocardial
injury or a cause of myocardial injury by increasing myocardial oxygen
requirements?
Vasodilatation
• Nitric oxide (NO) is released from the endothelium in response to cytokine
stimulation and results in profound vasodilatation. NO is synthesised from the
amino acid arginine by the action of NO synthase.
• In severe cases the vasculature can lose its responsiveness to vasopressors.
Capillary leak (relative hypovolaemia)
• The endothelial damage leads to neutrophil adhesion, activation and degranu-
lation with release of oxygen-free radicals and proteases causing further 
injury.
• The endothelial damage results in increased vascular wall permeability and
peripheral oedema.
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• This hypovolaemia is in addition to surgical “third space losses”: ﬂuid and blood
loss in surgical sepsis and peritonitis.
Distributive shock [9]
• Hypoperfusion occurs despite a normal or increased cardiac output due to
maldistribution of blood ﬂow. Splanchnic blood ﬂow is reduced and micro-
vascular shunting occurs.
Reduction in oxygen utilisation
• Oxygen consumption, VO2 is reduced with evidence of tissue hypoxia such as
elevated serum lactate, often despite well-maintained cardiac output and oxy-
gen delivery, DO2. This may be due to changes at the cellular level by cytokine
or NO induced mitochondrial inhibition, as well as maldistribution of ﬂow.
Metabolic changes
• Endotoxin and cytokines stimulate metabolic changes including protein
catabolism and pancreatic secretion of glucagon and insulin. This induces a
sequential progressive inability to use glucose, fat, then amino acids and
energy sources.
• Mitochondrial dysfunction may be present. This is expressed initially periph-
erally in the muscles and results in an increase in anaerobic metabolism and
gluconeogenesis.
• If prolonged this peripheral defect may result in central organ changes ulti-
mately culminating in multi-organ failure.
Diagnosis of sepsis
The diagnosis of sepsis is made on clinical or laboratory ﬁndings in the setting 
of conﬁrmed or suspected infection. At least two blood cultures should be
obtained; both peripherally and from each vascular access device. Cultures of
other sites such as urine, cerebrospinal ﬂuid and respiratory secretions should
be obtained if clinically indicated. Imaging is important to determine the source
of infection, for example ultrasound in suspected intra-abdominal collection.
Other occult sources of sepsis must be considered including otitis media and
sinusitis, as well as intravascular catheters.
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The consensus conference in 2001 [3] agreed the following list of symptoms
and signs of sepsis, however it must be noted that none are speciﬁc to sepsis:
Generalised symptoms:
• Fever
• Hypothermia
• Tachycardia
• Tachypnoea
• Altered mental status
• Hypotension
• High cardiac output
• Raised mixed venous oxygen saturation (SvO2 70%) reduced in shock
• Slow capillary reﬁll/mottling.
Signs of organ dysfunction:
• Hypoxia
• Oliguria
• Coagulopathy
• Thrombocytopenia
• Hyperbilirubinaemia
• Ileus
• Hyperglycaemia.
Laboratory signs:
• Leucocytosis or leucopenia
• Plasma C-reactive protein 2 standard deviations above normal range
• Plasma procalcitonin 2 standard deviations above normal range
• Hyperlactatemia.
Therapy of sepsis and septic shock
Prevention
• Follow guidelines in Chapter 13.
• Prophylactic antibiotics for certain surgical procedures are appropriate.
Eradicate the infection
• Prompt administration of antibiotic therapy should commence after appropriate
cultures have been obtained. In severe sepsis or septic shock, broad spectrum
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antibiotic therapy is warranted until the causative organism and its sensitiv-
ities have been identiﬁed.
• Surgical collections and foci of infection should be identiﬁed and drained
promptly. These include intra-abdominal abscesses, gastrointestinal perfor-
ation, cholangitis and pyelonephritis.
• Intravenous catheters suspected of being colonised or infected must be
removed and cultured.
• Antibiotic therapy or cardiovascular support alone will provide disappointing
results in the therapy of septic shock. Outcome is, perhaps obviously, improved
when both are combined.
Initial resuscitation
Resuscitation should begin as soon as a diagnosis of severe sepsis is made, and
not be delayed until ICU admission. In patients who are not hypotensive an 
elevated serum lactate indicates tissue hypoperfusion.
• A randomised-controlled trial into early goal-directed therapy [12] found a sig-
niﬁcant improvement in the 28-day mortality of severe sepsis or septic shock
when resuscitation in the ﬁrst 6 h of therapy was directed towards the following
parameters:
– central venous pressure (CVP) is 8–12 mmHg by infusion of crystalloid
(500 ml every 30 min),
– mean arterial pressure (MAP) 65 mmHg by administration of vasopressors,
– Central venous (superior vena cava, SVC) oxygen saturation 70%,
– if 70%, red blood cells were transfused to achieve a haematocrit of at least
30%; following this if the target was not attained dobutamine infusion was
commenced (up to 20g/kg/min).
• There appears to be no beneﬁt in attaining supranormal cardiovascular
parameter in patients with sepsis.
Fluid loading
Fluids must be given to optimise preload as an initial step:
• However, it has been shown that some patients with septic shock show a
diminished cardiovascular response to ﬂuid loading – further evidence for the
depressed cardiac function seen from sepsis.
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• For example, a study has shown that similar increases in preload, as assessed
with a pulmonary artery catheter, result in lesser increases in LV stroke work
compared to “control” critically ill patients without sepsis [13].
Fluid loading alone is unlikely to restore haemodynamic stability. Thus, almost
all patients will require cardiovascular support.
Inotropes and vasopressor (see also Chapter 12)
• Dobutamine is the inotrope of choice for optimising cardiac output in the
presence of adequate ﬂuid resuscitation and MAP.
• In the presence of hypotension, autoregulation in vascular beds may be lost
and perfusion can become linearly dependent on pressure. Vasopressor ther-
apy may be required to achieve a satisfactory perfusion pressure to maintain
adequate ﬂow.
• Noradrenaline increases MAP by vasoconstriction with minimal increase in
heart rate, and is commonly used as a ﬁrst-line vasopressor in sepsis. It may be
associated in with an improvement in outcome in septic shock [14]. Dopamine
is also used (especially in the USA), but its primary effects are via an increase 
in heart rate and stroke volume. Both are probably superior to epinephrine,
which may impair splanchnic perfusion.
• Vasopressin may be useful in low dose in refractory shock, but it should be used
in caution in patients with cardiac dysfunction and may result in decreased car-
diac output and splanchnic ﬂow. No outcome data are available as yet.
• The combination of ﬂuid resuscitation, dobutamine and noradrenaline has
much to commend it and it is the standard approach in many centres.
Renal replacement therapy
• There is no evidence currently to support the use of continuous venovenous
haemoﬁltration for the treatment of sepsis; however, in acute renal failure
renal replacement therapy may be indicated.
Corticosteroid therapy
• Corticosteroids inhibit exogenous NO synthase and the release of inﬂammatory
cytokines including IL-1 and TNF from monocytes. They prevent leucocyte
adhesion and complement activation, and also prevent prostaglandin synthesis
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by induction of phospholipase A2 inhibitor. Such anti-inﬂammatory properties
suggest therapeutic beneﬁt, however high-dose short-course steroid therapy
has previously been shown to be ineffective if not harmful in severe sepsis [15].
However, the hypothalamic–pituitary–adrenal axis is often suppressed in sep-
sis and there is new evidence that low-dose replacement therapy with steroids
improves outcome in septic shock.
• Initial studies suggested an improvement in haemodynamic parameters with
reduced vasopressor requirement following low-dose hydrocortisone (about
300 mg/day) [16].
• A subsequent multi-centre study demonstrated improved 28-day survival in
patients with septic shock and relative adrenal insufﬁciency treated with intra-
venous hydrocortisone 50 mg every 6 h and ﬂudrocortisone 50g enterally
daily for 7 days [17]. Relative adrenal insufﬁciency was deﬁned as non-responders
to the short corticotrophin (adrenocorticotrophic hormone, ACTH) test: 250g
of synacthen was administered and blood samples are taken 30 and 60 min
later. Non-responders had a cortisol response of 9g/dl or less. There were no
signiﬁcant adverse effects and the number needed to treat (NNT) to save one
additional life was seven.
• From this evidence it is recommended that low-dose steroids are commenced
in vasopressor-dependent septic shock. A short synacthen test should be per-
formed prior to commencing treatment and when the result is available, if
there is, an adequate response therapy may be discontinued.
Activated protein C
• Activated protein C levels are reduced in sepsis, probably due to down-regulation
of thrombomodulin by circulating cytokines. A large multi-centre randomised-
controlled trial was carried out to assess the efﬁcacy of recombinant human
activated protein C in severe sepsis: the Protein C Worldwide Evaluation in
Severe Sepsis (PROWESS) [18]. The 1690 patients were randomised before the
trial was stopped because of a signiﬁcant mortality beneﬁt in the treatment
group. Patients received either activated protein C (drotrecogin alfa activated)
24g/kg/h for 96 h, or a placebo infusion for the same period; and were eligible
for inclusion if they fulﬁlled the consensus criteria for severe sepsis with organ
dysfunction of 24 h duration. Those with increased risk of bleeding; either
congenital or acquired (e.g. recent surgery, active gastrointestinal bleed or
severe head injury) were excluded. The two groups were well matched for
demographic characteristics and disease severity and at 28-day mortality in the
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treatment group was 24.7% compared with 30.8% in the placebo group; an
absolute risk reduction of 6.1% (NNT  16). The incidence of serious bleeding
was higher in the treatment group (3.5% versus 2.0%), but this mainly occurred
in patients with an identiﬁable predisposition to bleeding. The anticoagulant
effect was only apparent during the period of infusion.
• Post hoc subgroup analysis has suggested that the greatest beneﬁt is to
patients with more severe disease [19]. Owing to this and cost implications the
US Food and Drug Administration have restricted the use of activated protein
C to patients with an Acute Physiology and Chronic Health Evaluation II
(APACHE II) score of 25 or more, and at least two organ failures.
• A larger follow-up trial (ADDRESS trial) looking at long-term outcome in
severe sepsis patients is as yet unpublished but early presentations at scientiﬁc
meetings has stated that there is no mortality difference between the therapy
and control groups irrespective of APACHE II scores greater or less than 25. The
main difference between this and the PROWESS trial is that the therapy win-
dow was increased to 48 h, emphasising the importance of early interventions
in septic shock.
Control of blood glucose
• Hyperglycaemia associated with relative insulin resistance is common in
critically ill patients with or without diabetes, and may increase the risk 
of severe infections, polyneuropathy, multiple organ failure and death. A 
large single-centre randomised-control trial of mainly post-operative surgi-
cal patients found a signiﬁcant improvement in intensive care mortality 
when intensive insulin therapy was used to maintain blood glucose 
between 4.4 and 6.1 mmol/l [20]. Hypoglycaemia was more common in the
treatment group but there were no serious sequelae. The greatest reduction 
in mortality involved deaths due to multiple organ failure with a proven septic
focus.
• A subsequent prospective observational study of mostly cardiothoracic sur-
gery patients suggested that a target blood glucose of 8 mmol/l may be ade-
quate and reduce the risk of hypoglycaemia; whilst infusing high doses of
insulin may be harmful [21].
• The control of blood glucose level appears to be more important than the
insulin dose administered [22], and a recent observational study found hyper-
glycaemia on admission to the ICU to be associated with increased serum con-
centrations of IL-6 [23].
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• When a glycaemic control strategy is employed it is important to provide a
continuous supply of glucose substrate, preferably by enteral feeding.
Sedation, analgesia and neuromuscular blockade
• The use of sedation protocols, along with either intermittent bolus sedation or
continuous infusions with daily interruptions or lightening may reduce the
duration of mechanical ventilation as well as length of ICU stay. Neuromuscu-
lar blocking drugs should be avoided if at all possible due to the risk of prolonged
muscle weakness.
Less commonly used therapies
• Attempts to block the excess effects of NO with analogues of arginine showed
initial promise in case series but later phase II trials were stopped due to unex-
pected adverse events.
• Methylene blue is a potent inhibitor of guanylate cyclase (the target enzyme in
the endothelium-dependent relaxation mediated by NO). Several studies show
improvement in haemodynamics but no improvement in survival. In addition
there may be problems in terms of pulmonary vasoconstriction and adverse
effect on oxygenation.
Experimental therapies
• Antithrombin III has been evaluated in severe sepsis and septic shock.
Unfortunately no beneﬁcial effect on 28-day mortality has been demonstrated
and there may be an increased risk of bleeding when high doses are adminis-
tered in combination with heparin.
• Recombinant tissue factor pathway inhibitor, a physiological inhibitor of coagu-
lation and thrombin generation has been investigated. A large phase III trial
failed to show any improvement in mortality or morbidity.
• Clinical trials of monoclonal antibodies against TNF- have so far proved 
disappointing.
Outcome and consideration for limitation of support
• Managing the patient with septic shock in an ICU run by trained ICU special-
ists has been shown to improve survival [24].
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• Lundberg in 1998 [25] showed that early interventions for septic shock 
were associated with reduced mortality. The data suggests that for patients
with septic shock on wards, there are clinically important delays in transfer 
of patients to the ICU, receipt of intravenous ﬂuid boluses, and receipt of
inotropic agents.
• Poor outcome is associated with excessive vasodilatation and resistance to cat-
echolamines [26], increased age, immunosuppression (including prior therapy
with steroids) and the development of multiple organ failure.
• Early and frequent discussions of likely outcome and realistic goals of treat-
ment should take place with patients and their families, to allow timely with-
drawal of life-sustaining therapy if it is considered futile or inappropriate.
• The use of noradrenaline may be life saving in many patients with septic shock
but giving it to patients who have already developed multiple organ failure
during their stay in the ICU is associated with a poor outcome (and may even
be considered futile by some authors [27]).
Future strategies [6]
Agents that neutralise microbial products or block their interaction with immune
cell receptors are potential therapeutic targets and monoclonal antibody therapy
against CD14, a plasma and membrane protein that binds to lipopolysaccharide
is being evaluated. However there is inherent risk in inactivating cells that are piv-
otal to innate immunity. Inhibition of macrophage migration inhibitory factor, a
cytokine that modulates the expression of TLR4, may be of beneﬁt in sepsis; and
targeted immunomodulatory therapies may be indicated in patients with genetic
polymorphisms that increase susceptibility to sepsis.
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Acute renal failure in the critically ill
R. Kishen
Introduction
• Acute renal failure (ARF) in the critically ill, almost always, develops as part of
multiple organ dysfunction (or failure) syndrome.
• ARF in the critically ill has high mortality.
• Understanding renal physiology and pathophysiology of ARF in the critically 
ill (especially those with sepsis-associated ARF or SAARF) provides logical guide-
lines for prevention and/or management of patients at risk.
• To date there are no proven pharmacological therapies that “prevent” ARF.
• Our understanding of ARF in the critically ill is far from complete.
• ARF in the critically ill is distinctly different from “medical” ARF; and manage-
ment of these patients is often challenging.
• Critically ill patients with ARF have higher mortality than a similar cohort of
patients without ARF.
Incidence and deﬁnition
• ARF in the critically ill is not properly deﬁned.
• In the literature, deﬁnitions for ARF, populations studied and timing of inter-
ventions seem to be different in different studies.
• This creates problems in interpreting the available literature.
• Besides that, deﬁning points at which interventions like renal replacement
therapy (RRT) should begin or stop also becomes difﬁcult.
• Lack of deﬁnition also means that it is difﬁcult to estimate accurate incidence
of this disease in our intensive care unit (ICU) patients.
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• In the literature, the incidence of ARF is quoted as 0.14% (community acquired
or “medical” ARF) to 33% in the critically ill. In some recent studies, ARF com-
plicating critical illness has been estimated to be of the order of 4–8%. Based on
unpublished data (1997–2001), the incidence of ARF in author’s ICU is about
15–20% (a tertiary referral unit).
• A recent survey of 53 centres in 23 countries gave an incidence of ARF of about
6.0% in ICU patients. However, another survey reported in 2003 showed an
incidence of about 36% in European ICUs. This only conﬁrms that the deﬁn-
ition of ARF is still a matter of debate.
• There is no universally accepted deﬁnition of ARF. I use the following working
deﬁnition:
– a precipitating factor (e.g., sepsis, major trauma),
– a reduction in urine volume to 0.25 ml/kg/h (480 ml in 24 h in 80 kg adult),
– a rise in plasma creatinine of 50% from the “usual” baseline creatinine,
– development of metabolic acidosis that cannot be explained by hypoperfu-
sion, untreated severe sepsis or other causes.
• This deﬁnition applies to patients with previously “normal” renal function and
who have been fully volume resuscitated and have had their perfusion
restored.
• Deﬁning renal failure in the critically ill with pre-existing renal failure (sepsis-
induced ARF in a patient with chronic non-dialysis dependent renal dysfunc-
tion) can be difﬁcult despite this deﬁnition.
• Recent attempts at deﬁning ARF as a “graded injury”, much like acute lung
injury (ALI) and acute respiratory distress syndrome (ARDS) may well be the
way forward. However, deﬁning a point at which RRT should be instituted in
ARF may still not be easy.
• Renal recovery may be deﬁned as the point when RRT is no longer required to
maintain normal or near normal biochemistry along with the return of urine
output of more than 500 ml/day. This, again, is an arbitrary deﬁnition of an end
point and will vary in different patients and progress of the on ongoing critical
illness.
• Notwithstanding the problems in deﬁning ARF in the critically ill, it has been
found that ARF is an independent factor for increased mortality in the critically
ill and despite advances in supportive treatment (e.g., better resuscitation,
technologically advanced equipment for supportive therapy), mortality remains
high in the region of 50–80%.
• Thus, it is important to understand mechanisms that cause ARF and the strat-
egies that may prevent it.
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Physiology in relation to ARF of critical illness
A brief account of some of the physiological principals that are important for
present discussion are given below:
• Kidneys receive about 20–25% of cardiac output (about 400 ml/gm tissue –
highest blood ﬂow for any single organ in adult). This high-blood ﬂow is pri-
marily for producing large quantities of glomerular ﬁltrate (which is modiﬁed
along the length of the nephron to ultimately be excreted as urine).
• Kidney’s metabolic (oxygen) demand is not a determinant of renal blood 
ﬂow (RBF).
• Renal vasculature is complex. There are also regional variations in blood ﬂow
in that the cortex is relatively well supplied whereas the medulla, especially
regions of outer medulla have sparse blood ﬂow.
• Afferent arteriole supplies blood to the glomerulus. Blood from glomerulus
drains via efferent arteriole, which then breaks up to become peritubular tuft
of capillaries (supplying blood to the cortical nephrons) or into vas recta (sup-
plying blood to juxta-medullary nephrons).
• RBF is autoregulated under normal physiological conditions (i.e., RBF stays
relatively constant over a wide range of blood pressure).
• Although the precise mechanisms for this autoregulation are still a matter of
debate, it is thought that local myogenic factors (affecting smooth muscle of
renal vessels) and tubulo-glomerular feedback (TGF) are important mech-
anism responsible.
• TGF is a protective mechanism for the nephron. It operates under various
physio-pathological conditions. For example in low-perfusion state, TGF will
cause afferent arteriolar constriction to reduce glomerular ﬁltrate coming
down the tubule in order to lessen oxygen demand of the later till perfusion
improves. Thus TGF protects the nephron during metabolic stress. Substances
like low-dose dopamine abolish TGF and are thus potentially harmful to
“metabolically stressed” tubules.
• Systemic blood pressure is not a good indicator of RBF (or renal perfusion)
especially under pathological conditions. For example, during hypovolaemia
or other shock states, kidneys act as “guardians” of blood pressure via the
angiotensin–renin mechanism. Thus RBF may severely be compromised
despite the blood pressure being well within the “normal” range.
• Blood ﬂowing through the medulla (especially in the vasa recta) has a low
haematocrit (important for countercurrent mechanism and maintenance of
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high osmolality of the medullary interstitium) and therefore, reduced oxygen
carrying capacity. The reduced oxygen delivery, high osmolality and counter-
current mechanisms (including that for oxygen) make the outer medullary
interstitium very hostile for the structures within it (e.g., loop of Henlé).
• Nephron is the functional unit of the kidney but the proximal tubule (PcT) and
the thick portion of the ascending limb of the loop of Henlé (mTAL) are the
metabolically very active parts of the tubule.
• PcT and mTAL are sites of active sodium reabsorption (60% sodium being
absorbed by PcT and 30% by mTAL); this sodium reabsorption accounts for
about 80–90% of renal oxygen consumption by the kidney.
• As the outer medulla does not have good oxygen delivery, parts of nephron in
or close to outer medulla (e.g., mTAL, part of PcT) are in a ﬁnely balanced envir-
onment, often at verge of hypoxia. Even a small upset in this balance can cause
hypoxic damage to these metabolically active parts of the tubule.
• This state of virtual hypoxia is the price that has to be paid for efﬁcient con-
centration of glomerular ﬁltrate and conservation of ﬂuid.
Important factors that ensure integrity of renal excretory function under differ-
ent physiological (and some pathological) conditions are:
• Integrity of RBF: adequate cardiac output and adequate circulating volume.
• Afferent and efferent arteriolar smooth muscle tone, and their control.
• Afferent arteriolar dilatation: to maintain ﬂow into the glomerulus.
• Efferent arteriolar constriction: to maintain glomerular ﬁltration pressure.
• Interplay and balance between dilatory (local prostacyclin) and constricting
(thromboxanes, especially TXA2) prostanoids.
• Interplay and balance between nitric oxide (NO) and endothelin (especially
endothelin 1, the most potent naturally occurring vasoconstrictor) under dif-
ferent conditions.
Pathophysiology of ARF (more speciﬁcally sepsis-associated ARF or
SAARF)
• Most of our present knowledge about ARF is derived from animal models of
ARF using rat kidneys.
• In most of these models, ARF is produced by either clamping of the renal artery
or by infusion of norepinephrine. Either technique stops the blood ﬂow to the
kidney almost completely.
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• However, this model does not accurately reﬂect the clinical situation where
blood ﬂow is never zero.
• Traditionally, it is common to describe ARF as acute tubular necrosis (ATN).
• Little human material has been studied as the biopsies in these patients are
lacking, thus making our knowledge of this condition far from complete.
• However, the sparsely available material that has been studied has shown little
necrosis in the renal tubular cells.
• Rather, there is evidence that renal tubular cells mostly show sub-lethal injury
and the process of damage is apoptosis (programmed cell death) rather than
necrosis. Apoptosis requires energy (requiring oxygen and blood ﬂow; cf. necro-
sis where there is cell death due to lack of perfusion).
• In sepsis, RBF may be normal or even enhanced in some; quite the reverse of
what has hitherto been believed.
• Clinically, there is a disproportionately greater functional derangement than
the pathological ﬁndings warrant. These ﬁndings distinguish this condition from
ARF in patients on nephrology wards (in whom ARF exists as a “single” organ
disease) where distinct and widespread pathological changes in renal
parenchyma are usually found.
• Thus ATN is a misnomer and does not reﬂect the pathology of ARF in the crit-
ically ill.
• A triggering factor is required to initiate the cell damage, for example, hypoxia,
hypotension (as may be seen in severe hypovolaemic shock), cytokines (in sep-
sis or trauma), etc.
• In morphological terms, the tubular cells show cellular and mitochondrial
swelling, lose their luminal brush boarder and show apical blebbing.
• In advanced injury, cells detach from the basement membrane, protrude into
the tubular lumen causing tubular obstruction.
• There is disruption of basolateral membrane (the part of tubular cell where,
after having been absorbed from the tubular lumen, sodium is actively extru-
ded into the medullary extra-cellular ﬂuid) and loss of cell function.
• Tight junctions (between the lateral walls of the tubular cells) are disrupted
causing back leak of tubular ﬂuid into the medullary interstitium.
• These changes cause cell dysfunction and tubular obstruction with gener-
alised oedema of the kidney.
• The important point to remember is that these apoptotic changes are
reversible (in time) with complete regeneration of functioning tubular cells
and thus nephrons, if appropriate resuscitation, treatment of the precipitat-
ing cause is undertaken without delay, further insults like furosemide and or 
Acute renal failure in the critically ill 327
“renal dose” dopamine are avoided and appropriate renal supportive therapy
is provided.
It is therefore clear that our traditional view of renal failure in the critically ill as a
mostly “haemodynamic problem” needs challenging and revising. Haemody-
namic upsets (especially shock and hypoperfusion) are important causes of ARF
in these patients but do not explain the mechanisms of this disease fully espe-
cially as ARF may develop despite adequate resuscitation and support. It is there-
fore important to remember that SAARF has other aetiology. There is evidence to
suggest that endotoxin lipo polysaccharide (LPS) and tumour necrosis factor
(TNF) (that macrophages release under its inﬂuence) have distinct damaging
effects on kidney (e.g., they are stimulators of Apoptosis). Moreover, in an episode
of severe sepsis, kidneys excrete LPS, TNF and many other cytokines (as waste
products), when these substances are found in concentrated amounts in renal
tubules, increasing their tubulotoxicity and therefore the risk of ARF.
Causes of ARF in the critically ill
Basic principles
• Single insults of short duration (e.g., a single short period of hypotension)
rarely cause ARF in patients with previously normally functioning kidneys.
• This may not hold true in patients with associated risk factors (see below).
• Absolute anuria (i.e., absolutely no urine in the drainage bag) is a blocked urin-
ary catheter unless proven otherwise. Occasionally this may require a change of
catheter.
• Truly obstructive causes, for example, ureteric obstructions (e.g., a stone caus-
ing hydropnephrosis in a single functioning kidney) are rare in ICU. However,
they must be sought for/ruled out as management is simple (e.g., a percutan-
eous nephrostomy) and very rewarding in terms of renal function recovery.
• Majority of critically ill patients admitted to ICU are dehydrated rather than
“overloaded”.
Aetiology in the critically ill
• The commonest cause of “oliguria” is hypovolaemia and must be vigorously
looked for and treated as the ﬁrst clinically relevant and preventable cause of ARF.
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• Relative or actual hypovolaemia is commonly present in patients presenting
with severe sepsis and may well be the initial or contributing factor for renal
dysfunction.
• Low-cardiac output syndromes (either primary cardiac failure or secondary
cardiac dysfunction due to sepsis) also contribute to development of ARF.
• As indicated above, sepsis is a major cause of ARF in the critically ill.
• In ICU patients, nephrotoxins (e.g., nephrotoxic antibiotics, NSAID’s) are also
a common cause.
• ARF also occurs in major or severe inﬂammation without infection (e.g., severe
acute pancreatitis).
• Major trauma can also cause ARF usually due to:
– crush injuries: because of severe hypovolaemia, rhabdomyolysis;
– rhabdomyolysis: due to myoglobinurea; hypovolaemia;
– delayed extrication: due to hypovolaemia;
– massive inﬂammatory response: from multiple trauma
– sepsis: late cause.
• Another important cause of ARF in trauma victims is abdominal compartment
syndrome and is now being increasingly recognised. Releasing abdominal
pressure by a laparostomy incision may help in this situation. Abdominal com-
partment syndrome can also occur in non-trauma situations like postopera-
tive patients and leaking aortic aneurysms (postoperative).
• Contrast nephropathy as a consequence of radiological contrast materials
used for angiography is also an aetiological factor for ARF.
• Look out for unusual causes in semiconscious/unconscious patients (e.g.,
dehydration and rhabdomyolysis) due to chemical intake like ecstasy.
Risk factors for ARF are:
advanced age;
pre-existing renal dysfunction;
hypertension, pre-existing peripheral vascular disease;
pre-existing cardiac failure (even when cardiac failure is well compensated);
diabetes;
atherosclerosis;
sickle cell anaemia, malaria.
excessive endothelin production (hypoxia, endotoxaemia, cyclosporin, etc.).
ARF in the critically ill is multifactorial in aetiology and often develops as part of
multiple organ dysfunction syndrome. Development of ARF in the critically ill
not only denotes a severely ill patient but also adds to their mortality.
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Prevention of ARF
• It is better to prevent ARF than to treat it.
• There are no “magic” bullets that prevent ARF in the critically ill.
• Attention to volume resuscitation is of paramount importance.
• This is especially true in crush injuries and rhabdomyolysis. Large quantities of
ﬂuids (6 l or more) may be required in such patients.
• As inadequate perfusion is one of the basic problems in the critically ill, it must
be vigorously treated. This may involve merely adequate intravenous access
and appropriate ﬂuid prescription to advanced invasive/non-invasive moni-
toring of ﬂow (i.e., cardiac output).
• Sepsis is perhaps the most important cause of ARF in ICU patients. Look for
and treat sepsis adequately. There is little advantage in prescribing antibiotics
(often nephrotoxic ones) for surgically drainable pus. Treatment of sepsis is as
important as adequate and vigorous resuscitation.
• Appropriate antibiotics should be prescribed in adequate doses. Monitoring 
of toxic antibiotic levels is mandatory. Single daily doses of aminoglycosides
(e.g., 4–5 mg/kg of gentamicin once daily) are more efﬁcacious (as higher peak
levels are obtained) and less nephrotoxic. “Prophylactic” antibiotics are often
not necessary, are given in inadequate doses and if given should be limited to
one or two large doses. Inappropriate use of antibiotics creates more problems
than it solves.
• Aggressive ﬂuid resuscitation of crush injury victims and those with rhabdomy-
olysis may be supplemented with bicarbonate infusion. Bicarbonate reduces
tubulo-toxic effect of muscle breakdown products. Alkaline urine dissolves myo-
globin and may help prevent tubular blockage.
• N-acetylcysteine has been suggested as a useful agent in preventing radio-
logical contrast media induced renal failure along with aggressive ﬂuid infusions.
However, a recent meta-analysis has not substantiated these ﬁndings and more
research is needed in this regard.
• Vasopressin has found some favour in hepato-renal syndrome. This is one of
the few drugs that increase RBF by inducing splanchnic vasoconstriction and
thus diverting blood to kidneys. However, it reduces cardiac output and has
deleterious effects on intestinal mucosa. Vasopressin (or its synthetic deriva-
tive ornipressin) is, therefore, not recommended for prevention of ARF.
• There is no such thing as “renal dose” dopamine. Dopamine may improve
renal function by augmenting cardiac output but its effect by so called “renal
vasodilatation”, although demonstrated in well-hydrated rats is not observed
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clinically. Besides, low-dose dopamine can be potentially nephrotoxic in hypo-
volaemic states as it abolishes TGF.
• Loop diuretics like furosemide reduce sodium reabsorption at the level of loop
of Hénle and thus reduce oxygen consumption of the tubular cells. This sub-
stance is therefore, theoretically attractive in preventing ARF. However, studies
in this regard have been disappointing.
• It has been suggested that furosemide converts oliguric ARF into polyuric ARF,
which has a better prognosis. This “assertion” is without any scientiﬁc founda-
tion and not borne out by prospective studies.
• Mannitol has been tried but in many studies its place in prevention of ARF has
not been proven.
• Various other agents like growth factors, etc. have been tried. Though animal
experiments are encouraging, clinical studies have been disappointing.
• Erythropoietin (EPO), commonly used for treatment of anaemia associated
with chronic renal failure, has been shown to be cytoprotective in experimen-
tal ARF. It acts by binding to EPO receptor and is believed to be anti-apoptotic.
Translating this beneﬁcial effect into clinical practice has not yet been 
accomplished.
There are no pharmacological “magic bullets” to prevent ARF. Aggressive ﬂuid
resuscitation and improving perfusion are the mainstays of preventing renal dys-
function. Of the myriad agents studied, none have so far proven of any depend-
able clinical usefulness.
ARF in the critically ill: a special disease?
• ARF in the critically ill, especially those with SAARF is distinct from ARF
encountered on the nephrology/medical wards (“medical ARF”).
• Medical ARF (including those requiring RRT) has a low mortality of about 8%
where as ARF in the critically ill (especially SAARF) has a mortality of about
50–80%.
• ARF in the critically ill is usually multifactorial (e.g., sepsis, hypovolaemia,
nephrotoxins) whereas medical ARF is caused by distinct causes (e.g., glomerulo-
nephrites, vasculites, etc.).
• Pathologically, ARF in critically ill shows less tubular cell damage than patients
who develop ARF as a single organ disease (“medical ARF”).
• Critically ill patients with ARF usually require simultaneous management of
other system dysfunction (e.g., respiratory, cardiovascular or gut failure).
Acute renal failure in the critically ill 331
• Management of ARF in the critically ill demands different approaches espe-
cially where ﬂuid or nutrition management are concerned. This can be very
challenging.
• Whereas many patients with “medical ARF” progress to chronic renal failure,
ARF in the critically ill is reversible in most.
• Thus ARF in the critically ill should be thought of as a different or distinct dis-
ease from ARF as a single organ disease (“medical ARF”).
Summary
• ARF in the critically ill has complex aetiology.
• It arises as part of multiple organ failure.
• Our knowledge of this condition is not complete given the sparsely studied
pathological material in humans.
• It is not well deﬁned, thus it is difﬁcult to interpret various studies. It also
makes it difﬁcult to estimate its prevalence.
• ARF increases mortality in the critically ill.
• Although hypoperfusion plays an important part in its development, sepsis-
associated mechanisms are important and are major factors in causing ARF in
the critically ill.
• There are, as yet, no pharmacological therapies that prevent ARF.
• Finally, ARF in the critically ill patients in ICU should be looked upon as a dif-
ferent disease entity from that seen on the nephrology wards.
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Acute lung injury and ARDS
J. Naisbitt and C. Clarke
Deﬁnition of acute respiratory distress syndrome
• The syndrome formerly known as adult respiratory distress syndrome (ARDS)
was ﬁrst described in 1967.
• Consensus on diagnostic criteria was ﬁnally reached in 1994 with the publica-
tion of American European Consensus Criteria (AECC) allowing simple appli-
cation to clinical trials [1]. Controversy persists due to a lack of correlation with
outcome.
• Many groups feel that the term ARDS should be reserved for patients at the
most severe end of a spectrum of acute lung injury (ALI).
Diagnosis
The most widely used diagnostic criteria (Table 24.1) in literature differentiate
ALI from ARDS by the PaO2/FiO2 or shunt fraction.
This deﬁnition is limited by its disregard of the level of positive end expiratory
pressure (PEEP). Increased PEEP improves recruitment and oxygenation and
therefore the shunt fraction considerably. It has however led to uniformity in
clinical trials enabling meaningful comparisons between ventilation strategies.
An alternate diagnostic score is the Murray Lung Injury Score (LIS) [2]. The LIS
is widely used in the literature and importantly is used in the current UK
“CESAR” trial. There are four components to the LIS, however not all need to be
assessed. A score between 1 and 4 is assigned for:
• degree of hypoxia,
• lung inﬁltrates,
24
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• level of PEEP,
• pulmonary compliance.
The total score is divided by the number of components assessed to give the 
LIS. A LIS 2.5 denotes ALI/ARDS, and a score 3 is one of the CESAR inclusion
criteria.
Predispositions to ARDS
Simply seen as a diffuse and overwhelming inﬂammatory reaction of the pul-
monary parenchyma, almost any cause of shock or neutrophil activation can
trigger the syndrome:
• The initial insult can be directly injurious to the pulmonary epithelium (e.g.
aspiration or pneumonia).
• Alternatively the injury can result as part of an extra-pulmonary systemic
inﬂammatory process (e.g. sepsis).
Although there is undoubtedly overlap, the distinction is a focus of interest and
there may be implications for ventilation strategies. Gattinoni has proposed that
ARDS may be divided into “pulmonary” (ARDSp) and extra-pulmonary (ARDSexp)
lung injury [3]. Patients with ARDSp, typically complicating pneumonia have stiff
lungs and exhibit minimal recruitment with PEEP. ARDSexp patients have much
greater chest wall stiffness which correlates with the increased intra-abdominal
pressure. ARDSexp patients exhibit signiﬁcant recruitment with PEEP. Although
Table 24.1. AECC criteria
Criteria Oxygenation Chest Pulmonary artery wedge 
radiograph pressure
ALI PaO2/FiO2 300 mmHg Bilateral inﬁltrates 18 mmHg when measured 
(regardless of PEEP level) (or no clinical evidence of 
left atrial hypertension)
ARDS PaO2/FiO2 200 mmHg Bilateral inﬁltrates 18 mmHg when measured 
(regardless of PEEP level) (or no clinical evidence of 
left atrial hypertension)
336 J. Naisbitt and C. Clarke
these concepts are exciting studies looking at “medical” and “surgical” ARDS do
not conﬁrm Gattinoni’s ﬁndings.
Predispositions do affect outcome:
• The prognosis of ARDS following aspiration or trauma is better than that of
ARDS complicating sepsis.
• Multiple or combined pulmonary and extra-pulmonary insults confer drastic-
ally increased mortality.
• Genetic polymorphisms in cytokines and angiotensinogen converting enzyme
have been shown to predict the development of ARDS.
Predispositions to ARDS split into pulmonary and extra-pulmonary causes
(Table 24.2).
Incidence
The precise incidence of ARDS is not clear, as uniformity on diagnostic criteria
has only recently been reached:
• Using AECC deﬁnitions the incidence is around 13.5 per 100,000 [4, 5].
• The incidence of ALI is higher than previously thought.
• Certain pre morbid factors (history of chronic alcohol abuse) and higher
APACHE II scores confer a signiﬁcantly higher incidence of ARDS.
Table 24.2. Direct and indirect predispositions to ARDS
Direct lung injury Indirect lung injury
Gastric aspiration Sepsis
Severe pneumonia/pulmonary Pancreatitis
infection Hypovolaemic shock
Smoke inhalation Trauma
Pulmonary contusion Fat embolism syndrome
Near-drowning Burns
Massive transfusion
Transfusion-associated lung 
injury (TRALI)
Post cardiopulmonary bypass
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Pathophysiology
ARDS has classically been described by three phases after the initial injury [6]:
(1) Exudative phase.
(2) Proliferative phase.
(3) Fibrotic phase.
These phases are not distinct and the sequence of events is not fully understood.
An early rise in interleukin-8 has been used as a marker for high-risk patients
progressing to ARDS:
• The initial injury to the alveolar epithelium can be direct or endothelially
mediated.
• Rapid sequestration and activation of neutrophils as part of an inﬂammatory
cascade involving numerous cytokines, chemokines, complement activation,
arachidonic acid metabolites and activation of the coagulation cascade leads
to interstitial and alveolar oedema.
• There is intra-alveolar release of super oxide radicals, proteases and other
oxidants.
• Normal alveolar physiology is disrupted with the inhibition of surfactant pro-
duction, destruction of type I alveolar cells and proliferation of type II cells.
This results in alveolar collapse and derecruitment and increased vascular per-
meability. These changes are not uniform throughout West’s gravitational
zones and there may be areas of consolidation and alveolar collapse with near
normal lung adjacent to each other. This has been conﬁrmed on computerized
tomographical (CT) scan with the posterior dependant regions more exten-
sively affected [7].
• Functionally the patient may have a very limited area available for effective gas
exchange, an important element of Gattinoni’s “baby lung” hypothesis.
• Later stages of ARDS are characterized by the migration of myoﬁbroblasts 
to the alveolar side of the basement membrane and disorganized deposition of
collagens. There is subsequent organization of the exudates and abnormal
lung repair of the pulmonary capillary membrane with ﬁbrosis.
• Resolution of ARDS is slow. The alveolar oedema is cleared and pulmonary
membranes are remodelled. The regulation of this process is thought to be
humoral.
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Clinical features
• After an initial latent period of up to 72 h ARDS is a progressive disease.
• A predisposing factor followed by severe hypoxia refractory to oxygen therapy,
increasing respiratory distress and reducing pulmonary compliance.
• Chest radiographs may show the classical whiteout picture of diffuse alveolar
oedema, pleural effusion and atelectasis of dependent zones. The radiological
appearance often lags behind the clinical picture and degree of hypoxia. The
ﬁbroproliferative stages of ARDS may disrupt the pulmonary capillary bed
increasing resistance leading to pulmonary hypertension and progressive right
ventricular dysfunction.
Management
• The management of the syndrome remains supportive and the importance of
treating the predisposing condition cannot be overemphasized.
• The mainstay of management is currently centred on ventilation strategies,
which reduce ventilator-induced lung injury possibly reducing the severity of
ARDS [8] (discussed below).
• Pneumothoraces, ventilator-associated pneumonia [9] and ﬁbroproliferation
can be difﬁcult to differentiate between. Acute deterioration in a patient with
ARDS should prompt thorough investigation.
• Regular microbiological review, bronchoalveolar lavage and computed tomog-
raphy of the chest [10] play an important role.
• Many novel therapies have been tried but little evidence supports their 
routine use.
Ventilation strategies
ARDS is characterized by abnormal lung mechanics. Abnormal lung mechanics
are classically demonstrated using static pressure–volume (PV) loops. It must be
emphasized that obtaining these curves is a specialized procedure and these
loops are not equivalent to the dynamic PV loops displayed by modern ventila-
tors. Although PV loops have contributed much to our understanding of ARDS
unfortunately the values of the inﬂection points on the curve may vary depend-
ing on the technique used to obtain the curve [11].
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Collapsed, ﬂooded, open diseased and near normal alveoli coexists through-
out the lung. Each alveolus will have its own recruitment pressure and level of
ventilation/perfusion mismatch related to the extent of disruption to its normal
physiology and architecture and that of its neighbours (interdependence). The
two key components of current ventilation strategies are limitation of tidal vol-
ume (and airway pressure) and alveolar recruitment.
Traditional ventilation strategies employing low levels of PEEP and large tidal
volumes (10–12 ml/kg predicted body weight) may be seen to over-distend com-
pliant areas whilst possibly not fully recruiting collapsed or ﬂooded alveoli.
“Shear stress” may exist between alveoli with differing recruitment pressures.
Due to alveolar interdependence, shear stress can be dramatically increased
where near normal alveoli abut upon diseased alveoli [12].
• PV loops also demonstrate an upper inﬂection point (ﬂattening of the PV
curve). At this point there is near maximal recruitment and increasing over dis-
tention of alveoli. Maximal inspiratory pressure should therefore be limited to
just below this level. The AECC recommended limitation of trans-alveolar
pressure to 35 cmH2O.
• Hickling, in retrospective and later prospective papers in the early 1990s
demonstrated a signiﬁcant decrease in mortality when tidal volume (and air-
way pressure) was limited [13]. Limitation of tidal volume and “permissive
hypercapnia” was a landmark advance in our management of ARDS. During
the 1990s the emphasis shifted from a concept of “barotrauma” to one of “volu-
trauma”. Both these terms are now obsolete and have been replaced by a wider
concept of ventilator-induced lung injury (VILI).
• Limiting inspiratory pressure below the upper inﬂection point (UIP) and set-
ting PEEP above the lower inﬂection point (LIP) is an attractive theory often
referred to as open lung ventilation. The recent ALVEOLI study undertaken by
the ARDSNetwork attempted to investigate the importance of recruitment by
PEEP in a low tidal volume strategy but was terminated early due to lack of efﬁ-
cacy at its ﬁrst interim analysis [14].
• Assisted spontaneous ventilation and non-invasive positive-pressure
ventilation are often sufﬁcient to manage mild forms of ALI and resolving
ARDS.
• Reversed I:E ratio ventilation can be utilized and frequently results in intrinsic
or auto-PEEP allowing alveolar recruitment. Prolonged inspiration may allow
recruitment of alveoli with long time constants.
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The gold standard ventilation strategy was established by the ARDSNetwork
study [8]:
• 861 patients with ARDS were randomized to two groups: one receiving tradi-
tional tidal volumes of 12 ml/kg; the second low tidal volumes 6 ml/kg (lowered
to 4 ml/kg where necessary to achieve target airway pressure). Mortality in the
traditional group was 39.8% at 28 days in comparison to 31% in the low-
volume ventilation group.
• Three other trials showed no improvement in outcome with protective strat-
egies [15, 16, 17].
• Amato et al also showed a relative risk reduction in mortality with low tidal vol-
ume ventilation but the mortality in the traditional group was very high (71%)
limiting data interpretation [18].
• Comparison of the ﬁve trials shows that the two trials that showed beneﬁt had
greater differences in tidal volume and airway pressure between the groups
than the three negative trials. Amato’s study is of particular interest in the titra-
tion of PEEP to a level above LIP (Table 24.3).
Table 24.3. ARDSNet ventilatory strategy [12]
Variable Setting Comment
Ventilator mode Volume-assist control Relatively uncommon 
in UK
Pressure-controlled modes 
are in widespread use
Tidal volume (ml/kg) 6 Reduced if necessary to 
keep plateau pressure 
30 cmH2O
Plateau pressure 30 cmH2O
Rate 6–35 High rates may have 
generated auto-PEEP
I:E ratio 1:1 to 1:3
Oxygenation target
PaO2 (kPa) 7.3–10.7
SpO2 (%) 88–95
PEEP and FiO2 Set according to a Range 5–24 cmH2O
predetermined table
The implication from these studies was that in the pursuit of a normal blood
gases clinicians had inadvertently caused more VILI and increased the mortality
of ARDS:
• Ventilation with low tidal volumes presents problems related to an inability to
clear carbon dioxide. This is particularly problematic in patients with cranial
injury.
• A degree of respiratory acidosis is tolerated, the so-called permissive hyper-
capnia. Intriguingly acidosis is protective to the lung in animal models. No
consensus exists on the level of hypercapnia that is acceptable and it is of 
note that the protocol of the ARDSNet trial corrected the acidosis by infusing
sodium bicarbonate.
• Infusion of bicarbonate has its own problems and should be slow to prevent
worsening of intracellular acidosis and excretion of carbon dioxide.
• An exciting area is the demonstration that low tidal volume strategies may bene-
ﬁcially alter the pattern of inﬂammatory mediator release in the lung [19]. We
have known for 20 years that ARDS patients die not of hypoxia, but of multiple
organ failure. The concept that a traditional ventilatory strategy cause further
release of inﬂammatory mediators with ongoing inﬂammation has been
termed “biotrauma”.
Recruitment manoeuvres
Despite recent advances in lung protective ventilation strategies, critical oxy-
genation is commonplace in severe ARDS:
• Recruitment manoeuvres involving the application of high continuous posi-
tive airway pressures for 30 s, intermittent sighs or large tidal volumes may
improve oxygenation and lung mechanics, and can be useful following ventila-
tor disconnection. It is unknown whether regular recruitment manoeuvres
inﬂuence outcome [14, 20, 21].
• The respiratory rate in the ARDSNet trial was high. It has been demonstrated
that the ARDSNet strategy may cause signiﬁcant intrinsic PEEP and “gas trap-
ping”. ARDSNet patients may have beneﬁted from a degree of recruitment con-
sequent to the high respiratory rates.
• Recruitment is an inspiratory manoeuvre. PEEP is applied in expiration.
Response to a recruitment manoeuvre could indicate the need to apply more
PEEP.
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Adjuvant therapy
Fluid restriction
The balance of opinion is probably shifting towards keeping the injured lung dry
with the important proviso that cardiac function and end organ perfusion must be
maintained. Certainly administration of excessive ﬂuid will be detrimental [22].
Prone positioning
Ventilation in the prone position may improve oxygenation in some patients
allowing the reduction of inspired oxygen and PEEP. The exact mechanism is
unclear but:
• the prone position may increase functional residual capacity (FRC),
• it may increase recruitment of previously “protected” lung zones,
• there is redistribution of alveolar oedema,
• there is a decrease in the physiological shunt.
Pilot studies have reported beneﬁcial effects in oxygenation but no large trial has
demonstrated an improvement in outcome [23]:
• Proning is not without logistical and clinical pitfalls (pressure sores, facial
oedema, tube and line displacement, and decompensation on return to the
supine position).
• Prone positioning is not routine practice but may be of use in rescue oxygen-
ation in the most severe cases of ARDS.
High-frequency oscillatory ventilation
• High-frequency oscillatory ventilation (HFOV) can be regarded as an extreme
form of lung protective ventilation.
• HFOV oscillates the lung around a constant mean airway pressure, usually
higher than that applied in conventional ventilation. The pressure swings are
attenuated before reaching the alveoli and HFOV may prevent VILI, reduce
“biotrauma” and may be useful in the presence of air leak. Tidal volume is usu-
ally in the range of 1–3 ml/kg [24].
• A recent randomized-controlled trial involving 148 patients showed HFOV to
be safe and effective in ARDS. Although the study was not powered to assess
mortality high-frequency oscillation (HFO) patients had a non-signiﬁcant
trend towards reduced mortality at 30 days and 6 months [25].
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• HFOV tends to improve oxygenation in early ARDS and there is evidence that it
is most effective when applied early. HFOV may be an effective “rescue” ther-
apy for patients with critical oxygenation.
Inhaled nitric oxide
Theoretically the administration of inhaled nitric oxide (iNO) to the ARDS patient
is an attractive one:
• There is selective vasodilatation in ventilated lung areas redistributing blood to
ventilated regions and improving the shunt fraction.
• The subsequent reduction in pulmonary arterial hypertension may allow
improvements in right ventricular dysfunction.
Four prospective randomized-controlled studies demonstrated that iNO signiﬁ-
cantly increased oxygenation for up to 24 h but no differences in outcome were
detectable between the iNO and control groups. One study reported that
patients treated with iNO had a greater requirement for renal replacement ther-
apy. A recent large study of almost 400 patients concluded that iNO was associ-
ated with short-term oxygenation improvements but had no substantial impact
on the duration of ventilatory support or mortality [26]. In conclusion:
• Not all patients are responders but iNO may have a role in life-threatening
hypoxia or severe associated pulmonary hypertension.
• It appears that iNO consistently improves oxygenation in 60–80% of this popu-
lation but the effect may not be sustained and does not affect outcome.
Extra-corporeal membrane oxygenation
The mortalities in the two randomized-controlled trials of extra-corporeal oxy-
genation, published in 1979 [27] and 1994 [28] were 10% and 33%, respectively.
New technology and the development of extra-corporeal removal of carbon diox-
ide have improved the mortality of extra-corporeal techniques but failed to show
beneﬁt over conventional therapy. Small series of selected patients, for example
those with varicella pneumonia have been encouraging.
The current UK CESAR study has recruited over 100 patients. Recruitment is
due to end in November 2005. Inclusion criteria are adult patients with severe
but reversible respiratory failure (LIS 3). Exclusion criteria include prolonged
high-pressure and high-inspired oxygen ventilation, intracranial bleed or other
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contraindications to limited heparinization. Extra-corporeal membrane oxy-
genation (ECMO) cannot be justiﬁed outside the setting of the ongoing trial.
Other novel ventilatory strategies
Partial liquid ventilation and independent lung ventilation have been trialled 
but failed to effect outcome. There is no role for these therapies in current best
practice.
Drug therapy
Many drugs have been subject to randomized-controlled trial in ARDS. These
include prostaglandin, N-acetylcysteine, surfactant and early high-dose corti-
costeroids. All are ineffective. Small trials have demonstrated a limited effect of
pentoxyfylline in a group of patients with ARDS complicating metastatic disease
and corticosteroids in late phase ARDS. A recent systematic review has concluded
that the options for effective pharmacotherapy in ARDS remain extremely limited
[29]. The ARDSNet group have examined the use of ketaconazole and liso-
phylline. In practice the only drug treatment in widespread use is corticosteroids
in late phase ARDS:
• The use of low-dose methylprednisolone (2 mg/kg) during the ﬁbroprolifera-
tive phase of ARDS, signiﬁcantly improved lung injury, organ dysfunction and
survival rate in 24 patients with ARDS (88% versus 38%) [30]. The results of
larger randomized studies without crossover are awaited to conﬁrm this result.
• Activated protein C (Xigris) has improved outcome in septic patients and
caused interest in the role of the coagulation cascade in ARDS but trials have
yet to improve outcome.
Outcome
• The in-hospital mortality for ARDS (using AECC deﬁnitions) was 61% in the UK
in 2002.
• Most studies report ARDS related mortality to be in the 50–60% range.
• Lung-protective ventilation strategies as previously described are the mainstay
of ARDS management.
• There is a role for late low-dose steroids.
• Combinations of adjuvant therapies may decrease mortality in the future.
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The patient with gastrointestinal problems
V. Godbole
Gastrointestinal (GI) disease may be the primary reason for admission to the 
intensive care unit (ICU).
The GI system may also become involved in multiple organ failure, whether as
source or victim is still a matter of debate.
The gut as the propagator of systemic inﬂammatory response 
syndrome
• During critical illness GI perfusion may become compromised resulting in tissue
hypoxia. This in turn leads to mucosal damage and disruption of the mucosal
barrier allowing pathogens and/or toxins to access the circulation.
• The liver normally removes these substances from the portal circulation but
this leads to an inﬂammatory response with the production of cytokines and
initiation of systemic inﬂammatory response syndrome (SIRS).
• The gut is particularly sensitive to reperfusion injury, which results in the produc-
tion of oxygen-derived free radicals.
The opposing view is that the gut is an innocent bystander in shock. GI dysfunction
may simply reﬂect the development of organ failure rather than precede it.
The gut as a source of infection
The GI tract forms a portal to the external environment. Within it is over 400
species of microbial organisms. Ordinarily they cause no problems; indeed they
25
are an essential component of normal host defences:
• In the critically ill patient, however, they may become the source for nosocomial
infections and sepsis.
• Colonisation of the upper GI tract and oropharynx occurs with the same species
isolated in nosocomial infections, particularly ventilator-associated pneumonia.
Bacterial translocation
• Systemic absorption of live organisms from the GI tract.
• Well demonstrated in animal studies.
• Enteric organisms have been identiﬁed in sterile human tissue.
• Exact role played by bacterial translocation in sepsis remains unclear.
Monitoring GI perfusion
• Early detection of intestinal ischaemia may allow directed therapy to improve
outcome in critically ill patients.
• Tonometry relies on measurement of GI mucosal PCO2 to assess gut perfusion.
Gastric monitors are most frequently used.
• Mucosal pH (pHi) may be calculated from PCO2 (usually gastric, PgCO2) using
the Henderson–Hasselbach equation. Studies using pHi to direct therapy 
suggest a value of less than 7.25 is predictive of a poor outcome [1].
• pHi is a composite variable and may not adequately reﬂect gut perfusion. More
recent studies have examined the PgCO2/PaCO2 difference as an indicator of
ischaemia. However, the use of this gradient is also ﬂawed, as PgCO2 may not
be representative of the rest of the GI tract.
• The beneﬁts of using pHi and PgCO2 as therapeutical indices are still being
evaluated.
Selective decontamination of the GI tract
Selective digestive decontamination (SDD) was ﬁrst described in 1984.
It was hoped that the incidence of nosocomial infections arising from enteric
organisms would be reduced by using speciﬁc antimicrobial agents for the gut –
in effect sterilising the GI tract.
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The classic SDD technique consists of four aspects:
(1) A parenteral antibiotic (e.g. cefotaxime) administered for 3 days.
(2) Application of antibiotics topically within the oro-pharyngeal cavity and
administration of these antibiotics enterally via nasogastric tube (e.g. polymixin
B, tobramycin).
(3) Optimal hygiene to prevent cross-contamination.
(4) Monitoring effectiveness of the regime by checking regular throat-swabs and
faeces.
Whilst early work demonstrated a reduction in the incidence of nosocomial pneu-
monia there was little evidence to suggest the use of SDD reduced ICU mortality.
Furthermore there were concerns that the use of SDD would encourage the
emergence of antibiotic-resistant pathogens.
A 30-year meta-analysis by Nathens and Marshall demonstrated that mortal-
ity was signiﬁcantly reduced in critically ill surgical patients, but not in medical
patients [2]. The greatest effect was seen in studies where both the topical and
systemic components of the regimen were used.
The incidence of pneumonia was reduced in both surgical and medical
patients, whilst a reduction in bacteraemia was seen only in surgical patients.
Antibiotic resistance
A recent study from France observed an increase in methicillin resistance of
Staphylococcus epidermidis but not Staphylococcus aureus [3]. Resistance amongst
Enterobacter, Pseudomonas and Acinetobacter species remained unchanged.
Use of SDD in a Belgian ICU demonstrated signiﬁcantly more Gram-positive
bacteraemias and increased antimicrobial resistance, including that of methi-
cillin resistant S. aureus (MRSA) [4].
In areas with a low prevalence of MRSA SDD may be a useful adjunct to treat-
ment but many centres remain unconvinced of its overall usefulness in the gen-
eral ICU and fear the long-term consequences in terms of encouraging resistant
organisms.
Stress ulceration
Gastric erosion or ulceration is common in the ICU. Nearly 100% of patients will
have lesions identiﬁable by endoscopy. Clinically signiﬁcant bleeding is rare and
the incidence of fatal haemorrhage lower still. However, there should be a high
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index of suspicion of a GI bleed in patients who have an unexpected fall in their
haemoglobin (Hb) levels.
However, the mortality from overt GI bleeding remains high.
Patients most at risk include:
• head injuries,
• burns,
• multiple trauma,
• sepsis,
• prolonged intermittent positive pressure ventilation (IPPV).
It is debatable whether other ICU patients require routine stress ulcer prophylaxis.
As the underlying problem lies with gastric mucosal ischaemia, initial meas-
ures should include correction of hypoxaemia and ensuring an adequate circu-
lating volume.
The commonest agents used in stress ulcer prophylaxis are ranitidine and
sucralfate.
Ranitidine
• Histamine 2 receptor antagonist.
• Inhibits gastric acid secretion resulting in decreased volume and increased pH.
Sucralfate
• Complex of aluminium hydroxide and sulphated sucrose
• Protects gastric mucosa by:
– adsorbing pepsin and bile salts,
– increases prostaglandin secretion,
– increases gastric blood ﬂow,
– promoting epithelial healing.
Sucralfate reduces the incidence of gastric ulcer formation when compared to
placebo [5].
Which agent to use?
A major concern is the risk of developing nosocomial pneumonia, particularly
with ranitidine. By reducing gastric acidity one of the body’s main defences
against infection is removed. This allows bacterial colonisation of the upper GI
tract and oropharynx, with eventual colonisation of the trachea.
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It has been observed that Gram-negative bacteria, for example, Pseudomonas
will grow in the stomach at a pH 5 [6]. These organisms are most often impli-
cated in ventilator-associated pneumonia.
Cook et al recruited 1200 patients for a large multi-centre study [7]. They were
randomised to receive either ranitidine 50 mg 8 hourly or sucralfate 1 g 6 hourly.
The incidence of clinically important bleeding was signiﬁcantly less in the raniti-
dine group (1.7% versus 3.8%).
There was no signiﬁcant difference in the rates of ventilator-associated pneu-
monia, length of ICU stay or mortality. The difference in the protection from
bleeding led many ICUs to use ranitidine as their main prophylactic agent.
A recent meta-analysis looked at the effectiveness of each agent versus
placebo. Both the incidences of bleeding and pneumonia were examined. The
authors concluded “there are insufﬁcient data on effectiveness to be able to 
conclude anything one way or the other” [8].
Clearly further work needs to be done in this area!
The best protection for the gastric mucosa is probably enteral feeding, and
this should be established as early as possible.
Motility problems
Gastric stasis
Gastroparesis is not uncommon in the critically ill patient and may lead to failure
in establishing enteral feeding.
Gastric emptying may be delayed due to:
• sepsis,
• opiates,
• abdominal surgery,
• hyperglycaemia,
• hypokalaemia.
Initial management involves the use of prokinetic agents – metoclopramide and
erythromycin. Cisapride is no longer available due to its proarrhythmic activity.
Metoclopramide
• Dopamine 2 receptor antagonist.
• Promotes gastric emptying.
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• Increases gut motility.
• Anti-emetic.
Erythromycin
• Macrolide antibiotic.
• Agonist at motilin receptors gives increased gut motility.
The ideal dose of erythromycin remains unclear. A recent study that demon-
strated improved gastric emptying used 250 mg 6 hourly [9].
If gastric stasis persists then enteral feeding may be achieved by placement of
a postpyloric tube. This is most effectively performed with endoscopic control.
Blind placement of a nasojejunal tube is facilitated by erythromycin, whilst meto-
clopramide is ineffective [10–12].
Constipation
Constipation may be deﬁned as a frequency of bowel movement less than three
times a week. It is often overlooked in the critically ill patient, who may go for
days without passing a bowel motion. The most serious consequences of consti-
pation are GI obstruction and perforation.
Mostafa et al demonstrated an incidence of 83% in a UK ICU [13]. Constipated
patients were less likely to be successful at weaning from mechanical ventilation.
The most common cause of a patient becoming constipated is the use of opi-
ates. Other causes include immobility and total parenteral nutrition (TPN).
There are several laxatives available for the treatment of constipation. The com-
monest in use are osmotic laxatives (e.g. lactulose) and stimulants (e.g. senna).
Diarrhoea
Diarrhoea is an important cause of morbidity in the ICU patient. In its severest
form it can lead to profound ﬂuid loss and electrolyte disturbances. With the
need for frequent bedding changes there is an increased risk of dislodging lines
or even accidental tracheal extubation.
The deﬁnition of diarrhoea is even harder then that of constipation. Most
practitioners accept it as being frequent, loose or watery stools:
• Diarrhoea is often attributed to enteral feed. A small study of 62 patients failed
to demonstrate an increase in the incidence of diarrhoea in patients who were
enterally fed [14].
• The use of antibiotics may also predispose to diarrhoea, which is a common
side effect of many antibiotics.
• Infective causes for diarrhoea amongst the critically ill are rare, with the major-
ity being due to Clostridium difﬁcile. This spore-forming bacillus resides in the
colon. Diarrhoea results from expression of toxins, most commonly following
antibiotic therapy. Treatment is with oral metronidazole, or in severe cases the
intravenous form.
Acute pancreatitis
Acute pancreatitis is a common cause of admission to the ICU.
The severity of the disease ranges from mild, which is usually managed on the
surgical ward, to the severe, necrotising form that carries a mortality of up to 45%.
Aetiology
The majority of cases (70%) can be attributed to gallstones or alcohol abuse.
Other causes include:
• post-endoscopic retrograde cholangiopancreatography (post-ERCP),
• abdominal trauma,
• drug-induced (e.g. steroids, diuretics),
• metabolic (e.g. hypercalcaemia, hypertriglyceridaemia),
• infection (e.g. cytomagalovirus (CMV), mumps).
Twenty per cent are idiopathic but often associated with biliary sludge.
Prognosis
Ranson’s criteria have been used for the last 20 years to predict outcome. There
are 11 prognostic indicators.
• On admission:
(1) age,
(2) white cell count,
(3) blood glucose,
(4) lactate dehydrogenase,
(5) aspartate aminotransferase (AST).
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• After 48 h:
(6) calcium,
(7) PaO2,
(8) base deﬁcit,
(9) ﬂuid deﬁcit,
(10) decrease in haematocrit,
(11) increase in blood urea nitrogen.
Points are awarded for each factor, a higher score is associated with a worse 
prognosis:
• With the advent of readily available computed tomography (CT) scanning newer
scoring systems based on degree of necrosis have been developed.
• In a retrospective study Company et al noted the factors that signiﬁcantly
related to mortality were age, upper GI bleeding, acute renal failure, respira-
tory failure and shock [15].
• Werner et al postulate that C-reactive protein (CRP) is “the gold standard” in
predicting the severity of acute pancreatitis [16]. However, CRP is an acute
phase protein not speciﬁc to pancreatitis and an increase may reﬂect other
processes, for example development of ventilator-associated pneumonia.
Pathophysiology
• Primary insult leads to increase in free radical activity within the acinar cell.
• Normal regulation of secretory pathways is disrupted.
• Reversal of these pathways results in exocytosis and release of enzymes into
the interstitium.
• This in turn initiates a local inﬂammatory response.
• The production of cytokines and other inﬂammatory mediators leads to a 
systemic reaction.
Management
Largely supportive:
• analgesia,
• ﬂuids and nutrition,
• organ support as required.
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Current controversies in management
Feeding
• Parenteral feeding was the traditional method of delivering nutrition in order
to “rest the gut”. With the publication of studies demonstrating reduced mor-
bidity with enteral feeding the practice of feeding the gut was established [17].
• Indeed, a recent Cochrane review has suggested that whilst there is a trend
towards fewer complications in patients receiving enteral nutrition (EN) this is
not statistically signiﬁcant [18]. (It should be remembered in medicine that the
clinical signiﬁcance of an intervention is usually more relevant than the statis-
tical signiﬁcance.)
• A recent meta-analysis recommends that EN is to be preferred over TPN in
patients with pancreatitis [19]. EN is best administered jejunally, that is, distal
to the pancreatic duct.
Antibiotics
• Infection of necrotic pancreas develops 2–3 weeks after the onset of symptoms.
It is commoner in patients with a biliary aetiology. Subsequent sepsis is associ-
ated with a high mortality.
• Bacterial translocation is believed to play a part in the development of infec-
tion, as Gram-negative organisms are isolated in 75% of cases.
• Retroperitoneal air (as identiﬁed by CT scan) should alert to the presence of
anaerobic bacteria.
• Antibiotics should be considered in all patients with pancreatic necrosis. Two
recent meta-analyses have demonstrated reduced mortality in patients with
severe pancreatitis who received prophylactic antibiotics [20, 21].
• There is evidence to show carbapenems have good penetration into infected
tissue and are currently the agent of choice.
Anti-oxidants
• Oxidative stress is believed to play a part in the development of complications
in severe acute pancreatitis.
• Plasma levels of ascorbic acid, carotenoids and vitamins A and E, which 
have anti-oxidant properties, are signiﬁcantly lower in patients with acute
pancreatitis [22, 23].
• The role of anti-oxidants in the treatment of severe pancreatitis is still being
evaluated but a recent study has failed to identify any deﬁnite beneﬁts from a
comprehensive anti-oxidant regime in acute pancreatitis [24].
The role of surgery
Surgery is reserved for those patients with infective complications.
Recent guidelines by the International Association of Pancreatology (IAP) [25]
proposed:
• Fine needle aspiration be used to conﬁrm the presence of infection.
• Patients with sterile necrosis be treated conservatively.
• Early surgery (within 14 days) is not recommended in patients with necrotising
pancreatitis unless there are speciﬁc indications.
• Interventional management should favour an organ-preserving approach.
Acute hepatic failure
The incidence of de novo liver failure is rare with the majority of the cases in the
UK being due to paracetamol overdose. Even in this population the incidence is
low – fulminant liver failure developing in less than 1% of UK hospital episodes.
Worldwide the commonest cause is viral hepatitis.
O’Grady et al divided acute hepatic failure into three subgroups [26]:
(1) Hyperacute: encephalopathy developing within 7 days of the onset of jaundice.
(2) Acute: encephalopathy developing 8–28 days after the onset of jaundice.
(3) Subacute: encephalopathy that develops 5–26 weeks after the onset of jaundice.
In paracetamol-induced acute liver failure (ALF) the indicators of a poor prog-
nosis are:
• prothrombin time (PT) 100 s,
• arterial pH 7.3,
• serum creatinine 300mol/l.
More recently an elevated serum lactate (3.0) following resuscitation was shown
to correlate with a poor outcome [27].
In patients with viral or drug-induced hepatitis the poor prognostic indica-
tors are:
• aetiology (non-A and non-B hepatitis, and drug-induced reactions),
• age 11 or 40,
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• jaundice present for 7 days prior to the development of encephalopathy,
• serum bilirubin 300mol/l,
• PT 50 s.
Hepatic encephalopathy
Encephalopathy is due to the failure of the liver to metabolise and excrete toxins.
Raised plasma ammonia levels have been implicated but other chemicals may
also be involved, for example, fatty acids, aromatic chain amino acids, -amino-
butyric acid (GABA).
It is graded as follows:
• I: Mild drowsiness
• II: Increasing drowsiness, confusion
• III: Stupor
• IV: Coma.
Patients with grade III/IV encephalopathy are at major risk of developing cere-
bral oedema and raised intracranial pressure (ICP):
• Treatment involves the use of mannitol and mechanical ventilation to achieve
normocarbia.
• Controlled hypothermia may also have a role to play.
Lateralising signs are uncommon and should prompt a search for other causes.
Treatment
Orthoptic liver transplant is the only deﬁnitive treatment associated with
improved outcome. The King’s College Hospital criteria for liver transplantation
are based on the prognostic indicators above [26].
Transplantation is not appropriate for all patients with ALF so prompt referral
to a specialised liver unit will allow identiﬁcation of potential recipients.
Management on the general ICU
Supportive ICU measures should be initiated:
• invasive cardiovascular monitoring,
• correction of hypoglycaemia,
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• renal support with veno-venous haemoﬁltration if required,
• correction of coagulopathy should be avoided, as PT is an important prognostic
indicator,
• ICP monitoring for grade III/IV encephalopathy,
• N-acetylcysteine for paracetamol-induced hepatic failure.
Artiﬁcial liver support:
• hybrid systems with biological tissue now emerging,
• studies with small number of patients have been encouraging,
• awaiting larger trials to evaluate beneﬁt.
Chronic liver failure
Acute decompensation of chronic liver failure is the more common presentation
of hepatic failure to the ICU. In the UK this usually occurs in patients with a 
history of alcohol abuse. Decompensation may result from:
• sepsis,
• GI bleeding,
• dehydration,
• large protein load.
Although the outlook for these patients is poor, ICU management may be con-
sidered if there is a reversible cause.
Management is supportive with treatment of the underlying cause.
Ascites
• Respiration may be compromised by the presence of marked ascites.
• Drainage of ascites should be controlled as sudden changes can have profound
consequences on haemodynamic stability.
• Patients with ascites are at risk of developing spontaneous bacterial peritonitis.
Spontaneous bacterial peritonitis
• 30% mortality.
• Symptoms non-speciﬁc: abdominal pain, fever.
• 25% asymptomatic.
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• Diagnosis: positive culture from ascitic tap with associated high ascitic neu-
trophil count (250 cells/mm3) and no evident intra-abdominal source of
infection.
• Treatment: antibiotics.
Hepatic dysfunction in ICU
Two main syndromes of hepatic dysfunction occur in ICU patients [28]. Both are
relatively common and the occurrence and degree of dysfunction have adverse
prognostic signiﬁcance.
• Ischaemic hepatitis. Due to reduced hepatic perfusion during shock. Causes
necrosis with, often massive, elevations of AST within 24 h. Coagulopathy,
hypoglycaemia and increased lactate (partly due to reduced hepatic clearance)
are often seen. May predispose to the commoner.
• ICU Jaundice. More gradual onset (liver has considerable reserve). Associated with
sepsis (should prompt search for occult sepsis), trauma and massive blood trans-
fusion and is the liver component of multiple organ failure. Intrahepatic cholesta-
sis produces marked hyperbilirubinaemia with only mild elevation of enzymes.
In both situations, Kupffer’s cell (hepatic macrophage) dysfunction may predis-
pose to bacterial or endotoxin translocation from the gut, exacerbating the hepatic
dysfunction and promoting further general organ dysfunction.
Therapeutical principles include maintaining overall cardiac output, actively
increasing liver blood ﬂow with, for example, dopexamine, eradication of sepsis
and early enteral feeding.
Upper GI bleeding
GI bleeding is a common cause of admission to hospital but the majority 
of patients do not require ICU. Most respond well to prompt and aggressive
resuscitation.
Although the incidence of upper GI bleeding has decreased the risk of
rebleeding (20%) and death (14%) remain unchanged [29].
Reasons for admission to ICU include:
• Aspiration of blood.
• Massive blood transfusion.
• Persistent shock.
• Prolonged surgery.
Causes of bleeding:
• Peptic ulcer 50%.
• Gastric erosions 25%.
• Varices 10%.
• Others15%.
Management:
• Fluid resuscitation – Transfusion of blood and coagulation factors as required.
• Early liaison with multidisciplinary teams.
• Early diagnostic endoscopy.
• Speciﬁc treatment may be surgical or endoscopic.
Endoscopic treatment has revolutionised the management of upper GI bleeding:
• Techniques involve injecting ulcers (usually with adrenaline) and 
thermocoagulation.
• Routine re-look endoscopy is not recommended.
• High dose proton pump inhibitors should be used as an adjunct to treatment.
Variceal bleeds
• Patients presenting with bleeding varices have a worse prognosis due to the
associated hepatic dysfunction and portal hypertension.
• After an initial bleed the risk of rebleeding is 30–40% over the subsequent 
6 weeks. This carries with it an increased mortality.
• Endoscopic treatment involves sclerotherapy or banding of varices.
• A sengstaken tube may be used to tamponade the bleeding.
• Vasopressin and its derivative terlipressin, reduce blood ﬂow through the portal
system.
After successful management of an initial variceal bleed patients require deﬁnitive
treatment to prevent rebleeding. This may involve:
• -blockade,
• variceal band ligation,
• portosystemic shunt (TIPS) formation,
• liver transplantation.
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Lower GI bleeding
Accounts for 20% of GI bleeds.
Due to:
• diverticular disease,
• colitis,
• colonic carcinoma,
• angiodysplaia.
Treatment involves resuscitation and prompt referral. Most cases will require
surgical intervention.
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The comatose patient
S. Wiggans
This chapter will concentrate on the commonest causes of coma in the intensive
care unit (ICU), head injury, and “stroke” (cerebral infarction and haemorrhage).
The general principles of management of these patients are applicable for
other conditions that lead to coma in the ICU.
Other causes of coma and an account of other neurological conditions in the
ICU can be found in “Neurological complications in critically ill patients”, in the
section on Further reading.
General points
• The hallmark of diffuse brain injury is loss of consciousness. Coma is uncon-
sciousness where patients do not open eyes, obey commands or utter recog-
nisable words.
• The depth or duration of coma may gauge the severity of the patient’s condition.
• Duration of coma can only be judged in retrospect so therefore the depth of
coma as quantiﬁed by the glasgow coma scale (GCS) is widely used as an index
of the severity of injury. GCS:
Eye opening Verbal response Motor response
Spontaneous 4 Oriented 5 Obeys commands 6
To voice 3 Confused speech 4 Localises pain 5
To pain 2 Inappropriate words 3 Withdraws 4
None 1 Incomprehensible 2 Abnormal ﬂexion 3
sounds Extension 2
None 1 None 1
Score 3–15: mild head injuries, 14 or 15; moderate, 9–13; severe, 8 or less.
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General care of the comatose patient
• Skilled nursing care, especially with regard to pressure area care and protection
of joints.
• Physiotherapy – both respiratory care and prevention of contractures in immo-
bile limbs.
• Nutrition and hydration must be maintained.
• Stress ulcer prophylaxis – head injuries are at particular risk (Cushing’s ulcer).
Aims of intensive care
• Detect and treat complications of primary injury that may cause delayed damage.
• Prevent delayed hypoxic/ischaemic damage – largely through control of intracra-
nial pressure (ICP).
• Provide optimal conditions for recovery of brain function – natural recovery
only at present, perhaps therapy aided neurological recovery in the future.
Principles of neuroprotection
• Factors causing increases in ICP should be avoided.
• Encourage venous drainage and therefore minimise ICP by:
– neck maintained in neutral position;
– minimise the use of positive end expiratory pressure (PEEP) where possible;
– nurse with head up by 10°.
• Indications, complications and management of ICP monitoring will be discussed
in the section on Head injury in this chapter.
• Avoid hypotension. There is a loss of normal blood pressure (BP)/cerebral blood
ﬂow (CBF) autoregulation. Normal relationship:
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Normally CBF is constant between mean arterial pressure (MAP) of 50–100, auto-
regulation. This relationship may be lost in, for example, head injury. Therefore the
head injury patient is predisposed to ischaemic brain damage at levels of MAP nor-
mally considered satisfactory:
• Hyperventilation to reduce ICP. Controversial. See below.
• Mannitol to reduce ICP. Mannitol 0.5–1.0 g/kg if above ineffective. Continue until
osmolarity reaches 320 mosm/l. Furosemide is often used as either an adjunct or
an alternative.
• Normoglycaemia. Animal studies and studies on stroke patients clearly show
increased neuronal damage after global brain ischaemia in the presence of
hyperglycaemia [1]. Increasing evidence exists that maintaining normogly-
caemia is important in all critical care patients [2].
• Fever is thought to be harmful – by increasing cerebral metabolic oxygen
requirements. Despite early studies suggesting that controlled hypothermia
improved outcome [3], a recent multi-centre study claimed no beneﬁt [4].
Improved outcome may be possible if the side effects of cooling (abnormalities
of ﬂuid balance, electrolytes, coagulation and haemodynamic parameters) are
treated aggressively [5].
• Steroids have no proven role in the management of head injury or stroke [6]. 
A large multi-centred randomised trial examining the effects of corticosteroid
(methylprednisolone) infusion for 48 h after head injury (the MRC CRASH
trial) has shown a higher risk of death in the group given steroids [7].
• Indomethacin infusion (a cerebral vasoconstrictor) reduces ICP but there may
be a rebound if stopped suddenly.
• Experimental strategies. Interest is focusing on neuroprotective drugs (animal
studies so far) for example, free radical scavengers, inhibitors of lipid peroxida-
tion, glutamate antagonists and calcium channel blockers.
• Calcium channel blockers prevent Ca inﬂux in an ischaemic area and decrease
cell damage. Their smooth muscle relaxing properties also reduce vasospasm.
• On theoretical grounds, the combination of barbiturates (to reduce cerebral
oxygen demand) and positive inotropic drugs (to maintain cardiac output and
MAP) is attractive but remains experimental.
The problem of hyperventilation
• CBF and therefore ICP is directly related to PCO2 with a fall in PCO2 of 1 mmHg
being normally associated with a fall in ICP of approximately 1.3 mmHg. This
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effect may be short lived due to brain and cerebrospinal ﬂuid (CSF) pH 
compensation.
• In controlled studies prophylactic hyperventilation (i.e. in the absence of raised
ICP) resulted in a slightly worse outcome compared to the control group [8].
The danger of hyperventilation is that it may produce excessive cerebral vaso-
constriction and ischaemia.
• It seems illogical somehow to treat brain ischaemia by a measure that reduces
CBF. No other organ in the body is treated in this way.
• Hyperventilation will shift the haemoglobin (Hb) oxygen dissociation curve 
to the left impairing tissue oxygenation, regardless of any contested effect 
on CBF.
• An interesting study on head injury patients compared different therapies to
lower ICP – 25 g intravenous (IV) mannitol, 3 min of CSF drainage via ventricu-
lostomy and increase in respiratory rate of 4/min [9]. For similar decrease of
ICP, hyperventilation caused decreases in jugular venous saturation (SJO2),
implying worsening cerebral oxygenation by reducing CBF, while manni-
tol increased SJO2. CSF drainage was in between but not nearly as bad as 
hyperventilation:
• Thus, mannitol improved CBF while decreasing ICP and this study supports
many centres avoidance of “routine” hyperventilation.
• Although the routine use of hyperventilation is debatable there is no doubt
that hypercapnia is harmful and should be avoided.
• The majority of centres still practice therapeutical hyperventilation for short-
term control of raised ICP. Many use SJO2 measurements as a guide. Jugular
saturations less than 55–60% may indicate that hyperventilation is harmful.
ICP monitoring
• Although the origin of raised ICP after head injury is still debated, rational
management of the injured brain depends on knowledge of cerebral perfusion
pressure (CPP) that is, MAP – ICP.
• Changes in ICP are difﬁcult to identify clinically.
• ICP monitoring has been widespread since the 1970s after several reports indi-
cated a reduced mortality in severe head injuries (GCS9) subsequent to its use.
However, it is impossible to separate the contribution of ICP monitoring to this
improved survival from other advances, for example, routine computed tomog-
raphy (CT) scanning.
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• Nevertheless, there is a deﬁnite association between raised ICP and poor out-
come although cause and effect have never been proven. Certainly, uncontrol-
lable increases in ICP represent overwhelming brain damage.
• Several large, non-randomised trials have shown a beneﬁcial effect on head
injury mortality from the use of ICP monitoring [10, 11].
• ICP measurement is more useful when combined with measurement of SJO2.
With this information, a therapy such as hyperventilation (which can lower CBF)
can be more accurately judged.
• Less than 50% of severe head injuries in Europe receive ICP monitoring [12].
Indications
• GCS 9.
• Evidence of raised ICP on CT scan.
• Any CT abnormality.
• Post craniotomy for mass lesion.
• Space occupying mass lesion.
• Traumatic coma as part of multiple trauma requiring intermittent positive pres-
sure ventilation (IPPV).
Contraindications
• Frank coagulopathy.
• Obvious infection at insertion site.
• Paediatric head injury, unless in specialised centres.
Complications of ICP monitoring
• Haemorrhage requiring neurosurgical intervention – perhaps 5% in some studies.
• Infection.
• Occlusion of ﬂuid ﬁlled monitoring systems.
Complications are low compared to other ICU interventions:
• One study [13] from Italy of ICP monitors inserted by ICU staff as opposed to
neurosurgeons found the incidence of morbidity (3.3%) to be comparable to
that of central venous pressure (CVP) monitoring. There were no intracranial
haematomas attributed to the monitor in their 5 years study.
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• Another study found that ICP monitors are safe with the main problem being
accidental removal. ICP monitoring led to therapeutical changes in 81% of
patients [14].
• Older studies suggest a 10% incidence of infection. It is believed that the inci-
dence with modern solid state or ﬁbreoptic systems (i.e. not ﬂuid based system)
will be considerably less (3% in Ref. [8]). Of course, the disadvantage of the mod-
ern systems is that CSF drainage for therapeutical reduction of ICP is not possible.
Control of raised ICP
The skull contains brain, blood and CSF within a rigid closed container. An increase
in volume of one must be accompanied by a decrease in another or pressure will
rise (Monro-Kellie Doctrine). Initially the volume increase, whether it be due to
haematoma or increased CBF (hyperaemia), is compensated by displacement of
CSF followed by later large increases in ICP for a small further increase in volume.
This may lead to:
• acute hydrocephalus due to obstruction of CSF ﬂow,
• reduced CBF,
• brainstem herniation at the foramen magnum (“coning”).
Although the normal ICP is10 mmHg there is general agreement that treatment is
indicated when ICP is20 mmHg. The mainstays of treatment are diuretics (man-
nitol and/or furosemide) and therapeutical hyperventilation as discussed previ-
ously. Transient elevations occur during turning, physiotherapy, etc. and do not
usually require treatment. A bolus of sedation in the ventilated patient may be all
that is required to prevent these transient elevations in the patients most at risk, for
example, already elevated ICP. Care should be taken, however, to maintain CPP. 
In all cases of persistent elevation of ICP, a cause should be sought (e.g. obstructed
venous drainage of the head). “Fighting” the ventilator should be excluded. When
no cause is apparent repeat CT may be indicated. Thiopentone is often used as a
second or third line agent.
Head injury
Approximately 100,000 patients with head injuries are admitted to hospital each
year in the UK of which approximately 10,000 are severe. Most studies show a
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preponderance of males to females of between 2:1 and 4:1. The peak ages are in
the second and third decades. Common causes are:
• road trafﬁc accident (RTA),
• falls,
• assault,
• gunshot (especially in USA).
Younger cases are commonly a result of RTA – lower incidence of mass lesions on
CT scanning. Older cases are commonly a result of falls – higher incidence of
mass lesions. Depending on aetiology, 10–50% are intoxicated on admission.
Fifty per cent of multiple injury patients include a central nervous system (CNS)
component and brain injury is present in 75% of deaths from RTA.
Pathophysiology
Primary brain injury
• Occurs within milliseconds.
• Prevention is the only effective treatment.
The fact that some patients who subsequently die are conscious at the scene of
an accident, implies that there are secondary or delayed injuries which may be
preventable or reversible.
Secondary brain injury
In most cases later secondary damage is focal (i.e. related to contusions and/or
haematomas) but may also be due to metabolic changes, raised ICP and extracra-
nial events such as hypoxaemia, hypotension and hypercarbia.
CT scanning
• CT remains the scanning method of choice in head injuries and can evaluate
skull fractures, major contusions, haematomas and the cervical spine.
• CT can only provide information about ICP at the time of scanning.
• Effacement of basal cisterns is usually present when ICP 20.
• In general, scanning should be delayed until oxygenation and systemic BP are
satisfactory.
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• Despite early studies suggesting that only a small proportion of patients with a
normal CT scan develop raised ICP, recent studies suggest that severely injured
patients with a normal scan are at substantial risk of developing intracranial
hypertension [15].
• The prognosis in severe head injury is best when haematomas are diagnosed
by CT and evacuated prior to the patient’s deterioration from subsequent rises
in ICP or local mass effect. With increasing use of CT scanning, smaller mass
lesions or “smear” haematomas may be found.
• For patients at risk of delayed haemorrhage or oedema, repeat CT scanning may
be necessary (e.g. at 24 h, 72 h and 7 days). Unexpected deterioration (clinically
or persistent rises in ICP) should prompt a repeat scan to exclude the develop-
ment of secondary hydrocephalus or intracranial bleeding.
Indications for urgent CT scanning
NICE guidelines for the management of head injury state the following are indi-
cations for immediate request of CT. Imaging should be performed (imaging car-
ried out and results analysed) within 1 h of the request having been received by
the radiology department (see Further reading in this chapter).
• GCS 13 at any point since the injury.
• GCS 13 or 14 at 2 h after the injury.
• Suspected open or depressed skull fracture.
• Any sign of basal skull fracture.
• Post-traumatic seizure.
• Focal neurological deﬁcit.
• More than one episode of vomiting.
• Coagulopathy (clotting disorder, warfarin, etc.) if amnesia experienced since
the injury.
• Age 65 years or over if amnesia experienced since the injury.
In addition, the following are indications for CT within 8 h of the injury.
• Amnesia for greater than 30 min of events before impact.
• Dangerous mechanism of injury.
Management
As for all trauma patients, ABC and VIP principles are crucial. If these are not
maintained appropriately the neurological outcome is likely to be poor because
of secondary ischaemic/hypoxic brain damage, even if the patient “survives”.
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General management
Airway must be maintained. Neck should be immobilised in cervical collar due
to association of head injury with cervical spine injury until cervical spine shown
to be intact.
Breathing. Indications for intubation include:
• loss of protective laryngeal reﬂexes,
• GCS 9,
• severe facial and/or multiple injuries,
• hypercapnia, hypoxaemia or marked tachypnoea,
• preparation for transfer,
• seizures.
Circulation. Head injury in the absence of other injuries is almost never associ-
ated with hypotension. Normal MAP should be maintained or even supranormal
MAP if ICP is raised (see below).
Ventilation. Twenty per cent may be hypoxic without chest injury as a result of:
• neurogenic pulmonary oedema,
• aspiration,
• ventilation and perfusion (V/Q) mismatch,
• pulmonary emboli (includes fat emboli after long bone fractures),
• nosocomial pneumonia (high incidence).
Appropriate respiratory care will maintain appropriate oxygenation. PEEP should
be avoided or at least minimised where possible as it can restrict cerebral venous
drainage and therefore contribute to raised ICP.
Duration of ventilatory support is controversial in head injured patients:
• If ICP monitoring is employed, IPPV is continued until ICP is stable and has
settled to near normal. Increasing ICP during weaning leads to re-sedation.
• If no ICP monitoring, many now suggest a minimum period of sedation and
ventilation of 3 days to allow the oedema to settle. Some centres repeat the CT
scan prior to allowing the patient to awaken.
Infusion. Appropriate ﬂuids should be administered. The presence of other injuries
will necessitate appropriate volume resuscitation. Fluid infusion will not necessar-
ily increase ICP [16]. Volume infusion is therefore “safe”. Dextrose containing and
hypotonic ﬂuids should be avoided.
Perfusion. CPP must be maintained especially in the presence of raised ICP
(CPP  MAP  ICP). Increasing emphasis in the literature is being placed on
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maintaining CPP at 70. It would also seem as if maintaining CPP by increasing
MAP is almost to be preferred to maintaining CPP by lowering ICP, especially if
ICP is resistant to therapy [17].
Additional measures
• Attention to the principle of neuroprotection (see above).
• Nasogastric tube for gastric decompression (gastric atony common).
• Early enteral nutrition – patients with head injury can be markedly catabolic.
• Stress ulcer prophylaxis.
• Physiotherapy.
• Antibiotics prophylactically if ICP monitored. Prophylactic antibiotics are not
indicated otherwise in head injury [18].
• Some authorities recommend routine anticonvulsants (e.g. phenytoin).
• Nimodipine if traumatic subarachnoid injury present, to reduce associated
vasospasm.
Outcome and quality control
The mortality from severe head injuries is 30–50% in most series. Factors sug-
gesting a poor outcome include:
• low GCS,
• increase age,
• signiﬁcant haemorrhage,
• signiﬁcant systemic injuries.
Fifty per cent who die do so from uncontrolled increases in ICP (often early).
A small number of patients will be left in a persistent vegetative state or alert
but totally dependent. The numbers of these are not increased in studies involv-
ing aggressive management strategies shown to reduce mortality. Recovery may
continue for up to 24 months but most improvement occurs in ﬁrst 6 months.
In a study of 41 US trauma centres [19] the outcomes varied from 43% below
expected to 52% above expected. 70% of this variation in outcome was found in
patients with moderate head injuries rather than severe. The outcomes varied
enormously between different centres. The implication is that the quality of pre-
hospital and ICU care can be expected to have a profound effect on the outcome
after head injury.
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Stroke
Subarachnoid haemorrhage
• Studies vary but approximately 10 per 100,000 per year.
• Ten per cent of all cerebrovascular accidents (CVA).
• Aneurysms identiﬁed in 75–80% but no discrete bleeding source found in 15–20%.
• Hypertension is a signiﬁcant risk factor for the development and for rupture of
aneurysms.
• Peak age is 55–60 years.
• Females more than males.
Pathophysiology of rupture
The resulting increase in ICP reduces CBF and is responsible for the decrease in
conscious level in all but the mildest cases. This increase in ICP may help stop the
bleeding by a “tamponade” effect. Patients admitted in a deep, persistent coma
develop persistent increases in ICP, secondary vasospasm and cerebral oedema.
There is a surge in catecholamine levels, which can cause:
• myocardial ischaemia,
• arrhythmias,
• tachycardias,
• prolonged QT interval on the electrocardiograph (ECG, itself associated with
ventricular arrhythmias,
• decreases in serum K (due to the action of adrenaline on the -2 receptor),
• neurogenic pulmonary oedema.
Clinical presentation
• Headache in 85–95%.
• Nausea and vomiting.
• Decreased conscious level.
• Photophobia.
• Variety of neurological deﬁcits.
Diagnosis
• CT scanning. Mainstay of diagnosis and gives information on location of 
bleed and likely origin. May also indicate the likelihood of development of
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vasospasm, for example, in the presence of signiﬁcant amounts of blood in the
basal cisterns.
• Magnetic resonance imaging (MRI) scanning. Although not the initial investi-
gation of choice may show even very small aneurysms.
• Lumbar puncture (LP). Very sensitive especially the presence of xanthochro-
mia (yellow discoloration of the CSF due to the presence of altered blood). A CT
scan should be done ﬁrst to detect increased ICP as performing an LP in a
patient with increased ICP can cause brain herniation.
• Angiography. Needed to deﬁne the source of bleeding and the presence of
other aneurysms.
Non-operative management
• Non-operative management is associated with a high mortality.
• Attention to the principles of neuroprotection (see above).
• Surgical referral is indicated in all patients apart from those in persistent coma.
• Re-bleeding occurs in 16–25% of patients in the ﬁrst 2 weeks with a peak inci-
dence at 4–9 days [20].
• If surgery is not feasible measures should be taken to lessen the risk of 
re-bleeding (e.g. control hypertension) and to prevent vasospasm. Simple meas-
ures such as prescribing laxatives to prevent constipation and subsequent
straining may be helpful. The use of antiﬁbrinolytics to reduce re-bleeding
increases mortality [21].
• Interventional neuroradiology (see below).
Prevention and treatment of vasospasm
The two mainstays of treatment to prevent vasospasm are:
• Nimodipine. Given IV as soon as possible at a rate of 1–2 mg/h (less if BP unstable)
and continued for 5–14 days. This is followed by oral nimodipine, 60 mg 4 hourly,
to complete 21 days of treatment. This therapy has been clearly shown to improve
outcome [22].
• “Triple H” therapy (hypervolaemia, haemodilution and hypertension). Generous
ﬂuid therapy (vasopressors), to maintain a high BP and lower viscosity, will
reduce the incidence of vasospasm [23]. This must only be practised following
aneurysm clipping.
• Before or after surgery, hypotension and hypovolaemia should be avoided.
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Surgical intervention
The timing of surgical intervention has always been controversial. In the 1960s
surgery was delayed and outcome was often poor. In the 1970s and 1980s early
surgery was claimed to offer better results. It seems that there are similar results
for surgery at 0–3 days and at 11–14 days. The worst outcome seems to be for sur-
gery between days 7–10 due to the development of vasospasm. In other words,
early or late surgery but not in between [24]. IV nimodipine should be continued
for 5 days postoperatively.
Interventional neuroradiology
An endovascular route may be used to treat aneurysms. “Coiling” of aneurysms
was originally developed as an alternative technique for patients not suitable 
for standard surgical intervention (e.g. medically unﬁt or surgically difﬁcult).
However, a multi-centred randomised trial comparing radiological and surgical
management has suggested “coiling” is superior to “clipping”, if both treatment
options are appropriate [25].
Prognosis
One-third will die before reaching medical attention. Of the remaining about one
third will die or remain severely disabled. An international co-operative study
found that 58% returned to their premorbid state [26].
Cerebral infarction
Ischaemic stroke is a common cause of coma in patients admitted to many ICUs.
However, the role of ICU is controversial.
On the one hand, prognosis is undoubtedly poor following a major cerebral
ischaemic event:
• Realistically, IPPV in the absence of deﬁnitive therapy able to restore brain
function cannot be expected to improve survival.
• A retrospective review of almost 1000 patients concluded that IPPV only delays an
inevitable fatal outcome in patients with respiratory failure following ischaemic
stroke [27].
• Another study suggests discontinuing IPPV for patients who remain comatose
for more than 72 h following stroke [28].
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On the other hand, some centres dispute this nihilistic attitude:
• “Stroke units” for “brain attack” (analogous to coronary care units for heart
attack) result in reduced mortality and complications for stroke patients com-
pared to medical wards [29]. However, this may be due, in part, to better 
rehabilitation rather than better acute care.
• Despite some increased incidence of intracranial haemorrhage, treatment with
recombinant tissue plasminogen activator within 3 h of the onset of an ischaemic
stroke improves outcome [30].
• The challenge (beyond the reach of most units) is to diagnose infarction (i.e. rule
out haemorrhage) within 3 h by CT scanning to identify those who are candidates
for thrombolysis.
• Surgical decompression to reduce ICP is being investigated for patients with
massive hemispheric infarction with initial encouraging results [31].
Management
• Attention to the principle of neuroprotection (see above).
• Treat severe hypertension but take care not to produce ischaemia from
hypotension.
• ICP monitoring is of limited value in massive stroke.
• Look for sources of emboli, for example, echocardiogram to look for valve
lesions or intracardiac thrombi, auscultate carotid arteries for bruits. Consider
antiplatelet drugs or anticoagulants if emboli likely.
• Nimodipine orally may have slight protective effect when given within 12 h but
the results are not as impressive as for subarachnoid haemorrhage. IV nimodip-
ine causes too much hypotension and should not be given.
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The critically ill asthmatic
J. Barker and G. Brear
The chapter highlights two main features:
• Acute severe asthma should be considered the unstable angina of respiratory
medicine.
• Asthma kills.
Incidence
In many countries, in the 30–40 years up to 2000, there was a steep rise in hos-
pital admissions for asthma, accounting for 100,000 per year in England and
Wales, half of which were 15 years of age. In children, males have a higher
admission rate than females, the opposite being true for adults. In the UK there
had been a similar but less marked increase in asthma deaths, which latterly
seems to be falling slowly probably because of better long-term prophylactic
treatment.
Over the period 1995–2001, acute severe asthma accounted for 1.7% of admis-
sions to adult general critical care units across England, Wales and Northern
Ireland. Of these, 57% were mechanically ventilated within the ﬁrst 24 h. Unit
mortality was 7.1% and hospital mortality 9.8%[1].
Causes
Asthma is an inﬂammatory disease of the lower airways that may be associated
with speciﬁc identiﬁable allergy (atopic or extrinsic asthma) or not (non-atopic
or intrinsic asthma). The latter starts more commonly in mid- and late adult life.
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It is a disease of exacerbation with either full remission or persistence of symptoms
(chronic severe asthma). Exacerbation may be due to:
• speciﬁc allergen exposure – environmental, food or occupational,
• air pollution – gaseous or particulate,
• treatment non-compliance,
• infection – viral or bacterial,
• thunderstorms.
Many exacerbations have no identiﬁable cause.
Differential diagnosis
The diagnosis may be obvious, but in adults, especially in the absence of a previ-
ous history of asthma or failure to respond to appropriate treatment, the follow-
ing alternatives should be considered:
• chronic obstructive airways disease,
• left ventricular failure,
• upper airways obstruction,
• pulmonary embolus.
Medical management
Much of the following broadly follows the British Thoracic Society Guidelines [2]
on asthma management.
Prevention of exacerbation
Avoiding severe exacerbation is preferable and is helped by:
• avoidance of allergens,
• monitoring of peak ﬂows and a written asthma action plan,
• avoid reliance just on short acting bronchodilators,
• prophylactic anti-inﬂammatory treatment (inhaled steroids, etc.),
• longer acting -agonists (e.g. Salmeterol),
• prompt treatment of worsening symptoms (e.g. oral steroids, hospitalization),
• prompt treatment of bacterial infections when appropriate.
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Presentation and signs of severity
Asthmatics may die before admission to hospital or intensive care unit (ICU)
because of one or more of the following identiﬁable and preventable factors [3, 4]:
• Doctors failing to assess severity by objective measurement.
• Patients and their relatives underestimating the severity of attacks.
• Under treatment of attacks (e.g. under use of oral corticosteroids).
• Very rapid progression from uncontrolled to life-threatening asthma.
The majority appears to have signiﬁcant psychosocial factors contributing to
their deaths and most occur in patients with chronic severe asthma.
Note: Hypoxia suppresses symptom perception in asthma.
Many clinical signs of acute severe and life-threatening asthma are unreliable.
The following are the most reliable.
Acute severe asthma
• Peak expiratory ﬂow rate (PEFR) is 33–50% of best previous recorded or predicted.
• Inability to complete a sentence in one breath.
• Tachycardia 110 beats/min.
• Respiratory rate 25 breaths/min.
Life-threatening asthma
• Peak ﬂow rate 33% of best previous recorded or predicted.
• Exhaustion, confusion, depressed level of consciousness or coma.
• Shock or dysrhythmia.
• Silent chest, cyanosis or feeble respiratory effort.
Not all patients with acute severe or life-threatening asthma display all features.
Extreme caution should be exercised in the presence of any of them.
The importance of blood gas estimation
Physical signs can be unreliable. A PEFR 33% predicted is rarely associated
with CO2 retention. All patients with oxygen saturation 92% or who have 
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life-threatening features should have arterial blood gases measured. The follow-
ing indicate a very severe attack:
• acidosis–respiratory or metabolic,
• severe hypoxia (PaO2 8 kPa, 60 mmHg),
• normal or raised PaCO2.
Initial treatment
The following measures should be taken immediately:
• Oxygen in high concentration. Clinically important CO2 retention is not aggra-
vated by high-concentration oxygen in asthmatics.
• High-dose nebulized (oxygen driven) 2-agonists.
• Intravenous (i.v.) hydrocortisone 200 mg.
The patient should receive no sedatives and should have a chest X-ray to exclude
pneumothorax. Response to treatment must be monitored with PEFR and repeat
blood gas estimation. If life-threatening features are present include:
• Nebulized ipratropium 0.5 mg in addition to the 2-agonist.
• Aminophylline 250 mg i.v. over 20 min – not to be given if already on oral theo-
phylline. Alternatively 250g salbutamol or terbutaline i.v.
If the patient improves with the above:
• continue a high-concentration oxygen,
• give oral prednisolone 40–50 mg daily or hydrocortisone 100 mg 6 hourly,
• regular nebulized 2-agonists,
• monitor the patient’s saturations, blood gases and PEFR closely.
If the patient does not improve in 15–30 min:
• continue oxygen and steroids as above;
• give 2-agonists more frequently (up to 15–30 min or even continuously);
• add ipratropium 0.5 mg 6 hourly;
• consider aminophylline infusion 750–1500 mg/24 h – dose depending on size;
• consider salbutamol or terbutaline infusion as an alternative to aminophylline.
Response to treatment must be monitored with PEFR, “clinical” assessment of the
patient and blood gas estimations if life-threatening features persist or oximetry
is 92%.
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Indications for admission to ICU
Intensive care admission is indicated if:
• the PEFR deteriorates despite treatment,
• hypoxia persists or worsens,
• hypercapnea or acidosis persists or worsens,
• the patient has impaired consciousness or exhaustion,
• respiratory effort deteriorates clinically,
• the patient is comatose or has a respiratory arrest.
Staff able to intubate reliably must be immediately available.
Indications for intubation
Absolute indications for intubation and mechanical ventilation include:
• coma,
• respiratory arrest or ineffectual respirations,
• exhaustion.
Other considerations for early intubation include:
• progressive hypoxaemia despite increasing inspired oxygen,
• progressive hypercapnea (note that a normal PaCO2 may denote a rising level
passing through the normal range),
• progressive acidosis particularly if metabolic,
• ineffectual cough/retained secretions.
These non-mandatory indications should be used in conjunction with the gen-
eral state and appearance of the patient.
The most experienced intubator available must carry out intubation. A standard,
rapid sequence method with pre-oxygenation should be used and gastric aspiration
prevented using cricoid pressure. The standard ﬁbreoptic bronchoscopes in ICU
general use will usually only ﬁt down an endotracheal (ET) tube7.5 mm.
Mechanical ventilation of the asthmatic patient
Two broad overlapping groups of patients requiring mechanical ventilation are
recognized.
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Acute asphyxic asthma [5]
It is characterized by:
• often short onset of action from relatively normal respiratory function baseline,
• extremely severe airﬂow obstruction overwhelming relatively normal respiratory
muscles,
• response to treatment may be rapid (but often not).
These patients are very difﬁcult to ventilate using standard parameters [6] – which
often causes:
• cardiovascular instability,
• high airway pressures,
• severe air trapping with intrinsic positive end-expiratory pressure (PEEP),
• high risk of barotrauma,
• mortality from obstructive shock, tissue hypoxia or pneumothorax.
Acute severe asthma
It is characterized by:
• lengthier onset of attack – may be days,
• often not from normal respiratory function baseline,
• more secretions and airway oedema problems,
• moderate or severe airway obstruction but respiratory muscle fatigue may be a
signiﬁcant problem,
• response of airway disease to treatment may be very slow – steroids can take
many days to work,
• at one end of spectrum, may be relatively easy to ventilate with standard settings,
• if respiratory muscle fatigue is the major problem then rapid recovery occurs.
Cardiovascular instability and barotrauma can be avoided by limiting peak and
mean airway pressures, extending expiratory time, minimizing intrinsic PEEP,
maintaining oxygen saturations 92% and supporting cardiac output [7].
This can be achieved by:
• low respiratory rates (down to 1–2/min, if necessary by manual ventilation, in
extreme cases),
• low tidal volumes and low inspiratory ﬂow rates to keep peak airway pres-
sures 50 mmHg,
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• long I:E ratios to allow adequate expiration to occur,
• high-concentration oxygen to maintain adequate saturations.
This strategy will result in high concentrations of PaCO2, but patients are more at
risk from hypoxia, low cardiac output and barotrauma than from hypercapnea.
Pressure-controlled ventilation can be used but tidal volumes have to be
monitored very closely since the ﬂuctuating changes of airway resistance typical
of asthma affects tidal volume greatly.
Anecdotal therapies
There are reports of beneﬁt for the following treatments in the resistant asthmatic.
Most are controversial or anecdotal reports only. They should be considered after
the above management fails.
i.v. magnesium sulphate
• Used in both adults and children.
• Reports of improvement and even avoidance of intubation and mechanical
ventilation.
• Optimal dose is unclear but as a guide, 8–16 mmol over 30–60 min followed by
64 mmol over 24 h is a regimen suggested for arrhythmias.
Volatile anaesthetic agents
• Halothane, isoﬂurane and sevoﬂurane are the most commonly used.
• Patients are usually already intubated and ventilated.
• They are bronchodilators but may be associated with cardiovascular side effects,
and halothane may cause hepatotoxicity with repeated use.
Ketamine
• An i.v. anaesthetic agent that has bronchodilating properties.
• Anecdotal reports of ketamine used as an adjunct to standard bronchodilators,
substituting as sedative of choice.
• Side effects include hallucinations, psychosis and increase in blood pressure.
• Less likely to be respiratory depressant and the airway better maintained than
with many other anaesthetic agents.
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Helium–oxygen mixture
• Use of helium–oxygen mixture in asthma is controversial.
• Available in various oxygen concentrations.
• Less dense than air and offers less resistance to gas ﬂow. Encourages laminar
rather than turbulent ﬂow in medium and larger airways.
• Work of breathing may be reduced and the onset of respiratory muscle fatigue
delayed in awake patients.
• Has been shown to reduce dyspnoea and pulsus paradoxus and improve PEFR
in children with status asthmaticus.
• It has been suggested that may help in the ﬁrst hour of use [8].
Bronchoscopy and bronchial lavage
• Bronchoscopy can be helpful in removing the mucous (particularly in the upper
lobes) plugs that may cause bronchial occlusion and worsen gas exchange.
• Tenacious secretion can be difﬁcult to aspirate through the small channel of a
ﬁbreoptic bronchoscope – saline (not water) instillation can help and the pro-
cedure may need repeating.
• Single, whole-lung saline lavage has been used although it may be associated
with an increase incidence of pneumonia.
Extracorporeal membrane oxygenation (ECMO)
• ECMO has been used in some patients with success, although it has many
practical and other problems.
• Indications have included hypoxaemia and shock unresponsive to treatment,
excessively high PaCO2 and excessively low pH.
• It is associated with a high incidence of a serious side effect (e.g. bleeding).
• It is only available in specialist centres.
• It is only considered as last resort in centres where the technique is available.
Leukotriene receptor antagonists
• Sporadic early reports with i.v. preparation suggest possible beneﬁt.
• Seems to work rapidly when as adjunct to other therapy.
• Relatively few side effects.
• Not yet widely available.
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Cardiorespiratory arrest in asthmatics
Very little has been written of the management of cardiorespiratory arrest in the
asthmatic patient. The following applies:
• Resuscitation is often unsuccessful or associated with residual cerebral anoxic
damage.
• Standard resuscitation guidelines do not address the speciﬁc problem of car-
diorespiratory arrest due to acute severe asthma.
• Inappropriate application of standard guidelines may turn a respiratory arrest
into a cardiorespiratory arrest and death.
• Cardiac arrest may be secondary to hypoxia, electrolyte disturbance or
obstructive shock.
• The cardiac arrest is often due to electromechanical dissociation (EMD) or
asystole.
The general recommendation during resuscitation of 12 breaths/min with 3–4 s
for exhalation is inappropriate in intubated asthmatics following respiratory
arrest, whose passive exhalation time may be measured in minutes. The following
problems arise:
• High levels of intrinsic PEEP.
• Marked air trapping and increases in residual capacity.
• High intrathoracic pressures.
• Obstructive shock with progressive reduction in cardiac output leading to car-
diac arrest and cerebral hypoxic damage.
• Ineffectual external cardiac massage.
• High risk of tension pneumothorax and other barotrauma.
The following measures should be considered in these extreme circumstances:
• Low respiratory rates of 1–4 slow manual breaths/min.
• Apnoeic oxygenation with intratracheal oxygen insufﬂation (as performed during
brain stem testing [9].
• Manual extrathoracic compression to mimic active exhalation and reduce
intrathoracic volume.
• High suspicion of tension pneumothorax – if in doubt insert bilateral chest drains.
• If external cardiac massage ineffective in producing output – early recourse to
internal cardiac massage.
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Asthmatics can survive cardiorespiratory arrest but the longer the above methods
are inappropriately delayed, the more likely cerebral anoxic damage will result.
Patients die of a lack of cardiac output and tissue hypoxia, not of hypercapnea
from hypoventilation.
Prognosis and causes of mortality
• In England and Wales there are 2000 deaths per year in adults from asthma.
• From the ICNARC database increasing age and cardiopulmonary resuscitation
(CPR) or neurological insult before ICU admission are associated with mortality
• Over a quarter of deaths occurred after discharge from ICU.
• Despite fears of deaths related to over treatment, most asthmatic deaths are
associated with under treatment.
• Many deaths may be preventable with early recognition of exacerbation and
prompt treatment particularly with systemic steroids.
• Mortality rates vary greatly in a reported series of mechanically ventilated 
asthmatics – from 28% to 0 – is it explained by different types/severity and the
threshold for intubation between units?
• The commonest causes of death are asphyxia, cardiovascular insufﬁciency,
cerebral hypoxia, pneumothorax and overwhelming infection.
• Many deaths occur in patients who are known to be bad asthmatics and/or
who have recently been seen by a doctor for asthma.
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The critically ill diabetic
I. McConachie
Diabetes is a common medical condition: almost 5% of the population, although
a much smaller proportion, are insulin-dependent diabetics. Consideration of
diabetes in this text is worthwhile not least due to the important points regarding
ﬂuid therapy in diabetic hyperglycaemic coma.
Diabetic coma, the commonest endocrine emergency, falls into three categories:
• Hypoglycaemic coma: easy to understand and treat once recognised. Therefore
not discussed here.
• Diabetic ketoacidosis (DKA).
• Hyperosmolar non-ketotic coma.
DKA
DKA is relatively common:
• approximately 5% of insulin-dependent diabetic patients per year,
• mainly under the age of 40 years but can also affect elderly patients,
• said to affect women more than men.
Precipitated by infection in 30%, management errors in 15% but no obvious
cause in 40%. Previously undiagnosed diabetes is the cause in 10% of DKA.
The hallmarks of DKA are:
• Hyperglycaemia: Lack of insulin causes the increase in blood sugar by decreasing
cellular glucose uptake, increasing protein breakdown (thus promoting gluco-
neogenesis) and glycogenolysis.
• Dehydration (5–10 l of water) lost by osmotic diuresis, hyperventilation and
vomiting.
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• Loss of electrolytes, approximately 500 mmol in total of both Na and K.
• Acidosis (ketosis and, in later stages, lactic acidosis from tissue hypoperfusion).
Much of the ﬂuid lost, comes from the intracellular space and therefore is rela-
tively hypotonic. Therefore, although distinction is made between DKA and
hyperosmolar non-ketotic coma (HNC) this is slightly arbitrary as DKA patients
are always signiﬁcantly hyperosmolar. Ketosis progresses to ketoacidosis when
ﬂuid loss exceeds intake due to:
• osmotic diuresis,
• vomiting,
• renal compensation overwhelmed by decreasing renal function.
Presentation
The average time of onset of condition to presentation is approximately 3 days.
Commonly present with combinations of the following:
anorexia vomiting thirst
weakness polyuria weight loss
reduced conscious level blurred vision abdominal pain
gastrointestinal bleed hyperventilation tachycardia
ketones on breath hypotension hypothermia (rarely fever)
It is dangerous to assume that the abdominal pain is due to DKA. Conversely, it
would be inappropriate to take a patient with DKA for laparotomy!
Laboratory signs are:
• Increased blood sugar, haematocrit, urea, white blood corpuscles (WBC),
triglycerides.
• Decreased pH, bicarbonate, serum K, Mg and phosphate.
The raised WBC is not necessarily an indicator of associated infection.
The interpretation of serum Na is more complex. It is well demonstrated but
underappreciated that an elevated serum glucose “dilutes” the plasma Na result-
ing in an inappropriately low measured Na [1]. The plasma Na decreases by
approximately 1 mmol/l for each 3 mmol/l rise in blood sugar.
In addition, if the Na is measured by a ﬂame emission spectrophotometer
technique an elevated hyperlipidaemia (as in DKA) will cause a “pseudohypona-
traemia” due to the increase of the “solids” component of plasma. Thus a low 
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Na may be “normal” in DKA, a normal Na may be “high” and a high Na signiﬁes
marked hyperosmolarity.
Indications for admission to ICU
Most DKA patients do not need to go to ICU. Indications include:
• airway compromise,
• severe acidosis, unless rapidly responsive to ﬂuid therapy,
• hypotension, unless rapidly responsive to ﬂuid therapy,
• hypoxia,
• severe coexisting medical conditions,
• lower threshold in the elderly patient.
In one large American study, DKA was the admitting diagnosis in 7.6% of patients
[2]. This is probably an overestimate for UK practice.
Management
General
• The airway must be protected; by tracheal intubation if necessary.
• A nasogastric tube is essential due to the gastric atony.
• Urinary catheter, risk of renal shutdown outweighs the risk of infection.
• Close observation, regular electrolyte and blood sugar measurements.
• Infection screen but no routine antibiotics unless clinical evidence of infection.
• Subcutaneous heparin prophylaxis due to risk of thrombosis.
• CVP monitoring if hypotensive despite initial rapid ﬂuid therapy.
• Elderly patients, severely acidotic patients, patients who do not respond to col-
loid infusion or patients developing adult respiratory distress syndrome (ARDS)
(see below) warrant a pulmonary artery ﬂotation catheter (PAFC).
Fluid and electrolyte therapy
Fluid replacement is the ﬁrst priority taking precedence over the administration
of insulin. Delay may lead to a poor outcome. Fluid therapy alone will:
• reduce the blood sugar by dilution (by up to 20%),
• restore cardiac output, organ blood ﬂow, cardiac output and blood pressure
and correct acidosis,
• restore renal function which will aid the correction of acidosis,
• deliver insulin to its tissue receptors.
The choice of ﬂuid is controversial between 0.9% saline, 0.45% saline and colloids.
Arguments in favour of 0.9% saline being the main ﬂuid:
• Restores plasma volume and interstitial ﬂuid.
• Na content being higher than plasma may prevent too rapid decreases in
osmolarity.
• Clinically found to be sufﬁcient and effective for many DKA.
Arguments against large volumes of 0.9% saline:
• Danger of late hyperchloraemic acidosis [3].
• Danger of late hypernatraemia.
• May over expand the interstitial space while not replenishing the intracellular
space.
• Patients have lost more water than Na.
Arguments in favour of 0.45% saline:
• Closer in composition to that of ﬂuid deﬁcit.
• Replenishes all ﬂuid spaces equally.
• Avoids hypernatraemia.
Arguments against 0.45% saline:
• Slow to expand plasma and interstitial spaces.
• Potentially more rapid fall in plasma osmolarity (see below re cerebral oedema).
Arguments in favour of colloid:
• Initial rapid correction of plasma volume and shock.
Arguments against colloid:
• Not necessary for less severe cases that is those not admitted to ICU.
A suggested approach is:
(1) Initial 1000 ml N saline rapidly if hypotensive.
(2) 2000 ml of colloid rapidly if hypotension or acidosis are severe or no response
in BP to above.
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(3) Continue with 0.45% saline at approximately 500 ml/h for 4 h then approximately
250 ml/h so as to aim for 4–6 l of ﬂuid in 24 h. Be prepared to adjust according
to responses.
(4) No 0.9% saline or colloid if Cl 110 or Na 150.
(5) When blood sugar 20 mmol/l switch ﬂuids to dextrose 5% or dextrose/
saline.
(6) Give K early in form of KCl at 20 mmol/h unless K is very high (due to the acid-
osis) or there is no urine output. Rate may have to be increased if K is very low. 
If K is very low Mg should also be checked. Consider giving some of the K as 
K phosphate if Cl high or serum phosphate very low, but at lower rates of 
infusion.
Insulin
Soluble insulin should be given at a rate of 5–10 U/h. Previously recommended
higher doses are rarely necessary [4]. The aim is to bring the blood sugar down
relatively slowly over 24 h to avoid precipitate falls in osmolarity.
Adsorption of insulin to plastic syringes is irrelevant as the infusion rate and
dose are titrated to the clinical effect. Occasionally higher rates of insulin infu-
sion are required.
Bicarbonate
Bicarbonate administration is usually unnecessary and potentially dangerous:
• rapid falls in K as acidosis corrected,
• shifts Hb dissociation curve to the left inhibiting tissue oxygenation,
• 8.4% Bicarbonate is extremely hyperosmolar,
• Danger of “overshoot”.
There may be no difference in outcome with bicarbonate therapy [5] and it is 
recommended that bicarbonate be reserved for those patients with pH 7.0 or 
electrocardiogram (ECG) signs of hyperkalaemia; 8.4% Na bicarbonate should be
avoided or diluted in 0.45% saline. The same degree of acidosis in DKA is better
tolerated than in lactic acidosis due to the lesser degree of tissue hypoxia.
Interestingly the degree of acidosis does not correlate with the degree of 
hyperglycaemia [6].
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Phosphate
Often low. In theory replacement should replenish the low levels of 2,3 diphos-
phoglycerate (2,3DPG) in red blood corpuscles (RBC) and aid oxygen release
from Hb [7]. However, the harmful effects of a low 2,3DPG on Hb oxygen afﬁnity
are mitigated by the presence of acidosis and routine phosphate administration,
with its dangers of hypocalcaemia is not recommended.
Complications of DKA
Common complications of severe DKA and, therefore, complications seen in
DKA patients admitted to ICU are as follows:
Cerebral oedema
It may occur from too rapid lowering of osmolarity either by overhydration or
rapid lowering of blood sugar. It is commoner in children than adults and is asso-
ciated with an increased mortality. Unnecessary administration of bicarbonate
may cause a paradoxical cerebro spinal ﬂuid (CSF) acidosis and cerebral oedema
as carbon dioxide crosses the blood–brain barrier but bicarbonate cannot.
Animal studies strongly support the rapid reduction and fall in osmolarity rather
than the degree of acidosis as the main mechanism [8].
In a small study [9], patients with DKA underwent CT brain scans before and
after rehydration with ﬂuids of differing Na content and osmolarity. The brains of
patients with DKA were denser than control patients without DKA (thought to
represent dehydration). There were no differences in brain density after 24 h of
ﬂuid therapy with either of the intravenous ﬂuid choices suggesting that ﬂuid
osmolarity and Na content are not major factors in the development of cerebral
oedema. Reasons why some patients, but not others, develop cerebral oedema,
even following expert management, are unclear.
ARDS
ARDS can lead to a requirement for intermittent positive pressure ventilation
(IPPV) in severe DKA. The cause is the thought to be related to severe acidosis
and its effects on membrane permeability. Physiological shunt may increase
despite no increase in lung water [10]. Curiously, even when adjusted for other
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variables, it seems as if septic diabetic patients develop ARDS less frequently
than other septic non-diabetic patients [11]. The reasons for and signiﬁcance of
this is unclear.
Miscellaneous
• Hypoglycaemia is a common complication of therapy of DKA [12].
• A recent study found that 14% of patients admitted to the ICU with DKA suffer
signiﬁcant upper GI haemorrhage [13].
Prognosis
Reported mortality from DKA varies in the literature but in the ICU is probably
about 5%. There were no deaths in patients admitted with DKA in a recent study
[2] but the authors admit that the patients had a lower severity of illness score
than other patient groups in the study. Many deaths are due to preventable meta-
bolic complications. Increasing age and coexisting disease signiﬁcantly increase
mortality [14]. The mortality is probably better correlated with the osmolarity
rather than the degree of acidosis. Development of either ARDS or cerebral
oedema is a poor prognostic sign.
Length of stay in the ICU is related to the underlying cause of the DKA [2].
HNC
In HNC the abnormalities of lipid metabolism seen in DKA do not occur 
and therefore ketosis and acidosis is not a feature. The reason for this difference
is not known for certain but one theory is that residual insulin levels may be 
sufﬁcient to prevent this. Hyperglycaemia is severe, water loss is often greater 
(up to 25% total body water) and hyperosmolarity is marked. Most patients are
over the age of 50 and infection is a common precipitating cause. Mortality may
approach 50%.
Hyperosmolarity is a feature of DKA and therefore overall presentation and
management are similar with several important differences:
• onset is slower: over 5–10 days,
• aggressive ﬂuid loading may lower osmolarity too rapidly; therefore slower
rehydration may be appropriate. 0.45% saline recommended,
• often more sensitive to insulin, therefore uncommon to require 5 U/h,
• empirical antibiotics are indicated due to the high incidence of associated
infection,
• Thromboembolic complications are common, including hemiplegia, therefore
full anticoagulation is indicated.
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The cardiac surgical patient in the ICU
J. Dunning and C. Harle
Approximately 30,000 cardiac surgical operations are performed annually in the
UK. Almost all of these patients are admitted to either a general or a cardiac
intensive care unit (ICU) for initial postoperative management. These patients
often have clinical issues peculiar to cardiac surgery. This makes a sound under-
standing of the preoperative and postoperative decision making process
together with an understanding of the operative techniques used, essential for
intensivists involved in the care of these patients.
Preoperative
History and examination
These patients will frequently have undergone comprehensive investigation
before their operation, particularly in regard to their primary cardiac pathology.
Nonetheless a thorough examination and full review of the notes is needed, as
these patients frequently have other pathology including carotid arterial disease,
femoral arterial disease, abdominal aneurysmal disease, respiratory and renal
disease which may not have been recognised or have progressed since their last
examination.
Risk assessment
Since the advent of national publication of centre-speciﬁc and surgeon-speciﬁc
mortality data for all cardiac operations, cardiac surgical patients are rigorously
assessed in order to estimate their perioperative mortality risk. The Parsonett
score has been superseded by the Euroscore and most patients have their 
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mortality risk assessed by this score. The score estimates the patient’s percentage
risk of mortality and thus a patient with a Euroscore of 5 has a 5% risk of death.
This score is illustrated in Table 29.1 [1, 2].
Preoperative pharmacological considerations
• Ideally, clopidogrel should be stopped at least a week before surgery in order to
reduce the risk of postoperative bleeding. Patients on warfarin for atrial ﬁbril-
lation (AF) should also have this discontinued preoperatively. In low risk
patients undergoing coronary artery bypass grafting (CABG), aspirin should
probably be stopped about 5 days before surgery.
• Beta-blockers should be continued through to the morning of surgery. They
protect against intra-operative ischaemia and reduce the incidence of post-
operative dysrhythmias.
• Angiotensin-conversion enzyme (ACE) inhibitors should be stopped 2 days
preoperatively as ACE inhibition contributes to vasodilatation and a resistance
to vasoconstrictors such as noradrenaline.
• Patients on high doses of nitrates should have these continued and a nitrogly-
cerin (GTN) infusion may be commenced with anaesthesia.
• Diabetes should be meticulously managed, to avoid hyper or hypo glycaemia
in the perioperative period.
• Other antihypertensive medication may be continued until the time of operation.
• It is important that ACE inhibitors, beta-blockers, aspirin, statins and antihy-
pertensive agents are recommenced postoperatively along with the patient’s
non-cardiac medication and mechanisms to ensure that this is not omitted
should be in place.
Preoperative investigations
• Pre-operative full blood count (FBC), and clotting screen are important, as pre-
operative anaemia and postoperative transfusion is associated with signiﬁcant
morbidity. Leukocytosis may indicate systemic infection or inﬂammation,
which may be greatly exacerbated by cardiopulmonary bypass (CPB). A new
low platelet count may indicate heparin-induced thrombocytopenia, which is
not uncommon in patients who have been receiving unfractionated heparin
(UH) or low-molecular weight heparin (LMWH).
• Urea and electrolytes: preoperative hypokalaemia is often associated with
diuretic use and predisposes to perioperative dysrhythmias. Hypokalaemia is
an independent predictor of increased postoperative mortality.
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Table 29.1. The Euroscore
Weights
Risk factors Deﬁnition (score)
Patient-related factors
Age Per 5 years or part thereof over 60 years 1
Sex Female 1
Chronic pulmonary Long-term use of bronchodilators or steroids 1
disease for lung disease
Extracardiac Any one or more of the following: claudication, 2
arteriopathy carotid occlusion or 50% stenosis, previous or 
planned intervention on the abdominal aorta, 
limb arteries or carotids
Neurological Disease severely affecting ambulation or 2
dysfunction day-to-day functioning
Previous cardiac surgery Requiring opening of the pericardium 3
Serum creatinine 200 mol/l preoperatively 2
Active endocarditis Patient still on antibiotic treatment for 3
endocarditis at the time of surgery
Critical preoperative Any one or more of the following: VT or VF 3
state or aborted sudden death, preoperative cardiac 
massage, positive pressure ventilation before 
anaesthesia, preoperative inotropic support, 
intra-aortic balloon counter pulsation or 
preoperative acute renal failure. (Anuria or 
oliguria 10 ml/h)
Cardiac-related factors
Unstable angina Rest angina requiring i.v., nitrates before 2
induction of anaesthesia
LV dysfunction Moderate (LVEF 30–50%) or 1
Poor (LVEF 30%) 3
Recent MI 90 days 2
Pulmonary hypertension Systolic PA pressure 60 mmHg 2
Operation-related factors
Emergency Carried out on referral before the next 2
working day
Other than isolated Major cardiac procedure other than or in 2
CABG addition to CABG
Surgery on thoracic aorta For disorder of ascending aorta 3
i.v.: intravenous; VT or VF: ventricular tachycardia or ﬁbrillation; LV: left ventricle; LVEF: left 
ventricular ejection fraction; MI: myocardial infraction.
• Renal impairment as evidenced by elevated serum Creatinine (120mol/l) is
associated with an increased mortality and where possible, surgery should be
delayed while this is further investigated.
• Methicillin-resistant Staphylococcus aureus (MRSA) colonisation should be
identiﬁed, and eradication therapy and antibiotics directed towards these
multi-resistant organisms should be given.
• Chest radiography can identify lung pathology in patients with a history of
smoking and cardiac disease such as lung malignancy, cardiac failure or
chronic obstructive pulmonary disease (COPD). Calciﬁcation of the ascending
aorta should be identiﬁed, as this will signiﬁcantly increase the risk of stroke
perioperatively.
• Electrocardiography (ECG) is an essential test, both as a baseline reference 
and to identify dysrhythmias, heart block, ischaemia or recent myocardial
infarction (MI).
• Echocardiography is useful to assess the ventricular function, valvular pathol-
ogy, structural anomalies, volume resuscitation and success of valve repair or
replacement surgery. It is also useful to identify aortic pathology.
• Cardiac catheterisation will have been performed in virtually all patients; this
provides detailed imaging of coronary anatomy, data on ejection fraction,
chamber pressures and aortic root anatomy.
Operations
CABG
About 80% of CABG operations in the UK are performed using CPB, with sys-
temic anticoagulation. 20% of operations are performed off pump, using a sys-
tem of stabilisers to allow the operation to proceed without arresting the heart.
Putative beneﬁts may include reduced mortality and neurological morbidity in
speciﬁc patient subgroups, although this remains controversial [3].
Conduit usually includes the left internal thoracic (also called the left internal
mammary artery or LIMA artery which is usually anastomosed to the left ante-
rior descending branch of the left main coronary artery), and saphenous vein
grafts to other vessels. Occasionally a radial artery may also be used as conduit.
Valve surgery
Aortic and mitral valves may be replaced with either mechanical or biological
valves. Mitral valve repair is an increasingly successful surgical intervention for
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regurgitant mitral valve disease, preserving the native mitral valve cusps and
subvalvular apparatus, reducing the need for lifelong anticoagulation. The tri-
cuspid valve is infrequently replaced, and occasionally repaired with annulo-
plasty. The pulmonary valve is also infrequently replaced.
Aortic arch surgery
This is performed for either dissection or aneurysm. These are high-risk oper-
ations, and occasionally deep hypothermic circulatory arrest (DHCA) with sys-
temic cooling of the patient to 15–22°C is required. Coagulopathy and bleeding
frequently occur following complicated aortic surgery.
Postoperative care
Postoperative cardiac surgical patients differ from other postoperative patients
in many respects. CBP initiates a range of inﬂammatory cascades causing a sys-
temic inﬂammatory response, the severity of which is unpredictable. The period
of low, non-pulsatile ﬂow during CPB may contribute to cerebral and mesenteric
ischaemia, which may be exacerbate subclinical vascular disease.
The CPB circuit contains about 2 litres of priming solution, which may con-
tribute to extravascular oedema. The patient may have also undergone a period
of induced hypothermia, and they are frequently mildly hypothermic and usu-
ally intubated and ventilated on return to the ICU.
Anticipation of common postoperative complications along with an under-
standing of monitoring strategies employed is vital for effective postoperative
care. Postoperative care will generally be assisted by signiﬁcant input from the
surgical team as well as from the resident intensivists.
Monitoring
ECG
Continuous ECG monitoring identiﬁes dysrhythmias, and early ST segment
changes, which may herald early graft occlusion and ischaemia.
Pulse oximetry
Continuous pulse oximetry supplements intermittent arterial blood gas analysis
and may identify hypoxaemia.
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Invasive monitoring
Along with ECG and oximetry, invasive arterial blood pressure monitoring, cen-
tral venous pressure (CVP) monitoring and hourly urine output are minimum,
mandatory monitoring standards. Pulmonary artery ﬂotation catheters (PAFC)
and other means of monitoring cardiac output may guide volume replacement
and the use of inotropic and vasopressor drugs.
Mediastinal drainage
Continuous mediastinal drainage measurement is routinely employed, with
documentation initially at 1⁄4 to 1⁄2 hourly intervals:
• Drainage of 100 ml/h is regarded as moderate drainage.
• 200 ml/h is regarded as high.
• 400 ml/h is severe, and is invariably a trigger for re-operation.
• The absence of measurable drainage from the drains may be misleading as
bleeding can occur into the chest cavity, and not be reﬂected in the drainage.
Urine output
Oliguria is an ominous ﬁnding in these patients, and may reﬂect hypovolaemia,
hypotension and/or poor splanchnic perfusion. Oliguria frequently precedes
acute renal failure. Urine output should be recorded hourly, and hourly urine
outputs of less than 0.5 ml/kg is a cause for concern.
Chest radiography
A postoperative chest X-ray (CXR) will identify the correct placement of central
lines, Swan-Ganz catheters and mediastinal drains. It may also identify pneumo-
thorax or occult bleeding into the left or right hemi-thorax, especially when the
pleura have been opened.
Blood gas monitoring
Blood gas analysis should be performed at regular intervals to guide ventilatory
strategy, as well as to monitor metabolism and to identify anaemia and electrolyte
abnormalities.
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Haematology
A FBC should be requested early in order to quantify thrombocytopaenia, or
anaemia, and if there is a suspicion of bleeding, a coagulation screen can help
guide treatment. The activated clotting time (ACT) is routinely checked, as high
ACTs are associated with increased bleeding.
Postoperative complications
Bleeding
Excessive postoperative bleeding is common, and between 1% and 5% of patients
may require re-operation for bleeding. Bleeding and transfusion of blood and
blood products is associated with increased morbidity and mortality. Early identi-
ﬁcation, and distinction between surgical bleeding and coagulopathy is essential.
Quantiﬁcation of, and rational intervention for coagulopathy and/or surgical
bleeding may reduce morbidity associated with inappropriate blood transfusion.
Bleeding may be “surgical”, or related to coagulopathy, or both.
Investigation of coagulopathy
In addition to the ACT, and the clotting screen (International Normalised Ratio
(INR), prothrombin time (PT), activated partial thromboplastin time (APTT)),
speciﬁc tests exist that are in common usage in cardiac ICU. The Hepcon™
machine uses protamine titration to estimate heparin levels, and gives an accu-
rate indication of residual heparin that may require supplemental protamine.
The Thrombelastogram® (TEG) is a point of care test which can graphically illus-
trate reduced clotting factors, platelet dysfunction or inadequate heparin reversal.
Surgical bleeding
• Perioperative changes in blood pressure, cardiac output and regional blood
ﬂow occur frequently in these patients, and bleeding from the operative ﬁeld
may not manifest during the operative time.
• Sudden bleeding after haemodynamic changes, bleeding from speciﬁc drain
sites, as well as sustained or high-volume blood loss raise the suspicion of
ongoing surgical bleeding. Early surgical exploration and intervention to stop
bleeding is indicated in cases of surgical bleeding.
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Coagulopathy
Coagulopathy is often multi-factorial, and may be associated with the following.
Thrombocytopenia/platelet dysfunction
Modest reductions in platelet numbers will increase bleeding in patients on
antiplatelet medications at the time of surgery are more so than in controls who
have not taken antiplatelet drugs. Platelet transfusion is associated with increased
risk of serious adverse outcome, and the decision to transfuse platelets has to be
balanced against potential risks.
Depletion of clotting factors
A prolonged PT associated with continued bleeding suggests coagulation factor
deﬁciency, and treatment with fresh frozen plasma (FFP) may be indicated. In
the context of markedly abnormal coagulation with a low ﬁbrinogen count, par-
ticularly after administration of large FFP, blood and platelet transfusion, consid-
eration should be given to administration of cryoprecipitate.
Inadequate heparin reversal
The ACT is a crude measure of heparinisation. A prolonged ACT does not neces-
sarily imply residual heparin. Heparin rebound is the reappearance of anticoagu-
lant activity, despite apparently adequate neutralisation with protamine. This
may be due to delayed release of heparin from binding sites on plasma proteins
after elimination of protamine. The clinical contribution of measured heparin
rebound to ongoing bleeding has not been shown to be signiﬁcant in many stud-
ies. Protamine has serious side effects, and before it is given to postoperative
patients, consideration must be given to the pharmacokinetics of heparin, and
the doses of both heparin and protamine already given in the operating theatre.
Ideally it should only be given when there is clear evidence for circulating
heparin. The Hepcon™ device, and the Thrombelastograph® can demonstrate
quantitative and qualitative heparin recirculation, respectively, and where they
are available; they should be used to guide supplemental administration of prot-
amine. Protamine to heparin dose ratios of 2.6:1 have been shown to actually
increase the ACT. It is easy to exceed this dose of protamine if it is given empir-
ically based on total doses of heparin given, without considering the elimination
and excretion of heparin during the surgery. If protamine is given, the ACT must
be rechecked, as excessive protamine can make bleeding worse, and a rise in ACT
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following supplemental protamine suggests this to be the case. Routine and
repeated administration of protamine in response to prolonged ACTs in the post-
operative period is neither rational nor safe. Protamine should not be given in
dose ranges in excess of 2.6:1 of circulating heparin levels [4, 5].
Prothrombotic drugs
In bleeding patients, aprotinin and tranexamic acid have been shown to reduce
postoperative bleeding and should be considered [6]. There is growing interest in
the use of recombinant factor VIIa in the management of severe life-threatening
haemorrhage.
Miscellaneous
Judicious use of positive end-expiratory pressure (PEEP), and elevation of the
back of the bed can reduce bleeding.
Hypothermia and shivering can exacerbate coagulopathy and bleeding, and
active warming should be employed in hypothermic patients who are bleeding.
Tamponade
Mediastinal drains cannot be relied on to drain all blood loss from the peri-
cardium. Accumulated blood in the pericardium can block the mediastinal
drains. Hypotension with high CVP and oliguria suggest tamponade and it
should be speciﬁcally excluded by echocardiography, radiography or re-operation.
Tamponade may occur more slowly and manifest with increased inotrope
requirement, metabolic acidosis and oliguria. Low cardiac index should alert
physicians to this possibility.
The risk of tamponade decreases considerably after 6–12 h. However late tam-
ponade may occur, particularly after removal of epicardial pacing wires up to 4 or
more days postoperatively.
Hypotension
This should be approached systematically in order to avoid a cascade of compli-
cations due to end-organ hypoperfusion and also to identify treatable causes:
• Preload: This should be addressed ﬁrst. Hypovolaemia is a common reason 
for hypotension post-cardiac surgery. CPB is associated with haemodilution,
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capillary leakage and postoperative vasodilatation, all of which cause intravascu-
lar hypotension. Fall in CVP, urine output, and pulmonary arterial wedge pressure,
and increasing arterial pulse pressure variability suggest hypovolaemia and ﬂuid
replacement should be initiated (Table 29.2).
• Afterload: If intravascular volume is deemed adequate, but hypotension per-
sists, this may be due to vasodilatation. The inﬂammatory response to CPB,
and patient warming contribute to this. Clinical examination should reveal
warm peripheries and low dose noradrenaline is commonly needed. If increas-
ing doses are required a Swan-Ganz catheter should be considered, to guide
management.
• Contractility: Persistent hypotension with appropriate pre- and afterload con-
ditions suggest “pump failure”. Remediable causes of low cardiac output
including dysrhythmia, ischaemia, tamponade and other mechanical causes
must be sought and addressed. Inotropic drugs (see Table 29.3) should be com-
menced, and consideration given to the placement of an intra-aortic balloon
pump (IABP).
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Table 29.2. Fluid replacement therapy
Crystalloid 1 ml/kg/h (dextrose/saline) Maintenance therapy
Colloid (gelatine, hetastarch), 10–20 ml/kg Boluses as required to treat hypovolaemia
Blood To give if Hb 7.5–8 g/dl
Platelets, FFP Guided by coagulation studies
Table 29.3. Vasoactive drugs in common usage
Drug with dose (g/kg/min) HR SVR CI PAWP MAP
Dopamine (3–10)     /
Adrenaline (0.01–0.6)  /   
Noradrenaline (0.01–0.3)     
Milrinone (0.35–0.75)     
Isoprenaline (0.01–0.1)     /
Dopexamine (0.5–6.0)     
Dobutamine (5–20)     
HR: heart rate; CI: cardiac index; SVR: systemic vascular resistance; PAWP: pulmonary arterial
wedge pressure; MAP: mean arterial pressure.
Pneumothorax
Pneumothorax is a common complication due to either intentional or uninten-
tional opening of either pleura, particularly when positive pressure ventilation is
employed. Surgeons may or may not have placed a drain into the pleura and 
the presence of a drain does not exclude the possibility of pneumothorax.
Pneumothorax may present with increasing ventilatory requirements in venti-
lated patients, hypoxaemia, and hypotension with or without a high CVP.
Pneumothorax should be excluded by clinical examination, followed only by
CXR if the patient is stable.
Tension pneumothorax should be considered early in the management of
patients with acute circulatory collapse, and immediate drainage is necessary.
Graft occlusion/perioperative MI
Repeated studies suggest that the incidence of postoperative graft occlusion is in
the order of 5% [7]. Graft occlusion correlates poorly with conventional signs 
of MI. Graft occlusion may occur because of technical failure or thrombosis. MI
may occur in the absence of graft occlusion due to distal embolisation of air or
debris during the operation.
ST elevation in the territory of one of the grafted vessels should alert physicians
to this possibility, as should dysrhythmias, in particular ventricular tachycardia or
ﬁbrillation (VT or VF). Widespread myocardial depression may indicate subendo-
cardial infarction due to inadequate myocardial protection intra-operatively and
Troponin T or I may help retrospective diagnosis of perioperative MI [8]. If blood
pressure is adequate, intravenous nitrates may be indicated, but if blood pressure
is low, an IABP and possibly re-operation with revision of the anastomoses should
be considered.
Ischaemic bowel
This is a feared complication, which is difﬁcult to diagnose and treat and is often
fatal. It occurs in around 2–3% of patients, but when it occurs, mortality may be
as high as 60% [9, 10]. It may be caused by perioperative rupture of atheroma in
the mesenteric arteries, emboli or ischaemia induced by perioperative hypoper-
fusion. Intubated patients may not complain of abdominal pain and the ﬁrst
signs are often metabolic acidosis with falling systemic vascular resistance and
increasing requirement for vasoconstrictors. Absent bowel sounds, abdominal
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distension and abdominal pain (in extubated patients), and a high index of sus-
picion, should generate urgent abdominal surgical referral. Prompt surgical
intervention is imperative in this situation.
Renal failure
Oliguria (0.5 ml/kg/h) is a common postoperative complication and may be
caused by renal insult secondary to hypotension or a low cardiac output state
combined with the effects of CPB. Prompt treatment is required to prevent acute
tubular necrosis. Primary intervention should be directed at optimising renal
blood ﬂow paying attention to volume replacement, cardiac output and renal
perfusion pressure. The role of diuretics and of dopamine agonists remains con-
troversial; however, diuresis is desirable while awaiting renal recovery, and their
use is often associated with natriuresis and diuresis. Severe hyperkalaemia, acid-
osis, uraemia and marked ﬂuid overload may require haemoﬁltration.
Prevention and identiﬁcation of stroke
The incidence of stroke varies from under 1% in patients under 65 years to over
10% in elderly patients with ascending aortic atheromatous disease. Symptomatic
carotid arterial disease should be treated with preoperative or intra-operative
carotid endarterectomy. Minimisation of aortic manipulation in patients with
aortic atheroma may also reduce the risk of stroke, but patients with focal neurol-
ogy or abnormal behaviour on attempted extubation may have suffered a stroke.
Computerised tomography (CT) scanning when the patient is stable for transfer
to the radiology department will conﬁrm the diagnosis.
Dysrhythmia
Twenty percent of cardiac surgical patients will develop AF postoperatively. This is
often transient and related to endogenous or exogenous catecholamines. Serum
electrolytes, oxygenation and hydration should all be optimised, and potassium
should be kept above 4.5 mmol/l. Antidysrythmics or rate controlling drugs may
be used and occasionally synchronised DC cardioversion may be required if AF
causes signiﬁcant hypotension. Overdrive pacing is also occasionally attempted
using atrial epicardial pacing wires.
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Ventricular dysrhythmias may also occur and electrolyte correction, intra-
venous lignocaine, amiodarone and deﬁbrillation may be required to correct this.
Epicardial pacing
Epicardial pacing wires are commonly placed onto the right atrium and/or 
the right ventricle. Patients undergoing valve surgery and especially mitral valve
surgery are particularly susceptible to damage of conduction pathways intra-
operatively. Atrial pacing is indicated for sinus bradycardia or slow junctional
rhythms, atrioventricular pacing is useful in complete heart block or second-
degree heart block, and ventricular pacing is effective in slow AF with a slow ven-
tricular rate.
The IABP
An IABP has two major beneﬁcial effects. On inﬂation, it provides increased dia-
stolic blood pressure, which improves coronary blood ﬂow. Deﬂation occurs just
prior to systole, reducing afterload, and decreasing the work of the heart.
The IABP is usually inserted via the right femoral artery, and the balloon lies in
the descending thoracic aorta, 1–2 cm distal to the left subclavian artery. After
insertion, the left radial pulse should be checked to ensure that the tip has not
entered or occluded the left subclavian artery and a CXR should be performed to
conﬁrm correct placement.
Heparin infusion should be considered to prevent thrombosis around the
IABP and the balloon should never be left in situ without active counterpulsation
for more than a few minutes.
Inﬂation should occur just after the aortic valve closes (the dicrotic notch on
the arterial trace or the peak of the T-wave) and deﬂation should occur prior to
systole (or the R-wave) in order to ensure that the end-diastolic pressure is as low
as possible. Inﬂation and deﬂation may be adjusted manually in order to opti-
mise it, although the most modern IABPs have an automatic setting to optimise
this (Figure 29.1).
The complication rate is around 2–5% [11] and an IABP is contraindicated in
severe aortic regurgitation or severe aorto-iliac atheromatous disease. The com-
plications are listed in Table 29.4.
Mechanical cardiac support is increasingly being used electively as a bridge 
to cardiac transplantation, or as salvage in critically ill cardiac patients. Left 
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and right ventricular assist devices (LVADs, RVADs), and biventricular assist
devices (BIVADs) as well as mechanical pump devices (Impella device) and
extracorporeal membrane oxygenation (ECMO) are used with varying degrees of
success in different centres, for a variety of clinical reasons. Familiarity with the
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Table 29.4. Complications of IABP
Complication Prevention/treatment
Limb ischaemia Regular assessment of peripheral pulses by Doppler ultrasound
Thromboembolism/ Regular monitoring of ACT and titration of i.v. heparin 
insertion site 
bleeding
Balloon rupture/leak Blood down the drive line heralds this uncommon complication 
but the IABP must be immediately removed to prevent thrombus 
forming in the semi-inﬂated balloon, preventing subsequent 
removal
Aortic dissection Haemodynamic instability may herald this life-threatening 
complication
Renal failure/GI Misplacement of the IABP with the lower portion of the balloon 
ischaemia placed intra-abdominally
GI: gastrointestinal; i.v.: intravenous.
Increased coronary
artery perfusion
120
m
m
H
g
100
Reduced
myocardial O2 demand
A
B
E
FD
C
80
Figure 29.1 An arterial trace augmented by an IABP. A, one complete cardiac cycle; B,
unassisted aortic end-diastolic pressure; C, unassisted systolic pressure; D, diastolic 
augmentation; E, assisted aortic end-diastolic pressure; F, reduced systolic pressure.
application and restrictions of these technologies are essential for their success-
ful use.
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Cardiac arrest
I. McConachie
Cardiac arrest is cessation of effective circulation due to asystole, ventricular ﬁb-
rillation (VF) or pulseless electrical activity (PEA, previously known as electro-
mechanical dissociation EMD).
• Brain damage will occur within 4–6 min (unless protected by hypothermia).
Therefore this is the ultimate cardiac emergency.
• One of the truly landmark papers in the 20th century was that on closed chest
cardiac resuscitation in 1960 by Kouwenhoven.
• This was the start of the modern concept of cardiopulmonary resuscitation (CPR).
This chapter will brieﬂy review current guidelines for basic life support (BLS) and
advanced life support (ALS) and discuss some of the controversies in resuscita-
tion research. The practical aspects of BLS and ALS are not covered in detail as
these are best learnt at formal resuscitation courses.
All hospital doctors should be proﬁcient at CPR and should receive regular train-
ing/practice at BLS and ALS.
Causes
• Asystole is the ﬁrst diagnosed rhythm in approximately 30% of cardiac arrest
victims. In some, especially out-of-hospital arrests this will be due to untreated
VF (especially if bystander CPR has not been initiated). In hospital, asystole
may be due to severe coronary artery disease and myocardial infarction (MI).
Occasionally hypoxia and other acute, severe medical conditions may result in
30
asystolic arrest. Rarely asystole may be due to excess vagal stimulation or
carotid sinus hypersensitivity.
• “Sudden death” outside hospital is a major form of cardiac death. The majority
of these are VF or pulseless ventricular tachycardia (VT) and are due to
ischaemic heart disease. If untreated, all VF will degenerate into asystole. One
study of over 1700 patients found that if the paramedics arrived within 4 min
53% were found to have VF/VT. With time the incidence of VF/VT decreased to
27% at 20 min [1]. Bystander CPR maintained VF.
• PEA usually has a potentially reversible cause, for example,
Hypovolaemia Tension pneumothorax
Hypoxia Tamponade
Hyperkalaemia Drug Toxicity
Hypokalaemia Thromboembolism
Hypothermia
Survival
Overall, results are, to say the least, disappointing. Survival depends, in part, on the
institution of bystander CPR and the time from arrest to deﬁbrillation. Survival of
up to 25% in out-of-hospital arrests is possible with rapid bystander CPR: survival
is often higher for arrests in public than arrests at home.
One might expect survival from arrests in hospital to be better due to rapid
availability of trained personnel and equipment but overall results are equally
poor. This is due to the presence of other pathology than ischaemic heart disease
in many of these patients. The exception is cardiac arrest due to VF in CCU for
which survival is high because of immediate deﬁbrillation, though many of these
patients will not receive formal CPR.
Factors increasing survival
• VF versus asystole.
• Rapid CPR.
• Rapid deﬁbrillation: survival of out-of-hospital arrest 43% if BLS 4 min and
deﬁbrillation, 8 min [2].
• Short duration of CPR.
• Witnessed arrest.
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• Bystander CPR if out-of-hospital.
• Deﬁbrillation at scene if out-of-hospital.
• Effectiveness of CPR (see later).
• Skill and training of resuscitation personnel.
• Location of arrest in hospital: favourable if arrest in CCU. Although cardiac
arrest under anaesthesia is rare, these have highest resuscitation success rates.
BLS protocols
Reference should be made to the latest guidelines as listed in Further reading.
This brief summary assumes two rescuers. In summary:
• First establish the need for intervention by feeling carotid pulse.
• Call for expert help.
• First rescuer: If no sign of respirations, assess and open airway by tilting head
backwards and lifting jaw. Inﬂate lungs using equipment provided in your
institution at a ratio of 1 breath per 5 cardiac compression (2:15 if only one 
rescuer).
• Second rescuer: If no signs of circulation, provide external cardiac massage
(ECM) using two interlocked hands over lower third of sternum. Aim for car-
diac compression rate of approximately 100/min.
• Monitor BLS for return of pulse and breathing.
• Remember: Early BLS and deﬁbrillation shown to improve outcome.
Exceptions to the above include a witnessed VF arrest in CCU where BLS need not
be performed if deﬁbrillation can be immediately performed (unless deﬁbrillation
unsuccessful!). A precordial thump may be attempted while deﬁbrillator mobilised.
Mechanisms of ECM
• Original theory: Heart squeezed between sternum and vertebral column with
blood expelled with each compression. Relaxation “sucks” blood back into the
thorax. Some animal studies lend some credence to this theory.
• Thoracic pump theory: Coughing during cardiac arrest can generate effective
systolic pressures suggesting that high intrathoracic pressures can promote car-
diac output. In this theory the heart serves as a conduit and increasing thoracic
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pressures during ECM expel blood out of the heart down a pressure gradient
between intrathoracic and extrathoracic vasculature.
Controversies in BLS/ECM
Awareness of the thoracic pump theory of cardiac output during ECM led to
reﬁnements which could be expected lead to increased output.
Active compression/decompression
A “kitchen sink plunger” type of mechanism attached to the chest which improved
ventricular ﬁlling and forward ﬂow by “sucking” blood into the chest has been
investigated. However, a large trial has found no differences in outcome [3].
Abdominal counterpulsation
Pressure on the abdominal aorta during ECM to improve ﬁlling of the heart again
showed initial promise.
Pneumatic vest
Circumferential pressure on the thorax with a pneumatic system increase intratho-
racic pressure and again showed initial promise.
However, the message from all these adjuncts to standard ECM is that non-
supplant standard ECM at present.
Duration of compressions
Increasing the duration of compressions to about 50% of the ECM cycle is bene-
ﬁcial in animals and is a useful practical “side effect” of increasing the rate of
compressions to approximately 100/min.
Open chest massage
Usefulness is limited to trauma and in the operating theatre especially during
cardiac surgery. Such heroics do not lend themselves to routine performance by
cardiac arrest teams. Similarly, placing the arrested patient onto cardiopul-
monary bypass is limited mainly to cardiac surgery patients.
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Infectious diseases
There is no doubt that fear of human immunodeﬁciency virus (HIV) transmission
is limiting the application of BLS techniques by lay bystanders. This is despite
education that HIV has not been reported to be transmitted by saliva contact.
Nevertheless it is prudent to take precautions (tuberculosis (TB) and viruses
such as herpes can deﬁnitely be transmitted during BLS). All hospital personnel
should have access to devices such as pocket masks, etc. which should negate the
necessity for “mouth to mouth” resuscitation.
However, this has no impact on the fear of lay bystanders. It has, therefore, been
suggested [4] that lay CPR should concentrate on ECM only (i.e., no “mouth to
mouth”), particularly if there is only one rescuer. The rationale is based on animal
studies showing that ventilation during CPR is not as important as ECM.
Clinical studies clearly show:
• Bystander ventilation only gives no increased survival cf. no resuscitation.
• Bystander ECM only gives increased survival.
• No further increased survival with both ECM and ventilation.
ALS protocols
BLS alone will rarely result in successful resuscitation. The purpose of BLS is to
maintain organ blood ﬂow until techniques can be applied to restore spontan-
eous circulation.
Summary of ALS principles:
• Maintain CPR/BLS.
• Precordial thump if VF witnessed followed by immediate deﬁbrillation if 
necessary.
• Verify rhythm. Deﬁbrillate with 200, 200 then 360 J. Care with paddle positions.
Note: Eighty percent of successful deﬁbrillations occur in ﬁrst three shocks.
Many modern deﬁbrillators employ biphasic technology which is more efﬁ-
cient than monophasic deﬁbrillation shocks that are used in older devices. The
UK Resuscitation Council recommends following manufacturers advice regard-
ing shock energy for biphasic devices rather than adhering to protocols devel-
oped for the older monophasic units.
• Appropriate intravenous access (see below).
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• Ensure oxygenation and intubation if appropriate personnel present. Oxy-
genate prior to attempting intubation and avoid prolonged attempts without 
reoxygenation.
• In general, patients do not die of failure to intubate, they die of failure to oxy-
genate. However, intubation is probably worthwhile if only to protect against
aspiration of stomach contents.
• Drug administration is simpliﬁed in latest guidelines (see Further reading).
Basically consists of 1 mg of adrenaline every 3 min. Atropine, 3 mg, may be given
once in asystole.
• Be aware of potentially reversible causes of EMD (see Causes).
Immediate transthoracic external pacing is recommended in some protocols 
for management of asystole but does not occupy a position of priority in 
the European guidelines (possibly due to lack of routine access to the 
equipment).
Drug controversies in ALS
Adrenaline
One milligram boluses of Adrenaline intravenously is currently the recom-
mended drug of choice in almost all circumstances in cardiac arrest. However,
this is despite a lack of convincing clinical evidence showing that adrenaline
improves survival or neurological outcome. Certainly there are animal studies
showing improved myocardial and cerebral blood ﬂow and survival but patient
studies are conﬂicting.
The rationale for the administration of adrenaline includes:
•  vasoconstricting effect raising coronary and cerebral perfusion pressures.
This improves the chances of successful deﬁbrillation in VF.
• The 1 effect may coarsen ﬁne VF or promote VF in asystole. Its positive
inotropic effects are of lesser importance.
• Positive chronotropic effects may be useful if bradycardia occurs.
Because of favourable animal studies higher doses have been tried (up to 10 mg)
but have not led to improved survival. In fact, disappointingly, neither “normal”-
or “high”-dose adrenaline produced improved survival compared to placebo in a
recent study [5].
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Vasopressin
Disenchantment with clinical results from the use of adrenaline have resulted 
in other vasoconstrictors being investigated. For example, in a randomised 
controlled study the use of 40g of vasopressin (a non-catecholamine vaso-
pressor) produced increased 24 h survival compared to 1 mg of adrenaline [6]. 
A larger European multicentre study comparing two injections of 40g of vaso-
pressin with 1 mg of adrenaline found improved survival and hospital discharge
in the vasopressin group. They also showed that the combination was more effec-
tive than either drug alone in refractory cardiac arrest [7]. Although these results
are encouraging it is still too early for widespread adoption of vasopressin in ALS.
Atropine
The rationale for the use of atropine comes from studies showing high-endogenous
catecholamine levels during cardiac arrest (implying presumably a limited effect
from additional exogenous catecholamines) and a relatively high-vagal tone [8].
However, atropine administration has not been shown to improve survival from
cardiac arrest and its role is currently secondary to that of adrenaline.
Calcium chloride
Although calcium salts have a positive inotropic action its use has not been
shown to improve survival in cardiac arrest. Now the use should be restricted to
hyperkalaemia, hypocalcaemia or arrests secondary to overdosage of calcium-
blocking drugs. There is also concern that high blood levels of calcium could pre-
cipitate coronary spasm in patients with ischaemic heart disease and also
potentially increase cerebral damage during periods of ischaemia. For similar
reasons dextrose containing ﬂuids should be avoided during cardiac arrest.
Sodium bicarbonate
No longer routinely administrated due to concerns regarding the production of a
hyperosmolar state, “overshoot” alkalosis (detrimental effect on oxyhaemoglo-
bin dissociation curve limiting oxygen release at the tissues) and hyperna-
traemia. The use of bicarbonate is best reserved for prolonged resuscitation (i.e.,
pH 7.1) where the myocardium may be directly compromised. Most useful in
hyperkalaemic arrest or arrest following tricyclic antidepressant overdosage.
Antiarrhythmic administration
The usefulness of many antiarrhythmic drugs during cardiac arrest is limited by
their negative inotropic properties.
• Lidocaine is currently widely used during prolonged VF arrests and to prevent
recurrence of VF. Although controversial this use is supported by studies show-
ing improved outcome from sustained VF arrests [9]. Interestingly, lidocaine is
known to increase deﬁbrillation threshold.
• Bretylium lowers deﬁbrillation threshold and is beneﬁcial in sustained VF.
Convincing evidence for improved survival, however, is lacking.
• The cardiac depressant effect of amiodarone is relatively mild and well tolerated.
An important randomised, controlled trial of out-of-hospital cardiac arrest has
been presented at a major scientiﬁc meeting. The ARREST trial found that a
300 mg bolus of amiodarone improved survival to hospital compared to placebo
[10]. If this is substantiated by further studies and the improved survival trans-
lates to improved survival to discharge this will have important implications.
Route of drug administration
• Initial administration of drugs is best via good peripheral venous access. Drug
injections should be well ﬂushed.
• With prolonged resuscitation central venous catheterisation may be appropri-
ate if performed by experienced personnel (pneumothorax from unskilled cen-
tral venous attempts is counterproductive!). Many ﬁnd it difﬁcult to catheterise
a central vein during ECM – but this is not an indication to stop CPR.
• If no vascular access possible, adrenaline, lidocaine and atropine may all be
given via the endotracheal tube at twice the normal dose, preferably diluted to
10 ml. Blood levels of drugs given by the endotracheal route are unpredictable.
• Intracardiac injection is no longer recommended due to the potential for trauma.
Monitoring effectiveness of CPR
Cardiac output only, at best, 10–30% of normal during CPR. Flow is especially
poor to organs below the diaphragm. Presence of a carotid pulse is not a reliable
quantitative indicator of cardiac output. Pupillary responses during CPR are not
helpful, beware of the effects of adrenaline and atropine.
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Indicators of effective CPR:
• Arterial pressure tracing if arterial line in situ, especially with diastolic
40 mmHg.
• Measured CO2 in expired gas or end tidal CO2. Measured with simple hand held
device attachable to breathing circuit. Chemical indicators provide a semi-
quantitative indicator of pCO2. Increases with CPR indicate increasing cardiac
output and pulmonary artery blood ﬂow and a likely successful outcome.
Indicators of ineffective CPR:
• As above, lack of increasing end tidal CO2 predicts a poor outcome.
• Worsening metabolic acidosis indicates poor tissue blood ﬂow. Venous pH may
be more useful than arterial as will better reﬂect the acid–base state of the tissues.
Complications of CPR
• Ineffective ECM, including situations where circulation has been reestablished
but neurological outcome is poor because of relatively ineffective ECM.
• Stomach distension, potentially leading to regurgitation and pulmonary 
aspiration.
– Arguably fear of this complication is one of the main reasons for endotra-
cheal intubation of the patient.
• Rib and sternal fractures.
• Laceration of liver and other abdominal organs has been reported.
• Complications of central vascular access (e.g., pneumothorax).
• Potential proarrhythmic effects of drugs administered. Certainly, tachycardia
following successful resuscitation is widespread.
• Complications of deﬁbrillation – including burns to patient, shocks to operator
(no deaths reported) and explosion of glyceryl trinitrate (GTN) patches. It is 
recommended that patches be removed and to keep paddles 10–15 cm away
from pacemakers.
Neurological outcome
• One study found that an arrest time prior to resuscitation (or “down time”)
6 min and CPR time 15 min always produced neurological impairment.
However, down times 6 min and CPR times of 30 min resulted in satisfactory
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neurological recovery in 50% of patients [11]. One implication of this is to limit
resuscitation attempts to 15 min where down time exceeds 6 min.
• Scoring systems have been developed using various clinical signs to try and
predict the likelihood of neurological recovery but, unfortunately, none are
sufﬁciently accurate to enable deﬁnite pronouncements on prognosis to be
made in advance.
• Electroencephalogram (EEG) monitoring may occasionally be useful and
improves our ability to predict outcome.
• Many believe that lack of corneal reﬂexes or pupillary light reﬂexes after 24 h
indicates a uniformly poor outcome.
• Some points from the literature:
– Most who recover show rapid improvement in the ﬁrst 24–48 h.
– Coma persisting more than 4 h makes neurological damage more likely.
– Long duration of coma (especially 4 days) leads to very poor outcome.
Post resuscitation care
• Depends on underlying cause of the arrest. Speciﬁc causes may obviously need
speciﬁc treatment.
• VF associated with MI – treatment largely that of MI.
• In USA, many patients undergo emergency cardiac catheterisation with aggres-
sive reperfusion attempted in some centres.
• Control blood glucose. Hyperglycaemia is associated with a worse neurological
outcome.
• Blood pressure (BP) autoregulation is impaired – avoid hypo or hypertension.
• Occasionally patients have a low-cardiac output and develop multiple organ
failure. The myocardial dysfunction is suggestive of some degree of “myocar-
dial stunning”. Animal studies support the use of dobutamine.
• Drug therapy to improve neurological outcome is still experimental and has
much interest, so far fruitless, in the use of Ca blockers.
• Intracranial pressure is not usually increased. Recent research conﬁrms that, as
for head injuries, routine hyperventilation in an attempt at “cerebral salvage”
can lower cerebral blood ﬂow.
• Many centres offer intermittent positive pressure ventilation (IPPV) and inten-
sive care unit (ICU) care in an effort to optimise haemodynamics and oxygena-
tion but there is no evidence that this approach improves outcome in this
rather depressing clinical situation.
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Hypothermia
There have been two prospective randomized trials published comparing mild
hypothermia with normothermia in comatose survivors of out-of-hospital car-
diac arrest [12, 13]. Although there were some adverse effects in the hypothermia
group, overall survival and recovery of neurological was improved compared to
normothermia. On the basis of the published evidence to date, the International
Liaison Committee on Resuscitation recommends:
• Unconscious adult patients with spontaneous circulation after out-of-hospital
cardiac arrest should be cooled to 32–34°C for 12–24 h when the initial rhythm
was VF.
• Such cooling may also be beneﬁcial for other rhythms or in-hospital cardiac arrest.
Family presence during CPR
Traditionally this has been seen as a distraction and has been discouraged due, in
part, to fears of medicolegal consequences. However, family members being
present at the resuscitation is now seen as beneﬁcial to the grieving process and
should be allowed if the family wish to be present.
Training
• In general, studies showing best survival in out-of-hospital arrests are those in
which early bystander CPR is initiated. Therefore, community wide programmes
of BLS modelled on Seattle and Belgian experience would seem important.
• Unfortunately poor knowledge amongst doctors is still a problem [14]. This 
is despite the studies clearly demonstrating that patient survival varies with
knowledge of correct management as well as availability of equipment. All
doctors (indeed all health care personnel) should undergo training and prac-
tice of CPR skills. The majority of hospitals now have full time Resuscitation
Training Ofﬁcers for this purpose. Six monthly reinstruction has been shown to
maintain adequate skills.
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